US20200165570A1 - Methods for reprogramming cells and uses thereof - Google Patents

Methods for reprogramming cells and uses thereof Download PDF

Info

Publication number
US20200165570A1
US20200165570A1 US16/752,462 US202016752462A US2020165570A1 US 20200165570 A1 US20200165570 A1 US 20200165570A1 US 202016752462 A US202016752462 A US 202016752462A US 2020165570 A1 US2020165570 A1 US 2020165570A1
Authority
US
United States
Prior art keywords
cell
cells
pluripotent
expression
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/752,462
Inventor
Jan-Eric Ahlfors
Rouwayda EL-AYOUBI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genesis Technologies Ltd
Original Assignee
Genesis Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genesis Technologies Ltd filed Critical Genesis Technologies Ltd
Priority to US16/752,462 priority Critical patent/US20200165570A1/en
Publication of US20200165570A1 publication Critical patent/US20200165570A1/en
Priority to US18/188,421 priority patent/US20230227785A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/065—Modulators of histone acetylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/09—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from epidermal cells, from skin cells, from oral mucosa cells
    • C12N2506/094—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from epidermal cells, from skin cells, from oral mucosa cells from keratinocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1384—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from adipose-derived stem cells [ADSC], from adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells

Definitions

  • the present invention relates to the field of eukaryotic cell reprogramming, and particularly to cell dedifferentiation.
  • the invention is also concerned with methods of generating stable Neural Stem-Like Cells (NSLCs) from human somatic cells (and other cells) and the use of the cells so generated in human therapy.
  • NSLCs Neural Stem-Like Cells
  • a stem cell can naturally divide or differentiate into another stem cell, progenitor, precursor, or somatic cell.
  • somatic cell can sometimes transiently change its phenotype or express certain markers when placed in certain conditions, and then revert back when placed back into the original conditions.
  • the phenotype of many cells can be changed through forced expression of certain genes (for example, stably transfecting the c-myc gene into fibroblasts turns them into immortal cells having neuroprogenitor characteristics), however once this forced gene expression is removed, the cells slowly revert back to their original state.
  • the first is considered natural differentiation which is part of a cell program that is already in place (going from a more undifferentiated to a more differentiated state)
  • the second is a transient phenotypical change
  • the third is a constantly forced cell type.
  • a true stem cell (i) self-renews almost ‘indefinitely’ (for significantly longer than a somatic cell), (ii) is not a cancerous cell, (iii) is not artificially maintained by forced gene expression or similar means (must also be able to be maintained in standard stem cell media), (iv) can differentiate to progenitor, precursor, somatic or other more differentiated cell type (of the same lineage), and (v) has all the characteristics of a stem cell and not just certain markers or gene expression or morphological appearance.
  • iPS cells induced pluripotent stem cells
  • Yamanaka's group Yamanaka et al., 2007
  • Thomson's group Yamanaka et al., 2007
  • These cells can be induced by true reprogramming since it was later shown that they can also be induced by non-gene integrating transient transfection (Soldner et al., 2009; Woltjen et al., 2009; Yu et al., 2009) as well as by RNA (Warren et al., 2010) or protein (Kim et al., 2009; Zhou et al., 2009) alone or by small molecules (Lyssiotis et al., 2009), and by similar methods.
  • these cells are essentially identical to embryonic stem cells and have the same problems of uncontrolled growth, teratoma formation, and potential tumor formation.
  • a more desirable option is to have multipotent stem cells or pluripotent-like cells whose lineage and differentiation potential is more restricted so that they do not readily form teratomas and uncontrolled growth.
  • NSLC Neural Stem-Like Cells
  • Neural stem cells have promise for tissue regeneration from disease or injury; however, such therapies will require precise control over cell function to create the necessary cell types. There is not yet a complete understanding of the mechanisms that regulate cell proliferation and differentiation, and it is thus difficult to fully explore the plasticity of neural stem cell population derived from any given region of the brain or developing fetus.
  • the CNS traditionally believed to have limited regenerative capabilities, retains a limited number of neural stem cells in adulthood, particularly in the dentate gyrus of the hippocampus and the subventricular zone that replenishes olfactory bulb neurons (Singec I et al., 2007; Zielton R, 2008).
  • the availability of precursor cells is a key prerequisite for a transplant-based repair of defects in the mature nervous system.
  • donor cells for neural transplants are largely derived from the fetal brain. This creates enormous ethical problems, in addition to immuno-rejection, and it is questionable whether such an approach can be used for the treatment of a large number of patients since neural stem cells can lose some of their potency with each cell division.
  • Neural stem cells provide promising therapeutic potential for cell-replacement therapies in neurodegenerative disease (Mimeault et al., 2007). To date, numerous therapeutic transplantations have been performed exploiting various types of human fetal tissue as the source of donor material. However, ethical and practical considerations and their inaccessibility limit the availability as a cell source for transplantation therapies (Ninomiy M et al., 2006).
  • Mammalian epithelial cells can be induced to acquire muscle-like shape and function (Paterson and Rudland, 1985), pancreatic exocrine duct cells can acquire an insulin-secreting endocrine phenotype (Bouwens, 1998a, b), and bone marrow stem cells can be differentiated into liver cells (Theise et al., 2000) and into neuronal cells (Woodbury et al., 2000). Other such as Page et al.
  • MASH1, NeuroD, NeuroD2, MATH1-3, and Neurogenin 1-3 are bHLH transcription factors expressed during mammalian neuronal determination and differentiation (Johnson et al., 1990; Takebyashi et al., 1997; McCormick et al., 1996; Akazawa et al., 1995).
  • Targeted disruptions of MASH1, Ngn1, Ngn2 or NeuroD in mice lead to the loss of specific subsets of neurons (Guillemot et al., 1993; Fode et al., 1998; Miyata et al., 1999).
  • U.S. Pat. No. 6,087,168 (Levesque et al.,) describes a method for converting or transdifferentiating epidermal basal cells into viable neurons.
  • this method comprises the transfection of the epidermal cells with one or more expression vector(s) containing at least one cDNA encoding for a neurogenic transcription factor responsible for neural differentiation.
  • Suitable cDNAs include: basic-helix-loop-helix activators, such as NeuroD1, NeuroD2, ASH1, and zinc-finger type activators, such as Zic3, and MyT1.
  • the transfection step was followed by adding at least one antisense oligonucleotide known to suppress neuronal differentiation to the growth medium, such as the human MSX1 gene and/or the human HES1 gene (or non-human, homologous counterparts).
  • the transfected cells were grown in the presence of a retinoid and a least one neurotrophin or cytokine, such as brain derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin 3 (NT-3), or neurotrophin 4 (NT-4).
  • BDNF brain derived neurotrophic factor
  • NGF nerve growth factor
  • NT-3 neurotrophin 3
  • NT-4 neurotrophin 4
  • a later process mentions the conversion of the epidermal basal cell into a neural progenitor, neuronal, or glial cell by exposing the epidermal basal cell to an antagonist of bone morphogenetic protein (BMP) and growing the cell in the presence of at least one antisense oligonucleotide comprising a segment of a MSX 1 gene and/or HES1 gene.
  • BMP bone morphogenetic protein
  • the present invention addresses these needs and provides various types of stem-like and progenitor-like cells and cells derived or differentiated from these stem-like or progenitor-like cells, as well as methods that can result in true cell dedifferentiation and cell reprogramming.
  • the present invention relates to stem-like and progenitor-like cells and cells derived or differentiated from these stem-like or progenitor-like cells.
  • the invention further relates to methods for cell dedifferentiation and cell reprogramming.
  • the invention further features compositions and methods that are useful for reprogramming cells and related therapeutic compositions and methods.
  • One particular aspect relates to the development of a technology to reprogram a somatic cell or non-neuronal cell to a cell having one or more morphological physiological, and/or immunological features of a neural stem cell and which possess the capacity to differentiate along neuronal and glial lineages.
  • the invention is more particularly concerned with methods of generating stable Neural Stem-Like Cells (NSLCs) from human somatic cells, human progenitor cells and/or of human stem cells, as well as cells, cell lines and tissues obtained by using such methods.
  • NSLCs Neural Stem-Like Cells
  • the invention further relates to compositions and methods to induce de-differentiation of human somatic cells into Neural Stem-Like Cells that express neural stem cell specific markers.
  • the present invention it is possible to effect the conversion of cells to various types of differentiated neuronal cells that can be created from a single cell type taken from an individual donor and then reprogrammed and transplanted into the same individual.
  • Upon induction cells according to the invention express neural stem-cell specific markers and become Neural Stem-Like cells.
  • the invention relates to a method of transforming a cell of a first type to a desired cell of a different type.
  • The comprises i) obtaining a cell of a first type; ii) transiently increasing in the cell of a first type intracellular levels of at least one reprogramming agent, whereby the transient increase induces direct or indirect endogenous expression of at least one gene regulator; iii) placing the cell in conditions for supporting the growth and/or the transformation of the desired cell and maintaining intracellular levels of the at least one reprogramming agent for a sufficient period of time to allow stable expression of the at least one gene regulator in absence of the reprogramming agent; and iv) maintaining the cell in culture conditions supporting the growth and/or the transformation of the desired cell.
  • Such conditions are maintained for a sufficient period of time to allow a stable expression of a plurality of secondary genes.
  • the expression of one or more of the secondary genes is characteristic of phenotypical and functional properties of the desired cell while being not characteristic of phenotypical and functional properties of an embryonic stem cell. Therefore, at the end of the period of time, the desired cell of a different type is obtained.
  • the invention relates to a method of transforming a cell of a first type to a cell of a second different type.
  • the method comprises contacting the cell of a first type with one or more agents capable of increasing within said cell levels of at least one reprogramming agent and directly or indirectly remodeling the chromatin and/or DNA of the cell.
  • the at least one reprogramming agent is selected for inducing directly or indirectly the expression of morphological and functional characteristics of a desired cell of a different type or different cell lineage.
  • the invention relates to a method of transforming a cell of a first type to a cell of a second different type.
  • the method comprises contacting the chromatin and/or DNA of a cell of a first type with an agent capable of remodeling chromatin and/or DNA of said cell; and increasing intracellular levels of at least one reprogramming agent.
  • the at least one reprogramming agent is selected for inducing directly or indirectly the expression of morphological and functional characteristics of a desired cell of a different type or cell lineage.
  • a further aspect of the invention relates to a method of transforming a cell of a first type to a cell of a desired cell of a different type, comprising increasing intracellular levels of at least one reprogramming agent, wherein the at least one reprogramming agent is selected for inducing directly or indirectly the expression of morphological and functional characteristics of a desired second cell type; and maintaining the cell of a first type in culture conditions for supporting the transformation of the desired cell for a sufficient period of time to allow stable expression of a plurality of secondary genes whose expression is characteristic of phenotypical and functional properties of the desired cell, wherein at least one of the secondary genes is not characteristic of phenotypical and functional properties of an embryonic stem cell.
  • the desired cell of a different type is obtained and the obtained cell is further characterized by a stable repression of a plurality of genes expressed in the first cell type.
  • a further aspect of the invention concerns a process wherein a cell of a first type is reprogrammed to a desired cell of a different type, the process comprising:
  • the at least one reprogramming agent in the process is a Msi1 polypeptide, or a Ngn2 polypeptide together with a MDB2 polypeptide.
  • the at least one gene regulator is Sox2 Msi1, or both.
  • the at least one gene regulator may is one or more of the genes listed in Table A for Neural Stem-Like Cells.
  • the invention relates to a method of obtaining a Stem-Like Cell (SLC), comprising:
  • the invention relates to a method of obtaining a Stem-Like Cell.
  • the method comprises increasing intracellular levels of at least one polypeptide specific to the desired stem cell type that is able to drive directly or indirectly transformation of the cell of the first type into the Stem-Like Cell.
  • the method may further comprises contacting chromatin and/or DNA of a cell of a first type with a histone acetylator, an inhibitor of histone deacetylation, a DNA demethylator, and/or an inhibitor of DNA methylation; and/or increasing intracellular levels of at least one other polypeptide specific to the desired stem cell type that is able to drive directly or indirectly transformation of the cell of the first type into a Stem-Like Cell.
  • the invention relates to a method of obtaining a Neural Stem-Like Cell (NSLC).
  • the method comprises increasing intracellular levels of at least one neural stem cell specific polypeptide that is able to drive directly or indirectly transformation of the cell of the first type into a NSLC.
  • the method further comprises. contacting chromatin and/or DNA of a cell of a first type with a histone acetylator, an inhibitor of histone deacetylation, a DNA demethylator, and/or an inhibitor of DNA methylation; and/or increasing intracellular levels of at least one other neural stem cell specific polypeptide that is able to drive directly or indirectly transformation of the cell of the first type into a NSLC.
  • Another aspect of the invention concerns a method of obtaining a Neural Stem-Like Cell (NSLC).
  • the method comprises transfecting a skin cell with a polynucleotide encoding Musashi1, Musashi1 and Neurogenin 2, Musashi1 and Methyl-CpG Binding Domain Protein 2 (MBD2), or Neurogenin 2 and Methyl-CpG Binding Domain Protein 2, thereby reprogramming the skin cell into a NSLC.
  • MBD2 Methyl-CpG Binding Domain Protein 2
  • the method comprises exposing a skin cell to: (i) an inhibitor of histone deacetylation, (ii) an inhibitor of DNA methylation, (iii) a histone acetylator, and/or (iv) a DNA demethylator such as a MBD2 polypeptide and/or transfecting with a polynucleotide encoding a MBD2 polypeptide; and further transfecting the cell (either simultaneously, before, or afterwards) with a polynucleotide encoding MUSASHI1 and/or with a polynucleotide encoding NGN2, thereby reprogramming the skin cell into a NSLC.
  • Some other cells such as keratinocytes and CD34 + cells, can also be used and reprogrammed.
  • the method of obtaining a Neural Stem-Like Cell comprises:
  • NSLC is obtained and the obtained NSLC is further characterized by a stable repression of a plurality of genes expressed in the first cell type.
  • the method of obtaining a Neural Stem-Like Cell comprises:
  • the method of obtaining a Neural Stem-Like Cell comprises:
  • Certain aspects of the invention concerns isolated cells, cell lines, compositions, 3D assembly of cells, and tissues comprising cells obtained using the methods described herein. Additional aspects concerns the use of such isolated cells, cell lines, compositions, 3D assembly of cells, and tissues of medical treatment and methods of regenerating a mammalian tissue or organ.
  • a further aspect concerns a method for repairing or regenerating a tissue in a subject.
  • the method comprises the administration of a reprogrammed cell as defined herein to a subject in need thereof, wherein the administration provides a dose of reprogrammed cells sufficient to increase or support a biological function of a given tissue or organ, thereby ameliorating the subject's condition.
  • the benefits of the present invention are significant and include lower cost of cell therapy by eliminating the need of immuno-suppressive agents, no need for embryos or fetal tissue, thus eliminating ethical and time constraints, lower cost of production, and no health risks due to possible transmission of viruses or other disease.
  • the cells since the cells are created fresh, they tend to be more potent than cells that have been passaged multiple times.
  • FIG. 1 is a panel of light micrograph (10 ⁇ ) presenting cell morphology changes of untransfected and transfected cells with Msi1 and MBD2 at various time points.
  • FIG. 2 is a panel of photomicrographs obtained using CellomicsTM (10 ⁇ ) and revealing NCAM positive cells in transfected cells with Msi1 or Ngn2 in the presence of MBD2.
  • HFFs were pre-treated with cytochalasin B (10 ⁇ g/ml) and transfected with pCMV6-XL5-Msi1 and pCMV6-XL5-MBD2 or pCMV6-XL4-Ngn2 and pCMV6-XL5-MBD2.
  • proliferation medium NPBM, Lonza
  • NbActive Basal growth factor
  • bFGF bFGF
  • ATRA 5 ⁇ M
  • Forskolin 10 ⁇ M
  • FIG. 3 is a panel of photomicrographs obtained using CellomicsTM (10 ⁇ ) and revealing MAP2b positive cells in transfected cells with Msi1 or Ngn2 in the presence of MBD2.
  • MAP2b positive cells were undetectable in untransfected cells and cells transfected with Pax6/MBD2.
  • HFFs were pre-treated with cytochalasin B (10 ⁇ g/ml) and transfected with pCMV6-XL5-Msi1, pCMV6-XL4-Ngn2 or pCMV6-XL5-Pax6, and pCMV6-XL5-MBD2.
  • NPBM proliferation medium
  • Peprotech Peprotech
  • bFGF ng/ml, Peprotech
  • Differentiation was induced by changing the medium to NbActive (BrainBitsTM) supplemented with NT-3 (20 ng/ml), bFGF (20 ng/ml), ATRA (5 ⁇ M) and Forskolin (10 ⁇ M).
  • Cells were incubated at 37° C., 5% CO 2 , 5% O 2 for 2 weeks.
  • FIG. 4 is a panel of photographs showing that neurospheres formed by NSLCs from Example V were completely dissociated into single cell suspensions using Accutase and one single cell was monitored over time to reveal neurosphere formation capacity (Light microscope observation). Neurospheres stained positive for Sox2.
  • B is a panel of photographs from immunohistochemistry results obtained using CellomicsTM. Immunohistochemistry was performed, on day 20, to detect makers for neurospheres and compared to expression levels in neurospheres formed by normal human neuroprogenitor cells (hNPC, Lonza). In addition to Sox2, cells stained positive for the neural stem cells markers Musashi, CD133, Nestin, and GFAP.
  • Cells also stained positive for ⁇ III-tubulin (a marker for neurons), O4 (a marker for oligodendrocytes), and GFAP (a marker for astrocytes), indicating the tri-potent differentiation potential of both sets of cells (NSLC and hNPC), and negative for NGFrec and NeuN (markers for differentiated neurons) indicating that the cells were not terminally differentiated.
  • ⁇ III-tubulin a marker for neurons
  • O4 a marker for oligodendrocytes
  • GFAP a marker for astrocytes
  • FIG. 5 is a panel photomicrographs from immunohistochemistry results obtained using CellomicsTM. Immunohistochemistry was performed on HFFs, NSLCs, and hNPCs to detect expression of markers for fibroblasts as well as neural stem cells (Sox2, Nestin, GFAP) in adherent cultures (that prevented cells from floating and forming neurospheres). Nuclei were stained with Hoechst (upper level pictures). HFFs expressed fibroblasts markers while NSLCs created from these HFFs did not. In comparison, the NSLCs expressed neural stem cell markers similarly to hNPCs while the HFFs did not express any of these markers.
  • Sox2, Nestin, GFAP neural stem cells
  • FIG. 6 is a panel photomicrographs showing Human NSLCs.
  • Human NSLCs were induced to differentiate into neuronal lineages in the presence of NS-A differentiation medium (StemCell Technologies) in the presence of BDNF (20 ng/ml, Peprotech) and bFGF (40 ng/ml, Peprotech) for three weeks.
  • BDNF 20 ng/ml, Peprotech
  • bFGF 40 ng/ml, Peprotech
  • immunostaining using CellomicsTM (10 ⁇ ) revealed differentiation of the cells as shown by the decrease of Sox2 positive cells and increase in the number and intensity of staining of p75, ⁇ III-tubulin and GABA positive cells, as well as differentiated morphology, while the total number of cells increased as shown by Hoechst staining.
  • FIG. 7 is another panel of photomicrographs.
  • HFF, Keratinocytes, and CD34+ were transfected with pCMV6-Msi1-Ngn2 and pCMV6-XL5--MBD2.
  • the medium was changed to proliferation medium (StemCell Technologies) supplemented with EGF (20 ng/ml. Peprotech) and bFGF (20 ng/ml, Peprotech) for two week and then analyzed.
  • Photomicrographs using CellomicsTM (10 ⁇ ) show that NSLCs created from all three types of cells are positive for Nestin, Sox2 and GFAP (markers for neural stem cells), while the original HFFs are not.
  • FIG. 8 is panel of photomicrographs showing the effect of CDM medium on the trans-differentiation of HFF towards neurons.
  • HFF were pre-treated with cytochalasin B (10 ⁇ g/ml) and histone deacetylation inhibitor (VPA, 4 mM) and DNA methylation inhibitor (5-Aza, 5 ⁇ M and cultured in CDM medium containing 3:1 ratio of Dulbecco's modified Eagle medium (DMEM, high glucose (4.5 g/L) with L-glutamine and sodium pyruvate) and Ham's F-12 medium supplemented with the following components: EGF (4.2 ⁇ 10 ⁇ 10 M), bFGF (2.8 ⁇ 10 ⁇ 10 M), ITS (8.6 ⁇ 10 ⁇ 5 M), dexamethasone (1.0 ⁇ 10 ⁇ 7 M), L-ascorbic acid phosphate magnesium salt n-hydrate (3.2 ⁇ 10 ⁇ 4 M), L-3,3′,5-triiodothyronine (2.0 ⁇ 10 ⁇ 10 M),
  • FIG. 9 is panel of photomicrographs showing characterization of reprogrammed cells within CDM at different time points following the transfection with Msi1 and Ngn2.
  • the transfected cells were treated with Cytochalasin B (10 ⁇ g/ml), VPA (4 mM) and 5-AZA (5 ⁇ M) resulting in a disruption of the microfilaments and rounding up of the cells and loosening of the chromatin.
  • Immunohistochemistry on the 3-Dimensional CDM was performed after one and two weeks using CellomicsTM (10 ⁇ ). The cells were positive for neuronal mature marker, such as MAP2b, but were absent in the untransfected control CDM.
  • FIG. 10 is another panel of photomicrographs.
  • Cells within Day 4 CDM were lipotransfected with the two vectors pCMV6-XL5-Msi1 and pCMV6-XL4-Ngn2 individually or together in combination with pCMV-XL5-MBD2 for a period of 6 hours.
  • transfection was performed on fresh HFFs after the 6 hours using Nucleofection, and these fresh HFFs were placed on top of the CDM at the same time as the lipofectamine media was changed to fresh CDM medium after 6 hours.
  • Neural proliferation medium (NPBM, Lonza) with the presence of Noggin (50 ng/ml, Peprotech), recombinant hFGF (20 ng/ml, Peprotech), and recombinant hEGF (20 ng/ml, Peprotech) for one week.
  • Differentiation was induced at day 7, by adding NS-A differentiation medium (StemCell Technologies) for 24 days. Immunohistochemistry was performed at various time points using CellomicsTM (10 ⁇ ).
  • the CDM was stained with a specific antibody against Nestin (a marker for neural stem cells), and cells within the CDM expressed Nestin at all timepoints tested (Day 8, 15, and 21) following transfection. Cells within the untransfected control CDM did not express any Nestin.
  • FIG. 11 is a panel showing a picture of a polyacrylamide gel electrophoresis.
  • NSLCs grown as adherent cultures or suspension cultures (as neurospheres) both express telomerase (which is expresses in all stem cells, but not in normal differentiated somatic cells). Both early (p5) and late (p27) passage NSLCs express telomerase. (The original HFFs from which the NSLCs were created did not express telomerase.) The samples (NSLCs) were spun down and protein concentration of the supernatant was determined using the BCA Assay.
  • telomere extension primer 900 ng of protein from each cell extract was added directly to the TRAP reaction mixture containing TRAP reaction buffer, dNTPs, template substrate (TS) primer, TRAP primer mix and Taq polymerase.
  • the reaction mixtures were incubated at 30° C. for 30 minutes for template synthesis, followed by a PCR procedure (95° C./15 min for initial denaturation, 94° C./30 sec, 59° C./30 sec, 72° C./1 min for 32 cycles) for amplification of the extended telomerase products.
  • PCR polyacrylamide gel electrophoresis
  • FIG. 12 is a panel showing a picture showing Southern blot analysis of two different NSLC samples analyzed for Msi1 and Ngn2 gene integration two weeks after transient transfection.
  • the Dig-labeled PCR probe revealed distinct signals in the positive control samples where the Msi1/Ngn2 plasmid DNA was spiked into HFF genomic DNA for the equivalence of 1, 10 or 100 integrations per genome. There were a few weak and identical bands that appeared in the restriction enzyme digested genomic DNA from untransfected HFF and NSLC samples #1 and #2, suggesting that there was no plasmid DNA integration into the genomic DNA of NSLCs.
  • FIG. 13 is a panel with a line graph and a bar graph showing improvement and significantly better clinical scores in EAE mice treated with NSLCs.
  • Female 8 weeks old C57BL/6 mice were immunized with MOG 35-55 (Sheldon Biotechnology Centre McGill University) in CFA containing 5 mg/ml of desiccated (killed and dried) Mycobacterium tuberculosis H37Ra (Difco, inc) at two sites on the back, and injected with 200 ng of pertussis toxin (List Biological Laboratories, Inc) in PBS intraperitoneally on days 0 and 2.
  • mice Once the mice started showing symptoms of EAE (on Day 13 post-immunization), they were intravenously injected with 200 ⁇ l of NSLC (1 million cells), hNPC (1 million cells), saline, or saline with cyclosporine. All mice except the saline control group received daily injections of cyclosporine. Mice were scored daily for clinical disease; data represent average daily scores. Mice that received a single injection of NSLCs had a significantly lower disease severity than mice that received hNPCs or cyclosporine alone.
  • FIG. 14 is a line graph showing the results of rotarod assessments according to Example XVII part 2. Rats were trained on the rotarod prior to the start of the experiment. Rats were placed on a stationary and rotating rotarod (rotating at 20 rpm) and the amount of time spent by the rats walking on the rotarod before falling off was monitored. Measurements were taken before (pre-surgery) and after (post-surgery) surgical left brain hemisphere ablation and treatment. The data points represent the mean number of falls by each animal during each 60 second testing session carried out at a constant speed of 20 rpm. Each group consisted of eight rats.
  • FIG. 15 is a line graph showing the results of the walking beam assessments according to Example XVII part 2. Rats were measured on their ability to cross a 100 cm long beam after surgical left brain hemisphere ablation and treatment. Two days after surgery, all groups fail to pass the test, and the animals are not able to stay in balance on the beam. One week after the surgery, all the animals show an improvement on their walking capacity, but no significant difference was noticeable between the different treated groups. From week 4 until week 26, the animals treated with NSLCs show significant improvement in their walking capacity compared to the other groups.
  • FIG. 16 is a panel showing photographs of ADSCs transiently transfected with various pluripotent vectors using nucleofector as described in Example XIX. Following the transfection cells were cultured in 6-well plates in suspension with a 50:50 mixture of ADSC complete medium (StemProTM-43) and embryonic stem cells medium (mTeSR1TM, StemCell Technologies).
  • FIG. 17 is a panel showing photographs of ADSCs transiently transfected with pCMV6-XL5-Rex1/pCMV6-XL5-Klf4 and pCMV6-XL5-Rex1/pCMV6-XL4-Oct4.
  • ADSCs were cultured in 96-well plates coated with MatrigelTM for 24 days in the presence of mTeSR1TM medium supplemented with SB341542 and PD0325901 at 37° C., 5% CO 2 , 5% O 2 .
  • live staining, immunohistochemistry and AP staining were used.
  • FIG. 18 is a panel showing photographs of ADSCs transiently transfected with various pluripotent vectors. Following transfection the cells were plated in StemProTM MSC SFM medium on MatrigelTM (BD Biosciences) coated 24 well plates and incubated at 37° C., 5% CO 2 , 5% 0 2 . On day 1, media was changed to a mix of 75% StemProTM MSC and 25% hES cell medium; the percentage of StemProTM MSC SFM medium was decreased every day over four days to have 100% hES cell medium by day 4. Then medium was changed every two days.
  • StemProTM MSC SFM medium MatrigelTM (BD Biosciences) coated 24 well plates and incubated at 37° C., 5% CO 2 , 5% 0 2 .
  • media was changed to a mix of 75% StemProTM MSC and 25% hES cell medium; the percentage of StemProTM MSC SFM medium was decreased every day over four days to have 100% hES cell medium by day 4.
  • the hES cell medium consisted in Dulbecco's Modified Eagle's Medium (DMEM, Invitrogen) supplemented with 20% KnockoutTM Serum Replacement (KSR, Invitrogen), 1 mM GlutaMAXTM, 100 ⁇ M Non-essential Amino acids, 100 ⁇ M 3-mercaptoethanol and 10 ng/ml Fgf-2.
  • DMEM Dulbecco's Modified Eagle's Medium
  • KSR KnockoutTM Serum Replacement
  • GlutaMAXTM 100 ⁇ M Non-essential Amino acids
  • 100 ⁇ M 3-mercaptoethanol 100 ⁇ M 3-mercaptoethanol
  • 10 ng/ml Fgf-2 10 ng/ml Fgf-2.
  • Transfected cells transfected with Oct4/UTF1/MBD2, Oct4/Dppa4/MBD2, FoxD3/Dppa4/MBD2, Oct4/FoxD3/Dppa4, and Sox2/FoxD3/UTF1 were positive for SSEA-4 + , TRA1-60, and TRA-1-81 + phenotype (early pluripotency markers) at day 14.
  • FIG. 19 is a panel showing photographs of transiently transfected HFFs.
  • HFFs were transiently transfected using the Nucleofector® II Device (Lonza) following the procedure described in Example II with the exception that 1 ⁇ g of each of the following 3 DNA plasmids was used: pCMV-Oct4nuc-IRES2-Sox2nuc, pCMV-Klf4nuc-IRES2-Cmycnuc and pCMV-Nanognuc-IRES2-Lin28. The cells were pre-treated with or without VPA and 5-Aza.
  • the cells were plated in the fibroblast medium, supplemented with or without VPA (2 mM) and 5-AZA (2.5 ⁇ M) on MatrigelTM (BD Biosciences) coated 6-well plates and incubated at 37° C., 5% CO 2 .
  • media was changed to 100% mTeSR1TM medium (StemCell Technologies) supplemented with or without VPA and 5-AZA.
  • cells were re-transfected as above and plated on MatrigelTM coated plates in mTeSR1TM medium supplemented with or without VPA and 5-AZA. Media was changed daily as above.
  • FIG. 20 is a panel showing photographs of transfected NSLCs and BG-01.
  • NSLCs and BG-01 NS were transfected as previously described in Example II by two episomal vectors, pEF-Oct4nuc-IRES2-MBD2 (NC1) or pCMV-FoxD3-2A-Oct4-2A-Klf4 (F72).
  • N-C1 pEF-Oct4nuc-IRES2-MBD2
  • F72 pCMV-FoxD3-2A-Oct4-2A-Klf4
  • FIG. 21 is a panel showing bright field pictures at day 17 of fibroblasts transfected with Msi1/Ngn2 and pCMV6-XL5-MBD2 placed in different media conditions and showing different morphologies and degree of differentiation.
  • FIG. 22 is a panel showing pictures of immunochemistry results at day 17 of fibroblasts transfected with Msi1/Ngn2 and pCMV6-XL5-MBD2 in FIG. 21 .
  • a and B Cells were in NS-A Proliferation Medium from day 1 to day 12, and then in NS-A Differentiation Medium (A) or NBActive4 medium (B) with cytokines from day 12 to 17. There were more cells in B, but Differentiation from day 12-17 was too short to induce expression of ⁇ III-tubulin in both cases.
  • FIGS. 22C-E Cells were in NS-A Differentiation Medium (C) or NbActive4 medium (D) from day 1-17 (with FGF-2 supplementation from day 1-12), or CDM II medium from day 1-12 and then NS-A Differentiation Medium from day 12-17 (E). There were a large number of cells in C and a much smaller number of cells in D and E. Cells were immunopositive for both GFAP and ⁇ III-tubulin in all cases and placing the cells in differentiation or non-proliferation media from day 1 onwards appears to have induced a more direct transformation into neurons and glia, with more intense ⁇ III-tubulin than GFAP positive cells in E.
  • FIG. 23 is a panel showing two heat maps providing a global overview of the gene expression comparison between either NSLC vs. HFF (Set 1), or NSLC vs. hNPC (Set 2).
  • NSLC has a distinct gene expression profile when compared to either HFF or hNPC. Based on the intensity (the higher the intensity, the higher the relative change in expression), NSLC is much more similar to hNPC than to HFF.
  • FIG. 24 is a panel showing pictures of NSLCs.
  • NSLCs were tested to determine if they are a population of Skin-Derived Precursors Cells (SKPs).
  • SKPs capable of proliferating in response to EGF and bFGF, express nestin and fibronectin, and can differentiate into both neuronal and mesodermal progeny including into adipocytes.
  • adipocyte-derived stem cells ADSCs
  • NSLCs StemProTM proliferation medium
  • differentiation towards adipocytes were induced by culturing these cells in differentiation medium consisting in DMEM/F12 (50:50), ITS (1:100), HEPES (1:100), GlutaMAXTM (1:100), T3 (0.2 nM), Rosiglitasone (0.5 ⁇ g/ml), IBMX (100 ⁇ M) and Dexamethasone (1 ⁇ M).
  • IBMX and Dexamethasone were withdrawn from the medium.
  • NSLCs are not a population of Skin-Derived Precursors Cells (SKPs).
  • the present invention relates to methods for cell dedifferentiation and cell reprogramming.
  • a significant aspect of the present invention is that it permits the use of a patient's own cells to develop different types of cells that can be transplanted after steps of in vitro dedifferentiation and in vitro reprogramming.
  • this technology eliminates the problems associated with transplantation of non-host cells, such as, immunological rejection and the risk of transmitting disease.
  • the cells since the cells are “newly created”, they have the potential to be more potent than alternative sources of natural cells that have already divided multiple times.
  • polynucleotide refers to any DNA or RNA sequence or molecule, comprising encoding nucleotide sequences.
  • the term is intended to encompass all polynucleotides whether occurring naturally or non-naturally in a particular cell, tissue or organism. This includes DNA and fragments thereof, RNA and fragments thereof, cDNAs and fragments thereof, expressed sequence tags, artificial sequences including randomized artificial sequences.
  • polypeptide refers to any amino acid sequence having a desired functional biological activity (e.g. DNA demethylation).
  • the term is intended to encompass complete proteins, fragments thereof, fusion proteins and the like, including carbohydrate or lipid chains or compositions.
  • Trans-differentiation refers to a direct switch of an already differentiated cell to another type of differentiated cell.
  • De-differentiation refers to the loss of phenotypic characteristics of a differentiated cell by activating or deactivating genes or metabolic pathways.
  • Marker refers to a gene, polypeptide, or biological function that is characteristic of a particular cell type or cellular phenotype.
  • Genetically-engineered DNA sequence is meant a DNA sequence wherein the component sequence elements of DNA sequence are organized within the DNA sequence in a manner not found in nature.
  • “Signal sequence” refers to a nucleic acid sequence which, when incorporated into a nucleic acid sequence encoding a polypeptide, directs secretion of the translated polypeptide from cells which express said polypeptide, or allows the polypeptide to readily cross the cell membrane into a cell.
  • the signal sequence is preferably located at the 5′ end of the nucleic acid sequence encoding the polypeptide, such that the polypeptide sequence encoded by the signal sequence is located at the N-terminus of the translated polypeptide.
  • signal peptide is meant the peptide sequence resulting from translation of a signal sequence.
  • “Ubiquitous promoter” refers to a promoter that drives expression of a polypeptide or peptides encoded by nucleic acid sequences to which promoter is operably linked.
  • Preferred ubiquitous promoters include human cytomegalovirus immediate early (CMV); simian virus 40 early promoter (SV40); Rous sarcoma virus (RSV); or adenovirus major late promoter.
  • Gene expression profiling means an assay that measures the activity of multiple genes at once, creating a global picture of cellular function. For example, these profiles can distinguish between human neural stem cells and somatic cells that are actively dividing or differentiating.
  • Transfection refers to a method of gene delivery that introduces a foreign nucleotide sequences (e.g. DNA molecules) into a cell preferably by a non-viral method.
  • foreign DNA is introduced to a cell by transient transfection of an expression vector encoding a polypeptide of interest, whereby the foreign DNA is introduced but eliminated over time by the cell and during mitosis.
  • transient transfection is meant a method where the introduced expression vectors and the polypeptide encoded by the vector, are not permanently integrated into the genome of the host cell, or anywhere in the cell, and therefore may be eliminated from the host cell or its progeny over time. Proteins, polypeptides, or other compounds can also be delivered into a cell using transfection methods.
  • Neuron-like Cell refers to an immature cell of the nervous system, which can differentiate into neurons and glia (oligodendrocytes and astrocytes).
  • Neuro Stem Cell is an ectoderm germ layer derived multipotent stem cell having, as a physiological feature, a capacity to form neuroprogenitor cells and under physiological conditions that favor differentiation to form neurons and glia.
  • Neuro Stem-Like Cell or “NSLC” refers to any cell-derived multipotent stem cell having, as a physiological feature, a capacity to form other neural stem-like cells and neuroprogenitor-like cells and under physiological conditions that favor differentiation to form neuron-like cells and glial-like cells.
  • Neurosphere refers to a cellular aggregate of neural stem cells and neuroprogenitor cells that form a floating sphere formed as a result of proliferation of the neural stem cells and neuroprogenitor cells in appropriate proliferation conditions.
  • NSLCs also form neurospheres consisting of aggregates of NSLCs and neuroprogenitor-like cells.
  • Reprogrammed cell refers to a cell that has undergone stable trans-differentiation, de-differentiation, or transformation. Some reprogrammed cells can be subsequently induced to re-differentiate. The reprogrammed cell stably expresses a cell-specific marker or set of markers, morphology, and/or biological function that was not characteristic of the original cell. “Reprogrammed somatic cell” refers to a process that alters or reverses the differentiation status of a somatic cell, which can be either complete or partial conversion of the differentiated state to an either less differentiated state or a new differentiated state.
  • Regeneration refers to the capability of contributing to the repair or de novo construction of a cell, tissue or organ.
  • “Differentiation” refers to the developmental process of lineage commitment of a cell.
  • Differentiation can be assayed by measuring an increase in one or more cell-differentiation specific markers relative to the expression of the undifferentiated cell markers.
  • Lineage refers to a pathway of cellular development, in which a more undifferentiated cell undergoes progressive physiological changes to become a more differentiated cell type having a characteristic function (e.g., neurons and glia are of a neuroprogenitor lineage, which is of an ectoderm lineage which formed from blastocysts and embryonic stem (ES) cells).
  • a characteristic function e.g., neurons and glia are of a neuroprogenitor lineage, which is of an ectoderm lineage which formed from blastocysts and embryonic stem (ES) cells.
  • tissue refers to an ensemble of cells (identical or not) and an extracellular matrix (ECM) that together carry out a specific function or set of functions.
  • ECM extracellular matrix
  • CDM is meant a living tissue equivalent or matrix, a living scaffold, or cell-derived matrix.
  • Some aspects of the invention concerns methods and cells to transform or reprogram a given somatic cell into a pluripotent, multipotent and/or unipotent cell. Some aspects of the invention relates to methods for conditioning a somatic cell to reprogramming into a pluripotent, multipotent or unipotent cell.
  • transform or “reprogram” are used interchangeably to refer to the phenomenon in which a cell is dedifferentiated or transdifferentiated to become pluripotent, multipotent and/or unipotent.
  • the dedifferentiated cell could subsequently be redifferentiated into a different type of cell.
  • Cells can be reprogrammed or converted to varying degrees. For example, it is possible that only a small portion of cells are converted or that an individual cell is reprogrammed to be multipotent but not necessarily pluripotent.
  • the terms “transforming” or “reprogramming” methods can refer to methods wherein it is possible to reprogram a cell such that the “new” cell shows morphological and functional characteristics of a new or different specific cell lineage (e.g. the transformation of fibroblast cells into neuronal cells).
  • somatic cell refers to any differentiated cell forming the body of an organism, apart from stem cells, progenitor cells, and germline cells (i.e. ovogonies and spermatogonies) and the cells derived therefrom (e.g. oocyte, spermatozoa).
  • stem cells progenitor cells
  • germline cells i.e. ovogonies and spermatogonies
  • the cells derived therefrom e.g. oocyte, spermatozoa
  • oocyte, spermatozoa e.g. oocyte, spermatozoa
  • Somatic cells according to the invention can be differentiated cells isolated from adult or can be fetal somatic cells. Somatic cells are obtained from animals, preferably human subjects, and cultured according to standard cell culture protocols available to those of ordinary skill in the art.
  • “Stem cell” refers to those cells which retain the ability to renew themselves through mitotic cell division and which can differentiate into a diverse range of specialized cell types. It includes both embryonic stem cells that are found in blastocysts, and adult stem cells that are found in adult tissues. “Totipotent cells” refers to cells that have the ability to develop into cells derived from all three embryonic germ layers (mesoderm, endoderm and ectoderm) and an entire organism (e.g., human being if placed in a woman's uterus in the case of humans). Totipotent cells may give rise to an embryo, the extra embryonic membranes and all post-embryonic tissues and organs.
  • multipotent cells refers to cells that can produce only cells of a closely related family of cells (e.g. hematopoietic stem cells differentiate into red blood cells, white blood cells, platelets, etc.).
  • unipotent cells refers to cells that have the capacity to develop/differentiate into only one type of tissue/cell type (e.g. skin cells).
  • the present invention allows the reprogramming of any cell to a different type of cell.
  • the present application focuses primarily on the preparation of Stem-Like cells, especially, Neural Stem-Like Cells (NSLCs)
  • the invention is not so restricted because many different types of cells can be generated according to the principles described herein.
  • NSLCs Neural Stem-Like Cells
  • the Examples section describes embodiments where fibroblasts, keratinocytes, CD34 + cells, adipose-derived stem cells (ADSCs), neural stem cells (including NSLCs), and cells within a Cell-Derived Matrix (CDM) are reprogrammed
  • the invention is not limited such cells.
  • the invention may be employed for the reprogramming of virtually any cell of interest.
  • a general aspect of the invention relates to a method of transforming a cell of a first type to a cell of a second different type.
  • examples of cells of a first type include, but are not limited to germ cells, embryonic stem cells and derivations thereof, adult stem cells and derivations thereof, progenitor cells and derivations thereof, cells derived from mesoderm, endoderm or ectoderm, and a cell of mesoderm, endoderm or ectoderm lineage such as an adipose-derived stem cell (ADSC), mesenchymal stem cell, hematopoietic stem cell (CD34 + cell), skin derived precursor cell, hair follicle cell, fibroblast, keratinocyte, epidermal cell, endothelial cell, epithelial cell, granulosa epithelial cell, melanocyte, adipocyte, chondrocyte, hepatocyte, lymphocyte (B and T lymphocyte),
  • ADSC
  • examples of cells of a second type include, but are not limited to germ cells, embryonic stem cells and derivations thereof, adult stem cells and derivations thereof, progenitor cells and derivations thereof, cells derived from mesoderm, endoderm or ectoderm, and a cell of mesoderm, endoderm or ectoderm lineage such as an adipose-derived stem cell, mesenchymal stem cell, hematopoietic stem cell, skin derived precursor cell, hair follicle cell, fibroblast, keratinocyte, epidermal cell, endothelial cell, epithelial cell, granulosa epithelial cell, melanocyte, adipocyte, chondrocyte, hepatocyte, lymphocyte (B and T lymphocyte), granulocyte, macrophage, monocyte, mononuclear cell, pancreatic islet cell, sertoli cell, neuron, glial cell, cardiac muscle cell, and other muscle
  • the method of transforming a cell of a first type into a cell of a second different type comprises the steps of:
  • step iii) may be carried out consecutively to step ii), simultaneously with step ii), or before step ii).
  • the invention relates to a process wherein a cell of a first type is reprogrammed to a desired cell of a different type, the process comprising:
  • transiently increasing refers to an increase that is not necessarily permanent and therefore, which may decrease or disappear over time.
  • transiently increasing intracellular levels of at least one reprogramming agent in a cell it means that the increase in present for a sufficient period of time for causing particular cellular events to occur (e.g. inducing stable endogenous expression of a gene regulator).
  • a transient increase is not permanent and is not associated for instance to genome integration of an expression vector.
  • the term “reprogramming agent” refers to a compound that is capable of inducing directly or indirectly the expression of morphological and/or functional characteristics of the desired cell of a different type. Preferred compounds include those capable of driving directly or indirectly transformation of the cell of the first type into the desired cell of a different type.
  • the reprogramming agent is selected for inducing a direct or indirect endogenous expression of at least one gene regulator as defined herein. There are many compounds that may be helpful in reprogramming a cell according to the invention and these compounds can be used alone or in combinations.
  • the reprogramming agent is a polynucleotide or polypeptide selected according to TABLE A:
  • the reprogramming agent is a polypeptide which shares at least 75%, 80%, 85%, 90%, 95%, 97%, 99% or more of the functionality or sequence identity of any one of the reprogramming agents in the table hereinbefore.
  • the sufficient or proper time period will vary according to various factors, including but not limited to, the particular type and epigenetic status of cells (e.g. the cell of the first type and the desired cell), the amount of starting material (e.g. the number of cells to be transformed), the amount and type of reprogramming agent(s), the gene regulator(s), the culture conditions, presence of compounds that speed up reprogramming (ex, compounds that increase cell cycle turnover, modify the epigenetic status, and/or enhance cell viability), etc.
  • the sufficient period of time to allow a stable expression of the at least one gene regulator in absence of the reprogramming agent is about 1 day, about 2-4 days, about 4-7 days, about 1-2 weeks, about 2-3 weeks or about 3-4 weeks.
  • the sufficient period of time in which the cells are to be maintained in culture conditions supporting the transformation of the desired cell and allow a stable expression of a plurality of secondary genes is about 1 day, about 2-4 days, about 4-7 days, or about 1-2 weeks, about 2-3 weeks, about 3-4 weeks, about 4-6 weeks or about. 6-8 weeks.
  • the number of transformed desired cells is substantially equivalent or even higher than an amount of cells a first type provided at the beginning.
  • the present invention encompasses various types of compounds that are suitable for increasing in a cell of a first type the intracellular levels of at least one reprogramming agent.
  • the compound should also be able to directly or indirectly remodel the chromatin and/or DNA of the cell, thus resulting directly or indirectly in the expression of morphological and functional characteristics of the desired cell of a different type.
  • Preferred compounds are reprogramming agents as defined herein or any other compound having a similar activity and having the ability to activate or enhance the expression of the endogenous version of genes listed in the table of reprogramming agents hereinbefore and which are capable of driving directly or indirectly transformation of the cell of the first type into the desired cell of a different type.
  • the increase in intracellular levels of the at least one reprogramming agent can be achieved by different means.
  • the reprogramming agent is a polypeptide and increasing intracellular levels of such polypeptide include transfection (or co-transfection) of an expression vector having a polynucleotide (ex. DNA or RNA) encoding the polypeptide(s), or by an intracellular delivery of polypeptide(s).
  • transient expression is generally preferable.
  • Additional suitable compounds may include compounds capable of increasing the expression of the endogenous version of genes listed in the table of reprogramming agents and gene regulators including, but not limited to, reprogramming factors listed in Table B.
  • gene regulator refers to a polynucleotide or polypeptide whose expression is associated with a series of intracellular events leading to the transformation of a given cell of a first type into a pluripotent, multipotent and/or unipotent cell.
  • expression of a gene regulator directly or indirectly activates genes necessary for the phenotypical and functional characteristic of pluripotent, multipotent and/or unipotent cells, while repressing genes of the cell of a first type.
  • the gene regulator may be the same or be different than the reprogramming agent. Examples of gene regulators according to the invention include, but are not limited to, the polynucleotides and polypeptides listed herein before in TABLE A.
  • the gene regulator is a polypeptide which shares at least 75%, 80%, 85%, 90%, 95%, 97%, 99% or more of the functionality or sequence identity of any one of the gene regulators provided in the Table A hereinbefore.
  • condition supporting growth or “conditions supporting the transformation” when referring to a desired cell refers to various suitable culture conditions (temperature, pH, O 2 tension, cell media, factors, compounds, growth substrate (ex. laminin, collagen, fibronectin, MatrigelTM, low-bind surface, nanostructured or charged surface, etc.), 3D environment, etc.)
  • suitable culture conditions e.g. culture conditions
  • suitable conditions e.g. culture conditions
  • phenotypical and functional properties when referring to a desired cell or to an embryonic stem cell, means the biological, biochemical, physiological and visual characteristics of a cell, including expression of certain genes and cell surface markers, which can be measured or assessed for confirming its identity or function(s).
  • MUSASHI1 An example of a suitable reprogramming agent according to preferred embodiments of the invention is MUSASHI1.
  • this polypeptide is preferred for driving a first cell, such as a fibroblast, into a Neural Stem-Like Cell (NSLC).
  • the at least one reprogramming agent which said intracellular levels is increased is(are) either Musashi1 (Msi1) alone; Musashi1 (Msi1) and Neurogenin 2 (Ngn2); Musashi1 (Msi1) and methyl-CpG binding domain protein 2 (MBD2); or Neurogenin 2 (Ngn2) and methyl-CpG binding domain protein 2 (MBD2).
  • Adequate intracellular levels of these polypeptides are preferred since they tend to be expressed throughout an entire cell lineage, from as early as embryonic stem cells (or even earlier) to pre-somatic cells (or even later).
  • MBD2 is a member of a family of methyl-CpG-binding proteins that has been reported to be both a transcriptional repressor and a DNA demethylase (dMTase).
  • MBD2 generally refers to the human methyl-CpG binding domain protein 2.
  • NCBI GeneBankTM accession number of human MBD2 is NM_003927.3/AF072242, the UniProtTM accession number is NP-003918/Q9UBB5 and the UniGeneTM accession number is Hs.25674.
  • Msi1 generally refers to the human musashi homolog 1.
  • the GeneBankTM (NCBI) accession number of human Msi1 is NM_002442.2/AB012851, the UniProtTM accession number is NP-002433/043347 and the UniGeneTM accession number is Hs.158311.
  • Ngn2 generally refers to the human neurogenin 2.
  • the GeneBankTM (NCBI) accession number of human Ngn2 is NM_024019.2/BC036847, the UniProtTM accession number is NP-076924/Q9H2A3 and the UniGeneTM accession number is Hs.567563.
  • the method of transforming a cell of a first type to a desired cell of a different type comprises the steps of either:
  • step 2) may be carried out consecutively to step 1), simultaneously with step 1), or before step 1).
  • the invention relates to a method for obtaining a Neural Stem-Like Cell (NSLC), comprising:
  • the term “remodelling the chromatin and/or DNA” refers to dynamic structural changes to the chromatin. These changes can range from local changes necessary for transcriptional regulation, to global changes necessary for opening up the chromatin structure or chromosome segregation to allow transcription of the new set of genes characteristic of the desired cell of a different type, to closing up of the chromatin structure or chromosome segregation to prevent transcription of certain genes that are not characteristic of the desired cell of a different type.
  • opening up of the chromatin structure refers more specifically to acetylation of histones, and demethylation of DNA
  • closing up of the chromatin structure refers more specifically to deacetylation of histones, and methylation of DNA.
  • compound refers to a compound capable of effecting a desired biological function.
  • the term includes, but is not limited to, DNA, RNA, protein, polypeptides, and other compounds including growth factors, cytokines, hormones or small molecules.
  • compounds capable of remodeling chromatin and/or DNA include, but are not limited to, histone acetylators, inhibitors of histone deacetylation, DNA demethylators, inhibitors of DNA methylation and combination thereof.
  • “Inhibitor of DNA methylation” refers to an agent that can inhibit DNA methylation.
  • DNA methylation inhibitors have demonstrated the ability to restore suppressed gene expression.
  • Suitable agents for inhibiting DNA methylation include, but are not limited to 5-azacytidine, 5-aza-2-deoxycytidine, 1- ⁇ -D-arabinofuranosil-5-azacytosine, and dihydro-5-azacytidine, and zebularine (ZEB), BIX (histone lysine methytransferase inhibitor), and RG108.
  • “Inhibitor of histone deacetylation” refers to an agent that prevents the removal of the acetyl groups from the lysine residues of histones that would otherwise lead to the formation of a condensed and transcriptionally silenced chromatin.
  • Histone deacetylase inhibitors fall into several groups, including: (1) hydroxamic acids such as trichostatin (A), (2) cyclic tetrapeptides, (3) benzamides, (4) electrophilic ketones, and (5) aliphatic acid group of compounds such as phenylbutyrate and valporic acid.
  • Suitable agents to inhibit histone deacetylation include, but are not limited to, valporic acid (VPA), phenylbutyrate Trichostatin A (TSA), Na-butyrate, and benzamides.
  • VPA valporic acid
  • TSA phenylbutyrate Trichostatin A
  • Na-butyrate Na-butyrate
  • benzamides valporic acid
  • VPA promotes neuronal fate and inhibits glial fate simultaneously through the induction of neurogenic transcription factors including NeuroD.
  • Histone Acetylator refers to an agent that inserts acetyl groups to the lysine residues of histones that opens up the chromatin and turns it into a transcriptionally active state.
  • Suitable Histone Acetylator agents include, but are not limited to, Polyamine, CREB (cAMP element binding protein), and BniP3.
  • DNA demethylator refers to an agent that removes the methyl groups from DNA and possesses the ability to inhibit hypermethylation and restore suppressed gene expression. A demethylase is expected to activate genes by removing the repressive methyl residues. Suitable DNA demethylators include, but are not limited to, MBD2 and Gadd45b.
  • the reprogramming agent has one or more of the following functions: it decrease the expression of one or more markers of cells of the first type (ex. see Table C), and/or increase the expression of one or more markers of the desired cell of the different type (ex. see Table A). Cells that exhibit a selectable marker for the desired cell of a different type are then selected and assessed for characteristics of the desired cell of a different type.
  • transformation into the desired cell results in stable expression of a plurality of secondary genes whose expression is characteristic of phenotypical and/or functional properties of the desired cell.
  • Genes whose expression is characteristic of phenotypical and/or functional properties of the desired cell include, but is not limited to, those listed in Table A.
  • expression of secondary genes whose expression is characteristic of phenotypical and functional properties of the desired cell results in the expression of markers defined according to the following table:
  • Desired cell type Markers Neural stem-like cells Nestin, Sox2, GFAP, Msi1 Neural-like cells ⁇ III-tubulin, Map2b, Synapsin, ACHE Ectoderm-like cells Sox2, Sox1, Zic1, Nestin, Notch 1, FoxJ3, Otx2, Cripto1, Vimentin Mesendoderm-like cells Sox17, FoxA2, CXCR4, GATA4, MixI1, Eomesodermin Pluripotent-like cells Oct4, SSEA4, TRA-1-60, TRA-1-81, AP
  • transformation of a cell of a first type into the desired cell results in a stable repression of a plurality of genes typically expressed in the cell of the first type.
  • suppressed genes include, but are not limited to, those defined in Table C:
  • Keratin 14 isoform 1 TP63, NM_001114978.1 Q9H3D4 Hs.137569 Basonuclin isoform 2 TP63, NM_001114979.1 Q9H3D4 Hs.137569 P63 isoform 3 TP63, NM_001114980.1 Q9H3D4 Hs.137569 isoform 4 TP63, NM_001114981.1 Q9H3D4 Hs.137569 isoform 5 TP63, NM_001114982.1 Q9H3D4 Hs.137569 isoform 6 BNC1 NM_001717.3 Q01954 Hs.459153 BCN2 NM_017637.5 Q6ZN30 Hs.656581 KRT14 NM_000526.4 P02533 Hs.654380 Involucrin NM_005547.2 P07476
  • stable repression of any one or more of the genes listed in Table C being expressed in the first cell type is also characterized by a disappearance of the corresponding markers (see Table C).
  • Those skilled in the art will understand that there exist many alternative steps for facilitating cell reprogramming. Those include destabilizing the cell's cytoskeletal structure (for example, by exposing the cell to cytochalasin B), loosening the chromatin structure of the cell (for example, by using agents such as 5 azacytidine (5-Aza) and Valproic acid (VPA) or DNA demethylator agents such as MBD2), transfecting the cell with one or more expression vector(s) containing at least one cDNA encoding a neurogenic transcription factor (for example, Msi1 or Ngn2), using an appropriate medium for the desired cell of a different type and an appropriate differentiation medium to induce differentiation commitment of the desired cell of a different type, inhibiting repressive pathways that negatively affects induction into commitment the desired cell of a different type, growing the cells on an appropriate substrate for the desired cell of a different type (for example, laminin for NSLCs or a low-bind surface for culturing floating neurospheres), and
  • the method of transforming a cell of a first type into a cell of a second different type may comprise additional facultative steps.
  • the method of transforming a cell further comprises the step of pretreating the cell of a first type with a cytoskeleton disruptor.
  • cytoskeleton refers to the filamentous network of F-actin, Myosin light and heavy chain, microtubules, and intermediate filaments (IFs) composed of one of three chemically distinct subunits, actin, tubulin, or one of several classes of IF protein.
  • cytoskeleton disruptor refers to any molecules that can inhibit the cell cytoskeleton to destabilize the cell and consequently remove the feedback mechanisms between the cell's shape and cellular and nuclear function.
  • Suitable cytoskeleton disruptor according to the invention include, but are not limited to, the cytochalasin family of actin cytoskeleton inhibitors, such as Cytochalasin B or D, and myosin inhibitors such as 2,3-butanedione monoxime. Such pretreatment may boost reprogramming.
  • the cell is cultured in the presence of at least one cytoskeleton inhibitor one day before, during, or after introducing a neurogenic transcription factor(s).
  • Placing the cell in conditions in conditions for supporting the transformation of the desired cell, and/or maintaining the cell in culture conditions supporting the transformation of the desired cell may comprises culturing the cell in a media comprising one or more factors appropriate for inducing the expression of the morphological and functional characteristics of the desired desired cell of a different type.
  • the one or more factors are reprogramming factors helpful in reprogramming a cell and these reprogramming factors can be used alone or in combinations.
  • the step of culturing the cell in a media comprising one or more factors appropriate for inducing the expression of the morphological and functional characteristics of the desired cell of a different type is carried out subsequently or simultaneously to steps iii) or iv), or subsequently or simultaneously to steps 1) or 2), as defined hereinbefore.
  • the reprogramming factor is selected according to TABLE B.
  • reprogramming factors have one or more of the following functions: decrease the expression of one or more markers of the first type of cell and/or increase the expression of one or more markers of the desired cell. Cells that exhibit a selectable marker for the desired cell are then selected and assessed for unipotency, multipotency, pluripotency, or similar characteristics (as appropriate).
  • the cells are cultured in serum-free medium before, during or after any one of steps i) to iv) as defined hereinbefore, or during or after steps 1) or 2), as defined hereinbefore.
  • NSCs Neural Stem-Like Cells
  • the methods of the invention are carried out such that cells are treated with selected agents, compounds and factors to promote the reprogramming and/or dedifferentiation towards Stem-Like Cells (SLCs).
  • SLCs Stem-Like Cells
  • NSLCs Neural Stem-Like Cells
  • NSLCs have the potential to differentiate to neuronal-like and/or glial-like cells, as well as neuronal and/or glial cells, for potential treatment of neurological diseases and injuries such as Parkinson's disease and spinal cord injury.
  • the methods described herein are also useful for producing histocompatible cells for cell therapy.
  • some aspects of the present invention relates to generating neurons from an individual patient, thus making autologous transplantations possible as a treatment modality for many neurological conditions including neurotrauma, stroke, neurodegenerative diseases such as Multiple Sclerosis, Parkinson's disease, Huntington disease, Alzheimer's diseases.
  • the invention provides for neurological therapies to treat the disease or trauma of interest.
  • NSC Neural Stem-Like Cell
  • the step 1) comprises increasing intracellular levels of a MUSASHI1 polypeptide.
  • this can be achieved by different means including, but not limited to, transient expression of the MUSASHI1 polypeptide, preferably by transfecting an expression vector encoding the polypeptide.
  • the step 2) comprises increasing intracellular levels of a MBD2 polypeptide or treating the cells with VPA and 5-AZA.
  • this can be achieved by different means including, but not limited to, transient expression of the MBD2 polypeptide, preferably by transfecting an expression vector encoding the polypeptide(s), and/or pre-treating and/or treating the cells with VPA and 5-AZA.
  • reprogramming a cell of a first type to another type of cell that exhibits at least two selectable markers for neural stem cells requires transfecting the cell of a first type with one vector containing a cDNA encoding for a neurogenic transcription factor and one DNA demethylator.
  • the cells are exposed or pre-exposed to an agent(s) that inhibits DNA methylation, inhibits histone deacetylation, and/or disrupts the cell cytoskeleton.
  • the dedifferentiation can be enhanced by pre-treating the cells with an agent that disrupts the cell cytoskeleton followed by transfecting the cells with one or more vector(s) containing two neurogenic transcription factors in the presence of a DNA demethylator and/or inhibitor of DNA methylation and histone deacetylation.
  • the histone deacetylator, inhibitor of histone deacetylation, DNA demethylator, and/or an inhibitor of DNA methylation are as defined previously.
  • the method may further comprise a preliminary step of pre-treating the cell of a first type with a cytoskeleton disruptor, as defined previously, and/or culturing the cell in a media comprising one or more reprogramming factors appropriate for appearance and maintenance of the morphological and functional characteristics of NSLCs as defined previously (e.g. a retinoid compound, a neurotrophic factor, bFGF, EGF, SHH, Wnt 3a, neuropeptide Y, Estrogen).
  • the method further comprises inhibiting cellular BMP signaling pathways (e.g. by NOGGIN, fetuin, or follistatin).
  • generation of a NSLC from a first cell comprises the use of one or more reprogramming agents.
  • Suitable agents include, but are not limited to, Musashi-1 (Msi1) and Neurogenin 2 (Ngn2). Other potential agents are listed in Table A and B.
  • the present invention is also directed to the use of DNA expression vectors encoding a protein or transcript which upregulates the expression of neurogenesis.
  • the genetically-engineered DNA sequence, encoding a defined reprogramming agent such as Msi1 and Ngn2 can be introduced into cells by using a mono-, bi-, or poly-cistronic vectors.
  • the expression of an endogenous multipotency gene indicates that the cDNA encodes a protein whose expression in the cell result directly or indirectly in the de-differentiation of the cell.
  • the newly de-differentiated mammalian cells are capable of re-differentiating to neuronal lineages to regenerate said mammalian cells, tissues, and organs.
  • the present invention is further directed to a method for generating NSLCs by introducing a genetically-engineered DNA sequence into human somatic cells via transient transfection. Since the DNA introduced in the transfection process is not inserted into the nuclear genome, the foreign DNA decreases over time and when the cells undergo mitosis. Nonviral vectors remain in a non-replicative form, have low immunogenicity, and are easy and safe to prepare and to use. Furthermore, plasmids may accommodate large fragments of DNA.
  • the method starts with obtaining cells from the individual, and reprogramming the cells in vitro to generate NSLCs.
  • the significant aspect of the present invention is the stable reprogramming of a somatic cell or non-neuronal cell into a NSLC that can give rise to different types of, neuronal or glial cells (including neuronal-like or glial-like cells). These can then be implanted back into the same patient from which the cells were obtained, thus making an autologous treatment modality for many neurological conditions including neurotrauma, stroke, and neurodegenerative disease possible. These can also be implanted into a different individual from which the cells were obtained.
  • the cells and methods of the present invention may be helpful to treat, prevent, or to stabilize a neurological disease such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, or spinal cord injury.
  • a neurological disease such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, or spinal cord injury.
  • This technology provides an ample source of neural stem cells, neuro-progenitor cells, neurons and glia for clinical treatment, which can be performed by implantation of NSLCs in vivo or inducing the differentiation in vitro and implantation of neuro-progenitor cells or specific neurons or glia in vivo.
  • the method comprises isolating somatic or non-neuronal cells and exposing the cells to one or more agents that alter cell morphology and chromatin structure, and transfecting the cells with one or more genes containing at least one cDNA encoding for a neurogenic transcription factor.
  • the gene transfection step may be replaced with alternative agents that induce the expression of the neurogenic transcription factor(s) in the cell.
  • Inducing epigenetic modifications to DNA and histones (especially DNA demethylation and an open chromatic structure) facilitate true reprogramming of the cells.
  • the cells are incubated in a low oxygen environment, for example 5% O 2 , thereby helping in reprogramming the cells.
  • This methodology allows the reprogramming of a cell into a NSLC.
  • the further course of development and the expansion of the reprogrammed cell depend on the in situ environment cues to which it is exposed.
  • the embodiments of the invention further include growing the reprogrammed cell in an appropriate proliferation medium to expand the generated NSLC, for example Neural Progenitor proliferation Medium (StemCell Technologies) with the presence of epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF), to promote the neural stem cell to proliferate.
  • an appropriate proliferation medium for example Neural Progenitor proliferation Medium (StemCell Technologies) with the presence of epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF), to promote the neural stem cell to proliferate.
  • EGF epidermal growth factor
  • bFGF basic fibroblast growth factor
  • the NSLCs obtained according to the invention can be differentiated into neuronal, astrocyte, and/or oligodendrocyte lineages in appropriate differentiation medium, for example NS-A differentiation medium (StemCell, Technologies) or NbActive medium (BrainBitsTM) including a retinoid compound, such as all-trans-retinoic acid or vitamin A, and BDNF, to induce the differentiation of NSLCs towards neuronal and/or glial cells.
  • NS-A differentiation medium Stein Cell, Technologies
  • NbActive medium Neuronal cells include cells that display one or more neural-specific morphological, physiological, functional and/or immunological features associated with a neuronal cell type.
  • Useful criteria features includes: morphological features (e.g., long processes or neurites), physiological and/or immunological features such as expression of a set of neuronal-specific markers or antigens, synthesis of neurotransmitter(s) such as dopamine or gamma aminobutyric acid (GABA), and functional features such as ion channels or action potentials characteristic of neurons.
  • morphological features e.g., long processes or neurites
  • physiological and/or immunological features such as expression of a set of neuronal-specific markers or antigens
  • synthesis of neurotransmitter(s) such as dopamine or gamma aminobutyric acid (GABA)
  • functional features such as ion channels or action potentials characteristic of neurons.
  • reprogrammed cells can be selected based on differential adherence properties as compared to untransfected cells; for example, reprogrammed cells can form floating neurospheres or grow well on laminin while untransfected fibroblasts attach and grow well on regular cell culture treated plates.
  • Reprogrammed cells include cells that exhibit one or more neural stem specific markers and morphology and the loss of some or all of the specific markers related to the original cells.
  • some of the functionality of the neural-like cells (NLCs) can be assessed at different time points by, for example, patch-clamping, immunostaining for synaptophysin and MAP2b, and by immunochemical means such as by enzyme-linked immunosorbent assay (ELISA).
  • ELISA enzyme-linked immunosorbent assay
  • the present invention provides NSLCs that are able to initiate and direct central nervous system regeneration at a site of tissue damage and can be customized for individual patients using their own cells as the donor or starting cell.
  • the present invention can be used to generate cells from an individual patient, thus making autologous transplantations possible as a treatment modality for many neurological conditions.
  • this technology eliminates the problems associated with transplantations of non-host cells, such as, immunological rejection and the risk of transmitted disease.
  • the great advantage of the present invention is that it provides an essentially limitless supply for autologous grafts suitable for transplantation. Therefore, it will obviate some significant problems associated with current source of materials and methods of transplantation.
  • the invention concerns the use of polynucleotides, e.g. a polynucleotide encoding a MBD2 polypeptide, a MUSASHI1 polypeptide and/or a Ngn2 polypeptide.
  • a polynucleotide encoding a MBD2 polypeptide, a MUSASHI1 polypeptide and/or a Ngn2 polypeptide Means for introducing polynucleotides into a cell are well known in the art. Transfection methods of a cell such as nucleofection and/or lipofection, or other types of transfection methods may be used. For instance a polynucleotide encoding a desired polypeptide can be cloned into intermediate vectors for transfection in eukaryotic cells for replication and/or expression.
  • Intermediate vectors for storage or manipulation of the nucleic acid or production of protein can be prokaryotic vectors, (e.g., plasmids), shuttle vectors, insect vectors, or viral vectors for example.
  • a desired polypeptide can also be encoded by a fusion nucleic acid.
  • a cloned nucleic acid is typically subcloned into an expression vector that contains a promoter to direct transcription.
  • Suitable bacterial and eukaryotic promoters are well known in the art and described, e.g., in Sambrook and Russell (Molecular Cloning: a laboratory manual, Cold Spring Harbor Laboratory Press).
  • the promoter used to direct expression of a nucleic acid of choice depends on the particular application. For example, a strong constitutive promoter is typically used for expression and purification. In contrast, when a dedifferentiation protein or compound is to be used in vivo, either a constitutive or an inducible promoter or compound is used, depending on the particular use of the protein.
  • a weak promoter can be used, such as HSV TK or a promoter having similar activity.
  • the promoter typically can also include elements that are responsive to transactivation, e.g., hypoxia response elements, Ga14 response elements, lac repressor response element, and small molecule control systems such as tet-regulated systems and the RU-486 system.
  • an expression vector typically contains a transcription unit or expression cassette that contains additional elements required for the expression of the nucleic acid in host cells, either prokaryotic or eukaryotic.
  • a typical expression cassette thus contains a promoter operably linked, e.g., to the nucleic acid sequence, and signals required, e.g., for efficient polyadenylation of the transcript, transcriptional termination, ribosome binding, and/or translation termination. Additional elements of the cassette may include, e.g., enhancers, and heterologous spliced intronic signals.
  • Expression vectors containing regulatory elements from eukaryotic viruses are often used in eukaryotic expression vectors, e.g., SV40 vectors, papilloma virus vectors, and vectors derived from Epstein-Barr virus.
  • eukaryotic vectors include pMSG, pAV009/A+, pMT010/A+, pMAMneo-5, baculovirus pDSVE, and any other vector allowing expression of proteins under the direction of the SV40 early promoter, SV40 late promoter, metallothionein promoter, murine mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter, or other promoters shown effective for expression in eukaryotic cells.
  • Standard transfection methods can be used to produce bacterial, mammalian, yeast, insect, or other cell lines that express large quantities of dedifferentiation proteins, which can be purified, if desired, using standard techniques. Transformation of eukaryotic and prokaryotic cells is performed according to standard techniques.
  • Any procedure for introducing foreign nucleotide sequences into host cells can be used. These include, but are not limited to, the use of calcium phosphate transfection, DEAE-dextran-mediated transfection, polybrene, protoplast fusion, electroporation, lipid-mediated delivery (e.g., liposomes), microinjection, particle bombardment, introduction of naked DNA, plasmid vectors, viral vectors (both episomal and integrative) and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (see, e.g., Sambrook et al., supra). It is only necessary that the particular genetic engineering procedure used be capable of successfully introducing at least one gene into the host cell capable of expressing the protein of choice.
  • Non-viral vector delivery systems include DNA plasmids, naked nucleic acid, and nucleic acid complexed with a delivery vehicle such as a liposome.
  • Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell.
  • nucleic acids include lipofection, microinjection, ballistics, virosomes, liposomes, immunoliposomes, polycation or lipid-nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA.
  • Lipofection reagents are sold commercially (e.g., TransfectamTM and LipofectinTM). Cationic and neutral lipids suitable for efficient receptor-recognition lipofection of polynucleotides are known.
  • Nucleic acid can be delivered to cells (ex vivo administration) or to target tissues (in vivo administration). The preparation of lipid:nucleic acid complexes, including targeted liposomes such as immunolipid complexes, is well known to those of skill in the art.
  • RNA or DNA virus-based systems for the delivery of nucleic acids take advantage of highly evolved processes for targeting a virus to specific cells in the body and trafficking the viral payload to the nucleus.
  • Viral vectors can be administered directly to patients (in vivo) or they can be used to treat cells in vitro, wherein the modified cells are administered to patients (ex vivo).
  • Conventional viral based systems for the delivery include retroviral, lentiviral, poxviral, adenoviral, adeno-associated viral, vesicular stomatitis viral and herpesviral vectors, although integration in the host genome is possible with certain viral vectors, including the retrovirus, lentivirus, and adeno-associated virus gene transfer methods, often resulting in long term expression of the inserted transgene. Additionally, high transduction efficiencies have been observed in many different cell types and target tissues.
  • pLASN and MFG-S are examples of retroviral vectors that have been used in clinical trials.
  • adenoviral-based systems are useful.
  • Adenoviral based vectors are capable of very high transduction efficiency in many cell types and are capable of infecting, and hence delivering nucleic acid to, both dividing and non-dividing cells. With such vectors, high titers and levels of expression have been obtained.
  • Adenovirus vectors can be produced in large quantities in a relatively simple system.
  • Gene therapy vectors can be delivered in vivo by administration to an individual patient, typically by systemic administration (e.g., intravenous, intraperitoneal, intramuscular, subdermal, or intracranial infusion) or topical application.
  • vectors can be delivered to cells ex vivo, such as cells explanted from an individual patient (e.g., lymphocytes, bone marrow aspirates, tissue biopsy) or universal donor hematopoietic stem cells, followed by reimplantation of the cells into a patient, usually after selection for cells which have been reprogrammed.
  • Ex vivo cell transfection for diagnostics, research, or for gene therapy (e.g., via re-infusion of the transfected cells into the host organism) is well known to those of skill in the art.
  • cells are isolated from the subject organism, transfected with a nucleic acid (gene or cDNA), and re-infused back into the subject organism (e.g., patient).
  • a nucleic acid gene or cDNA
  • Various cell types suitable for ex vivo transfection are well known to those of skill in the art.
  • Vectors e.g., retroviruses, adenoviruses, liposomes, etc.
  • therapeutic nucleic acids can be also administered directly to the organism for transfection of cells in vivo.
  • naked DNA can be administered.
  • Administration is by any of the routes normally used for introducing a molecule into ultimate contact with blood or tissue cells. Suitable methods of administering such nucleic acids are available and well known to those of skill in the art, and, although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route.
  • compositions are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition.
  • an alternative possibility consists of bypassing the use of a polynucleotide and contacting a cell of a first type cell directly with a compound (e.g. a polypeptide) for which an increased intracellular level is desired.
  • a compound e.g. a polypeptide
  • the cells are cultured in a medium containing one or more functional polypeptides.
  • polypeptides have the ability to traverse the plasma membrane of a cell, or the membrane of an intra-cellular compartment such as the nucleus.
  • Cellular membranes are composed of lipid-protein bilayers that are freely permeable to small, nonionic lipophilic compounds and are inherently impermeable to polar compounds, macromolecules, and therapeutic or diagnostic agents.
  • proteins, lipids and other compounds, which have the ability to translocate polypeptides across a cell membrane have been described.
  • membrane translocation polypeptides have amphiphilic or hydrophobic amino acid subsequences that have the ability to act as membrane-translocating carriers.
  • Polypeptides for which an increased intracellular level is desired according to the invention can be linked to suitable peptide sequences for facilitating their uptake into cells.
  • suitable chemical moieties that provide enhanced cellular uptake can also be linked, either covalently or non-covalently, to the polypeptides.
  • suitable carriers having the ability to transport polypeptides across cell membranes may also be used.
  • a desired polypeptide can also be introduced into an animal cell, preferably a mammalian cell, via liposomes and liposome derivatives such as immunoliposomes.
  • liposome refers to vesicles comprised of one or more concentrically ordered lipid bilayers, which encapsulate an aqueous phase.
  • the aqueous phase typically contains the compound to be delivered to the cell.
  • the invention encompasses the cells, cell lines, stem cells and purified cell preparations derived from any of the methods described herein.
  • the cells, cells lines, stem cells and purified cells preparations of the invention are of mammalian origins, including but not limited to human, primates, rodent, dog, cat, horse, cow, or sheep. In preferred embodiments, they originate from a human.
  • another aspect of the invention relates to modified cells, cell lines, pluripotent, multipotent or unipotent cells and purified cell preparations, wherein any of these cells comprise an exogenous polynucleotide encoding Musashi1 (Msi1); Msi1 and Ngn2; Msi1 and MBD2; and Ngn2 and MBD2; Msi1, Ngn2 and MBD2; Msi1, Ngn2, Nestin and MBD2; and other potential combinations from Table A preferably including Msi1 and Ngn2 and MBD2.
  • the cell according to the invention is a stem-like cell, more preferably a Neural Stem-Like Cell (NSLC), the cell possessing one or more of the following characteristics:
  • NSLC Neural Stem-Like Cell
  • a NSLC according to the inventions possesses all of the following characteristics:
  • the reprogrammed cells (NSLCs) according to the invention are capable of proliferating for several months without losing their neural stem cell markers and their ability to differentiate towards neuron-like, astrocyte-like, and oligodendrocyte-like cells.
  • the generation of the neural lineages is characterized based on morphology, phenotypic changes and functionality.
  • the cells of the invention may have one or more of the following characteristics and properties: self-renewal, multilineage differentiation in vitro and in vivo, clonogenicity, a normal karyotype, extensive proliferation in vitro under well defined culture conditions, and the ability to be frozen and thawed, as well as any of the commonly known and/or desired properties or characteristics typical of stem cells.
  • the cells of the invention may further express molecular markers of multipotent or pluripotent cells (i.e. gene and surface markers as defined previously).
  • tissue specific autologous (self) stem and/or progenitor cells may be used in cell therapy applications to treat diseases of cellular degeneration.
  • Diseases of cellular degeneration include, for example, neurodegenerative diseases such as stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis, Amyotrophic lateral sclerosis, macular degeneration, osteolytic diseases such as osteoporosis, osteoarthritis, bone fractures, bone breaks, diabetes, liver injury, degenerative diseases, myocardial infarct, burns and cancer. It is envisioned that cells according to the invention may be implanted or transplanted into a host.
  • An advantage of the invention is that large numbers of autologous stem cells can be produced for implantation without the risk of immune system mediated rejection. Those cells can lead to production of tissue suitable for transplant into the individual. Since the tissue is derived from the transplant recipient, it should not stimulate an immune response, as would tissue from an unrelated donor.
  • Such transplants can constitute tissues (e.g. vein, artery, skin, muscle), solid organ transplants (e.g., heart, liver, kidney), neuronal cell transplants, or bone marrow transplants such as are used in the treatment of various malignancies such as, for example, leukemias and lymphomas.
  • Neural stem cell, neuroprogenitor, or neuronal cell (as well as NSLCs and derivations thereof) transplants can also be used in the treatment of, for example, neurological disorders, stroke, spinal cord injury, Parkinson's disease, and the like, as well as potentially some non-neurological disorders such as a cardiac infarct.
  • Another aspect of the invention relates to a method to produce ex vivo engineered tissues for subsequent implantation or transplantation into a host, wherein the cellular components of those engineered tissues comprise cells according to the invention, or cells derived therefrom.
  • expanded cultures of the cells of the invention may be differentiated by in vitro treatment with growth factors and/or morphogens. Populations of differentiated cells are then implanted into the recipient host near the site of injury or damage, or cultured in vitro to generate engineered tissues, as described.
  • the methods and cells of the invention described herein can be used to immortalize cells, for example to generate a cell line.
  • a somatic cell can be transformed into one possessing a dedifferentiated phenotype, thereby facilitating the generation of cell lines from a variety of tissues. Therefore, the invention encompasses such immortalized cells.
  • the methods of deriving the cells according to the invention may be helpful in scientific and therapeutic applications including, but not limited to, (a) scientific discovery and research involving cellular development and genetic research (e.g. uses in lieu of human stem cells as a model cell line to study the differentiation, dedifferentiation, or reprogramming of human cells), (b) drug development and discovery (e.g., screening for efficacy and toxicity of certain drug candidates and chemicals, screening for prospective drugs or agents which mediate the differentiation, dedifferentiation, or reprogramming of cells), (c) gene therapy (e.g., as a delivery device for gene therapy), and (d) treatment of injuries, trauma, diseases and disorders including, but not limited to, Parkinson's, Alzehimer's, Huntington's, Tay-Sachs, Gauchers, spinal cord injury, stoke, burns and other skin damage, heart disease, diabetes, Lupus, osteoarthritis, liver diseases, hormone disorders, kidney disease, leukemia, lymphoma, multiple sclerosis
  • Additional aspects concern therapeutic methods, methods of treatment and methods of regenerating a tissue or organ in a mammal (e.g. a human subject).
  • One particular method concerns a method of regenerating a mammalian tissue or organ which comprises contacting the tissue or organ to be regenerated with a SLC, NSLC, or other desired cell or artificial tissue construct as defined herein.
  • the SLC, NSLC, desired cell or artificial tissue construct may be placed in proximity to the tissue or organ to be regenerated by administering to the subject using any suitable route (e.g. injecting the cell intrathecally, directly into the tissue or organ, or into the blood stream).
  • Another method for repairing or regenerating a tissue or organ in a subject in need thereof comprises administering to the subject a compound inducing a direct or indirect endogenous expression of at least one gene regulator in cells of the tissue or organ and/or a compound inducing a direct or indirect endogenous expression of at least one gene regulator in cells capable of transformation or dedifferentiation in vivo in the subject.
  • the expression of the at least one gene regulator reprograms the cells into desired cells of a different type (e.g. neural stem-like cells), and these cells of a different type are effective in repairing or regenerating said tissue or organ.
  • Another method comprises obtaining cells or tissue from a patient (e.g. hematopoietic stem cells, fibroblasts, or keratinocytes), reprogramming a plurality of such cells or the tissue, and reintroducing the reprogrammed cells or tissue into the patient.
  • a related aspect concerns pharmaceutical compositions comprising a plurality of a desired cell, SLC and/or Neural Stem-Like Cell (NSLC) or reprogrammed tissue as defined herein.
  • the therapeutic methods of the invention may be applicable to the regeneration or repair of various tissues and organs including, but not limited to, the brain, the spine cord, the heart, the eye, the retina, the cochlea, the skin, muscles, intestines, pancreas (including beta cells), kidney, liver, lungs, bone, bone marrow, cartilage, cartilage discs, hair follicles, teeth, blood vessels, glands (including endocrine and exocrine glands), ovaries, reproductive organs, mammary and breast tissue.
  • various tissues and organs including, but not limited to, the brain, the spine cord, the heart, the eye, the retina, the cochlea, the skin, muscles, intestines, pancreas (including beta cells), kidney, liver, lungs, bone, bone marrow, cartilage, cartilage discs, hair follicles, teeth, blood vessels, glands (including endocrine and exocrine glands), ovaries, reproductive organs, mammary and breast tissue.
  • a related aspect concerns pharmaceutical compositions comprising a plurality of desired cell, SLC and/or Neural Stem-Like Cell (NSLC) as defined herein.
  • Another aspect of the invention relates to a tissue containing reprogrammed cells as defined herein that can be implanted into a subject in need thereof.
  • the present invention provides for the reprogramming of cells within a tissue, for example an in vitro produced 3D tissue construct comprising cells and extracellular matrix produced by these cells.
  • a tissue for example an in vitro produced 3D tissue construct comprising cells and extracellular matrix produced by these cells.
  • transfected cells can be seeded on top of these 3D tissue constructs that can be made completely autologously, thus preventing host rejection, making it completely immunocompatible and as carrier for reprogrammed cells to be transplanted in vivo.
  • these newly created cells can be used in their undifferentiated and/or differentiated state within these tissues for in vitro diagnostic purposes or transplanted into a patient in need of such a construct in cell therapy/tissue replacement approaches.
  • the invention further encompasses 3D Neuronal-Like multilayer tissue.
  • Cells within CDM reprogrammed to Neural Stem-Like Cells according to the invention readily differentiate into neuronal-like cells, astrocyte-like cells, and oligodendrocyte-like cells within the CDM. It is thus possible to use CDM and reprogramming methods of the invention to reprogram the cells within the CDM to form 3D Neuronal-Like multilayer tissue (up to >30 cell layers).
  • Such 3D tissue comprises neurons (or specifically, neuron-like cells), astrocytes (or specifically, astrocyte-like cells), and oligodendrocytes (or specifically, oligodendrocyte-like cells) and it can be made completely autologously, can be manually handled and implanted with relative ease, or can used as an in vitro CNS tissue model.
  • One particular aspect concerns an artificial tissue construct which comprises a 3D assembly of in vitro cultured cells and extracellular matrix produced by these cells.
  • the cells may be desired cells, SLC and/or a plurality of Neural Stem-Like Cell (NSLC) obtained using any one of the methods described herein.
  • NSLC Neural Stem-Like Cell
  • Another aspect of the invention relates to methods for identifying new compounds (e.g. small molecules, drugs, etc) capable of transforming a cell of a first type to a desired cell of a different type.
  • new compounds e.g. small molecules, drugs, etc
  • These new compounds may be usefull for research purposes or as medicaments for use in repairing or regenerating tissues in a subject.
  • a candidate compound to be tested e.g. a library of small molecules or compounds
  • Individual or mixture of active compounds would be selected if they have the same activity and/or if they can provide the same or similar effects as these polypeptides (e.g. cell transformation and/or appearance of any desirable markers or desirable characteristics as defined hereinbefore).
  • a compound or mixture of compounds capable of transforming a fibroblast into a NSLC could be identified by:
  • stem-like cells including pluripotent-like cells, mesendoderm-like cells, pancreatic progenitor-like cells, etc.
  • Tables A and B, and the Examples section provides, for each of these types of cells, a list of potential genes and/or compounds to be considered in such screening methods.
  • the present invention encompasses these and any equivalent screening methods where candidate compounds are tested for their efficacy in transforming a cell of a first type to a desired cell of a different type when compared to the efficacy of the reprogramming factor and/or gene regulator as defined herein.
  • a related aspect of the invention relates to overcoming these problems by using NSLC cells and cell lines according to the invention which can stably express and secrete growth factors of potential interest after transplantation.
  • the present invention provides a plentiful source of Neural Stem-Like Cells, Neuron-Like Cells, Astrocyte-Like Cells or Oligodendrocyte-Like Cells for potential clinical treatments which require transplantation of neural stem cells, neurons, astrocytes or oligodendrocytes 1) to compensate for a loss of host cells (ex. neurons) or 2) as vehicles to deliver genetically-based drugs. Further, the invention provides a novel neurological tool for use in basic research and drug screening.
  • NSCs Neural Stem-Like Cells
  • exemplary protocols for obtaining Reprogrammed and Dedifferentiated cells, including Neural Stem-Like Cells (NSLCs). Also provided are exemplary protocols, molecular tools, probes, primers and techniques.
  • HFF Human Foreskin fibroblast
  • DMEM Dulbecco's Modified Eagle's Medium
  • FCS heat-inactivated fetal calf serum
  • FCS Hyclone Laboratories
  • Cells were trypsinized using Trypsin 0.25% for 4 minutes at 37° C., followed by adding trypsin inhibitor solution, pelleting the cells by centrifugation, washing the cells once with PBS, and plating the cells at a ratio of 1:2 onto tissue culture flasks until a suitable number of cells was reached.
  • CDM I Medium consisting of a 3:1 ratio of Dulbecco's modified Eagle medium (DMEM, high glucose (4.5 g/L) with L-glutamine and sodium pyruvate) and Ham's F-12 medium supplemented with the following components: EGF (4.2 ⁇ 10 ⁇ 1 ° M), bFGF (2.8 ⁇ 10 ⁇ 1 ° M), ITS (8.6 ⁇ 10 ⁇ 5 M), dexamethasone (1.0 ⁇ 10 ⁇ 7 M), L-3,3′,5-triiodothyronine (2.0 ⁇ 10 ⁇ 1 ° M), ethanolamine (10 ⁇ 4 M), GlutaMAXTM (4 ⁇ 10 ⁇ 3 M), and glutathione (3.3 ⁇ 10 ⁇ 6 M), but without the presence of L-ascorbic acid.
  • DMEM Dulbecco's modified Eagle medium
  • bFGF 2.8 ⁇ 10 ⁇ 1 ° M
  • ITS 8.6 ⁇ 10 ⁇ 5 M
  • dexamethasone 1.0 ⁇ 10
  • CDM II Medium consisting of a 3:1 ratio of Dulbecco's modified Eagle medium (DMEM, high glucose (4.5 g/L) with L-glutamine and sodium pyruvate) and Ham's F-12 medium supplemented with the following components: EGF (2.5 ng/ml), bFGF (10 ng/ml), ethanolamine (2.03 mg/ml), insulin (10 mg/ml), Selenious acid (2.5 ⁇ g/ml), dexamethasone (19.7 ⁇ g/ml), L-3,3′,5-triiodothyronine (675 ng/ml), GlutaMAXTM (4 ⁇ 10 ⁇ 3 M), and glutathione (3.3 ⁇ 10 ⁇ 6 M).
  • DMEM Dulbecco's modified Eagle medium
  • bFGF 10 ng/ml
  • ethanolamine 2.03 mg/ml
  • insulin 10 mg/ml
  • Selenious acid 2.5 ⁇ g/ml
  • dexamethasone (19
  • NPBM Neural Progenitor Basal Medium
  • Noggin (20 ng/ml, Peprotech
  • EGF (20 ng/ml, Peprotech)
  • bFGF 20 ng/ml, Peprotech
  • reprogrammed cells Visual observation of reprogrammed cells was performed by light microscopic observation every day following transfection using bright field at 10 ⁇ magnification. Samples were collected at different time points (6, 12, and 20 days) to analyze neuronal gene expression and protein levels by gene array and immunohistochemistry. Following transfection, reprogramming cells displayed a rapid change in cellular morphology within 3 days post-transfection ( FIG. 1 ). The cells were more rounded and the cell's cytoplasm retracted towards the nucleus forming contracted cell bodies with extended cytoplasmic extensions and exhibiting neuronal perikaryal appearance at day 6 and 12, which was maintained until day 20. However, this morphology was not observed in untransfected cells at day 6 and 12.
  • Characterization of the newly engineering cells after transfection was performed using a neuronal gene-array containing 48 partial cDNAs coding for these genes and controls.
  • TLDA TaqmanTM low-density array
  • TLDA TaqmanTM low-density array
  • Each 2 ⁇ l well contains specific, user-defined primers and probes, capable of detecting a single gene.
  • a customized Neuronal Markers 2 TLDA was configured into eight identical 48-gene sets, i.e. 1 loading port for each 48-gene set. Genes were chosen based on literature.
  • Each set of 48 genes also contains three housekeeping genes: ACTIN, GAPDH, and PPIA.
  • a sample-specific master mix was made for each sample by mixing cDNA (160 ng for each loading port), 2 ⁇ TaqmanTM Gene Expression Master Mix (Applied Biosystems) and nuclease-free water (USB) for a total of 100 ⁇ l per loading port. After gentle mixing and centrifugation, the mixture was then transferred into a loading port on a TLDA card. The array was centrifuged twice for 1 minute each at 1200 rpm to distribute the samples from the loading port into each well. The card was then sealed and PCR amplification was performed using Applied Biosystems 7900HTTM Fast Real-time PCR system. Thermal cycler conditions were as follows: 2 minutes at 50° C., 10 minutes at 94.5° C., and 30 seconds at 97° C., 1 minute at 59.7° C. for 40 cycles. 1 TLDA's was prepared for 8 samples.
  • Relative Expression values were calculated using the Comparative C T method. Briefly, this technique uses the formula 2 ⁇ CT to calculate the expression of target genes normalized to a calibrator.
  • the threshold cycle (C T ) indicates the cycle number at which the amount of amplified target reaches a fixed threshold. C T values range from 0 to 40 (the latter representing the default upper limit PCR cycle number that defines failure to detect a signal).
  • oligodendrocyte gene expression allowed identification of the majority of the genes that are differentially expressed in reprogrammed cells. Data in Table 1 were analyzed by using a significance analysis algorithm to identify genes that were reproducibly found to be enriched in reprogrammed cells compared to untransfected cells. After the transfection with Msi1 or Ngn2 in the presence of MBD2, the expression of oligodendrocytes progenitors such as NKx2.2, olig2, and MAG and two markers for astrocytes (GFAP and AQP4) were highly increased. Also, several markers of early neuronal cells were enhanced after the transfection of HFF.
  • TDLA data revealed a remarkable increase in specific markers for interneurons, such as somatostatin and calbindin1.
  • DCX Doublecortin
  • ACHE acetylcholine
  • Transfection increased the expression of dihydropyrimidinase-like 3 (DPYSL3), an early marker of newborn neurons, to fivefold with Msi1 and seven fold with Ngn2.
  • MAP2 Microtubule-Associated Protein 2
  • GAP-43 growth associated protein
  • receptors for growth and neurotrophin factors were increased, such as type III receptor tyrosine kinase, neurotrophic tyrosine kinase, and neurotrophic tyrosine kinase receptor.
  • type III receptor tyrosine kinase a type III receptor tyrosine kinase
  • neurotrophic tyrosine kinase a type III receptor tyrosine kinase
  • neurotrophic tyrosine kinase receptor e.g., fibronectin, markers for fibroblasts
  • NCAM was present in cells during the 6 days post-transfection and increase at day 12 and 20 following differentiation, while the inverse pattern was observed for the nestin staining.
  • This study showed the ability to reprogram HFF cells using one neurogenic transcription factor with the presence of a DNA demethylator towards cells that expressed neuronal genes and proteins specific to neural stem cells and neuronal cells. These reprogrammed cells were stable in culture for at least 2 weeks.
  • HFF cells were cultured as described in Example I and plated in CDM I medium. Cells were transfected using the Amaxa NucleofectorTMTM Device (Lonza). The HFFs were harvested with TrypLETM (Gibco), resuspended in CDM Medium and centrifuged for 10 min at 90 ⁇ g (1 ⁇ 10 6 cells/tube). The supernatant was discarded and gently resuspended in 100 ⁇ l of Basic NucleofectorTM Solution (basic NucleofectorTM kit for primary mammalian fibroblasts, Lonza).
  • Basic NucleofectorTM Solution basic NucleofectorTM kit for primary mammalian fibroblasts, Lonza.
  • Each 100 ⁇ l of cell suspension was combined with a different mix of plasmid DNA (for example, sample 1 was mixed with 2 ⁇ g of pCMV6-XL5-Pax6 and 2 ⁇ g pCMV6-XL5-MBD2).
  • Cell suspension was transferred into an Amaxa certified cuvette and transfected with the appropriate program (U023).
  • the sample was transferred without any further resuspension into a coated culture plate with LAS-Lysine/Alanine (BrainBitsTM, 50 ⁇ g/ml) and the cells were incubated at 37° C., 5% CO 2 . These steps were repeated for each sample that was transfected. After 24 hours, the medium was changed to Proliferation Medium.
  • RNA isolation and quantification was performed as previously described in Example I.
  • cDNA was prepared using the High Capacity cDNA RT kit (Applied Biosystems) as per the manufacturer's instructions with a final cDNA concentration of 2 ng/ ⁇ l.
  • Real-time PCR was then performed for each gene of interest using the FAST PCR master mix (Applied Biosystems) and the TaqmanTM® Gene Expression Assays (Applied Biosystems) listed below:
  • the FAST 96-well reaction was performed with 8 ng cDNA per well in a 10 ⁇ l reaction with 40 cycles.
  • Thermal cycler conditions were as follows: 20 seconds at 95° C., and 1 second at 95° C., 20 seconds at 60° C. for 40 cycles.
  • Relative Expression values were calculated as previously described in Example I, except the Average of 2 Housekeeping genes (GAPDH & PPIA) was used for normalization instead of the Average of 3 Housekeeping genes. Identification of neuronal lineage genes was investigated following the transfection with three independent vectors containing Msi1, Ngn2, and Pax6.
  • mRNAs level of the tripotent-associated genes ⁇ III-tubulin, MAP2b, acetylcholine, and GFAP were undetectable in Pax6 transfected cells, indicating that Pax6 alone was not implicated in the reprogramming process toward neuronal lineage.
  • Cells were co-transfected with either of two DNA demethylators, MBD2 or GAdd45B, (e.g. 2 ⁇ 10 6 cells were transfected with pCMV6-XL5Msi1 (2 ⁇ g) and pCMV6-XL5-MBD2 (2 ⁇ g)).
  • Neural Proliferation Medium NeuroCultTM proliferation Kit, StemCell Technologies
  • DMEM/F12 1:1
  • glucose 0.8%
  • sodium bicarbonate 0.1%)
  • glutamine 20 mM
  • HEPES 5 mM
  • insulin 230 ⁇ g/ml
  • transferrin 100 ⁇ g/ml
  • progesterone 200 nM
  • putrescine 90 ⁇ g/ml
  • sodium selenite 300 nM
  • recombinant hFGF 20 ng/ml, Peprotech
  • recombinant hEGF 20 ng/ml, Peprotech
  • RT-PCR analysis showed that the relative expression of Sox2, nestin and GFAP was enhanced after transfecting the cells with the neurogenic transcription factors.
  • Table 3 transfecting the cells with one transcription factor Msi1 in the presence of Gadd45b was associated with up-regulation of relative expression of Sox2 (22.3 ⁇ 5.26) and GFAP (10.14 ⁇ 0.15) and the expression of the these genes was highly increase when transfecting the cells with Ngn2 by 20 fold and 10 fold respectively.
  • Combining the two neurogenic factors (Msi1 and Ngn2) with Gadd45b enhanced further the expression of Sox2 and GFAP.
  • Transfecting the cells with one transcription factor (Msi1 or Ngn2) in the presence of MBD2 was associated with up-regulation of relative expression of Sox2, Nestin, and GFAP and down-regulation of Col5A2, while co-transfection with Gadd45b did not increased the expression of nestin and the expression of Col5A2 was not regulated.
  • the enhancement of neural stem cells relative expression was observed when transfecting the cells with two neurogenic genes in combination with MBD2; a small increase in the expression was noticed in the presence of cytochalasin B under certain conditions.
  • Cells were co-transfected pCMV-Msi1-Ngn2 with different DNA demethylators (MBD1, MBD2, MBD3, MBD4, MeCP2, AICDA). Another assay was performed to assess the effect of nestin on the reprogramming efficiency; therefore cells were transfected with nestin individually or in combination with one vector containing one neurogenic factor (Msi1 or Ngn2) or both neurogenic factors in the presence of MBD2. Cells were cultured following transfection in the presence of proliferation medium supplemented with EGF (20 ng/ml), FGF (20 ng/ml), and Noggin (20 ng/ml) with and without VPA (1 mM) treatment for 12 days at 37° C., 5% CO 2 and 5% O 2 .
  • EGF EGF
  • FGF ng/ml
  • Noggin 20 ng/ml
  • Immunohistochemistry analysis revealed a small increase of immunopositive Sox2 cells (89.49 ⁇ 3.18) after co-transfecting the cells with nestin and Msi1/Ngn2 in the presence of MBD2 (Table 6).
  • HFF cells were cultured as described in Example I, and transfected using the NucleofectorTM® 96-well Shuttle® Device (Lonza) following procedure described in Example IV, except for the untreated HFF control and the untransfected HFF control (for determining the effect of the complete media & compound treatments on the cells).
  • the cells that had been pre-treated with VPA and 5-Aza and the untreated cells were transfected with the mixes of DNA as described in Table 7.
  • the cells were plated on Laminin-coated plates and incubated at 37° C., 5% CO 2 . Media was changed daily according to Table 7. Cells were analysed at day 3, 7, 12 by immunohistochemistry analysis and at Day 9 by gene array for multipotent and pluripotent gene expression.
  • Embryonic Stem Cell Markers OCT4* 1.04 0.38 7.27 0.81 6.26 0.05 6.63 0.51 3.15 0.58 OCT4 (5′UTR) 1.04 0.41 0.08 0.00 2.07 0.11 1.82 0.53 0.55 0.59 NANOG (5′UTR) 1.02 0.32 19.29 2.23 11.27 0.89 16.73 6.86 9.94 6.32 FBXO15* 1.05 0.46 2.58 0.45 3.57 0.23 5.89 1.22 1.13 0.39 ALPL* 1.03 0.33 0.57 0.73 652.20 46.60 194.23 10.82 13.04 4.04 SALL4* 1.02 0.25 9.20 1.35 9.76 0.62 15.84 0.92 2.35 0.55 NR0B1 (DAX1)* 1.01 0.19 18.62 4.70 2.64 0.11 11.59 3.17 0.06 0.00 Ectoderm Markers ZIC1* 1.01 0.24 2.01 0.25 1889.80 93.48 1158.21 80.43 156.40 12.64 SOX1* 1.00 0.01 2.05 0.06 1776.83 128.63
  • NS-A Differentiation Medium SteinCell Technologies
  • NbActive4 (BrainBitsTM) medium that were both supplemented with BDNF (20 ng/ml), NT-3 (20 ng/ml), NGF (20 ng/ml), Retinoic acid (5 ⁇ M), Noggin (20 ng/ml) and Forskolin (10 ⁇ M).
  • BDNF 20 ng/ml
  • NT-3 20 ng/ml
  • NGF 20 ng/ml
  • Retinoic acid (5 ⁇ M
  • Noggin 20 ng/ml
  • NS-A Differentiation Medium StemCell Technologies
  • NbActive4 BrainBits
  • CDM II CDM II medium
  • these first two were supplemented with the same cytokines as previously described but with the addition of Fgf-2 (20 ng/ml).
  • Fgf-2 was removed from the first two differentiation media while cells in the CDM II medium were switched to the NS-A Differentiation Medium (StemCell Technologies) supplemented with cytokines without Fgf-2.
  • media was changed every two to three days.
  • TUBB3 neuronal genes ⁇ III-tubulin (TUBB3) and Map2b were slightly elevated already from Day 2 onwards, but significantly increased on Day 5 onwards.
  • ACHE acetylcholine esterase
  • Sox2 was highly and early expressed which could then be directly or indirectly interact with the exogenous Msi/Ngn2 and/or other genes in the activation of Nestin, GFAP, and endogenous Msi1 and Ngn2 and other genes that promote the reprogramming and cell fate change, as well as the activation of neuronal genes like ⁇ III-tubulin (TUBB3), Map2b, and ACHE.
  • TUBB3 ⁇ III-tubulin
  • Map2b Map2b
  • ACHE ⁇ III-tubulin
  • HFF cells were cultured as described in Example I, and transfected using the NucleofectorTM® II Device (Lonza) as previously described in Example II or the NucleofectorTM® 96-well Shuttle® Device (Lonza).
  • the HFFs were harvested with TrypLETM (Gibco), and 1 ⁇ 10 6 cells/transfection with the NucleofectorTM® II Device for 10 min at 90 g and 6 ⁇ 10 5 cells/transfection with the NucleofectorTM® 96-well Shuttle® Device for 5 min at 80 ⁇ g.
  • each 100 ⁇ l of cell suspension was combined with 2 different mixes of plasmid DNA (sample 1 was mixed with 2 ⁇ g of pCMV6-XL5-Msi1 and 2 ⁇ g pCMV6-XL5-MBD2, and sample 2 with 2 ⁇ g of Msi1/Ngn2 and 2 ⁇ g pCMV6-XL5-MBD2).
  • Each cell suspension was transferred into an Amaxa certified cuvette and transfected with the appropriate program (U-023). Right after transfection, 900 ⁇ l of warm CDM1 medium was added to each cuvette and the sample was transferred into a culture plate coated with Laminin (Stemgent, 10 ⁇ g/ml) at a cell density of 1 ⁇ 10 5 to 1.5 ⁇ 10 5 cells per cm 2 or into non-cell culture treated Petri dishes for neurosphere formation. The cells were incubated at 37° C., 5% CO 2 overnight.
  • the steps described before were similar with the following exceptions: the cell suspension was mixed with 0.6 ⁇ g of each DNA of the same 2 DNA mixes, the cell suspension was transferred to a well of a 96-well NucleoplateTM (Lonza) and transfected with the program FF-130TM. After transfection, 80 ⁇ l of warm CDM1 medium was added to each well and the samples were left for 10 min in the incubator prior to being transferred into a laminin coated plate or non-cell culture treated Petri dishes at the same cell density as previously mentioned. For both devices, these steps were repeated for each sample that was transfected. Prior to transfection cells were cultured in CDM1 as described in Example I.
  • the medium was switched to a mix of 75% CDM medium and 25% Proliferation Medium which was supplemented with EGF (20 ng/ml), FGF-2 (20 ng/ml), Noggin (20 ng/ml) and Cytochalasin B (10 ⁇ g/ml) and the cells were incubated at 37° C., 5% CO 2 and 5% O 2 .
  • the medium was changed daily with an increased proportion of Neural proliferation medium up to 100% by Day 4 and a decreased proportion of Cytochalasin B that was completely omitted by Day 5.
  • Forskolin (10 ⁇ M) was added to the medium from Day 4 onwards.
  • the cells in floating conditions were pelleted by centrifugation and their medium changed daily as described for the adherent condition. Cells were collected at Day 3, 7, and 12 for immunohistochemistry analysis.
  • the highest percentage at Day 12 was obtained with Msi1/Ngn2 and pCMV6-XL5-MBD2 transfected with the NucleofectorTM® 96-well Shuttle® Device ( ⁇ 80%).
  • the same combination transfected with the NucleofectorTM® II yielded only ⁇ 35% positive cells.
  • the pCMV6-XL5-Musashi and pCMV6-XL5-MBD2 with the Shuttle® produced ⁇ 20% positive cells, while generally none were observed with the NucleofectorTM® II.
  • the percentage of positive cells varied strongly between wells. The staining indicated that the cell population was not homogenous, since fields of densely arranged Sox2 positive cells and complete fields with only negative cells could be found in all cases.
  • the Shuttle® was initially more toxic to cells than the NucleofectorTM® II, however at least in the case of Msi1/Ngn2 and pCMV6-XL5-MBD2 shuttle, the Sox2 positive population rapidly expanded from Day 7 to Day 12 to have twice as many Sox2 positive cells as compared to the NucleofectorTM® II.
  • the cells in floating conditions did not form spheres during the 12 day experiment in any of the conditions, suggesting that the formation of neurospheres requires either the generation of neural stem-like cells in adherent conditions first or more time.
  • Table 11 shows the percentage of Sox2 positive cells with a typical neural stem cell morphology using both the NucleofectorTM® II Device and the NucleofectorTM® 96-well Shuttle® Device. The latter had the advantages of requiring a smaller starting material (less cells and less DNA required) and in addition gave rise to a higher number of Sox2 positive cells. Moreover a very small population of Sox2 positive cells was observed with the Shuttle® Device only upon transfection with only one neurogenic transcription factor (Msi) in the presence of the DNA demethylator MBD2.
  • Msi neurogenic transcription factor
  • HFFs were cultured and treated with cytochalasin B as described in Example III, and treated simultaneously with VPA (1 mM) and 5-Azacytidine (0.5 ⁇ M). After two days of treatment, cells were transfected by Nucleofection as described in Example II with the constructed vector Msi1/Ngn2. After preparing the cells, they were mixed with 2 ⁇ g of total DNA (Msi1/Ngn2) and cells that had not been treated with chemical inhibitors (VPA and 5-Aza) were co-transfect with MBD2 (2 ⁇ g), using the appropriate program (U023).
  • the samples were transferred into a coated culture plate with Laminin (10 ⁇ g/ml, Sigma) and incubated in a humidified 37° C./5% O 2 /5% CO 2 incubator.
  • the medium was changed to the proliferation basal media, Neural Proliferation Medium (NeuroCultTM proliferation Kit, StemCell Technologies), with the presence of Noggin (20 ng/ml, Peprotech), recombinant hFGF (20 ng/ml, Peprotech), and recombinant hEGF (20 ng/ml, Peprotech).
  • neurospheres were dissociated into single cells and these single cells were isolated and cultured in proliferation medium in suspension, and neurosphere formation was monitored by taking bright field images using light microscope (Nikon, 10 ⁇ ) and by CellomicsTM. These cells started to proliferate and grew as spheres starting day 6 to day 10 ( FIG. 4A ). Immunohistochemistry analysis of these spheres (Table 12 and FIG. 4 ) on Day 20, revealed immunopositive staining for the neural stem cells markers Sox2, Musashi, CD133, Nestin, and GFAP.
  • Cells also stained positive for ⁇ III-tubulin (a marker for neurons), O4 (a marker for oligodendrocytes), and GFAP (a marker for astrocytes), indicating the tri-potent differentiation potential of both sets of cells (NSLC and hNPC), and negative for NGFrec and NeuN (markers for differentiated neurons) indicating that the cells were not terminally differentiated.
  • ⁇ III-tubulin a marker for neurons
  • O4 a marker for oligodendrocytes
  • GFAP a marker for astrocytes
  • HFF cells were cultured as described in Example I, and transfected using the NucleofectorTM II device (Lonza) as described in Example II. Cells were co-transfected with pCMV6-XL5-Msi/pCMV6-XL4-Ngn2, pCMV-Msi1-Ngn2 with MBD2 or pre-treated with VPA/5aza. Cells were cultured in proliferation medium as suspension or adherent cultures.
  • Sample ID Sample Name TLDA Port 1 HFF Ctrl 1 2 ReNcell Undifferentiated Ctrl 2 3 Msi1-Ngn2/MBD2 3 4 Msi1-Ngn2/MBD2 4 5 Msi1-Ngn2/VPA+AZA 5 6 Msi1-Ngn2 6 7 Msi1-Ngn2/MBD2, neurospheres 7 8 Msi1-Ngn2/MBD2, neurospheres 8
  • fibroblast-specific genes (Col3A1, Lox, S100A4) were down-regulated in reprogrammed cells, indicating the loss of fibroblast-specific genes following transfection (note that not all cells got transfected and reprogrammed, so the presence of fibroblast-specific gene expression in the cultures is mostly from the un-programmed fibroblasts left in the culture).
  • the expression of these genes is observed to increase when HFFs were transfected in the absence of DNA demethylator or the DNA methylation inhibitor, indicating that down-regulation of differentiated markers of fibroblast cells requires DNA demethylation.
  • the expression of ectoderm genes such as Msi1, Sox2, and Nestin was remarkably increased following transfection in conjunction with DNA demethylation.
  • neuronal markers such as synaptogamin1 (a synaptic vesicle protein) and NeuroD1 was up-regulated in transfected cells with Msi1/Ngn2/MBD2, and slightly increased in transfected cells with Msi1/Ngn2/VPA and 5-AZA.
  • the selected three markers of oligodendrocytes were detected in the transfected cells with a strong increase of Olig2.
  • Two markers for astrocytes, GFAP and ALDH1L1, were enhanced following transfection. The results support the idea that neurospheres are composed of heterogeneous progenitor subtypes.
  • GAP-43 neuropeptide Y
  • NPY neuropeptide Y
  • GAP-43 has long been acknowledged to play a pivotal role in axonal plasticity and is used as a marker of regenerating neurite outgrowth and synaptogenesis, both in embryonic development and in neuronal regeneration in injured brain and spinal cord.
  • Expression of receptors for growth and neurotrophic factors was increased, such as neurotrophic receptor tyrosine kinase expression.
  • fibronectin and fibroblast protein marker while these markers were undetectable in reprogrammed cells, demonstrating that the reprogrammed cells lost markers of the original cells and adopted morphology and markers of neural stem cells and a neuronal lineage.
  • Transfected cells possess a high percentage of neural stem markers but a very low percentage of fibroblast markers as compared to untransfected cells.
  • NSLCs were maintained in proliferation conditions for 35 passages in a 37° C., 5% CO 2 and 5% O 2 incubator.
  • the average generation time was 25.4 h over 35 passages.
  • Microarray expression analysis was performed to get a global overview to compare the gene expression profile of passage 7 NSLC to both HFF (the cells that the NSLC were created from) and hNPCs.
  • Genotypics extracted RNA from the samples and performed Quality Control using an Agilent BioanalyzerTM. Labelling was done using Agilent's Quick AmpTM kit (cDNA synthesis and in vitro transcription), followed by Labelling QC. Hybridization was then performed using the 8 ⁇ 60K array, and scanning was done using high throughput Agilent scanner with SureScanTM technology. The Agilent Feature Extraction software was used for automated feature extraction, followed by Raw Data QC and Image QC. Advanced Data Analysis was then performed, including Pathway and Gene Ontology analysis using Agilent's GeneSpring GXTM v10.0 and Genotypic's Biointerpreter Software.
  • the NSLC samples were compared to the HFF samples (Set 1) and hNPC samples (Set 2)
  • the NSLC samples had a global gene expression pattern that was much closer to the hNPCs than the HFFs from which the NSLCs were created ( FIG. 23 ).
  • Pearson correlation analysis revealed that NSLCs are closely related to hNPCs, including in terms of neuronal lineage markers, regenerative genes and migration genes. These data confirm that NSLCs are similar, but not identical, to hNPCs.
  • Microarray analysis revealed an up-regulation of neural precursor genes in the NSLC samples as compared to the HFF samples.
  • ACTL6A and PHF10 which both belong to the neural progenitors-specific chromatin remodelling complex (npbaf complex) and are required for the proliferation of neural progenitors, were up-regulated by 2.9-fold and 2.3 fold respectively.
  • MSI2 which plays a role in the proliferation and maintenance of stem cells in the central nervous system, was up-regulated by 6-fold (Table X1).
  • Glia genes were up-regulated in the NSLC samples as compared to the HFF samples.
  • GFAP is a neural stem cell- and astrocyte-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells, is highly up-regulated in the NSLC sample as compared to HFF (690-fold).
  • OLIG1 which promotes formation and maturation of oligodendrocytes, especially within the brain, is also highly up-regulated in NSLC sample as compared to HFF (370-fold) (Table X2).
  • Table X3 lists a subset of regenerative genes that are up-regulated in the NSLC samples as compared to the HFF samples.
  • SOX2 a gene critical for early embryogenesis and for embryonic stem cell pluripotency as well as neural stem cells, is highly up-regulated in the NSLC samples as compared to the HFF samples (5000-fold).
  • CCND2 which is essential for the control of the cell cycle at the G1/S (start) transition, is also up-regulated in NSLC samples (70-fold as compared to HFF samples).
  • numerous fibroblast genes were down-regulated in the NSLC samples as compared to the HFF samples. This shows that the NSLC lose the expression of numerous fibroblast genes as it gets reprogrammed from HFF to NSLC.
  • Table X5 show that neural precursor genes were also up-regulated in the NSLC samples as compared to the hNPC samples.
  • BDNF which promotes the survival and differentiation of selected neuronal populations of the peripheral and central nervous systems during development, is even more highly expressed in NSLC samples than in hNPC samples (34-fold up-regulation).
  • Table X6 shows that a subset of Glia genes are also up-regulated in the NSLC samples as compared to the hNPC samples.
  • GFAP a neural stem cell- and astrocyte-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells, is more highly expressed in NSLC samples than hNPC samples (13-fold).
  • PLP1 the major myelin protein of the central nervous system which plays an important role in the formation or maintenance of the multilamellar structure of myelin, is also more highly expressed in NSLC samples than in hNPC samples (20-fold).
  • Regenerative genes were also up-regulated in the NSLC samples as compared to the hNPC samples (Table X7).
  • BMP2 a neural crest marker, but which induces growth especially of cartilage and bone formation
  • BMP4 which in turn induces cartilage and bone formation and acts in mesoderm induction, tooth development, limb formation and fracture repair, but also in neural stem cells, were both more highly expressed in NSLC samples than in hNPC samples (18-fold and 20-fold respectively).
  • GAP43 which is a major component of the motile growth cones that form the tips of elongating axons was more highly expressed in NSLC samples than hNPC samples (4-fold). This suggests the regenerative potential of NSLC.
  • HOXB4 a transcription factor that is involved in development and also in the expansion of neural stem cells as well as hematopoietic stem and progenitor cells in vivo and in vitro making it a potential candidate for therapeutic stem cell expansion, was also more highly expressed in NSLCs than in hNPCs. This data indicates that NSLCs are more ‘stem-like’ or have more ‘sternness’ than hNPCs.
  • neurospheres were dissociated and plated in laminin/poly-D-Lysine (10 ⁇ g/ml; Sigma) in differentiation medium for two weeks.
  • NbActive medium Brain Derived Neurotrophin Factor (BDNF, 20 ng/ml, Peprotech)
  • BDNF Brain Derived Neurotrophin Factor
  • ATRA all-trans-retinoic acid
  • bFGF 40 ng/ml, Peprotech
  • NeuroCultTM differentiation medium NeuroCultTM Differentiation kit, StemCell Technologies
  • the cells were stained with the neuronal marker ⁇ III-tubulin, astrocyte markers GFAP and Sloop, and oligodendrocyte marker CNPase.
  • the cells were fixed with 4% formaldehyde and the primary antibodies were added in 5% normal goat serum/PBS as follows: Mouse antibody ⁇ III-tubulin (1:200, Abcam), rabbit antibody s100 ⁇ (1:100, Abcam), and Chicken antibody CNPase (1:50, Abcam).
  • NbActive medium promoted the differentiation equally to neuronal (48.66 ⁇ 14.07%, ⁇ III-tubulin) and potential early oligodendrocyte lineages (50.01 ⁇ 4.04%, CNPase) and to a lower percentage of astrocyte cells (2.68 ⁇ 1.13%, sloop), while NS-A differentiation medium induced the differentiation mainly to neurons (64.89 ⁇ 4.11%, ⁇ III-tubulin) and astrocytes (35.94 ⁇ 4.04%, S100beta), and a low percentage of potential early oligodendrocytes cells (8.68 ⁇ 2.71%, CNPase).
  • the NSC-A medium was selected over NbActive for further differentiation studies.
  • NS-A differentiation medium Differentiation of cells in NS-A differentiation medium promote the differentiation of hNPC and NSLC similarly as shown in Table 17 by the decrease of the percentage of sox2, musashi and nestin positive cells.
  • NSLCs were differentiated to neuronal (74.3 ⁇ 0.1, GABA), astrocyte lineage (65.6 ⁇ 0.0, S100beta) and to a lower percentage of oligodendrocyte cells (5.2 ⁇ 0.6, CNPase). The same pattern of tripotent lineage differentiation was observed with hNPCs (Table 17).
  • NSLCs and hNPCs were cultured in NS-A-differentiation medium supplemented with BDNF (20 ng/ml) and FGF (40 ng/ml), cultures were incubated at 37° C., 5% CO 2 , 5% O 2 for three weeks.
  • MAP2b microtubule-associated protein
  • NCAM neuropeptide-binding protein
  • synaptophysin an antibody used to identify functional neuronal cells, was increased following 2 and 3 weeks of differentiation, indicating maturity of the neuronal cells.
  • GABA and acetylcholine markers were increased following 2 weeks of differentiation and decreased at week 3.
  • the morphological changes and expression of a number of neuronal antigens and genes show that the above method results in normal and viable neuronal cells. Additionally, the newly formed neuronal cells have the morphological criteria of neurons. In addition to the above markers, the differentiated cells were evaluated by characterizing morphological markers of neurite differentiation. Neuron type cells (cells strongly expressing ⁇ III-tubulin) showed neurite formation after differentiation, including an increase in the average number of neurites per neuron (from e.g. 1.38 ⁇ 0.1) The same pattern was observed in ⁇ III-tubulin positive cells. Accordingly, the average neurite length (118.3 ⁇ 3.5 ⁇ m) and the number of branch points (3.28 ⁇ 0.3) per neuron also increased. The differentiated neuron-like cells developed long neurites that were greater than three cell diameters in length with a growth cone at the end, expressed neuron-specific genes, and stopped proliferating after the induction of differentiation.
  • NSLCs and hNPCs were cultured in NS-A differentiation medium as described previously supplemented with FGF-2 (10 ng/ml, Peprotech) and sonic hedgehog (SHH, 100 ng/ml, Peprotech) for 4 days. After 4 days medium was changed to NS-A differentiation medium supplemented by T3 (60 ng/ml, Peprotech), IGF1 (10 ng/ml, Peprotech), NT-3 (10 ng/ml, Peprotech), and PDGF (10 ng/ml, Peprotech). Cells were cultured for 20 days at 37° C., 5% CO 2 .
  • NSLCs and hNPCs were cultured in differentiation medium supplemented with SHH (100 ng/ml, Peprotech), T3 (60 ng/ml, Peprotech), IGF1 (10 ng/ml, Peprotech), NT-3 (10 ng/ml, Peprotech), and PDGF (10 ng/ml, Peprotech) to induce differentiation towards oligodendrocytes.
  • SHH 100 ng/ml, Peprotech
  • T3 60 ng/ml, Peprotech
  • IGF1 10 ng/ml, Peprotech
  • NT-3 10 ng/ml, Peprotech
  • PDGF 10 ng/ml, Peprotech
  • NSLCs stable reprogrammed cells
  • epigenetic modification inhibition of acetylation and methylation
  • These cells possess and retain neural stem cell properties as determined by: (1) the expression of neural stem cell genes and proteins, (2) the capacity to generate and grow as neurospheres starting from a single cell, and (3) to differentiate to neuronal lineages in differentiation conditions.
  • neural stem cell properties as determined by: (1) the expression of neural stem cell genes and proteins, (2) the capacity to generate and grow as neurospheres starting from a single cell, and (3) to differentiate to neuronal lineages in differentiation conditions.
  • neurons display one or more neural-specific morphological, physiological and/or immunological features associated with a neuronal cell type.
  • Useful criteria include morphological features (long processes or neurites), physiological, and/or immunological features such as expression of a set of neuronal-specific markers or antigens.
  • NSLCs readily turn into a tripotent-like precursor cell with differentiation potential to a high percentage of neuronal, astrocytes and lower percentage of oligodendrocyte populations.
  • HFFs were cultured and treated with cytochalasin B as described in Example III. After two days of treatment, cells were transfected by Nucleofection as described in Example II with the constructed vector Msi1/Ngn2. Briefly, after preparing the cells, they were mixed with 2 ⁇ g of total DNA (Msi1/Ngn2) and were co-transfect with MBD2 (2 ⁇ g), by the Amaxa's NucleofectorTM according to the manufacturer's protocol.
  • the samples were then transferred into a Laminin (10 ⁇ g/ml, Sigma) coated culture plate and cultured in the presence of Neural Proliferation Medium (NeuroCultTM proliferation Kit, StemCell Technologies) with recombinant hFGF (20 ng/ml, Peprotech), recombinant hEGF (20 ng/ml, Peprotech), and with or without the presence of Noggin (20 ng/ml, Peprotech). Samples were collected at different time points (1, 3, 4, 6, and 8 days) to analyze neuronal gene expression by RT-PCR and protein expression levels by immunohistochemistry.
  • Neural Proliferation Medium NeuroCultTM proliferation Kit, StemCell Technologies
  • NSLCs Created from HFF Cells are not Skin-Derived Precursors (SKPs)
  • SSPs skin-derived precursors
  • ADSC Adipose derived stem cells
  • CellStartTM was diluted 1:100 in dPBS/Ca 2+ /Mg 2+ and the flask incubated for 2 hours at 37° C. Cells are passaged every 3 to 4 days using AccutaseTM and medium was changed every 2 days. Three to four days before initiating differentiation, ADSCs and NSLCs were seeded in 6-wellplates in CellStartTM (1:100 in dPBS/Ca 2+ /Mg 2+ /2 hours at 37° C.) coated tissue culture plates.
  • proliferation media were replaced by differentiation medium consisting in DMEM/F12 (50:50), ITS (1:100), HEPES (1:100), GlutaMAXTM (1:100), T3 (0.2 nM), Rosiglitasone (0.5 ⁇ g/ml), IBMX (100 ⁇ M) and Dexamethasone (1 ⁇ M).
  • cells were fixed with a 4% formaldehyde solution for 10 min and stained with Oil Red O (Invitrogen) staining solution for 15 min. Staining was removed and cells washed twice with PBS.
  • Adipose cells appeared red with lipid droplets specifically stained with Oil Red O, however NSLCs were stained negative, with no presence of lipid droplets in the cells, and the cells adopted neuronal cell morphology.
  • NSLCs are distinct from SKPs ( FIG. 24 ): NSLCs stained positive for p75NTR and negative for fibronectin and versican, while SKPs express fibronectin and versican and do not express p75NTR (Fernandes et al., 2004). This study indicates that NSLCs represent a tripotent-like precursor cell and they are not a subpopulation of SKPs.
  • NLCs Neural-Like Cells
  • Neural Stem-Like Cells differentiated into neuronal and glial cells were kept in culture for 55 days, and BDNF released in the conditioned medium was measured by antigen-capture ELISA at different time points and compared to the release in mature neurons (ScienCell), undifferentiated Neural Human Normal Precursor cells (NHNP, Lonza) as well as to undifferentiated NSLCs and untransfected cells (HFF).
  • Conditioned medium from each group was collected, centrifuged, and then stored at ⁇ 80° C. until assaying.
  • BDNF concentrations were measured by ELISA kits (BDNF E max Immunoassay System, Promega Corporation, USA), according to the manufacturer's instructions.
  • 96-well ELISA immunoplates were coated with Anti-BDNF (CatNb # G700B) diluted 1/1000 in carbonate buffer (pH 9.7) and incubated at 4° C. overnight. The following day, all wells were washed with TBS-TweenTM 0.5% before incubation with Block/Sample buffer 1 ⁇ at room temperature for one hour without shaking. After blocking, standards and samples were added to the plates and incubated and shaken (450 ⁇ 100 rpm) for 2 h at room temperature. Subsequently, after washing with TBS-TweenTM wash buffer, plates were incubated for 2 h with Anti-Human BDNF pAb (1:500 dilution in Block & Sample 1 ⁇ Buffer) at 4° C.
  • Anti-BDNF CatNb # G700B
  • BDNF was released at the same concentration from differentiated Neuron-Like Cells (NLCs differentiated from NSLCs) and normal Human neuron cells starting at day 11 and remained until day 55 (Table 20), while no BDNF (except for tiny amounts in the untransfected HFF group) was released in the other groups.
  • NLCs Neural-Like Cells
  • NSLCs Neural Stem-Like Cells
  • the NLCs were functional and possessed the capacity to release neurotrophic factor (BDNF).
  • BDNF neurotrophic factor
  • Generating reprogrammed neuronal-like cell lines that can locally deliver these neurotrophic factors could be used as a method to treat several neurological conditions and may offer crucial benefits in regeneration and functional recovery from brain and other injuries.
  • keratinocytes Invitrogen
  • human Adipocytes Derived Stem Cells ADSCs, Invitrogen
  • human hematopoietic stem cells CD34 + , Invitrogen
  • Human mobilized peripheral blood CD34 + cells were purchased from StemCell Technologies and expanded as a floating culture in Petri Dishes in complete StemProTM®-34 Serum-free Medium (Invitrogen) supplemented with Stem Cell Factor (SCF, 150 g/ml, Peprotech), Granulocyte Colony-Stimulating Factor (GM-CSF, 37.5 ng/ml, Peprotech) and IL-3 (75 ng/ml, Peprotech).
  • SCF Stem Cell Factor
  • GM-CSF Granulocyte Colony-Stimulating Factor
  • IL-3 75 ng/ml, Peprotech
  • ADSC Human Adipose-Derived Stem Cells
  • cells Prior to transfection, cells were trypsinized and transiently co-transfected with pCMV-Msi1-Ngn2 and pCMV6-XL5-MBD2 as previously described in Example IV using the Shuttle and plated into a culture plate coated with laminin (Sigma, 10 ⁇ g/ml). Starting one day after transfection, cells were treated with VPA (1 mM) for 4 days and the medium was changed gradually to proliferation medium supplemented with FGF (20 ng/ml) and EGF (20 ng/ml) and were cultured for 18 days at 37 2 C, 5% CO 2 and 5% O 2 . Cells were then analyzed for neural stem cell markers by RT-PCR and Immunohistochemistry.
  • RT-PCR Analysis revealed an increase of relative expression of neural stem cell markers such as Sox2, nestin, GFAP, and ⁇ III-tubulin after transfecting Keratinocyte and CD34 + by Msi1 and Ngn2. Relative expression of nestin and GFAP was enhanced in NSLCs created from keratinocytes and CD34 + cells as compared to NSLCs from HFFs; however, the reverse was true for Sox2 and ACHE expression.
  • ⁇ III-tubulin (TUBB3) and Map2b expression was highest in NSLCs created from CD34 + cells, followed by NSLCs created from HFF (Table 21). This data shows that different types of NSLCs with different gene expression profiles (and characteristics) can be created from different types of starting/source cells (and the same has been observed for creating some other types of stem-like cells discussed in this application).
  • RT-PCR analysis was performed after one month of transfection of human fibroblasts (HFF), Keratinocytes, and CD34 + cells with Msi1/Ngn2 (MSI1/NGN2), in the presence MBD2 with VPA treatment.
  • Cells were cultured on coated culture plates in proliferation medium (StemCell Technologies) supplemented with EGF (20 ng/ml) and FGF (20 ng/ml) for 18 days. Untransfected cells were considered as negative control.
  • NSLCs developed from HFF yield a higher percentage of positive staining for Sox2 and GFAP (55.8 ⁇ 3.8 and 78.1 ⁇ 2.4) as compared to CD34 + cells (42.8 ⁇ 2.7 and 24.2 ⁇ 4.4), and keratinocytes (47.1 ⁇ 2.1 and 43.4 ⁇ 8.9).
  • the percentage of nestin positive cells was high in Keratinocytes (77.6 ⁇ 10.7) and HFF (68.45 ⁇ 12.9) and lower in CD34 + cells (15.5 ⁇ 2.7) (Table 22). Sox2 and Nestin positive staining was undetectable in ADSCs.
  • NSLCs generated from keratinocytes and CD34 + cells were tested for tripotent capacity. Further differentiation studies were performed to induce differentiation of these NSLCs towards neuronal lineage, using NeuroCultTM differentiation medium (NeuroCultTM differentiation Kit, StemCell Technologies) supplemented with BDNF (20 ng/ml, Peprotech) and bFGF (40 ng/ml, Peprotech) as described in Example V.
  • NeuroCultTM differentiation medium NeuroCultTM differentiation Kit, StemCell Technologies
  • BDNF 20 ng/ml, Peprotech
  • bFGF 40 ng/ml, Peprotech
  • RT-PCR analysis revealed decrease of undifferentiated genes (Nestin and Sox2) and increased of differentiated genes (Map2, ⁇ III-tubulin, CNPase, and GFAP) as shown in Tables 23A, 23B, 23C and 23D.
  • RT-PCR analysis was performed on NSLCs generated from human fibroblasts (HFF), keratinocytes, and CD34 + cells that were cultured on Poly-D-Lysin/Laminin coated culture plates in differentiation medium for 28 days (StemCell Technologies) supplemented with BDNF (20 ng/ml) and FGF (40 ng/ml).
  • hNPCs (Lonza) were considered as a positive control.
  • hNPCs had a much lower increase in ACHE, GFAP, and MAP2b (which actually decreased in hNPCs), but an increase in Nestin, compared to NSLCs under differentiation conditions.
  • HFF-NS 0.62 0.02 0.90 0.08 5.14 0.21 6.47 0.78 5.70 0.15 1.30 0.02 0.79 0.03 1.41 0.01 Day 28
  • HFF-NS 1.27 0.05 1.48 0.11 1.59 0.03 24.62 1.00 576.80 20.98 1.52 0.00 0.86 0.08 2.74 0.23 Day 28 Kerat-NS 1.00 0.06 1.00 0.02 1.00 0.03 1.00 0.11 1.00 0.01 1.00 0.07 1.00 0.02 1.00 0.01 Control Diff. Kerat-NS 2.43 0.06 3.48 0.08 2.82 0.11 56.22 5.58 665.91 10.52 3.09 0.29 1.01 0.14 3.72 0.17 Day 14 Diff.
  • hNPC 1.00 0.05 1.00 0.07 1.00 0.12 1.15 0.80 1.00 0.07 1.00 0.11 1.00 0.08 1.00 0.03 Day 14 Diff.
  • NSLC 0.44 0.00 0.18 0.02 0.47 0.00 0.22 0.03 0.40 0.03 0.26 0.00 0.31 0.00 0.34 0.01 Day 14 Diff.
  • the % of Sox2 positive cells decreased faster, the % of Nestin positive cells generally decreased slower, and the % of cells expressing one of the differentiation markers (sloop, ⁇ III-tubulin, GFAP) generally increased slower in hNPCs than in the NSLCs during differentiation.
  • the % of cells expressing one of the differentiation markers generally increased slowest in NSLCs created from keratinocytes and fastest in NSLCs created from HFFs.
  • NSLCs can be created from keratinocytes and CD34 + blood cells, and these cells share morphology and markers similarly to NSLCs generated from HFF.
  • NSLCs created from keratinocytes, CD34 + cells, and HFFs had a tendency to differentiate more towards an astrocyte lineage than a neuronal lineage (except NSLCs created from HFFs had an almost similar number of ⁇ III-tubulin positive and GFAP positive cells) as shown by the high percentage of GFAP positive cells during differentiation, which was confirmed by S100beta staining.
  • NSLCs generated from HFF, Keratinocytes, and CD34 + cells can give rise to a higher number of neuronal and astrocyte cells as compared to hNPCs.
  • NSLCs whether created from HFFs, Keratinocytes or CD34 + cells (or potentially even some other cell), are tripotent cells and possess the capacity to differentiate to neurons, astrocytes, and oligodendrocytes similarly to hNPCs.
  • RT-PCR and immunohistochemistry analysis of transfected ADSCs did not reveal any significant expression of neural stem cell genes, indicating a need to optimize conditions for turning ADSCs to NSLCs or to investigate the effect of others neurogenic factors that could turn these into NSLCs.
  • Fibroblast cells were cultured in DMEM medium in the presence of 10% FCS as described in Example I, followed by seeding onto 12-well plates pre-coated with laminin (10 ⁇ g/ml) at a concentration of 2 ⁇ 10 6 cells/ml in defined CDM Medium consisting of a 3:1 ratio of Dulbecco's modified Eagle medium (DMEM, high glucose (4.5 g/L) with L-glutamine and sodium pyruvate) and Ham's F-12 medium supplemented with the following components: EGF (4.2 ⁇ 10 ⁇ 10 M), bFGF (2.8 ⁇ 10 ⁇ 10 M), ITS (8.6 ⁇ 10 ⁇ 5 M), dexamethasone (1.0 ⁇ 10 ⁇ 7 M), L-ascorbic acid phosphate magnesium salt n-hydrate (3.2 ⁇ 10 ⁇ 4 M), L-3,3′,5-triiodothyronine (2.0 ⁇ 10 ⁇ 10 M), ethanolamine (10 ⁇ 4 M), GlutaMAXTM (4 ⁇ 10 ⁇ 3 M), gluta
  • LTE living tissue equivalent
  • CDM de novo 3D extracellular matrix
  • CDM samples were treated with cytochalsin B (10 ⁇ g/ml, Calbiochem), with the concentration of cytochalsin B reduced from 10 ⁇ g/ml to 0 ⁇ g/ml (none) over 5 days while at the same time switching the medium from CDM Medium to NbActive medium.
  • Samples were cultured for another 12 days at 37° C., 5% CO 2 , and the medium was changed every day. Samples were fixed to perform immunohistochemistry as described previously to detect Neuronal markers. The following antibodies were used: mouse anti-nestin 647 (1:100, BD) and anti- ⁇ III-tubulin (1:200, Neuromics).
  • FIG. 18 shows immunostained cells with ⁇ III-tubulin at day 7, indicating the de-differentiation of fibroblast cells to neurons. However, one week later, these trans-differentiated cells reverted back to fibroblast cells and ⁇ III-tubulin expression was lost ( FIG. 8 ). The loss of morphology and ⁇ III-tubulin expression after withdrawal of the priming agents indicate that complete conversion to functional and stable reprogrammed cells did not occur.
  • CDM was treated with VPA (4 mM), 5-Aza (5 ⁇ M) and cytochalasin B (10 ⁇ g/ml) as above.
  • fibroblast cells within the CDM were transfected with DNA using Lipofectamine reagent (Invitrogen) as per the manufacturer's protocol.
  • 15 ⁇ g of the eukaryotic DNA expression vectors pCMV6-XL5-Pax6, pCMV6-XL5-Msi1 and pCMV6-XL4-Ngn2 (Origene) were used to transfect the cells.
  • Neural Progenitor Basal Medium (Lonza) supplemented with Noggin (50 ng/ml), EGF (20 ng/ml), and bFGF (20 ng/ml), and the cells were cultured at 37° C., 5% CO 2 and 5% O 2 , and the medium was changed every day.
  • differentiation was initiated by adding gradually NBActive medium (BrainBitsTM) supplemented with NT-3 (20 ng/ml, Peprotech), all-trans-retinoic acid (ATRA, 5 ⁇ M, Spectrum), BDNF (20 ng/ml, Peprotech), and bFGF (40 ng/ml, Peprotech).
  • FIG. 19 shows that expression of these genes was enhanced when the cells were transfected with Msi1 and Ngn2, with ⁇ III-tubulin enhanced to almost 6-fold at day 12.
  • NbActive BrainBits TM
  • NT-3 (20 ng/ml
  • bFGF 20 ng/ml
  • ATRA 5 ⁇ M
  • Forskolin 10 ⁇ M
  • Cells were incubated at 37° C., 5% CO 2 , 5% O 2 for 12 days.
  • Relative expression of Msi1, Ngn2, Pax6, nestin, ⁇ III-tubulin, ACHE, MAP2b and GFAP in NSLCs and NLCs was increased after transfection with both transcription factors Ngn2 and Msi1 with MBD2 as the DNA demethylator.
  • Medium was changed every day by increasing the percentage of NPBM and decreasing CDM medium.
  • Cells were cultured for 6 days at 37 2 C, 5% CO 2 and 5% O 2 .
  • differentiation was initiated by gradually supplementing the NPBM Medium with NT-3 (20 ng/ml, Peprotech), all-trans-retinoic acid (ATRA, 5 ⁇ M, Spectrum), BDNF (20 ng/ml, Peprotech), and bFGF (40 ng/ml, Peprotech). Samples were collected at the end of the study (day 14) and data were analyzed by gene array to identify genes that were reproducibly found to be specific for neuronal lineages.
  • oligodendrocyte genes such as NKx2.2, olig2, and MAG was increased by Msi1 and Ngn2; however, the increased was more pronounced by Msi1 as compared to Ngn2 (Table 26).
  • Two markers for astrocytes (GFAP and AQP4) were highly expressed after transfection with Msi1 and Ngn2 in the presence of the DNA demethylator MBD2.
  • TDLA data revealed increases in specific markers for interneurons, such as somatostatin and calbindin1.
  • Doublecortin (DCX) which is expressed by migrating immature cells during development, and acetylcholine (ACHE), an early marker of neuronal cells, were highly expressed in reprogrammed cells (Table 26).
  • Transfection with Msi1 or Ngn2 increased the expression of dihydropyrimidinase-like 3 (DPYSL3), an early marker of newborn neurons to five-fold with Msi1 and seven-fold with Ngn2.
  • MAP2 microtubule-associated protein 2
  • NCAM neuronal cell adhesion molecule
  • VEGF and GDNF genes were increased to almost five-fold and seven-fold by Msi1 and Ngn2, respectively.
  • BDNF, EGF, and bFGF were not activated and even down-regulated as compared to untransfected cells.
  • GAP-43 growth associated protein
  • receptors for growth and neurotrophic factors was increased, such as type III receptor tyrosine kinase, Neurotrophic tyrosine kinase receptor, and neurotrophic tyrosine kinase.
  • the fibroblast-specific markers vimentin and fibronectin were down-regulated in the reprogrammed cells.
  • This study was designed to improve transfection of CDM by combining lipofectamine and nucleofection and using two vectors pCMV6-XL5-Msi1 and pCMV6-XL4-Ngn2 individually or in combination together with pCMV-XL5-MBD2.
  • Cells within Day 4 CDM were lipotransfected for 6 hours with Msi1/MBD2, Ngn2/MBD2 or Msi/Ngn2/MBD2 after 2 days of pre-treatment with or without cytochalasin B.
  • transfection was performed on fresh HFFs after the 6 hours using Nucleofection as described in Example II, and transferred on top of the CDM when the lipofectamine media was changed to fresh CDM medium.
  • NPBM Neural Progenitor Basal Medium
  • Noggin 50 ng/ml, Peprotech
  • recombinant hFGF 20 ng/ml, Peprotech
  • recombinant hEGF 20 ng/ml, Peprotech
  • Telomerase is active in neural precursor cells and suggest that its regulation is an important parameter for cellular proliferation to occur in the mammalian brain (Caporaso G L et, 2003). This study was performed to evaluate telomerase activity in cell extracts of adherent NSLCs (NSLCs cultured on laminin-coated plates) as well as NSLCs in floating neurospheres (NSLCs cultured in plates with a low-bind surface) at early (P7) and late passage (P27). The telomerase activity of the 4 samples was measured by the PCR-based telomere repeat amplification protocol (TRAP) using the TRAPeze® Telomerase Detection Kit (Chemicon).
  • TRAP PCR-based telomere repeat amplification protocol
  • the cells were grown in 24-well plates, washed in PBS, and homogenized for 30 min on ice in buffer containing 10 mM Tris-HCl, pH 7.5, 1 mM MgCl 2 , 1 mM EGTA, 0.1 mM Benzamidine, 5 mM ⁇ -mercaptoethanol, 0.5% CHAPS and 10% Glycerol (1 ⁇ CHAPS Lysis Buffer, provided in kit) and RNase Inhibitor. The samples were spun down and the protein concentration of the supernatant was determined using the BCA Assay.
  • 900 ng of protein from each cell extract was added directly to the TRAP reaction mixture containing TRAP reaction buffer, dNTPs, template substrate (TS) primer, TRAP primer mix and Taq polymerase.
  • the reaction mixtures were incubated at 30° C. for 30 minutes for template synthesis, followed by a PCR procedure (95° C./15 min for initial denaturation, 94° C./30 sec, 59° C./30 sec, 72° C./1 min for 32 cycles) for amplification of the extended telomerase products.
  • polyacrylamide gel electrophoresis PAGE
  • the gel was stained with SYBR® Green I Nucleic Acid Gel Stain for 30 minutes, followed by image capture using a Gel-Documentation System (Alpha Innotech).
  • telomerase positive samples were telomerase positive (as indicated by the TRAP product ladder) as shown in FIG. 11 .
  • the Heat-treated control ⁇ H
  • ⁇ H the Heat-treated control
  • S-IC A 36 bp internal control band
  • S-IC is used to monitor PCR amplification (to distinguish false-negative results). This S-IC band was observed for all samples except for the test samples. This may have been due to the excessively high telomerase activity in the test samples; amplification of the TRAP products and the S-IC control band are semi-competitive. All controls gave expected results (No TRAP products for CHAPS ctrl, and TRAP ladder of products for the positive control cells and the TSR8 control).
  • Malignantly transformed cells show reduced requirements for extracellular growth promoting factors, are not restricted by cell-cell contact, and are often immortal.
  • Anchorage-independent growth and proliferation is one of the hallmarks of malignant transformation, which is considered the most accurate and stringent in vitro assay for detecting malignant transformation of cells.
  • HFFs were used as a negative control and cervical carcinoma HeLa cells were used as a positive control.
  • Cells were sedimented by centrifugation at 150 ⁇ g for 3 min at room temperature (RT).
  • the assay was performed using the CytoSelectTM 96-well cell transformation assay (CellBiolabs).
  • the base agar layer (1.2%) was dissolved in 2 ⁇ DMEM/20% PBS solution and 50 ⁇ l of the agar solution was added to the plate and incubated for 30 min at 4° C. to solidify.
  • the plate Prior to adding the cell agar layer, the plate was allowed to warm up for 15 minutes at 37° C. The cells were resuspended at different density (20.000 and 5000 cells/well), except the hNPCs were resuspended only at 5000 cells/well due to a lack of enough cells. The cells were mixed with the 1.2% agar solution, 2 ⁇ DMEM/20% PBS, and cell suspension (1:1:1), and 75 ⁇ l of the mixture was transferred to wells already containing the solidified base agar layer, and was then placed in 4° C. for 15 minutes to allow the cell agar layer to solidify. 100 ⁇ l of proliferation medium (StemCell Technologies) was added and the plate was incubated for 8 days at 37° C.
  • proliferation medium Stem Technologies
  • the DNA plasmid Msi1/Ngn2 (designed and constructed in house) was used in transient transfection for generation of NSLCs along with MBD2 (for sample 1), or 5-Aza and VPA (for sample 2). Two weeks after transfection, Southern blot was performed to test for possible genomic integration of the plasmid DNA. 3 ⁇ g of genomic DNA extracted from the NSLC samples, as well as from HFF (a human fibroblast cell line) used as a negative control, was digested with several restriction enzymes including BgIII, PstI and StuI, subjected to electrophoresis on a 1% agarose gel and transferred to a positively charged nylon membrane (Roche).
  • the membrane was hybridized in the DIG Easy HybTM buffer (Roche) at 42° C. overnight with a 1.2 kb Dig-labeled PCR probe amplified from the plasmid DNA using a set of primers.
  • the membrane was washed twice at room temperature with 2 ⁇ SSC, 0.1% SDS for 5 min per wash, twice with 0.5 ⁇ SSC, 0.1% SDS at 65° C. for 15 min per wash.
  • Hybridization signals of the membrane were detected using the CDP-StarTM substrate (Roche).
  • the membrane was exposed to an X-ray film for analysis. The signals were stripped from the membrane using stripping buffer (0.2 M NaOH, 0.1% SDS).
  • the membrane was re-hybridized with a 0.9 kb Dig-labeled PCR probe amplified from the plasmid DNA using a set of primers.
  • MS Multiple Sclerosis
  • CNS central nervous system
  • EAE Experimental Allergic Encephalomyelitis
  • EAE can be induced in a variety of species and strains of animals [mice, Rat, marmoset monkey, rhesus macaques] using various CNS antigens [Myelin Oligodendrocyte Glycoprotein (MOG), proteolipid protein (PLP) and myelin basic protein (MBP)].
  • MOG Myelin Oligodendrocyte Glycoprotein
  • PGP proteolipid protein
  • MBP myelin basic protein
  • mice Female 7 to 8 weeks old C57BL/6 mice were purchased from Charles Rivers, and housed at MISPRO animal facility for one week before experimentation for adaption to the new environment. C57BL/6 mice were injected s.c. with 100 ⁇ g MOG 35-55 in CFA (Sheldon Biotechnology, McGill University) containing 5 mg/ml Mycobacterium tuberculosis H37Ra (Difco, inc), at 2 sites on the back. All mice received 200 ng pertussis toxin (List Biological Laboratories, Inc) i.p.
  • hNSLC and hNPCs (1.5 ⁇ 10 6 cells in 200 ⁇ l PBS/each mouse) were given by single injection i.v. via the tail vein when the animals started to show symptoms of EAE (day 13 i.v). Both animals groups received cyclosporine (10 mg/kg/day) one day before the injection of cells and daily from the day of transplantation to avoid any rejection of the human cells. Sham-treated age-, sex-, and strain-matched mice, injected i.p. with PBS alone, were used as controls. All groups of animals were observed for 43 days. Animals were sacrificed at 43 days p.t., brains and spinal cord were harvested in 30% sucrose in PBS.
  • the treatments (Alginate, Alginate+hNPC, Alginate+NSLCs, RM x +NSLCs, RM x Only, Fibrin Gel, or Saline) were applied directly on the brain after ablation.
  • the opening in the skull was then filled with Bone Wax.
  • small pieces of sterile homeostatic tissue were inserted into the lesion in order to stop the bleeding.
  • the sutures were performed using EthiconTM monofilament suture 1 ⁇ 2 circle needle shape.
  • Surgeries were performed in sterile clean rooms, and topical antibiotics (Cicatrin®, GlaxoSmithKline) were applied to the exposed skull and scalp to limit local infection. Rats were immunosuppressed by daily injection i.p.
  • cyclosporine A (10 mg/kg/day) starting the day before the surgery until the end of the study period.
  • the purpose of the cyclosporine A injection was to reduce the rat's immune reaction to the treatment.
  • the immune-suppression was sustained until the end of the study to ensure that any potential failure of regeneration (if taken place) was not due to the immune reaction against the treatment.
  • Functional scores were performed weekly, in all groups, sensorimotor impairment was evaluated based on the behavioural tests as described below.
  • the rotarod speed was manually calibrated for the 10 and 20 RPM speed before all procedures. Animals were required to perch on the stationary rod for 30 sec to acclimate themselves to the environment. During this time, if any animal fell, it was placed back on the rod until it had achieved stationary capabilities for a period of 30 seconds. The animals were allowed 3 trials. The animals that were comfortable staying on the stationary rod for 30 sec were allowed to run with a constant speed of 10 and 20 RPM for 60 sec, and the number of falls were electronically recorded.
  • HFF cells were cultured as described in CDM II medium as described in Example I with only modifying EGF (5 ng/ml) and FGF (10 ng/ml), and transfecting using the NucleofectorTM® 96-well Shuttle® Device (Lonza) following the procedure described in Example IV.
  • the cells were transfected with various combinations of cDNA clones as described in Table 29. After transfection, the cells were plated on 0.1% Gelatin-coated plates and incubated at 37° C., 5% CO 2 , 5% O 2 . Medium was changed every other day according to Table 30. Cells were analyzed at Day 4 by Quantitative Real-time PCR.
  • RNA isolation and quantification was performed as previously described in Example I.
  • cDNA was prepared and quantitative real-time PCR was performed as previously described in Example II, except the following TaqmanTM® Gene Expression Assays (Applied Biosystems) were used:
  • SOX17 is still highly expressed in the SOX17-transfected samples (50,000 to 400,000-fold as compared to the untreated HFF sample).
  • the SOX17 gene expression represents leftover plasmid DNA (exogenous SOX17) that still remains 4 days post-transfection, and any endogenous SOX17 expression that may have been induced.
  • Ectoderm markers CDH1, p63 and Sox2 were also up-regulated in some samples (e.g. Oct4/FoxD3/MBD2, Oct4/Sox17/MBD2).
  • HFF cells were cultured as described in Example I, and transfected using the NucleofectorTM® 96-well Shuttle® Device (Lonza) following the procedure described in Example IV.
  • the cells were transfected with various combinations of cDNA clones as described in Table 27. After transfection, the cells were plated on Fibronectin-coated collagen gels and incubated at 37° C., 5% CO 2 , 5% O 2 . Fibronectin-coated Collagen gel plates were prepared prior to transfection.
  • Rat Tail Collagen I (Gibco) was diluted to 1.125 mg/ml using 10 ⁇ PBS and distilled water, where 125 ⁇ l was added to each well of a 24-well plate and incubated in 37° C. for 40 minutes.
  • Fibronectin (BD Biosciences) was added on top of the gel at a concentration of 1.9 ug/well. Media was changed every other day according to Table 33. Cells were analyzed at Day 7 by Quantitative Real-time PCR.
  • Plasmids and media composition from Day 0 to Day 14 Plasmids transfected Media Composition 2 at Day 0 1 Day 0 Day 1 to Day 3 Day 4 to Day 14 1 FoxD3, Sox17, Pdx1, CDM II + Activin DMEM/F12 + NEAA + DMEM/F12 + NEAA + MBD2 A + HSA ITS + HSA + B27 + ITS + HSA + B27 + 2 FoxD3, Sox17, Ngn3, EGF + bFGF + Activin EGF + bFGF + Retinoic MBD2 A + CHIR99021 + Na Acid + FGF10 + 3 FoxD3, Mixl1, Pdx1, Butyrate Cyclopamine + Noggin MBD2 4 FoxD3, Mixl1, Ngn3, MBD2 5 Sox17, Mixl1, Pdx1, MBD2 6 Sox17, Mixl1, Ngn3, MBD2 7 FoxD3, Sox17, Mixl1, DMEM/F12 + NEAA
  • Activin A (Peprotech, 30 ng/ml), HSA (Baxter, 0.5%), NEAA (Gibco, 1X), ITS (Gibco, 1X), B27 (Gibco, 1%), EGF (Peprotech, 5 ng/ml), bFGF (Peprotech, 10 ng/ml), CHIR99021 (Stemgent, 2 uM), Na Butyrate (Stemgent, 1 mM), VPA (Stemgent, 1 mM), 5-Aza (Sigma, 0.5 uM), Retinoic Acid (Sigma, 2 uM), FGF10 (Peprotech, 50 ng/ml), Cyclopamine (Stemgent, 2.5 uM), Noggin (Peprotech, 50 ng/m1)
  • RNA isolation and quantification was performed as previously described in Example I.
  • cDNA was prepared and quantitative real-time PCR was performed as previously described in Example II, except the following TaqmanTM® Gene Expression Assays (Applied Biosystems) were used:
  • Pancreatic Progenitor-like cells were investigated by transfection with combinations of FoxD3, Sox17, Pdx1, Ngn3, MixI1, and MBD2.
  • FoxA2 a marker for Endoderm and Mesoderm, was slightly up-regulated for the FoxD3/Sox17/Ngn3/MBD2-transfected sample as compared to the GFP mock-transfected control sample.
  • CXCR4 also a marker for both endoderm and mesoderm, was slightly up-regulated (3-fold compared to GFP-ctrl) for the FoxD3/MixI1/Ngn3/MBD2-transfected sample.
  • SOX17 can still be detected for the samples transfected with SOX17 at varying levels (4 to 570-fold up-regulation as compared to the GFP-ctrl).
  • the highest SOX17 expression up-regulation is detected for the sample transfected with Sox17/MixI1/Pdx1/Ngn3 (570-fold as compared to GFP-ctrl), which may suggest that this gene combination may increase the amount of SOX17 RNA in cells.
  • ADSC Human Adipocytes Derived Stem Cells
  • PLSC Pluripotent-Like Stem Cells
  • ADSCs (Invitrogen Corporation) were cultured in cell culture flasks with complete StemProTM-43 medium (Invitrogen) at 37° C., 5% CO 2 and the medium was changed 3 times per week. After 3 days in culture cells (passage 5) were trypsinized and counted to be transfected.
  • Cells were transiently transfected with one plasmid: pCMV6-Oct4-2A-Klf4-2A-Nanog, pCMV-Sall4-2A-Oct4-2A-Klf4-2A-Nanog, pCMV-Dax1-2A-Oct4-2A-klf4, pCMV-FoxD3-2A-Oct4-2A-klf4, pCMV-Oct4-2A-Klf4-2A-Sall4, pCMV-MBD2-2A-Oct4-2A-Klf4-2A, pCMV-AGR2-2A-Oct4-2A-Klf4-2A, or Rex1-EF-Oct4-2A-Klf4 (2 ⁇ g); or by two plasmids: pEF-Oct4nuc-IRES2-MBD2 with pCMV-Sox2nuc-IREC-Lin28
  • adipocytes complete medium (StemProTM-43) and embryonic stem cells medium (mTeSR1).
  • mTeSR1 embryonic stem cells medium
  • cells were re-transfected with the same plasmids listed above and cells were plated in 96 well-plates coated with MatrigelTM (BD Biosciences) in the presence of mTesR complete medium supplemeneted with thiazovivin (0.5 ⁇ M), an ALK-5 inhibitor (SB 341542, Stemgent, 2 ⁇ M), and inhibitor of MEK (PD0325901, Stemgent, 0.5 ⁇ M).
  • ADSCs were transfected as above with pEF-Rex1-EF-Oct4-2A-Klf4-2A-RFP, pCMV6-XL5-Rex1, pCMV6-XL4-Oct4/pCMV6-XL5-Klf4, pCMV6-XL5-Rex1/pCMV6-XL4-Oct4, or pCMV6-XL5-Rex1/pCMV6-XL5-Klf4.
  • ADSC were cultured in 96-well plates coated with MatrigelTM for 24 days in the presence of mTeSR1 medium supplemented with SB341542 and PD 0.325901 at 37° C., 5% CO 2 , 5% O 2 .
  • live staining, immunohistochemistry, and AP staining was used to follow the change in pluripotent markers.
  • 1-5% of total cells transfected with Rex1/Oct4 or Rex1/Klf4 showed a SSEA4 + and TRA-1-81 + phenotype, and this pattern was stable until the end of the study period (Day 22).
  • ADSC cells were cultured as described in Example IX with 2 days VPA and 5-AZA pre-treatment (1 mM and 0.5 ⁇ M respectively) in StemProTM MSC SFM medium.
  • Cells were transfected using the NucleofectorTM® 96-well Shuttle® Device (Lonza) following procedure described in Example IV and using the transfection program EW-104 with the DNA mixes described in Table 34.
  • EW-104 with the DNA mixes described in Table 34.
  • the cells were plated in StemProTM MSC SFM medium described in example A on MatrigelTM (BD Biosciences) coated 24 well plates and incubated at 37° C., 5% CO 2 , 5% O 2 .
  • the hES cell medium consisted in Dulbecco's Modified Eagle's Medium (DMEM, Invitrogen) supplemented with 20% KnockoutTM Serum Replacement (KSR, Invitrogen), 1 mM GlutaMAXTM, 100 ⁇ M Non-essential Amino acids, 100 ⁇ M ⁇ -mercaptoethanol and 10 ng/ml Fgf-2. Different inhibitors and growth factors were added through the course of the experiment; these are listed in Table 34. Cells were analysed at Day 7 and Day 14 by immunohistochemistry analysis and at Day 7 by RT-PCR.
  • DMEM Dulbecco's Modified Eagle's Medium
  • KSR KnockoutTM Serum Replacement
  • ADSC 1.25 N/A 0.30 N/A ( ⁇ VPA/ ⁇ 5aza) #23 Day 7, GFP 1.01 0.20 1.87 2.23 (+VPA/+5aza) #24 Day 7, Untransf.
  • ADSC 1.45 N/A 0.27 N/A (+VPA/+5aza) Reprogramming Efficiency of Defined Pluripotency Factors on HFF after Triple Transfection (One Transfection Every 3 Days)
  • HFF cells were cultured as described in Example I with the exception of the concentrations of VPA and 5-AZA that were respectively 2 mM and 2.5 ⁇ M.
  • Cells were transfected using the NucleofectorTM® II Device (Lonza) following procedure described in Example II with the exception of the DNA quantity: 1 ⁇ g of each of the 3 plasmids DNA was used.
  • the cells that had been pre-treated with VPA and 5-Aza and the untreated cells were both transfected with a mix of pCMV-Oct4nuc-IRES2-Sox2nuc, pCMV-Klf4nuc-IRES2-Cmycnuc or pCMV-Nanognuc-IRES2-Lin28.
  • Example II Following transfection the cells were plated in the fibroblasts medium described in Example I, supplemented with or without VPA and 5-AZA on MatrigelTM (BDBiosciences) coated on 6-well plates and incubated at 37° C., 5% CO 2 .
  • media was changed to 100% mTeSR1 medium (StemCell Technologies) supplemented with or without VPA and 5-AZA.
  • mTeSR1 medium StemCell Technologies
  • cells from each condition were detached by incubation in TrypLETM for 5 min, counted and centrifuged. Cells were retransfected as above and plated on MatrigelTM coated plates in mTeSR1 medium supplemented with or without VPA and 5-AZA. Media was changed daily as described for day 1 and 2.
  • Y27632 Stemgent, 10 ⁇ M
  • Y27632 Stemgent, 10 ⁇ M
  • Cells were analysed at Day 20 using the Alkaline Phosphatase Detection Kit (Millipore) and by immunohistochemistry analysis.
  • NSLC and neuronal stem cells derived from BG-01 a human ES cell line that expresses markers that are characteristic of ES cells including SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, and OCT-3/4, were reprogrammed into pluripotency.
  • BG-01 cells had previously been cultured in conditions to induce the differentiation towards neural stem cells as described by Chambers S M et al., 2009.
  • NSLCs and BG-01-NSC were cultured in proliferation medium supplemented with FGF (20 ng/ml) and EGF (20 ng/ml).
  • NSLCs and BG-01-NSCs were transfected as previously described in Example 11 by two episomal vectors, pEF-Oct4nuc-IRES2-MBD2 (NC1) or pCMV-FoxD3-2A-Oct4-2A-Klf4 (F72). Following transfection cells were collected and plated onto uncoated petri-dishes in the presence of Proliferation medium and mTeSR1 medium (50:50) in proliferation conditions at 37° C., 5% CO2.
  • cells were re-transfected by the same plasmid and plated in 96-well plates coated with MatrigelTM and cultured in the presence of mTeSR1 medium supplemented by the small molecules BIX01294 (Stemgent, 2 ⁇ M) and BayK8644 (Stemgent, 2 ⁇ M) at 37° C., 5% O 2 for 22 days. Live staining and immunohistochemistry were performed to characterize subpopulations of cells for pluripotency markers.
  • NSLCs and BG-01-NSCs were positively stained with SSEA-4 starting on Day 7 and maintained until 22 days in culture (the end of the study) ( FIG. 20 ). Within ten days, cells that were morphologically similar to ESCs were observed and they expressed a wide panel of pluripotency markers, including SSEA-4, TRA1-81, Nanog and Oct4 ( FIG. 20 ).
  • This study identified another way to get pluripotent-like cells from somatic cells via Neural Stem-Like Cells (NSLCs).
  • the utility of NSLCs could offer multiple advantages for reprogramming towards pluripotent-like cells. For example, obviating the requirement for tumorigenic genes like c-Myc reduces the risk of inducing cancerous cells. For neurodegenerative and neurodegenerative applications these cells could represent an invaluable source of cells to investigate furthermore human pluripotent cell induction, and also represent a potential source of cells for deriving patient-specific multipotent and pluripotent stem cells for modeling human disease
  • SC pluripotent stem cells
  • SCID severely compromised immuno-deficient mice
  • mice were purchased from Charles Rivers, and housed at MISPRO animal facility for one week without any experimentation for adaption to the new environment.
  • One million human NSLCs, normal human neuroprogenitor cells (hNPCs), or human embryonic stem (ES) cells in 100 ⁇ l Phosphate buffered saline, calcium- and magnesium-free (CMF-PBS) were injected with a 21-G needle intramuscularly into the right hind limb of the 4-week-old male SCID-beige mice under anesthesia with Ketamine/xylazine (8 mice per group).
  • the syringe was aspirated up and down a couple of times in a culture dish containing medium to verify that the cells were injected and not stuck inside the syringe.
  • mice were maintained for 12 weeks and monitored for clinical signs and any tumor growth regularly. Any specialized tissue or teratoma growth was monitored by external examination and an increase in the size of the muscle relative to the same muscle on the left hind limb. When a specialized tissue or teratoma was identified, the location and size of the growth was measured (using measuring calipers) and recorded. The specialized tissue or teratoma is usually first identified as a small growth of the muscle size compared to the left control muscle. Animals were monitored weekly until onset of any tumor growth, and daily after tumors appeared. After 12 weeks, the mice were sacrificed by CO 2 euthanasia.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

A method of obtaining a pluripotent-like multipotent cell, including providing a cell of a first type which is not a pluripotent-like multipotent cell; contacting the cell of a first type with an agent capable of remodeling the chromatin and/or DNA of the cell; transiently increasing expression of at least one pluripotent gene regulator in the cell of a first type, to a level at which the at least one pluripotent gene regulator is capable of driving transformation of the cell of a first type into the pluripotent-like multipotent cell; and placing or maintaining the cell in a differentiation medium and maintaining intracellular levels of the at least one pluripotent gene regulator for a sufficient period of time to allow a stable pluripotent-like multipotent cell to be obtained; wherein the pluripotent-like multipotent cell so obtained does not exhibit teratoma formation in vivo.

Description

    FIELD OF THE INVENTION
  • The present invention relates to the field of eukaryotic cell reprogramming, and particularly to cell dedifferentiation. The invention is also concerned with methods of generating stable Neural Stem-Like Cells (NSLCs) from human somatic cells (and other cells) and the use of the cells so generated in human therapy.
    • BACKGROUND OF THE INVENTION
  • Cell Reprogramming
  • There is a desire in the medical, scientific, and diagnostic fields to reprogram an easily obtainable cell into a cell that is generally harder to obtain, or to reprogram a cell to have new or different functionalities, without fusing or exchanging material with an oocyte or another stem cell.
  • According to a first mechanism, a stem cell can naturally divide or differentiate into another stem cell, progenitor, precursor, or somatic cell. According to a second mechanism, somatic cell can sometimes transiently change its phenotype or express certain markers when placed in certain conditions, and then revert back when placed back into the original conditions. According to a second mechanism, the phenotype of many cells can be changed through forced expression of certain genes (for example, stably transfecting the c-myc gene into fibroblasts turns them into immortal cells having neuroprogenitor characteristics), however once this forced gene expression is removed, the cells slowly revert back to their original state. Therefore, none of the three above mechanisms should be considered true reprogramming: the first is considered natural differentiation which is part of a cell program that is already in place (going from a more undifferentiated to a more differentiated state), the second is a transient phenotypical change, and the third is a constantly forced cell type. A true stem cell: (i) self-renews almost ‘indefinitely’ (for significantly longer than a somatic cell), (ii) is not a cancerous cell, (iii) is not artificially maintained by forced gene expression or similar means (must also be able to be maintained in standard stem cell media), (iv) can differentiate to progenitor, precursor, somatic or other more differentiated cell type (of the same lineage), and (v) has all the characteristics of a stem cell and not just certain markers or gene expression or morphological appearance.
  • Despite the numerous scientific and patent publications claiming successful reprogramming or dedifferentiation, generally into a stem cell, almost all of these publications do not disclose true reprogramming because they fall under one of the mechanisms mentioned above. For instance, Bhasin (WO2010/088735), Cifarelli et al. (US2010/0003223), Kremer et al. (US2004/0009595), and Winnier et al. (US2010/0047908) all refer to reprogramming, dedifferentiation, and/or obtained stem cells (or progenitors) as phenotypical cell changes based only on a change in cell surface markers after culture in different media with supplements, with no evidence of true reprogramming or an actual stem cell (non-cancerous self-renewal with stem cells markers and no differentiation markers). The same is true for Benneti (WO2009/079007) who used increased expression of Oct4 and Sox2. Others, such as Akamatsu et al. (WO2010/052904) and You et al. (WO2007/097494, US2009/0246870), refer to having made stem cells, but these came about through constant artificial gene induction delivered by retrovirus (similar to cMyc) with no evidence of true stem cells that are not immortal/tumorigenic, and stable instead of transient. Others, such as Chen et al. (US2005/0176707) and You et al. (US2009/0227023), have made “multipotent cells”, but not stem cells. In addition these alleged multipotent cells were not stable (in the case of You et al. the cells could not even proliferate) and both used constant media supplements and conditions to force the phenotypical change. Yet others, such as Oliveri et al. (WO2009/018832) and Zahner et al. (US2002/0136709), have claimed the making of pluripotent, totipotent, multipotent, and/or unipotent cells automatically through genome-wide DNA demethylation and histone acetylation, but with no evidence of a stable, non-cancerous, true cell line.
  • True reprogramming appears to have been achieved with induced pluripotent stem cells (iPS cells) created independently by Yamanaka's group (Takahashi et al., 2007) and Thomson's group (Yu et al., 2007), and potentially by others before them, and although many of these cells were later found to be cancerous, some of them were not. These cells can be induced by true reprogramming since it was later shown that they can also be induced by non-gene integrating transient transfection (Soldner et al., 2009; Woltjen et al., 2009; Yu et al., 2009) as well as by RNA (Warren et al., 2010) or protein (Kim et al., 2009; Zhou et al., 2009) alone or by small molecules (Lyssiotis et al., 2009), and by similar methods. However, these cells are essentially identical to embryonic stem cells and have the same problems of uncontrolled growth, teratoma formation, and potential tumor formation.
  • A more desirable option is to have multipotent stem cells or pluripotent-like cells whose lineage and differentiation potential is more restricted so that they do not readily form teratomas and uncontrolled growth. There is thus a need for methods of creating multipotent stem cells, multipotent stem-like cells, and stem-like cells and method of reprogramming or transforming easily obtainable cells to highly desirable multipotent stem cells, multipotent stem-like cells, and stem-like cells.
    • Neural Stem-Like Cells (NSLC)
  • Repairing the central nervous system (CNS) is one of the frontiers that medical science has yet to conquer. Conditions such as Alzheimer's disease, Parkinson's disease, and stroke can have devastating consequences for those who are afflicted. A central hope for these conditions is to develop cell populations that can reconstitute the neural network, and bring the functions of the nervous system back in line. For this reason, there is a great deal of evolving interest in neural stem and progenitor cells. Up until the present time, it was generally thought that multipotent neural progenitor cells commit early in the differentiation pathway to either neural restricted cells or glia restricted cells.
  • Neural stem cells have promise for tissue regeneration from disease or injury; however, such therapies will require precise control over cell function to create the necessary cell types. There is not yet a complete understanding of the mechanisms that regulate cell proliferation and differentiation, and it is thus difficult to fully explore the plasticity of neural stem cell population derived from any given region of the brain or developing fetus.
  • The CNS, traditionally believed to have limited regenerative capabilities, retains a limited number of neural stem cells in adulthood, particularly in the dentate gyrus of the hippocampus and the subventricular zone that replenishes olfactory bulb neurons (Singec I et al., 2007; Zielton R, 2008). The availability of precursor cells is a key prerequisite for a transplant-based repair of defects in the mature nervous system. Thus, donor cells for neural transplants are largely derived from the fetal brain. This creates enormous ethical problems, in addition to immuno-rejection, and it is questionable whether such an approach can be used for the treatment of a large number of patients since neural stem cells can lose some of their potency with each cell division.
  • Neural stem cells provide promising therapeutic potential for cell-replacement therapies in neurodegenerative disease (Mimeault et al., 2007). To date, numerous therapeutic transplantations have been performed exploiting various types of human fetal tissue as the source of donor material. However, ethical and practical considerations and their inaccessibility limit the availability as a cell source for transplantation therapies (Ninomiy M et al., 2006).
  • To overcome barriers and limitations to the derivation of patient specific cells, one approach has been to use skin cells and inducing the trans-differentiation to neural stem cells and/or to neurons (Levesque et al., 2000). Transdifferentiation has been receiving increasing attention during the past years, and trans-differentiation of mammalian cells has been achieved in co-culture or by manipulation of cell culture conditions. Alteration of cell fate can be induced artificially in vitro by treatment of cell cultures with microfilament inhibitors (Shea et al., 1990), hormones (Yeomans et al., 1976), and Calcium-ionophores (Shea, 1990; Sato et al., 1991). Mammalian epithelial cells can be induced to acquire muscle-like shape and function (Paterson and Rudland, 1985), pancreatic exocrine duct cells can acquire an insulin-secreting endocrine phenotype (Bouwens, 1998a, b), and bone marrow stem cells can be differentiated into liver cells (Theise et al., 2000) and into neuronal cells (Woodbury et al., 2000). Other such as Page et al. (US 2003/0059939) have transdifferentiated somatic cells to neuronal cells by culturing somatic cells in the presence of cytoskeletal, acetylation, and methylation inhibitors, but after withdrawal of the priming agent, neuron morphology and established synapses last for not much than a few weeks in vitro, and complete conversion to a fully functional and stable type of neuron has never been demonstrated. These are thus transient cell phenotypes. Complete conversion to a fully functional and stable type of neuroprogenitor or neural stem cell has also never been demonstrated. Acquisition of a stable phenotype following transdifferentiation has been one of the major challenges facing the field.
  • Thus, there is a need in the biomedical field for stable, potent, and preferably autologous neural stem cells, neural progenitor cells, as well as neurons and glial cells for use in the treatment of various neurological disorders and diseases. The same is true for many other types of cells. Recently, evidence have been obtained that genes of the basic Helix-Loop-Helix (bHLH) class are important regulators of several steps in neural lineage development, and over-expression of several neurogenic bHLH factors results in conversion of non-determined ectoderm into neuronal tissue. Proneural bHLH proteins control the differentiation into progenitor cells and their progression through the neurogenic program throughout the nervous system (Bertrand et al., 2002). MASH1, NeuroD, NeuroD2, MATH1-3, and Neurogenin 1-3 are bHLH transcription factors expressed during mammalian neuronal determination and differentiation (Johnson et al., 1990; Takebyashi et al., 1997; McCormick et al., 1996; Akazawa et al., 1995). Targeted disruptions of MASH1, Ngn1, Ngn2 or NeuroD in mice lead to the loss of specific subsets of neurons (Guillemot et al., 1993; Fode et al., 1998; Miyata et al., 1999).
  • U.S. Pat. No. 6,087,168 (Levesque et al.,) describes a method for converting or transdifferentiating epidermal basal cells into viable neurons. In one example, this method comprises the transfection of the epidermal cells with one or more expression vector(s) containing at least one cDNA encoding for a neurogenic transcription factor responsible for neural differentiation. Suitable cDNAs include: basic-helix-loop-helix activators, such as NeuroD1, NeuroD2, ASH1, and zinc-finger type activators, such as Zic3, and MyT1. The transfection step was followed by adding at least one antisense oligonucleotide known to suppress neuronal differentiation to the growth medium, such as the human MSX1 gene and/or the human HES1 gene (or non-human, homologous counterparts). Finally, the transfected cells were grown in the presence of a retinoid and a least one neurotrophin or cytokine, such as brain derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin 3 (NT-3), or neurotrophin 4 (NT-4). This technology yields 26% of neuronal cells; however, neither functionality nor stability of these cells was established. In addition, neural stem cells or neuroprogenitor cells are not produced according to this method.
  • A later process (Levesque et al., 2005; U.S. Pat. No. 6,949,380) mentions the conversion of the epidermal basal cell into a neural progenitor, neuronal, or glial cell by exposing the epidermal basal cell to an antagonist of bone morphogenetic protein (BMP) and growing the cell in the presence of at least one antisense oligonucleotide comprising a segment of a MSX 1 gene and/or HES1 gene. However, there is no evidence or examples that any neural progenitors or glial cells were produced according to this method, let alone any details or evidence that morphological, physiological or immunological features of neuronal cells was achieved. In addition, since there is also no information on functionality, stability, expansion, and yield about the cells which may or may not have been produced, it is possible that these cells actually are skin-derived precursor cells (Fernandes et al., 2004) that have been differentiated into neuronal cells.
  • In view of the above, there is thus a need for stable, potent, and preferably autologous neural stem cells, neural progenitor cells, neurons and glial cells, as well as other types of cells, stem cells and progenitor cells. There is also a need for methods that could result in true cell dedifferentiation and cell reprogramming.
  • The present invention addresses these needs and provides various types of stem-like and progenitor-like cells and cells derived or differentiated from these stem-like or progenitor-like cells, as well as methods that can result in true cell dedifferentiation and cell reprogramming.
  • Additional features of the invention will be apparent from a review of the disclosure, figures and description of the invention herein.
    • SUMMARY OF THE INVENTION
  • The present invention relates to stem-like and progenitor-like cells and cells derived or differentiated from these stem-like or progenitor-like cells. The invention further relates to methods for cell dedifferentiation and cell reprogramming. The invention further features compositions and methods that are useful for reprogramming cells and related therapeutic compositions and methods.
  • One particular aspect relates to the development of a technology to reprogram a somatic cell or non-neuronal cell to a cell having one or more morphological physiological, and/or immunological features of a neural stem cell and which possess the capacity to differentiate along neuronal and glial lineages. According to some embodiments, the invention is more particularly concerned with methods of generating stable Neural Stem-Like Cells (NSLCs) from human somatic cells, human progenitor cells and/or of human stem cells, as well as cells, cell lines and tissues obtained by using such methods.
  • The invention further relates to compositions and methods to induce de-differentiation of human somatic cells into Neural Stem-Like Cells that express neural stem cell specific markers. According to the present invention it is possible to effect the conversion of cells to various types of differentiated neuronal cells that can be created from a single cell type taken from an individual donor and then reprogrammed and transplanted into the same individual. Upon induction cells according to the invention express neural stem-cell specific markers and become Neural Stem-Like cells.
  • According to one particular aspect, the invention relates to a method of transforming a cell of a first type to a desired cell of a different type. The comprises i) obtaining a cell of a first type; ii) transiently increasing in the cell of a first type intracellular levels of at least one reprogramming agent, whereby the transient increase induces direct or indirect endogenous expression of at least one gene regulator; iii) placing the cell in conditions for supporting the growth and/or the transformation of the desired cell and maintaining intracellular levels of the at least one reprogramming agent for a sufficient period of time to allow stable expression of the at least one gene regulator in absence of the reprogramming agent; and iv) maintaining the cell in culture conditions supporting the growth and/or the transformation of the desired cell. Such conditions are maintained for a sufficient period of time to allow a stable expression of a plurality of secondary genes. According to the invention the expression of one or more of the secondary genes is characteristic of phenotypical and functional properties of the desired cell while being not characteristic of phenotypical and functional properties of an embryonic stem cell. Therefore, at the end of the period of time, the desired cell of a different type is obtained.
  • According to another particular aspect, the invention relates to a method of transforming a cell of a first type to a cell of a second different type. The method comprises contacting the cell of a first type with one or more agents capable of increasing within said cell levels of at least one reprogramming agent and directly or indirectly remodeling the chromatin and/or DNA of the cell. The at least one reprogramming agent is selected for inducing directly or indirectly the expression of morphological and functional characteristics of a desired cell of a different type or different cell lineage.
  • According to another aspect, the invention relates to a method of transforming a cell of a first type to a cell of a second different type. The method comprises contacting the chromatin and/or DNA of a cell of a first type with an agent capable of remodeling chromatin and/or DNA of said cell; and increasing intracellular levels of at least one reprogramming agent. The at least one reprogramming agent is selected for inducing directly or indirectly the expression of morphological and functional characteristics of a desired cell of a different type or cell lineage.
  • A further aspect of the invention relates to a method of transforming a cell of a first type to a cell of a desired cell of a different type, comprising increasing intracellular levels of at least one reprogramming agent, wherein the at least one reprogramming agent is selected for inducing directly or indirectly the expression of morphological and functional characteristics of a desired second cell type; and maintaining the cell of a first type in culture conditions for supporting the transformation of the desired cell for a sufficient period of time to allow stable expression of a plurality of secondary genes whose expression is characteristic of phenotypical and functional properties of the desired cell, wherein at least one of the secondary genes is not characteristic of phenotypical and functional properties of an embryonic stem cell. At the end of the period of time the desired cell of a different type is obtained and the obtained cell is further characterized by a stable repression of a plurality of genes expressed in the first cell type.
  • A further aspect of the invention concerns a process wherein a cell of a first type is reprogrammed to a desired cell of a different type, the process comprising:
      • a transient increase of intracellular levels of at least one reprogramming agent, wherein the at least one reprogramming agent induces a direct or indirect endogenous expression of at least one gene regulator, and wherein the endogenous expression of the said at least one gene regulator is necessary for the existence of the desired cell of a different type;
      • a stable expression of said at least one gene regulator;
      • stable expression of a plurality of secondary genes, wherein the stable expression of the secondary genes is the result of the stable expression of the at least one gene regulator, and wherein: (i) stable expression of the plurality of secondary genes is characteristic of phenotypical and/or functional properties of the desired cell, (ii) stable expression of at least one of said secondary genes is not characteristic of phenotypical and functional properties of an embryonic stem cell, and wherein (i) and (ii) are indicative of successful reprogramming of the cell of the first type to the desired cell of the different type.
  • In particular embodiments, the at least one reprogramming agent in the process is a Msi1 polypeptide, or a Ngn2 polypeptide together with a MDB2 polypeptide. In particular embodiments, the at least one gene regulator is Sox2 Msi1, or both. In additional embodiments the at least one gene regulator may is one or more of the genes listed in Table A for Neural Stem-Like Cells.
  • According to another aspect, the invention relates to a method of obtaining a Stem-Like Cell (SLC), comprising:
      • i) providing a cell of a first type;
      • ii) transiently increasing in the cell intracellular levels of at least one reprogramming agent, whereby the transient increase induces direct or indirect endogenous expression of at least one gene regulator;
      • iii) placing the cell in conditions for supporting the transformation into the stem-like cell and maintaining intracellular levels of the at least one reprogramming agent for a sufficient period of time to allow stable expression of the at least one gene regulator in absence of the reprogramming agent;
      • iv) maintaining the cell in culture conditions for supporting the transformation into the stem-like cell for a sufficient period of time to allow stable expression of a plurality of secondary genes whose expression is characteristic of phenotypical and/or functional properties of the stem-like cell, wherein at least one of the secondary genes is not characteristic of phenotypical and functional properties of an embryonic stem cell. At the end of said period of time a stem-like cell is obtained.
  • According to another aspect, the invention relates to a method of obtaining a Stem-Like Cell. The method comprises increasing intracellular levels of at least one polypeptide specific to the desired stem cell type that is able to drive directly or indirectly transformation of the cell of the first type into the Stem-Like Cell. For increasing the yield or type of Stem-Like Cell, the method may further comprises contacting chromatin and/or DNA of a cell of a first type with a histone acetylator, an inhibitor of histone deacetylation, a DNA demethylator, and/or an inhibitor of DNA methylation; and/or increasing intracellular levels of at least one other polypeptide specific to the desired stem cell type that is able to drive directly or indirectly transformation of the cell of the first type into a Stem-Like Cell.
  • According to another aspect, the invention relates to a method of obtaining a Neural Stem-Like Cell (NSLC). The method comprises increasing intracellular levels of at least one neural stem cell specific polypeptide that is able to drive directly or indirectly transformation of the cell of the first type into a NSLC. For increasing the yield or type of NSLC, the method further comprises. contacting chromatin and/or DNA of a cell of a first type with a histone acetylator, an inhibitor of histone deacetylation, a DNA demethylator, and/or an inhibitor of DNA methylation; and/or increasing intracellular levels of at least one other neural stem cell specific polypeptide that is able to drive directly or indirectly transformation of the cell of the first type into a NSLC.
  • Another aspect of the invention concerns a method of obtaining a Neural Stem-Like Cell (NSLC). In one embodiment the method comprises transfecting a skin cell with a polynucleotide encoding Musashi1, Musashi1 and Neurogenin 2, Musashi1 and Methyl-CpG Binding Domain Protein 2 (MBD2), or Neurogenin 2 and Methyl-CpG Binding Domain Protein 2, thereby reprogramming the skin cell into a NSLC. In another embodiment the method comprises exposing a skin cell to: (i) an inhibitor of histone deacetylation, (ii) an inhibitor of DNA methylation, (iii) a histone acetylator, and/or (iv) a DNA demethylator such as a MBD2 polypeptide and/or transfecting with a polynucleotide encoding a MBD2 polypeptide; and further transfecting the cell (either simultaneously, before, or afterwards) with a polynucleotide encoding MUSASHI1 and/or with a polynucleotide encoding NGN2, thereby reprogramming the skin cell into a NSLC. Some other cells, such as keratinocytes and CD34+ cells, can also be used and reprogrammed.
  • In one particular embodiment, the method of obtaining a Neural Stem-Like Cell (NSLC), comprises:
      • providing a cell of a first type;
      • introducing into the cell one or more polynucleotide capable of transient expression of one or more the following polypeptides: Musashi1 (Msi1); a Musashi1 (Msi1) and a Neurogenin 2 (Ngn2); a Musashi1 (Msi1) and methyl-CpG binding domain protein 2 (MBD2); and Neurogenin 2 (Ngn2) and methyl-CpG binding domain protein 2 (MBD2); and
      • placing the cell in culture conditions supporting the transformation into a NSLC for a sufficient period of time to allow a stable expression of a plurality of genes whose expression is characteristic of phenotypical and functional properties of a NSLC.
  • At the end of the period of time a NSLC is obtained and the obtained NSLC is further characterized by a stable repression of a plurality of genes expressed in the first cell type.
  • According to another embodiment, the method of obtaining a Neural Stem-Like Cell (NSLC), comprises:
      • providing a cell of a first type which is not a NSLC;
      • increasing intracellular levels of at least one neural stem cell specific polypeptide, wherein the polypeptide is capable of driving directly or indirectly transformation of the cell of the first type into a NSLC; and
      • contacting the chromatin and/or DNA of the cell of a first type with a histone acetylator, an inhibitor of histone deacetylation, a DNA demethylator, and/or a chemical inhibitor of DNA methylation.
  • According to another embodiment, the method of obtaining a Neural Stem-Like Cell (NSLC), comprises:
      • obtaining a non-NSLC;
      • co-transfecting the non-NSLC with a first polynucleotide encoding a MBD2 polypeptide and with at least one second polynucleotide encoding a MUSASHI1 polypeptide and/or encoding a NGN2 polypeptide;
      • placing the co-transfected cell in culture conditions for supporting the transformation of NSLC until said NSLC is obtained.
  • Certain aspects of the invention concerns isolated cells, cell lines, compositions, 3D assembly of cells, and tissues comprising cells obtained using the methods described herein. Additional aspects concerns the use of such isolated cells, cell lines, compositions, 3D assembly of cells, and tissues of medical treatment and methods of regenerating a mammalian tissue or organ.
  • Yet, a further aspect concerns a method for repairing or regenerating a tissue in a subject. In one embodiment the method comprises the administration of a reprogrammed cell as defined herein to a subject in need thereof, wherein the administration provides a dose of reprogrammed cells sufficient to increase or support a biological function of a given tissue or organ, thereby ameliorating the subject's condition.
  • The benefits of the present invention are significant and include lower cost of cell therapy by eliminating the need of immuno-suppressive agents, no need for embryos or fetal tissue, thus eliminating ethical and time constraints, lower cost of production, and no health risks due to possible transmission of viruses or other disease. In addition, since the cells are created fresh, they tend to be more potent than cells that have been passaged multiple times.
  • Additional aspects, advantages and features of the present invention will become more apparent upon reading of the following non-restrictive description of preferred embodiments which are exemplary and should not be interpreted as limiting the scope of the invention.
    • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 is a panel of light micrograph (10×) presenting cell morphology changes of untransfected and transfected cells with Msi1 and MBD2 at various time points.
  • FIG. 2 is a panel of photomicrographs obtained using Cellomics™ (10×) and revealing NCAM positive cells in transfected cells with Msi1 or Ngn2 in the presence of MBD2. HFFs were pre-treated with cytochalasin B (10 μg/ml) and transfected with pCMV6-XL5-Msi1 and pCMV6-XL5-MBD2 or pCMV6-XL4-Ngn2 and pCMV6-XL5-MBD2. After 24 h following transfection, the medium was changed and cells were cultured in proliferation medium (NPBM, Lonza) supplemented with EGF (20 ng/ml) and bFGF (20 ng/ml) for one week. Differentiation was induced by changing the medium to NbActive (BrainBits™) supplemented with NGF (20 ng/ml), bFGF (20 ng/ml), ATRA (5 μM) and Forskolin (10 μM). Cells were incubated at 37° C., 5% CO2, 5% O2 for 20 days.
  • FIG. 3 is a panel of photomicrographs obtained using Cellomics™ (10×) and revealing MAP2b positive cells in transfected cells with Msi1 or Ngn2 in the presence of MBD2. MAP2b positive cells were undetectable in untransfected cells and cells transfected with Pax6/MBD2. HFFs were pre-treated with cytochalasin B (10 μg/ml) and transfected with pCMV6-XL5-Msi1, pCMV6-XL4-Ngn2 or pCMV6-XL5-Pax6, and pCMV6-XL5-MBD2. After 24 h following transfection, the medium was changed and cells were cultured in proliferation medium (NPBM, Lonza) supplemented with EGF (20 ng/ml. Peprotech) and bFGF (20 ng/ml, Peprotech) for one week. Differentiation was induced by changing the medium to NbActive (BrainBits™) supplemented with NT-3 (20 ng/ml), bFGF (20 ng/ml), ATRA (5 μM) and Forskolin (10 μM). Cells were incubated at 37° C., 5% CO2, 5% O2 for 2 weeks.
  • FIG. 4. (A) is a panel of photographs showing that neurospheres formed by NSLCs from Example V were completely dissociated into single cell suspensions using Accutase and one single cell was monitored over time to reveal neurosphere formation capacity (Light microscope observation). Neurospheres stained positive for Sox2. (B) is a panel of photographs from immunohistochemistry results obtained using Cellomics™. Immunohistochemistry was performed, on day 20, to detect makers for neurospheres and compared to expression levels in neurospheres formed by normal human neuroprogenitor cells (hNPC, Lonza). In addition to Sox2, cells stained positive for the neural stem cells markers Musashi, CD133, Nestin, and GFAP. Cells also stained positive for βIII-tubulin (a marker for neurons), O4 (a marker for oligodendrocytes), and GFAP (a marker for astrocytes), indicating the tri-potent differentiation potential of both sets of cells (NSLC and hNPC), and negative for NGFrec and NeuN (markers for differentiated neurons) indicating that the cells were not terminally differentiated.
  • FIG. 5 is a panel photomicrographs from immunohistochemistry results obtained using Cellomics™. Immunohistochemistry was performed on HFFs, NSLCs, and hNPCs to detect expression of markers for fibroblasts as well as neural stem cells (Sox2, Nestin, GFAP) in adherent cultures (that prevented cells from floating and forming neurospheres). Nuclei were stained with Hoechst (upper level pictures). HFFs expressed fibroblasts markers while NSLCs created from these HFFs did not. In comparison, the NSLCs expressed neural stem cell markers similarly to hNPCs while the HFFs did not express any of these markers.
  • FIG. 6 is a panel photomicrographs showing Human NSLCs. Human NSLCs were induced to differentiate into neuronal lineages in the presence of NS-A differentiation medium (StemCell Technologies) in the presence of BDNF (20 ng/ml, Peprotech) and bFGF (40 ng/ml, Peprotech) for three weeks. At different time point of differentiation, immunostaining using Cellomics™ (10×) revealed differentiation of the cells as shown by the decrease of Sox2 positive cells and increase in the number and intensity of staining of p75, βIII-tubulin and GABA positive cells, as well as differentiated morphology, while the total number of cells increased as shown by Hoechst staining.
  • FIG. 7 is another panel of photomicrographs. HFF, Keratinocytes, and CD34+ were transfected with pCMV6-Msi1-Ngn2 and pCMV6-XL5--MBD2. After 24 h following transfection, the medium was changed to proliferation medium (StemCell Technologies) supplemented with EGF (20 ng/ml. Peprotech) and bFGF (20 ng/ml, Peprotech) for two week and then analyzed. Photomicrographs using Cellomics™ (10×) show that NSLCs created from all three types of cells are positive for Nestin, Sox2 and GFAP (markers for neural stem cells), while the original HFFs are not.
  • FIG. 8 is panel of photomicrographs showing the effect of CDM medium on the trans-differentiation of HFF towards neurons. HFF were pre-treated with cytochalasin B (10 μg/ml) and histone deacetylation inhibitor (VPA, 4 mM) and DNA methylation inhibitor (5-Aza, 5 μM and cultured in CDM medium containing 3:1 ratio of Dulbecco's modified Eagle medium (DMEM, high glucose (4.5 g/L) with L-glutamine and sodium pyruvate) and Ham's F-12 medium supplemented with the following components: EGF (4.2×10−10M), bFGF (2.8×10−10M), ITS (8.6×10−5M), dexamethasone (1.0×10−7M), L-ascorbic acid phosphate magnesium salt n-hydrate (3.2×10−4M), L-3,3′,5-triiodothyronine (2.0×10−10M), ethanolamine (10−4M), GlutaMAX™ (4×10−3M), glutathione (3.3×10−6M). After 24 h the culture medium was replaced with 75% of CDM medium and 25% of Neuronal Proliferation medium (Lonza, Cat # CC-3210); during the following 3 days, the ratio of the medias were changed to 50%:50%, 25%:75%, and then 100% Neuronal Proliferation medium by the third day. Photomicrographs were taken by Cellomics™ (10×) after immunostaining the cells with βIII-tubulin (neuronal marker) and Hoechst (to stain nuclei) at different time-points. Cells started trans-differentiating within a few days and the trans-differentiated cells were βIII-tubulin positive; however after one week a spontaneous reversion to fibroblastic shape and loss of βIII-tubulin expression was observed.
  • FIG. 9 is panel of photomicrographs showing characterization of reprogrammed cells within CDM at different time points following the transfection with Msi1 and Ngn2. The transfected cells were treated with Cytochalasin B (10 μg/ml), VPA (4 mM) and 5-AZA (5 μM) resulting in a disruption of the microfilaments and rounding up of the cells and loosening of the chromatin. Immunohistochemistry on the 3-Dimensional CDM was performed after one and two weeks using Cellomics™ (10×). The cells were positive for neuronal mature marker, such as MAP2b, but were absent in the untransfected control CDM.
  • FIG. 10 is another panel of photomicrographs. Cells within Day 4 CDM were lipotransfected with the two vectors pCMV6-XL5-Msi1 and pCMV6-XL4-Ngn2 individually or together in combination with pCMV-XL5-MBD2 for a period of 6 hours. In parallel, transfection was performed on fresh HFFs after the 6 hours using Nucleofection, and these fresh HFFs were placed on top of the CDM at the same time as the lipofectamine media was changed to fresh CDM medium after 6 hours. After 24 hours the medium was changed to Neural proliferation medium (NPBM, Lonza) with the presence of Noggin (50 ng/ml, Peprotech), recombinant hFGF (20 ng/ml, Peprotech), and recombinant hEGF (20 ng/ml, Peprotech) for one week. Differentiation was induced at day 7, by adding NS-A differentiation medium (StemCell Technologies) for 24 days. Immunohistochemistry was performed at various time points using Cellomics™ (10×). The CDM was stained with a specific antibody against Nestin (a marker for neural stem cells), and cells within the CDM expressed Nestin at all timepoints tested ( Day 8, 15, and 21) following transfection. Cells within the untransfected control CDM did not express any Nestin.
  • FIG. 11 is a panel showing a picture of a polyacrylamide gel electrophoresis. NSLCs grown as adherent cultures or suspension cultures (as neurospheres) both express telomerase (which is expresses in all stem cells, but not in normal differentiated somatic cells). Both early (p5) and late (p27) passage NSLCs express telomerase. (The original HFFs from which the NSLCs were created did not express telomerase.) The samples (NSLCs) were spun down and protein concentration of the supernatant was determined using the BCA Assay. 900 ng of protein from each cell extract was added directly to the TRAP reaction mixture containing TRAP reaction buffer, dNTPs, template substrate (TS) primer, TRAP primer mix and Taq polymerase. The reaction mixtures were incubated at 30° C. for 30 minutes for template synthesis, followed by a PCR procedure (95° C./15 min for initial denaturation, 94° C./30 sec, 59° C./30 sec, 72° C./1 min for 32 cycles) for amplification of the extended telomerase products. To detect telomerase activity, polyacrylamide gel electrophoresis (PAGE) was performed for the reaction products on a 10% non-denaturing TBE gel. After electrophoresis, the gel was stained with SYBR® Green I Nucleic Acid Gel Stain for 30 minutes, followed by image capture using the Gel-Documentation System (Alpha Innotech). All 4 samples were telomerase positive (as indicated by the TRAP product ladder).
  • FIG. 12 is a panel showing a picture showing Southern blot analysis of two different NSLC samples analyzed for Msi1 and Ngn2 gene integration two weeks after transient transfection. The Dig-labeled PCR probe revealed distinct signals in the positive control samples where the Msi1/Ngn2 plasmid DNA was spiked into HFF genomic DNA for the equivalence of 1, 10 or 100 integrations per genome. There were a few weak and identical bands that appeared in the restriction enzyme digested genomic DNA from untransfected HFF and NSLC samples #1 and #2, suggesting that there was no plasmid DNA integration into the genomic DNA of NSLCs. These faint bands may represent the endogenous Ngn2 gene since the 1.2 kb Dig-labeled PCR probe contains a small part of the Ngn2 gene. There were positive signals in the lane of the DNA kb ladder as the bands belong to a number of plasmids digested to completion with appropriate restriction enzymes (NEB). This data shows that no, or only a tiny number of, NSLCs had plasmid integration into the host genome after transient transfection, and that the transiently transfected genes were only present in the cells for a short period of time (less than two weeks).
  • FIG. 13 is a panel with a line graph and a bar graph showing improvement and significantly better clinical scores in EAE mice treated with NSLCs. Female 8 weeks old C57BL/6 mice were immunized with MOG35-55 (Sheldon Biotechnology Centre McGill University) in CFA containing 5 mg/ml of desiccated (killed and dried) Mycobacterium tuberculosis H37Ra (Difco, inc) at two sites on the back, and injected with 200 ng of pertussis toxin (List Biological Laboratories, Inc) in PBS intraperitoneally on days 0 and 2. Once the mice started showing symptoms of EAE (on Day 13 post-immunization), they were intravenously injected with 200 μl of NSLC (1 million cells), hNPC (1 million cells), saline, or saline with cyclosporine. All mice except the saline control group received daily injections of cyclosporine. Mice were scored daily for clinical disease; data represent average daily scores. Mice that received a single injection of NSLCs had a significantly lower disease severity than mice that received hNPCs or cyclosporine alone.
  • FIG. 14 is a line graph showing the results of rotarod assessments according to Example XVII part 2. Rats were trained on the rotarod prior to the start of the experiment. Rats were placed on a stationary and rotating rotarod (rotating at 20 rpm) and the amount of time spent by the rats walking on the rotarod before falling off was monitored. Measurements were taken before (pre-surgery) and after (post-surgery) surgical left brain hemisphere ablation and treatment. The data points represent the mean number of falls by each animal during each 60 second testing session carried out at a constant speed of 20 rpm. Each group consisted of eight rats.
  • FIG. 15 is a line graph showing the results of the walking beam assessments according to Example XVII part 2. Rats were measured on their ability to cross a 100 cm long beam after surgical left brain hemisphere ablation and treatment. Two days after surgery, all groups fail to pass the test, and the animals are not able to stay in balance on the beam. One week after the surgery, all the animals show an improvement on their walking capacity, but no significant difference was noticeable between the different treated groups. From week 4 until week 26, the animals treated with NSLCs show significant improvement in their walking capacity compared to the other groups.
  • FIG. 16 is a panel showing photographs of ADSCs transiently transfected with various pluripotent vectors using nucleofector as described in Example XIX. Following the transfection cells were cultured in 6-well plates in suspension with a 50:50 mixture of ADSC complete medium (StemPro™-43) and embryonic stem cells medium (mTeSR1™, StemCell Technologies). After two days in culture, cells were re-transfected with the same plasmids and plated in 96 well-plates coated with Matrigel™ (BD Biosciences) in the presence of mTeSR1™ complete medium supplemeneted with thiazovivin (0.50), an ALK-5 inhibitor (SB341542, Stemgent, 20), and an inhibitor of MEK (PD0325901, Stemgent, 0.50). Medium was changed every day and cells were cultured for 22 days at 37° C., 5% CO2, 5% O2, followed by AP staining and immunohistochemistry to analyse the expression of pluripotency markers. Cells formed colonies and were found to express both pluripotency markers Oct4 and AP after transfecting cells with pEF-Rex1-EF-Oct4-2A-Klf4-2A-RFP.
  • FIG. 17 is a panel showing photographs of ADSCs transiently transfected with pCMV6-XL5-Rex1/pCMV6-XL5-Klf4 and pCMV6-XL5-Rex1/pCMV6-XL4-Oct4. After the second transfection, ADSCs were cultured in 96-well plates coated with Matrigel™ for 24 days in the presence of mTeSR1™ medium supplemented with SB341542 and PD0325901 at 37° C., 5% CO2, 5% O2. In order to characterize subpopulations of cells after transfection, live staining, immunohistochemistry and AP staining were used. 1-5% of total cells transfected with Rex1/Oct4 or Rex1/Klf4 showed a SSEA-4+ and TRA-1-81+ phenotype (early pluripotency markers). The observation over time showed that the phenotype of these colonies moves from an early SSEA-4+ phenotype to a late Oct4+/Sox2/Nanog+ phenotype starting at Day 22, which was closer to the final reprogrammed state and a pluripotent-like cell.
  • FIG. 18 is a panel showing photographs of ADSCs transiently transfected with various pluripotent vectors. Following transfection the cells were plated in StemPro™ MSC SFM medium on Matrigel™ (BD Biosciences) coated 24 well plates and incubated at 37° C., 5% CO2, 5% 02. On day 1, media was changed to a mix of 75% StemPro™ MSC and 25% hES cell medium; the percentage of StemPro™ MSC SFM medium was decreased every day over four days to have 100% hES cell medium by day 4. Then medium was changed every two days. The hES cell medium consisted in Dulbecco's Modified Eagle's Medium (DMEM, Invitrogen) supplemented with 20% Knockout™ Serum Replacement (KSR, Invitrogen), 1 mM GlutaMAX™, 100 μM Non-essential Amino acids, 100 μM 3-mercaptoethanol and 10 ng/ml Fgf-2. In order to characterize subpopulations of cells after transfection, live staining, immunohistochemistry and AP staining were used. Transfected cells transfected with Oct4/UTF1/MBD2, Oct4/Dppa4/MBD2, FoxD3/Dppa4/MBD2, Oct4/FoxD3/Dppa4, and Sox2/FoxD3/UTF1 were positive for SSEA-4+, TRA1-60, and TRA-1-81+ phenotype (early pluripotency markers) at day 14.
  • FIG. 19 is a panel showing photographs of transiently transfected HFFs. HFFs were transiently transfected using the Nucleofector® II Device (Lonza) following the procedure described in Example II with the exception that 1 μg of each of the following 3 DNA plasmids was used: pCMV-Oct4nuc-IRES2-Sox2nuc, pCMV-Klf4nuc-IRES2-Cmycnuc and pCMV-Nanognuc-IRES2-Lin28. The cells were pre-treated with or without VPA and 5-Aza. Following transfection the cells were plated in the fibroblast medium, supplemented with or without VPA (2 mM) and 5-AZA (2.5 μM) on Matrigel™ (BD Biosciences) coated 6-well plates and incubated at 37° C., 5% CO2. On Day 1 and 2, media was changed to 100% mTeSR1™ medium (StemCell Technologies) supplemented with or without VPA and 5-AZA. On Day 3 and 6, cells were re-transfected as above and plated on Matrigel™ coated plates in mTeSR1™ medium supplemented with or without VPA and 5-AZA. Media was changed daily as above. Medium was supplemented with Y27632 (Stemgent, 10 μM) from Day 7 to Day 14 to promote viability and clonal expansion of potential reprogrammed cells. Cells were analysed at day 20 using the Alkaline Phosphatase Detection Kit (Millipore) and by immunohistochemistry analysis. Some cells stained positive for the pluripotency markers AP, SSEA-4 and TRA-1-81 (similar to MeI2 human embryonic stem cell line (positive control)). These clones were obtained only in the condition that did not contain inhibitors (i.e.: VPA and 5-AZA). No clones were observed for the condition treated with these inhibitors.
  • FIG. 20 is a panel showing photographs of transfected NSLCs and BG-01. NSLCs and BG-01 NS were transfected as previously described in Example II by two episomal vectors, pEF-Oct4nuc-IRES2-MBD2 (NC1) or pCMV-FoxD3-2A-Oct4-2A-Klf4 (F72). Following transfection cells were collected and plated onto uncoated petri-dishes in the presence of Proliferation medium and mTeSR1™ medium (50:50) into proliferation conditions at 37° C., 5% CO2. After 48 hours, cells were re-transfected by the same plasmid and plated in 96-well plates coated with Matrigel™ and cultured in the presence of mTeSR1™ medium supplemented by the small molecules BIX01294 (Stemgent, 2 μM) and BayK8644 (Stemgent, 2 μM) at 37° C., 5% O2 for 22 days, after which live staining and immunohistochemistry were performed to characterize subpopulations of cells for pluripotency markers. Cells formed colonies positive for both TRA-1-81 and SSEA-4 indicative of pluripotent-like cells.
  • FIG. 21 is a panel showing bright field pictures at day 17 of fibroblasts transfected with Msi1/Ngn2 and pCMV6-XL5-MBD2 placed in different media conditions and showing different morphologies and degree of differentiation. (a) Cells in neural proliferation medium from day 1 to day 12, and then in neural differentiation medium with cytokines from day 12 to 17. (b) Cells in neural proliferation medium from day 1 to day 12, and then in NbActive4 medium with cytokines from day 12 to 17. (c) Cells in neural differentiation medium with cytokines plus Fgf-2 from day 1 to day 12, and then in the same medium but without Fgf-2 from day 12 to 17. (d) Cells in NbActive4 medium with cytokines plus Fgf-2 from day 1 to day 12, and in then the same medium but without Fgf-2 from day 12 to 17. (e) Cells in CDM II medium with cytokines plus Fgf-2 from day 1 to day 12, and in then the same medium but without Fgf-2 from day 12 to 17.
  • FIG. 22 is a panel showing pictures of immunochemistry results at day 17 of fibroblasts transfected with Msi1/Ngn2 and pCMV6-XL5-MBD2 in FIG. 21. (A) and (B): Cells were in NS-A Proliferation Medium from day 1 to day 12, and then in NS-A Differentiation Medium (A) or NBActive4 medium (B) with cytokines from day 12 to 17. There were more cells in B, but Differentiation from day 12-17 was too short to induce expression of βIII-tubulin in both cases.
  • FIGS. 22C-E: Cells were in NS-A Differentiation Medium (C) or NbActive4 medium (D) from day 1-17 (with FGF-2 supplementation from day 1-12), or CDM II medium from day 1-12 and then NS-A Differentiation Medium from day 12-17 (E). There were a large number of cells in C and a much smaller number of cells in D and E. Cells were immunopositive for both GFAP and βIII-tubulin in all cases and placing the cells in differentiation or non-proliferation media from day 1 onwards appears to have induced a more direct transformation into neurons and glia, with more intense βIII-tubulin than GFAP positive cells in E.
  • FIG. 23 is a panel showing two heat maps providing a global overview of the gene expression comparison between either NSLC vs. HFF (Set 1), or NSLC vs. hNPC (Set 2). NSLC has a distinct gene expression profile when compared to either HFF or hNPC. Based on the intensity (the higher the intensity, the higher the relative change in expression), NSLC is much more similar to hNPC than to HFF.
  • FIG. 24 is a panel showing pictures of NSLCs. NSLCs were tested to determine if they are a population of Skin-Derived Precursors Cells (SKPs). SKPs capable of proliferating in response to EGF and bFGF, express nestin and fibronectin, and can differentiate into both neuronal and mesodermal progeny including into adipocytes. For this purpose a standard protocol for turning SKPs into adipocytes was performed, in which adipocyte-derived stem cells (ADSCs) and NSLCs were cultured in StemPro™ proliferation medium and differentiation towards adipocytes were induced by culturing these cells in differentiation medium consisting in DMEM/F12 (50:50), ITS (1:100), HEPES (1:100), GlutaMAX™ (1:100), T3 (0.2 nM), Rosiglitasone (0.5 μg/ml), IBMX (100 μM) and Dexamethasone (1 μM). Three days later, IBMX and Dexamethasone were withdrawn from the medium. At day 10, cells were fixed with a 4% formaldehyde solution for 10 min and stained with Oil Red O (Invitrogen) staining solution. Adipose cells appeared red with lipid droplets (bright white spots in left picture) specifically stained with Oil Red O; however NSLCs stained negative and had no presence of lipid droplet in the cells, but instead adopted neuronal cell morphology. These results conform that NSLCs are not a population of Skin-Derived Precursors Cells (SKPs).
    •  DETAILED DESCRIPTION OF THE INVENTION
  • The present invention relates to methods for cell dedifferentiation and cell reprogramming. A significant aspect of the present invention is that it permits the use of a patient's own cells to develop different types of cells that can be transplanted after steps of in vitro dedifferentiation and in vitro reprogramming. Thus, this technology eliminates the problems associated with transplantation of non-host cells, such as, immunological rejection and the risk of transmitting disease. In addition, since the cells are “newly created”, they have the potential to be more potent than alternative sources of natural cells that have already divided multiple times.
    • Definitions
  • As used herein and in the appended claims, the singular forms “a,” “an”, and “the”, include plural referents unless the context clearly indicates otherwise. Thus, for example, reference to “a cell” includes one or more of such cells or a cell line derived from such a cell, reference to “an agent” includes one or more of such agent, and reference to “the method” includes reference to equivalent steps and methods known to those of ordinary skill in the art that could be modified or substituted for the methods described herein.
  • As used herein, the term “polynucleotide” refers to any DNA or RNA sequence or molecule, comprising encoding nucleotide sequences. The term is intended to encompass all polynucleotides whether occurring naturally or non-naturally in a particular cell, tissue or organism. This includes DNA and fragments thereof, RNA and fragments thereof, cDNAs and fragments thereof, expressed sequence tags, artificial sequences including randomized artificial sequences.
  • As used herein, the term “polypeptide” refers to any amino acid sequence having a desired functional biological activity (e.g. DNA demethylation). The term is intended to encompass complete proteins, fragments thereof, fusion proteins and the like, including carbohydrate or lipid chains or compositions.
  • “Trans-differentiation” refers to a direct switch of an already differentiated cell to another type of differentiated cell.
  • “De-differentiation” refers to the loss of phenotypic characteristics of a differentiated cell by activating or deactivating genes or metabolic pathways.
  • “Marker” refers to a gene, polypeptide, or biological function that is characteristic of a particular cell type or cellular phenotype.
  • “Genetically-engineered DNA sequence” is meant a DNA sequence wherein the component sequence elements of DNA sequence are organized within the DNA sequence in a manner not found in nature.
  • “Signal sequence” refers to a nucleic acid sequence which, when incorporated into a nucleic acid sequence encoding a polypeptide, directs secretion of the translated polypeptide from cells which express said polypeptide, or allows the polypeptide to readily cross the cell membrane into a cell. The signal sequence is preferably located at the 5′ end of the nucleic acid sequence encoding the polypeptide, such that the polypeptide sequence encoded by the signal sequence is located at the N-terminus of the translated polypeptide. By “signal peptide” is meant the peptide sequence resulting from translation of a signal sequence.
  • “Ubiquitous promoter” refers to a promoter that drives expression of a polypeptide or peptides encoded by nucleic acid sequences to which promoter is operably linked. Preferred ubiquitous promoters include human cytomegalovirus immediate early (CMV); simian virus 40 early promoter (SV40); Rous sarcoma virus (RSV); or adenovirus major late promoter.
  • “Gene expression profiling” means an assay that measures the activity of multiple genes at once, creating a global picture of cellular function. For example, these profiles can distinguish between human neural stem cells and somatic cells that are actively dividing or differentiating.
  • “Transfection” refers to a method of gene delivery that introduces a foreign nucleotide sequences (e.g. DNA molecules) into a cell preferably by a non-viral method. In preferred embodiments according to the present invention foreign DNA is introduced to a cell by transient transfection of an expression vector encoding a polypeptide of interest, whereby the foreign DNA is introduced but eliminated over time by the cell and during mitosis. By “transient transfection” is meant a method where the introduced expression vectors and the polypeptide encoded by the vector, are not permanently integrated into the genome of the host cell, or anywhere in the cell, and therefore may be eliminated from the host cell or its progeny over time. Proteins, polypeptides, or other compounds can also be delivered into a cell using transfection methods.
  • “Neuroprogenitor Cell” refers to an immature cell of the nervous system, which can differentiate into neurons and glia (oligodendrocytes and astrocytes). “Neural Stem Cell” is an ectoderm germ layer derived multipotent stem cell having, as a physiological feature, a capacity to form neuroprogenitor cells and under physiological conditions that favor differentiation to form neurons and glia. “Neural Stem-Like Cell” or “NSLC” refers to any cell-derived multipotent stem cell having, as a physiological feature, a capacity to form other neural stem-like cells and neuroprogenitor-like cells and under physiological conditions that favor differentiation to form neuron-like cells and glial-like cells.
  • “Neurosphere” refers to a cellular aggregate of neural stem cells and neuroprogenitor cells that form a floating sphere formed as a result of proliferation of the neural stem cells and neuroprogenitor cells in appropriate proliferation conditions. NSLCs also form neurospheres consisting of aggregates of NSLCs and neuroprogenitor-like cells.
  • “Reprogrammed cell” refers to a cell that has undergone stable trans-differentiation, de-differentiation, or transformation. Some reprogrammed cells can be subsequently induced to re-differentiate. The reprogrammed cell stably expresses a cell-specific marker or set of markers, morphology, and/or biological function that was not characteristic of the original cell. “Reprogrammed somatic cell” refers to a process that alters or reverses the differentiation status of a somatic cell, which can be either complete or partial conversion of the differentiated state to an either less differentiated state or a new differentiated state.
  • “Regeneration” refers to the capability of contributing to the repair or de novo construction of a cell, tissue or organ.
  • “Differentiation” refers to the developmental process of lineage commitment of a cell.
  • Differentiation can be assayed by measuring an increase in one or more cell-differentiation specific markers relative to the expression of the undifferentiated cell markers.
  • “Lineage” refers to a pathway of cellular development, in which a more undifferentiated cell undergoes progressive physiological changes to become a more differentiated cell type having a characteristic function (e.g., neurons and glia are of a neuroprogenitor lineage, which is of an ectoderm lineage which formed from blastocysts and embryonic stem (ES) cells).
  • “Tissue” refers to an ensemble of cells (identical or not) and an extracellular matrix (ECM) that together carry out a specific function or set of functions.
  • “CDM” is meant a living tissue equivalent or matrix, a living scaffold, or cell-derived matrix.
    • Cell Transformation
  • Some aspects of the invention concerns methods and cells to transform or reprogram a given somatic cell into a pluripotent, multipotent and/or unipotent cell. Some aspects of the invention relates to methods for conditioning a somatic cell to reprogramming into a pluripotent, multipotent or unipotent cell.
  • The terms “transform” or “reprogram” are used interchangeably to refer to the phenomenon in which a cell is dedifferentiated or transdifferentiated to become pluripotent, multipotent and/or unipotent. The dedifferentiated cell could subsequently be redifferentiated into a different type of cell. Cells can be reprogrammed or converted to varying degrees. For example, it is possible that only a small portion of cells are converted or that an individual cell is reprogrammed to be multipotent but not necessarily pluripotent. Thus, the terms “transforming” or “reprogramming” methods can refer to methods wherein it is possible to reprogram a cell such that the “new” cell shows morphological and functional characteristics of a new or different specific cell lineage (e.g. the transformation of fibroblast cells into neuronal cells).
  • As used herein, the term “somatic cell” refers to any differentiated cell forming the body of an organism, apart from stem cells, progenitor cells, and germline cells (i.e. ovogonies and spermatogonies) and the cells derived therefrom (e.g. oocyte, spermatozoa). For instance, internal organs, skin, bones, blood, and connective tissue are all made up of somatic cells. Somatic cells according to the invention can be differentiated cells isolated from adult or can be fetal somatic cells. Somatic cells are obtained from animals, preferably human subjects, and cultured according to standard cell culture protocols available to those of ordinary skill in the art.
  • As used herein, “Stem cell” refers to those cells which retain the ability to renew themselves through mitotic cell division and which can differentiate into a diverse range of specialized cell types. It includes both embryonic stem cells that are found in blastocysts, and adult stem cells that are found in adult tissues. “Totipotent cells” refers to cells that have the ability to develop into cells derived from all three embryonic germ layers (mesoderm, endoderm and ectoderm) and an entire organism (e.g., human being if placed in a woman's uterus in the case of humans). Totipotent cells may give rise to an embryo, the extra embryonic membranes and all post-embryonic tissues and organs. The term “pluripotent” as used herein is intended to mean the ability of a cell to give rise to differentiated cells of all three embryonic germ layers. “Multipotent cells” refers to cells that can produce only cells of a closely related family of cells (e.g. hematopoietic stem cells differentiate into red blood cells, white blood cells, platelets, etc.). “Unipotent cells” refers to cells that have the capacity to develop/differentiate into only one type of tissue/cell type (e.g. skin cells).
  • The present invention allows the reprogramming of any cell to a different type of cell. Although the present application focuses primarily on the preparation of Stem-Like cells, especially, Neural Stem-Like Cells (NSLCs), the invention is not so restricted because many different types of cells can be generated according to the principles described herein. Similarly, while the Examples section describes embodiments where fibroblasts, keratinocytes, CD34+ cells, adipose-derived stem cells (ADSCs), neural stem cells (including NSLCs), and cells within a Cell-Derived Matrix (CDM) are reprogrammed, the invention is not limited such cells. The invention may be employed for the reprogramming of virtually any cell of interest.
  • Accordingly, a general aspect of the invention relates to a method of transforming a cell of a first type to a cell of a second different type. As used herein, examples of cells of a first type include, but are not limited to germ cells, embryonic stem cells and derivations thereof, adult stem cells and derivations thereof, progenitor cells and derivations thereof, cells derived from mesoderm, endoderm or ectoderm, and a cell of mesoderm, endoderm or ectoderm lineage such as an adipose-derived stem cell (ADSC), mesenchymal stem cell, hematopoietic stem cell (CD34+ cell), skin derived precursor cell, hair follicle cell, fibroblast, keratinocyte, epidermal cell, endothelial cell, epithelial cell, granulosa epithelial cell, melanocyte, adipocyte, chondrocyte, hepatocyte, lymphocyte (B and T lymphocyte), granulocyte, macrophage, monocyte, mononuclear cell, pancreatic islet cell, sertoli cell, neuron, glial cell, cardiac muscle cell, and other muscle cell.
  • As used herein, examples of cells of a second type include, but are not limited to germ cells, embryonic stem cells and derivations thereof, adult stem cells and derivations thereof, progenitor cells and derivations thereof, cells derived from mesoderm, endoderm or ectoderm, and a cell of mesoderm, endoderm or ectoderm lineage such as an adipose-derived stem cell, mesenchymal stem cell, hematopoietic stem cell, skin derived precursor cell, hair follicle cell, fibroblast, keratinocyte, epidermal cell, endothelial cell, epithelial cell, granulosa epithelial cell, melanocyte, adipocyte, chondrocyte, hepatocyte, lymphocyte (B and T lymphocyte), granulocyte, macrophage, monocyte, mononuclear cell, pancreatic islet cell, sertoli cell, neuron, glial cell, cardiac muscle cell, and other muscle cell. In addition, each of the above “-like” cell (a cell that has similar but not completely identical characteristics of the known natural type of the cell) is also included in the examples of cells of a second type.
  • According to one particular aspect, the method of transforming a cell of a first type into a cell of a second different type comprises the steps of:
      • i) providing a cell of a first type;
      • ii) transiently increasing in the cell of a first type intracellular levels of at least one reprogramming agent, whereby the transient increase induces direct or indirect endogenous expression of at least one gene regulator;
      • iii) placing the cell in conditions for supporting the transformation of the desired cell and maintaining intracellular levels of the at least one reprogramming agent for a sufficient period of time to allow stable expression of the at least one gene regulator in absence of the reprogramming agent; and
      • iv) maintaining the cell in culture conditions supporting the transformation of the desired cell for a sufficient period of time to allow a stable expression of a plurality of secondary genes whose expression is characteristic of phenotypical and functional properties of the desired cell. At least one of the stably expressed secondary genes is not characteristic of phenotypical and functional properties of an embryonic stem cell. At the end of said period of time the cell of the first type has been transformed into the desired cell of a different type. Preferably, the cell of a different type obtained after the transformation is further characterized by a stable repression of a plurality of genes expressed in the first cell type.
  • According to various embodiments, step iii) may be carried out consecutively to step ii), simultaneously with step ii), or before step ii).
  • According to a related aspect, the invention relates to a process wherein a cell of a first type is reprogrammed to a desired cell of a different type, the process comprising:
      • a transient increase of intracellular levels of at least one reprogramming agent, wherein the at least one reprogramming agent induces a direct or indirect endogenous expression of at least one gene regulator, wherein the endogenous expression of the at least one gene regulator is necessary for the existence of the desired cell of a different type;
      • a stable expression of said at least one gene regulator;
      • stable expression of a plurality of secondary genes, wherein the stable expression of the plurality of secondary genes is the result of the stable expression of the at least one gene regulator, and wherein: (i) stable expression of the plurality of secondary genes is characteristic of phenotypical and/or functional properties of the desired cell, (ii) stable expression of at least one of the secondary genes is not characteristic of phenotypical and functional properties of an embryonic stem cell, and wherein (i) and (ii) are indicative of successful reprogramming of the cell of the first type to the desired cell of the different type.
  • As used herein, “transiently increasing” refers to an increase that is not necessarily permanent and therefore, which may decrease or disappear over time. For instance, when referring to transiently increasing intracellular levels of at least one reprogramming agent in a cell, it means that the increase in present for a sufficient period of time for causing particular cellular events to occur (e.g. inducing stable endogenous expression of a gene regulator). Typically a transient increase is not permanent and is not associated for instance to genome integration of an expression vector.
  • As used herein the term “reprogramming agent” refers to a compound that is capable of inducing directly or indirectly the expression of morphological and/or functional characteristics of the desired cell of a different type. Preferred compounds include those capable of driving directly or indirectly transformation of the cell of the first type into the desired cell of a different type. In preferred embodiment, the reprogramming agent is selected for inducing a direct or indirect endogenous expression of at least one gene regulator as defined herein. There are many compounds that may be helpful in reprogramming a cell according to the invention and these compounds can be used alone or in combinations. In various embodiments, the reprogramming agent is a polynucleotide or polypeptide selected according to TABLE A:
  • TABLE A
    Reprogramming agent
    RefSeq/
    Examples of GenBank ™ UniProt ™/ UniGene ™
    Desired Cell (NCBI) Access. Swiss-Prot Accession
    Type Name No. Access. No. No. Markers
    Pluripotent- AGR2 NM_006408.3 O95994 Hs.530009 OCT4
    like AGR3 NM_176813.3 Q8TD06 Hs.100686 Nanog
    cells BRIX1 NM_018321.3 Q8TDN6 Hs.718510 SSEA-4
    CRABP2 NM_001878.2 P29373 Hs.405662 TRA1-60
    DNMT3B, NM_006892.3 Q9UBC3 Hs.713611 TRA1-80
    isoform 1
    DNMT3B, NM_175848.1 Q9UBC3 Hs.713611 AP
    isoform 2
    DNMT3B, NM_175849.1 Q9UBC3 Hs.713611
    isoform 3
    DNMT3B, NM_175850.1 Q9UBC3 Hs.713611
    isoform 6
    DPPA2 NM_138815.3 Q7Z7J5 Hs.351113
    DPPA3 NM_199286.2 Q6W0C5 Hs.131358
    (STELLA)
    DPPA4 NM_018189.3 Q7L190 Hs.317659
    DPPA5 NM_001025290.1 A6NC42 Hs.125331
    (ESG1)
    FOXD3 NM_012183.2 Q9UJU5 Hs.546573
    FOXH1 NM_003923.2 O75593 Hs.708365
    GABRB3, NM_000814.5 P28472 Hs.302352
    isoform 1
    GABRB3, NM_021912.4 P28472 Hs.302352
    isoform 2
    GABRB3, NM_001191320.1 P28472 Hs.302352
    isoform 3
    GABRB3, NM_001191321.1 P28472 Hs.302352
    isoform 4
    GBX2 NM_001485.2 P52951 Hs.184945
    GDF3 NM_020634.1 Q9NR23 Hs.86232
    GJA1 NM_000165.3 P17302 Hs.74471
    (CX43)
    GRB7 NM_005310.2 Q14451 Hs.86859
    NM_001030002.1 Q14451 Hs.86859
    HESRG NR_027122.1 Q1W209 Hs.720658
    IFITM1 NM_003641.3 P13164 Hs.458414
    IFITM2 NM_006435.2 Q01629 Hs.709321
    KLF2 NM_016270.2 Q9Y5W3 Hs.726356
    KLF4 NM_004235.4 O43474 Hs.376206
    LEFTY1 NM_020997.2 O75610 Hs.656214
    LEFTY2 NM_003240.3 O00292 Hs.520187
    (EBAF),
    isoform 1
    LEFTY2 NM_001172425.1 B4E332 Hs.520187
    (EBAF), (TrEMBL)
    isoform 2
    LIN28A NM_024674.4 Q9H9Z2 Hs.86154
    MYBL2 NM_002466.2 P10244 Hs.179718
    NANOG NM_024865.2 Q9H9S0 Hs.635882
    NODAL NM_018055.4 Q96S42 Hs.370414
    NOG NM_005450.4 Q13253 Hs.248201
    NR0B1 NM_000475.4 P51843 Hs.268490
    (DAX1)
    NR5A2, NM_205860.1 O00482 Hs.33446
    isoform 1
    NR5A2, NM_003822.3 O00482 Hs.33446
    isoform 2
    NR6A1, NM_033334.2 Q15406 Hs.586460
    isoform 1
    NR6A1, NM_001489.3 Q15406 Hs.586460
    isoform 2
    PHC1 NM_004426.2 P78364 Hs.305985
    PITX2, NM_153427.1 Q99697 Hs.643588
    isoform a
    PITX2, NM_153426.1 Q99697 Hs.643588
    isoform b
    PITX2, NM_000325.5 Q99697 Hs.643588
    isoform c
    PODXL, NM_001018111.2 O00592 Hs.726449
    isoform 1
    PODXL, NM_005397.3 O00592 Hs.726449
    isoform 2
    POU5F1 NM_002701.4 Q01860 Hs.249184
    (OCT4),
    isoform 1*
    POU5F1 NM_203289.4 N/A Hs.249184
    (OCT4), NM_001173531.1
    isoform 2
    PTEN NM_000314.4 P60484 Hs.500466
    REST NM_005612.4 Q13127 Hs.307836
    NM_001193508.1 Q13127 Hs.307836
    REX1 NM_020695.3 Q8N1G1 Hs.192477
    SALL4 NM_020436.3 Q9UJQ4 Hs.517113
    SEMA3A NM_006080.2 Q14563 Hs.252451
    SFRP2 NM_003013.2 Q96HF1 Hs.481022
    SOX2 NM_003106.2 P48431 Hs.518438
    TDGF1, NM_003212.3 P13385 Hs.385870
    isoform 1
    TDGF1, NM_001174136.1 P13385 Hs.385870
    isoform 2
    TERT, NM_198253.2 O14746 Hs.492203
    isoform 1
    TERT, NM_001193376.1 O14746 Hs.492203
    isoform 2
    TPT1 NM_003295.2 P13693 Hs.374596
    UTF1 NM_003577.2 Q5T230 Hs.458406
    ZFP42 NM_174900.3 Q96MM3 Hs.335787
    Ectoderm- ASCL1 NM_004316.3 P50553 Hs.703025 FoxJ3
    like (MASH1)
    cells CDX1 NM_001804.2 P47902 Hs.1545 Otx2
    DLX3 NM_005220.2 O60479 Hs.134194 E-cadherin
    DLX5 NM_005221.5 P56178 Hs.99348 TP73L
    FOXD3 NM_012183.2 Q9UJU5 Hs.546573
    MSI1 NM_002442.2 O43347 Hs.158311
    NANOG NM_024865.2 Q9H9S0 Hs.635882
    POU5F1 NM_002701.4 Q01860 Hs.249184
    (OCT4),
    isoform 1*
    POU5F1 NM_203289.4 N/A Hs.249184
    (OCT4), NM_001173531.1
    isoform 2
    SOX1 NM_005986.2 O00570 Hs.202526
    SOX2 NM_003106.2 P48431 Hs.518438
    SP8, NM_182700.4 Q8IXZ3 Hs.195922
    isoform 1
    SP8, NM_198956.2 N/A Hs.195922
    isoform 2
    ZIC1 NM_003412.3 Q15915 Hs.647962
    Mesendoderm- EOMES NM_005442.2 O95936 Hs.591663 MixI1
    like cells FOXA2, NM_021784.4 Q9Y261 Hs.155651 Mesp1
    isoform 1*
    FOXA2, NM_153675.2 Q9Y261 Hs.155651 Bry
    isoform 2
    FOXD3 NM_012183.2 Q9UJU5 Hs.546573 Flk1
    GATA4 NM_002052.3 P43694 Hs.243987 Pax2
    GATA6 NM_005257.3 Q92908 Hs.514746 Six1
    MIXL1 NM_031944.1 Q9H2W2 Hs.282079
    POU5F1 NM_002701.4 Q01860 Hs.249184
    (OCT4),
    isoform 1*
    POU5F1 NM_203289.4 N/A Hs.249184
    (OCT4), NM_001173531.1
    isoform 2
    SOX17 NM_022454.3 Q9H6I2 Hs.98367
    T NM_003181.2 O15178 Hs.389457
    (Brachyury)
    Desired
    second cell
    type
    Neural stem- CALB1 NM_004929.2 P05937 Hs.65425 Sox2
    like cells DLL1 NM_005618.3 O00548 Hs.379912 Nestin
    DLX1, NM_178120.4 P56177 Hs.407015 GFAP
    isoform 1
    DLX1, NM_001038493.1 P56177 Hs.407015 Msi1
    isoform 2
    DLX2 NM_004405.3 Q07687 Hs.419 Sox1
    FOXD3 NM_012183.2 Q9UJU5 Hs.546573 CD133
    GJD2 NM_020660.1 Q9UKL4 Hs.283816
    (CX36)
    HES1 NM_005524.2 Q14469 Hs.250666
    HES3 NM_001024598.3 Q5TGS1 Hs.532677
    HES5 NM_001010926.3 Q5TA89 Hs.57971
    HOXB1 NM_002144.3 P14653 Hs.99992
    MNX1 NM_005515.3 P50219 Hs.37035
    (HB9),
    isoform 1
    MNX1 NM_001165255.1 N/A Hs.37035
    (HB9),
    isoform 2
    MSI1 NM_002442.2 O43347 Hs.158311
    NANOG NM_024865.2 Q9H9S0 Hs.635882
    NEUROD1 NM_002500.2 Q13562 Hs.709709
    NEUROG1 NM_006161.2 Q92886 Hs.248149
    NEUROG2 NM_024019.2 Q9H2A3 Hs.567563
    NKX6.1 NM_006168.2 P78426 Hs.546270
    PAX6, NM_000280.3 P26367 Hs.270303
    isoform a*
    PAX6, NM_001127612.1 P26367 Hs.270303
    isoform a
    PAX6, NM_001604.4 P26367 Hs.270303
    isoform b
    SFRP2 NM_003013.2 Q96HF1 Hs.481022
    SIX3 NM_005413.3 O95343 Hs.567336
    SOX1 NM_005986.2 O00570 Hs.202526
    SOX2 NM_003106.2 P48431 Hs.518438
    Cardiac BAF60C NM_001003802.1 Q6STE5 Hs.647067 MLc2α
    progenitor- (SMARCD3),
    like isoform 1
    cells BAF60C NM_003078.3 Q6STE5 Hs.647067 Nkx2.5
    (SMARCD3),
    isoform 1
    BAF60C NM_001003801.1 Q6STE5 Hs.647067 IsI+
    (SMARCD3),
    isoform 2*
    FOXD3 NM_012183.2 Q9UJU5 Hs.546573 Bry
    GATA4 NM_002052.3 P43694 Hs.243987
    GATA6 NM_005257.3 Q92908 Hs.514746
    HAND1 NM_004821.2 O96004 Hs.152531
    HAND2 NM_021973.2 P61296 Hs.388245
    ISL1 NM_002202.2 P61371 Hs.505
    KDR NM_002253.2 P35968 Hs.479756
    MESP1 NM_018670.3 Q9BRJ9 Hs.447531
    MYOCD, NM_001146312.1 Q6N065 Hs.567641
    isoform 1 (TrEMBL)
    MYOCD, NM_153604.2 Q8IZQ8 Hs.567641
    isoform 2
    MYOCD, NM_001146313.1 Q8IZQ8 Hs.567641
    isoform 3
    NKX2.5, NM_004387.3 P52952 Hs.54473
    isoform 1*
    NKX2.5, NM_001166175.1 P52952 Hs.54473
    isoform 2*
    NKX2.5, NM_001166176.1 P52952 Hs.54473
    isoform 3*
    T (Brachyury) NM_003181.2 O15178 Hs.389457
    TBX5, NM_000192.3 Q99593 Hs.381715
    isoform 1*
    TBX5, NM_181486.1 Q99593 Hs.381715
    isoform 1
    TBX5, isoform NM_080718.1 Q99593 Hs.381715
    2
    TBX5, isoform NM_080717.2 Q99593 Hs.381715
    3
    SOX17 NM_022454.3 Q9H6I2 Hs.98367
    Pancreatic FOXA2, NM_021784.4 Q9Y261 Hs.155651 PDX1
    progenitor-like isoform 1*
    cells FOXA2, NM_153675.2 Q9Y261 Hs.155651 Sox17
    isoform 2
    FOXD3 NM_012183.2 Q9UJU5 Hs.546573 FoxA2
    MAFA NM_201589.2 Q8NHW3 Hs.670866 Ngn3
    MIXL1 NM_031944.1 Q9H2W2 Hs.282079 IsI1
    NEUROG3 NM_020999.3 Q9Y4Z2 Hs.532682
    NKX6.1 NM_006168.2 P78426 Hs.546270
    PAX4 NM_006193.2 O43316 Hs.129706
    PDX1 NM_000209.3 P52945 Hs.32938
    SOX17 NM_022454.3 Q9H6I2 Hs.98367
    Myogenic FOXC1 NM_001453.2 Q12948 Hs.348883 SMα actin
    progenitor-like FOXC2 NM_005251.2 Q99958 Hs.436448 Calponin
    cells MEF2C, NM_002397.4 Q06413 Hs.649965 MyoD
    isoform 1 NM_001193350.1 Q06413
    MEF2C, NM_001131005.2 Q06413 Hs.649965 MEF2C
    isoform 2
    MEF2C, NM_001193347.1 Q06413 Hs.649965 Pax3
    isoform 3
    MEF2C, NM_001193348.1 Q06413 Hs.649965 Pax7
    isoform 4
    MEF2C, NM_001193349.1 Q06413 Hs.649965
    isoform 5
    Pax3, isoform NM_181457.3 P23760 Hs.42146
    Pax3
    Pax3, isoform NM_000438.5 P23760 Hs.42146
    Pax3a
    Pax3, isoform NM_013942.4 P23760 Hs.42146
    Pax3b
    Pax3, isoform NM_181458.3 Q494Z3, Hs.42146
    Pax3d Q494Z4
    (TrEMBL)
    Pax3, isoform NM_181459.3 Q494Z3, Hs.42146
    Pax3e Q494Z4
    (TrEMBL)
    Pax3, isoform NM_181461.3 Q494Z3, Hs.42146
    Pax3g Q494Z4
    (TrEMBL)
    Pax3, isoform NM_181460.3 Q494Z3, Hs.42146
    Pax3h Q494Z4
    (TrEMBL)
    Pax3, isoform NM_001127366.2 Q494Z4 Hs.42146
    Pax3i (TrEMBL)
    PAX7, NM_002584.2 P23759 Hs.113253
    isoform 1
    PAX7, NM_013945.2 P23759 Hs.113253
    isoform 2
    PAX7, NM_001135254.1 P23759 Hs.113253
    isoform 3
  • In some embodiments, the reprogramming agent is a polypeptide which shares at least 75%, 80%, 85%, 90%, 95%, 97%, 99% or more of the functionality or sequence identity of any one of the reprogramming agents in the table hereinbefore.
  • Identifying the “sufficient period of time” to allow stable expression of the at least one gene regulator in absence of the reprogramming agent and the “sufficient period of time” in which the cell is to be maintained in culture conditions supporting the transformation of the desired cell is within the skill of those in the art. The sufficient or proper time period will vary according to various factors, including but not limited to, the particular type and epigenetic status of cells (e.g. the cell of the first type and the desired cell), the amount of starting material (e.g. the number of cells to be transformed), the amount and type of reprogramming agent(s), the gene regulator(s), the culture conditions, presence of compounds that speed up reprogramming (ex, compounds that increase cell cycle turnover, modify the epigenetic status, and/or enhance cell viability), etc. In various embodiments the sufficient period of time to allow a stable expression of the at least one gene regulator in absence of the reprogramming agent is about 1 day, about 2-4 days, about 4-7 days, about 1-2 weeks, about 2-3 weeks or about 3-4 weeks. In various embodiments the sufficient period of time in which the cells are to be maintained in culture conditions supporting the transformation of the desired cell and allow a stable expression of a plurality of secondary genes is about 1 day, about 2-4 days, about 4-7 days, or about 1-2 weeks, about 2-3 weeks, about 3-4 weeks, about 4-6 weeks or about. 6-8 weeks. In preferred embodiments, at the end of the transformation period, the number of transformed desired cells is substantially equivalent or even higher than an amount of cells a first type provided at the beginning.
  • The present invention encompasses various types of compounds that are suitable for increasing in a cell of a first type the intracellular levels of at least one reprogramming agent. Preferably, the compound should also be able to directly or indirectly remodel the chromatin and/or DNA of the cell, thus resulting directly or indirectly in the expression of morphological and functional characteristics of the desired cell of a different type. Preferred compounds are reprogramming agents as defined herein or any other compound having a similar activity and having the ability to activate or enhance the expression of the endogenous version of genes listed in the table of reprogramming agents hereinbefore and which are capable of driving directly or indirectly transformation of the cell of the first type into the desired cell of a different type.
  • As will be explained hereinafter, the increase in intracellular levels of the at least one reprogramming agent can be achieved by different means. In preferred embodiments the reprogramming agent is a polypeptide and increasing intracellular levels of such polypeptide include transfection (or co-transfection) of an expression vector having a polynucleotide (ex. DNA or RNA) encoding the polypeptide(s), or by an intracellular delivery of polypeptide(s). According to the invention, transient expression is generally preferable. Additional suitable compounds may include compounds capable of increasing the expression of the endogenous version of genes listed in the table of reprogramming agents and gene regulators including, but not limited to, reprogramming factors listed in Table B.
  • TABLE B
    Desired cell of
    different type Reprogramming Factor
    Pluripotent-like Nodal, ActivinA, Fgf-2, Wnt3a, L-Ascorbic
    cells Acid, BIO, CHIR99021, PD0325901,
    Thiazovivin, SB431542, Cyclic Pifithrin-α,
    Tranylcypromine hydrochloride, Kenpaullone,
    5-Azacytidine, Valproic Acid, BIX01294,
    R(+)BayK8644, RG108, Theanine, Sodium
    butyrate
    Ectoderm like cells: a retinoid compound, L-Ascorbic acid, SHH,
    1- Neural stem- Wnt 3a, a neurotrophic factor, bFGF, EGF,
    like cells Transforming growth factor alpha, neuropeptide
    Y, Estrogen, Noggin, Forskolin, 5-Azacytidine,
    Valproic Acid, BIX01294, R(+)BayK8644,
    RG108, Sodium butyrate, Lithium
    Mesoendoderm BMP4, Epidermal growth factor-Cripto/
    like cells: FRL-1/Cryptic (EGF-CFC) and the TGFβs,
    Activin, Nodal, SHH, Vg1/GDF1 (growth and
    differentiation factor-1)
    1- Cardiac 1- BMP4, bFGF, Activin A, VEGF, DKK1
    progenitor- (dickkopf homologue 1), Insulin-like growth
    like cells factor 1 (IGF-1) and hepatocyte growth factor
    (HGF), 5-Azacytidine, Valproic Acid, BIX01294,
    R(+)BayK8644, RG108, Cardiogenol
    C hydrochloride, Sodium butyrate
    2- Pancreatic 2- Activin A, GLP-1, bFGF, Reg1, nicotinamide,
    progenitor- Betacellulin, SHH, (−)-Indolactam V, a retinoid
    like cells compound, Cyclopamine, IDE-1 and 2, 5-
    Azacytidine, Valproic Acid, BIX01294,
    R(+)BayK8644, RG108, Sodium butyrate
    3- Myogenic 3- retinoic acid, HGF, FGF, IGF, transforming
    progenitor- growth factor-beta, Wnt3a, 5-Azacytidine,
    like cells Valproic Acid, BIX01294, R(+)BayK8644,
    RG108, Sodium butyrate
  • According to the principles of the invention, increasing intracellular levels of at least one reprogramming agent should induce a direct or indirect endogenous expression of at least one gene regulator. As used herein, “gene regulator” refers to a polynucleotide or polypeptide whose expression is associated with a series of intracellular events leading to the transformation of a given cell of a first type into a pluripotent, multipotent and/or unipotent cell. Typically expression of a gene regulator directly or indirectly activates genes necessary for the phenotypical and functional characteristic of pluripotent, multipotent and/or unipotent cells, while repressing genes of the cell of a first type. The gene regulator may be the same or be different than the reprogramming agent. Examples of gene regulators according to the invention include, but are not limited to, the polynucleotides and polypeptides listed herein before in TABLE A.
  • In some embodiments, the gene regulator is a polypeptide which shares at least 75%, 80%, 85%, 90%, 95%, 97%, 99% or more of the functionality or sequence identity of any one of the gene regulators provided in the Table A hereinbefore.
  • As used herein, “conditions supporting growth” or “conditions supporting the transformation” when referring to a desired cell refers to various suitable culture conditions (temperature, pH, O2 tension, cell media, factors, compounds, growth substrate (ex. laminin, collagen, fibronectin, Matrigel™, low-bind surface, nanostructured or charged surface, etc.), 3D environment, etc.) favorising growth of the desired cell type and/or favorising transformation towards such desired cell type. Those skilled in the art known that growth or transformation of particular cell types is stimulated under specific conditions, while inhibited by others, and it is within their skill to select suitable conditions (e.g. culture conditions) favorising growth or transformation of desired cell types.
  • The terms “phenotypical and functional properties”, when referring to a desired cell or to an embryonic stem cell, means the biological, biochemical, physiological and visual characteristics of a cell, including expression of certain genes and cell surface markers, which can be measured or assessed for confirming its identity or function(s).
  • An example of a suitable reprogramming agent according to preferred embodiments of the invention is MUSASHI1. In some embodiments this polypeptide is preferred for driving a first cell, such as a fibroblast, into a Neural Stem-Like Cell (NSLC). In other embodiments, the at least one reprogramming agent which said intracellular levels is increased is(are) either Musashi1 (Msi1) alone; Musashi1 (Msi1) and Neurogenin 2 (Ngn2); Musashi1 (Msi1) and methyl-CpG binding domain protein 2 (MBD2); or Neurogenin 2 (Ngn2) and methyl-CpG binding domain protein 2 (MBD2). Adequate intracellular levels of these polypeptides are preferred since they tend to be expressed throughout an entire cell lineage, from as early as embryonic stem cells (or even earlier) to pre-somatic cells (or even later).
  • MBD2 is a member of a family of methyl-CpG-binding proteins that has been reported to be both a transcriptional repressor and a DNA demethylase (dMTase). As used herein, the term “MBD2” generally refers to the human methyl-CpG binding domain protein 2. The GeneBank™ (NCBI) accession number of human MBD2 is NM_003927.3/AF072242, the UniProt™ accession number is NP-003918/Q9UBB5 and the UniGene™ accession number is Hs.25674.
  • As used herein, the term “Msi1” generally refers to the human musashi homolog 1. The GeneBank™ (NCBI) accession number of human Msi1 is NM_002442.2/AB012851, the UniProt™ accession number is NP-002433/043347 and the UniGene™ accession number is Hs.158311.
  • As used herein, the term “Ngn2” generally refers to the human neurogenin 2. The GeneBank™ (NCBI) accession number of human Ngn2 is NM_024019.2/BC036847, the UniProt™ accession number is NP-076924/Q9H2A3 and the UniGene™ accession number is Hs.567563.
  • According to additional aspects, the method of transforming a cell of a first type to a desired cell of a different type comprises the steps of either:
      • 1) contacting the cell of a first type with one or more compounds capable of increasing intracellular levels of at least one reprogramming agent within the cell and directly or indirectly remodeling the chromatin and/or DNA of the cell; or
      • 2) contacting the chromatin and/or DNA of a cell of a first type with an agent capable of remodeling the chromatin and/or DNA of the cell; and increasing intracellular levels of at least one reprogramming agent.
  • According to various embodiments, step 2) may be carried out consecutively to step 1), simultaneously with step 1), or before step 1).
  • According to a particular aspect, the invention relates to a method for obtaining a Neural Stem-Like Cell (NSLC), comprising:
      • providing a cell of a first type which is not a NSLC;
      • increasing intracellular levels of at least one neural stem cell specific polypeptide, wherein the polypeptide is capable of driving directly or indirectly transformation of the cell of the first type into a NSLC; and
      • contacting chromatin and/or DNA of a cell of a first type with a histone acetylator, an inhibitor of histone deacetylation, a DNA demethylator, and/or a chemical inhibitor of DNA methylation.
  • With respect to the second step, the term “remodelling the chromatin and/or DNA” refers to dynamic structural changes to the chromatin. These changes can range from local changes necessary for transcriptional regulation, to global changes necessary for opening up the chromatin structure or chromosome segregation to allow transcription of the new set of genes characteristic of the desired cell of a different type, to closing up of the chromatin structure or chromosome segregation to prevent transcription of certain genes that are not characteristic of the desired cell of a different type. In some embodiments, opening up of the chromatin structure refers more specifically to acetylation of histones, and demethylation of DNA, while closing up of the chromatin structure refers more specifically to deacetylation of histones, and methylation of DNA.
  • As used herein, “compound” refers to a compound capable of effecting a desired biological function. The term includes, but is not limited to, DNA, RNA, protein, polypeptides, and other compounds including growth factors, cytokines, hormones or small molecules. As used herein, compounds capable of remodeling chromatin and/or DNA include, but are not limited to, histone acetylators, inhibitors of histone deacetylation, DNA demethylators, inhibitors of DNA methylation and combination thereof.
  • “Inhibitor of DNA methylation” refers to an agent that can inhibit DNA methylation. DNA methylation inhibitors have demonstrated the ability to restore suppressed gene expression. Suitable agents for inhibiting DNA methylation include, but are not limited to 5-azacytidine, 5-aza-2-deoxycytidine, 1-β-D-arabinofuranosil-5-azacytosine, and dihydro-5-azacytidine, and zebularine (ZEB), BIX (histone lysine methytransferase inhibitor), and RG108.
  • “Inhibitor of histone deacetylation” refers to an agent that prevents the removal of the acetyl groups from the lysine residues of histones that would otherwise lead to the formation of a condensed and transcriptionally silenced chromatin. Histone deacetylase inhibitors fall into several groups, including: (1) hydroxamic acids such as trichostatin (A), (2) cyclic tetrapeptides, (3) benzamides, (4) electrophilic ketones, and (5) aliphatic acid group of compounds such as phenylbutyrate and valporic acid. Suitable agents to inhibit histone deacetylation include, but are not limited to, valporic acid (VPA), phenylbutyrate Trichostatin A (TSA), Na-butyrate, and benzamides. VPA promotes neuronal fate and inhibits glial fate simultaneously through the induction of neurogenic transcription factors including NeuroD.
  • “Histone Acetylator” refers to an agent that inserts acetyl groups to the lysine residues of histones that opens up the chromatin and turns it into a transcriptionally active state. Suitable Histone Acetylator agents include, but are not limited to, Polyamine, CREB (cAMP element binding protein), and BniP3.
  • “DNA demethylator” refers to an agent that removes the methyl groups from DNA and possesses the ability to inhibit hypermethylation and restore suppressed gene expression. A demethylase is expected to activate genes by removing the repressive methyl residues. Suitable DNA demethylators include, but are not limited to, MBD2 and Gadd45b.
  • In some embodiments, the reprogramming agent has one or more of the following functions: it decrease the expression of one or more markers of cells of the first type (ex. see Table C), and/or increase the expression of one or more markers of the desired cell of the different type (ex. see Table A). Cells that exhibit a selectable marker for the desired cell of a different type are then selected and assessed for characteristics of the desired cell of a different type.
  • According to the invention, transformation into the desired cell results in stable expression of a plurality of secondary genes whose expression is characteristic of phenotypical and/or functional properties of the desired cell. Genes whose expression is characteristic of phenotypical and/or functional properties of the desired cell include, but is not limited to, those listed in Table A.
  • In some embodiments, expression of secondary genes whose expression is characteristic of phenotypical and functional properties of the desired cell results in the expression of markers defined according to the following table:
  • Desired cell type Markers
    Neural stem-like cells Nestin, Sox2, GFAP, Msi1
    Neural-like cells βIII-tubulin, Map2b, Synapsin, ACHE
    Ectoderm-like cells Sox2, Sox1, Zic1, Nestin, Notch 1, FoxJ3,
    Otx2, Cripto1, Vimentin
    Mesendoderm-like cells Sox17, FoxA2, CXCR4, GATA4, MixI1,
    Eomesodermin
    Pluripotent-like cells Oct4, SSEA4, TRA-1-60, TRA-1-81, AP
  • In some embodiments, transformation of a cell of a first type into the desired cell results in a stable repression of a plurality of genes typically expressed in the cell of the first type. Examples of such suppressed genes include, but are not limited to, those defined in Table C:
  • TABLE C
    Examples of suppressed genes
    Cell-type specific genes typically repressed during Reprogramming
    RefSeq/
    GenBank ™ UniProt ™/
    (NCBI) Swiss-Prot UniGene ™
    Cell Type Name Accession No. Accession No. Accession No. Markers
    Keratinocytes TP63, NM_003722.4 Q9H3D4 Hs.137569 Keratin 14
    isoform 1
    TP63, NM_001114978.1 Q9H3D4 Hs.137569 Basonuclin
    isoform 2
    TP63, NM_001114979.1 Q9H3D4 Hs.137569 P63
    isoform 3
    TP63, NM_001114980.1 Q9H3D4 Hs.137569
    isoform 4
    TP63, NM_001114981.1 Q9H3D4 Hs.137569
    isoform 5
    TP63, NM_001114982.1 Q9H3D4 Hs.137569
    isoform 6
    BNC1 NM_001717.3 Q01954 Hs.459153
    BCN2 NM_017637.5 Q6ZN30 Hs.656581
    KRT14 NM_000526.4 P02533 Hs.654380
    Involucrin NM_005547.2 P07476 Hs.516439
    Fibroblasts THY1 NM_006288.3 P04216 Hs.724411 CoI5A2
    FBN2 NM_001999.3 P35556 Hs.519294 Fibronectin
    COL5A2 NM_000393.3 P05997 Hs.445827
    DNMT1, NM_001130823.1 P26358 Hs.202672
    isoform a
    DNMT1, NM_001379.2 P26358 Hs.202672
    isoform b
    CD34+ IsI1 NM_002202.2 P61371 Hs.505 VEGFR
    HOXA9 NM_152739.3 P31269 Hs.659350 Cytokeratin
    HOXB4 NM_024015.4 P17483 Hs.664706
    Klk-1 NM_002257.2 P06870 Hs.123107 CD34
    Bry NM_003181.2 O15178 Hs.389457
    Adipose- ALCAM NM_001627.2 Q13740 Hs.591293 ALBO
    derived stem VCAM-1 NM_001078.2 P19320 Hs.109225 Adiponectin
    cells (ADSC) VCAM-1, NM_080682.1 P19320 Hs.109225
    isoform b
    PROM1, NM_006017.2 O43490 Hs.614734 Leptin
    isoform 1
    PROM1, NM_001145847.1 O43490 Hs.614734
    isoform 2 NM_001145848.1
    PROM1, NM_001145852.1 O43490 Hs.614734
    isoform 4
    PROM1, NM_001145851.1 O43490 Hs.614734
    isoform 5
    PROM1, NM_001145850.1 O43490 Hs.614734
    isoform 6
    PROM1, NM_001145849.1 O43490 Hs.614734
    isoform 7
    FUT4 NM_002033.3 P22083 Hs.390420
  • In preferred embodiments, stable repression of any one or more of the genes listed in Table C being expressed in the first cell type is also characterized by a disappearance of the corresponding markers (see Table C).
  • Those skilled in the art will understand that there exist many alternative steps for facilitating cell reprogramming. Those include destabilizing the cell's cytoskeletal structure (for example, by exposing the cell to cytochalasin B), loosening the chromatin structure of the cell (for example, by using agents such as 5 azacytidine (5-Aza) and Valproic acid (VPA) or DNA demethylator agents such as MBD2), transfecting the cell with one or more expression vector(s) containing at least one cDNA encoding a neurogenic transcription factor (for example, Msi1 or Ngn2), using an appropriate medium for the desired cell of a different type and an appropriate differentiation medium to induce differentiation commitment of the desired cell of a different type, inhibiting repressive pathways that negatively affects induction into commitment the desired cell of a different type, growing the cells on an appropriate substrate for the desired cell of a different type (for example, laminin for NSLCs or a low-bind surface for culturing floating neurospheres), and growing the cells in an environment that the desired cell of a different type (or “-like” cell) would be normally exposed to in vivo such as the proper temperature, pH and low oxygen environment (for example about 2-5% O2). In various embodiments, the invention encompasses these and other related methods and techniques for facilitating cell reprogramming.
  • Accordingly, the method of transforming a cell of a first type into a cell of a second different type may comprise additional facultative steps. In one embodiment, the method of transforming a cell further comprises the step of pretreating the cell of a first type with a cytoskeleton disruptor. As used herein “cytoskeleton” refers to the filamentous network of F-actin, Myosin light and heavy chain, microtubules, and intermediate filaments (IFs) composed of one of three chemically distinct subunits, actin, tubulin, or one of several classes of IF protein. Accordingly, the term “cytoskeleton disruptor” refers to any molecules that can inhibit the cell cytoskeleton to destabilize the cell and consequently remove the feedback mechanisms between the cell's shape and cellular and nuclear function. Suitable cytoskeleton disruptor according to the invention include, but are not limited to, the cytochalasin family of actin cytoskeleton inhibitors, such as Cytochalasin B or D, and myosin inhibitors such as 2,3-butanedione monoxime. Such pretreatment may boost reprogramming. In a preferred embodiment, the cell is cultured in the presence of at least one cytoskeleton inhibitor one day before, during, or after introducing a neurogenic transcription factor(s).
  • Placing the cell in conditions in conditions for supporting the transformation of the desired cell, and/or maintaining the cell in culture conditions supporting the transformation of the desired cell may comprises culturing the cell in a media comprising one or more factors appropriate for inducing the expression of the morphological and functional characteristics of the desired desired cell of a different type. In some embodiments the one or more factors are reprogramming factors helpful in reprogramming a cell and these reprogramming factors can be used alone or in combinations.
  • In other embodiments, the step of culturing the cell in a media comprising one or more factors appropriate for inducing the expression of the morphological and functional characteristics of the desired cell of a different type is carried out subsequently or simultaneously to steps iii) or iv), or subsequently or simultaneously to steps 1) or 2), as defined hereinbefore.
  • Those skilled in the art know many different types of media and many reprogramming factors that may be helpful in reprogramming a cell and these reprogramming factors can be used alone or in combinations. In various embodiments, the reprogramming factor is selected according to TABLE B.
  • In some embodiments, reprogramming factors have one or more of the following functions: decrease the expression of one or more markers of the first type of cell and/or increase the expression of one or more markers of the desired cell. Cells that exhibit a selectable marker for the desired cell are then selected and assessed for unipotency, multipotency, pluripotency, or similar characteristics (as appropriate).
  • In particular embodiments, the cells are cultured in serum-free medium before, during or after any one of steps i) to iv) as defined hereinbefore, or during or after steps 1) or 2), as defined hereinbefore.
    • Obtaining Neural Stem-Like Cells (NSLCs)
  • According to preferred embodiments for creating Neural Stem-Like Cells (NSLCs), the methods of the invention are carried out such that cells are treated with selected agents, compounds and factors to promote the reprogramming and/or dedifferentiation towards Stem-Like Cells (SLCs).
  • Such reprogrammed somatic cells can then be further treated with agents and/or cultured under conditions suitable for promoting reprogramming towards Neural Stem-Like Cells (NSLCs), and expansion of the NSLCs for the long-term. NSLCs according to the invention have the potential to differentiate to neuronal-like and/or glial-like cells, as well as neuronal and/or glial cells, for potential treatment of neurological diseases and injuries such as Parkinson's disease and spinal cord injury. The methods described herein are also useful for producing histocompatible cells for cell therapy.
  • Accordingly, some aspects of the present invention relates to generating neurons from an individual patient, thus making autologous transplantations possible as a treatment modality for many neurological conditions including neurotrauma, stroke, neurodegenerative diseases such as Multiple Sclerosis, Parkinson's disease, Huntington disease, Alzheimer's diseases. Thus, the invention provides for neurological therapies to treat the disease or trauma of interest.
  • Therefore, another aspect of the invention concerns a method of obtaining a Neural Stem-Like Cell (NSLC), comprising either:
      • 1) contacting the cell of a first type with one or more neural stem cell regulating polypeptide capable of increasing intracellular levels of neural stem cell specific polypeptides within said cell and directly or indirectly remodeling the chromatin and/or DNA of the cell and driving directly or indirectly transformation of the cell of the first type into a NSLC; or
      • 2) contacting the chromatin and/or DNA of a cell of a first type with a histone acetylator, an inhibitor of histone deacetylation, a DNA demethylator, and/or an inhibitor of DNA methylation; and increasing intracellular levels of at least one neural stem cell specific polypeptide driving directly or indirectly transformation of the cell of the first type into a NSLC.
  • In preferred embodiments, the step 1) comprises increasing intracellular levels of a MUSASHI1 polypeptide. As it will be explained hereinafter this can be achieved by different means including, but not limited to, transient expression of the MUSASHI1 polypeptide, preferably by transfecting an expression vector encoding the polypeptide.
  • In preferred embodiments, the step 2) comprises increasing intracellular levels of a MBD2 polypeptide or treating the cells with VPA and 5-AZA. As it will be explained hereinafter this can be achieved by different means including, but not limited to, transient expression of the MBD2 polypeptide, preferably by transfecting an expression vector encoding the polypeptide(s), and/or pre-treating and/or treating the cells with VPA and 5-AZA.
  • In one particular embodiment, reprogramming a cell of a first type to another type of cell that exhibits at least two selectable markers for neural stem cells requires transfecting the cell of a first type with one vector containing a cDNA encoding for a neurogenic transcription factor and one DNA demethylator. To enhance the de-differentiation the cells are exposed or pre-exposed to an agent(s) that inhibits DNA methylation, inhibits histone deacetylation, and/or disrupts the cell cytoskeleton. For example, the dedifferentiation can be enhanced by pre-treating the cells with an agent that disrupts the cell cytoskeleton followed by transfecting the cells with one or more vector(s) containing two neurogenic transcription factors in the presence of a DNA demethylator and/or inhibitor of DNA methylation and histone deacetylation. The histone deacetylator, inhibitor of histone deacetylation, DNA demethylator, and/or an inhibitor of DNA methylation are as defined previously.
  • As defined previously, the method may further comprise a preliminary step of pre-treating the cell of a first type with a cytoskeleton disruptor, as defined previously, and/or culturing the cell in a media comprising one or more reprogramming factors appropriate for appearance and maintenance of the morphological and functional characteristics of NSLCs as defined previously (e.g. a retinoid compound, a neurotrophic factor, bFGF, EGF, SHH, Wnt 3a, neuropeptide Y, Estrogen). In some embodiment the method further comprises inhibiting cellular BMP signaling pathways (e.g. by NOGGIN, fetuin, or follistatin).
  • In preferred embodiments, generation of a NSLC from a first cell comprises the use of one or more reprogramming agents. Suitable agents include, but are not limited to, Musashi-1 (Msi1) and Neurogenin 2 (Ngn2). Other potential agents are listed in Table A and B.
  • The present invention is also directed to the use of DNA expression vectors encoding a protein or transcript which upregulates the expression of neurogenesis. The genetically-engineered DNA sequence, encoding a defined reprogramming agent such as Msi1 and Ngn2, can be introduced into cells by using a mono-, bi-, or poly-cistronic vectors. The expression of an endogenous multipotency gene indicates that the cDNA encodes a protein whose expression in the cell result directly or indirectly in the de-differentiation of the cell. The newly de-differentiated mammalian cells are capable of re-differentiating to neuronal lineages to regenerate said mammalian cells, tissues, and organs.
  • The present invention is further directed to a method for generating NSLCs by introducing a genetically-engineered DNA sequence into human somatic cells via transient transfection. Since the DNA introduced in the transfection process is not inserted into the nuclear genome, the foreign DNA decreases over time and when the cells undergo mitosis. Nonviral vectors remain in a non-replicative form, have low immunogenicity, and are easy and safe to prepare and to use. Furthermore, plasmids may accommodate large fragments of DNA.
  • In one particular embodiment, the method starts with obtaining cells from the individual, and reprogramming the cells in vitro to generate NSLCs. The significant aspect of the present invention is the stable reprogramming of a somatic cell or non-neuronal cell into a NSLC that can give rise to different types of, neuronal or glial cells (including neuronal-like or glial-like cells). These can then be implanted back into the same patient from which the cells were obtained, thus making an autologous treatment modality for many neurological conditions including neurotrauma, stroke, and neurodegenerative disease possible. These can also be implanted into a different individual from which the cells were obtained. Accordingly, the cells and methods of the present invention may be helpful to treat, prevent, or to stabilize a neurological disease such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, or spinal cord injury. This technology provides an ample source of neural stem cells, neuro-progenitor cells, neurons and glia for clinical treatment, which can be performed by implantation of NSLCs in vivo or inducing the differentiation in vitro and implantation of neuro-progenitor cells or specific neurons or glia in vivo.
  • In another embodiment, the method comprises isolating somatic or non-neuronal cells and exposing the cells to one or more agents that alter cell morphology and chromatin structure, and transfecting the cells with one or more genes containing at least one cDNA encoding for a neurogenic transcription factor. The gene transfection step may be replaced with alternative agents that induce the expression of the neurogenic transcription factor(s) in the cell. Inducing epigenetic modifications to DNA and histones (especially DNA demethylation and an open chromatic structure) facilitate true reprogramming of the cells. In another embodiment, the cells are incubated in a low oxygen environment, for example 5% O2, thereby helping in reprogramming the cells.
  • This methodology allows the reprogramming of a cell into a NSLC. The further course of development and the expansion of the reprogrammed cell depend on the in situ environment cues to which it is exposed. The embodiments of the invention further include growing the reprogrammed cell in an appropriate proliferation medium to expand the generated NSLC, for example Neural Progenitor proliferation Medium (StemCell Technologies) with the presence of epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF), to promote the neural stem cell to proliferate.
  • The NSLCs obtained according to the invention can be differentiated into neuronal, astrocyte, and/or oligodendrocyte lineages in appropriate differentiation medium, for example NS-A differentiation medium (StemCell, Technologies) or NbActive medium (BrainBits™) including a retinoid compound, such as all-trans-retinoic acid or vitamin A, and BDNF, to induce the differentiation of NSLCs towards neuronal and/or glial cells. Neuronal cells include cells that display one or more neural-specific morphological, physiological, functional and/or immunological features associated with a neuronal cell type. Useful criteria features includes: morphological features (e.g., long processes or neurites), physiological and/or immunological features such as expression of a set of neuronal-specific markers or antigens, synthesis of neurotransmitter(s) such as dopamine or gamma aminobutyric acid (GABA), and functional features such as ion channels or action potentials characteristic of neurons.
  • In accordance with the method, reprogrammed cells can be selected based on differential adherence properties as compared to untransfected cells; for example, reprogrammed cells can form floating neurospheres or grow well on laminin while untransfected fibroblasts attach and grow well on regular cell culture treated plates. Reprogrammed cells include cells that exhibit one or more neural stem specific markers and morphology and the loss of some or all of the specific markers related to the original cells. Furthermore, some of the functionality of the neural-like cells (NLCs) can be assessed at different time points by, for example, patch-clamping, immunostaining for synaptophysin and MAP2b, and by immunochemical means such as by enzyme-linked immunosorbent assay (ELISA).
  • In certain embodiments, the present invention provides NSLCs that are able to initiate and direct central nervous system regeneration at a site of tissue damage and can be customized for individual patients using their own cells as the donor or starting cell. The present invention can be used to generate cells from an individual patient, thus making autologous transplantations possible as a treatment modality for many neurological conditions. Thus, this technology eliminates the problems associated with transplantations of non-host cells, such as, immunological rejection and the risk of transmitted disease. The great advantage of the present invention is that it provides an essentially limitless supply for autologous grafts suitable for transplantation. Therefore, it will obviate some significant problems associated with current source of materials and methods of transplantation.
    • Delivery of Polynucleotides
  • In certain embodiments, the invention concerns the use of polynucleotides, e.g. a polynucleotide encoding a MBD2 polypeptide, a MUSASHI1 polypeptide and/or a Ngn2 polypeptide. Means for introducing polynucleotides into a cell are well known in the art. Transfection methods of a cell such as nucleofection and/or lipofection, or other types of transfection methods may be used. For instance a polynucleotide encoding a desired polypeptide can be cloned into intermediate vectors for transfection in eukaryotic cells for replication and/or expression. Intermediate vectors for storage or manipulation of the nucleic acid or production of protein can be prokaryotic vectors, (e.g., plasmids), shuttle vectors, insect vectors, or viral vectors for example. A desired polypeptide can also be encoded by a fusion nucleic acid.
  • To obtain expression of a cloned nucleic acid, it is typically subcloned into an expression vector that contains a promoter to direct transcription. Suitable bacterial and eukaryotic promoters are well known in the art and described, e.g., in Sambrook and Russell (Molecular Cloning: a laboratory manual, Cold Spring Harbor Laboratory Press). The promoter used to direct expression of a nucleic acid of choice depends on the particular application. For example, a strong constitutive promoter is typically used for expression and purification. In contrast, when a dedifferentiation protein or compound is to be used in vivo, either a constitutive or an inducible promoter or compound is used, depending on the particular use of the protein. In addition, a weak promoter can be used, such as HSV TK or a promoter having similar activity. The promoter typically can also include elements that are responsive to transactivation, e.g., hypoxia response elements, Ga14 response elements, lac repressor response element, and small molecule control systems such as tet-regulated systems and the RU-486 system.
  • In addition to a promoter, an expression vector typically contains a transcription unit or expression cassette that contains additional elements required for the expression of the nucleic acid in host cells, either prokaryotic or eukaryotic. A typical expression cassette thus contains a promoter operably linked, e.g., to the nucleic acid sequence, and signals required, e.g., for efficient polyadenylation of the transcript, transcriptional termination, ribosome binding, and/or translation termination. Additional elements of the cassette may include, e.g., enhancers, and heterologous spliced intronic signals.
  • Expression vectors containing regulatory elements from eukaryotic viruses are often used in eukaryotic expression vectors, e.g., SV40 vectors, papilloma virus vectors, and vectors derived from Epstein-Barr virus. Other exemplary eukaryotic vectors include pMSG, pAV009/A+, pMT010/A+, pMAMneo-5, baculovirus pDSVE, and any other vector allowing expression of proteins under the direction of the SV40 early promoter, SV40 late promoter, metallothionein promoter, murine mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter, or other promoters shown effective for expression in eukaryotic cells.
  • Standard transfection methods can be used to produce bacterial, mammalian, yeast, insect, or other cell lines that express large quantities of dedifferentiation proteins, which can be purified, if desired, using standard techniques. Transformation of eukaryotic and prokaryotic cells is performed according to standard techniques.
  • Any procedure for introducing foreign nucleotide sequences into host cells can be used. These include, but are not limited to, the use of calcium phosphate transfection, DEAE-dextran-mediated transfection, polybrene, protoplast fusion, electroporation, lipid-mediated delivery (e.g., liposomes), microinjection, particle bombardment, introduction of naked DNA, plasmid vectors, viral vectors (both episomal and integrative) and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (see, e.g., Sambrook et al., supra). It is only necessary that the particular genetic engineering procedure used be capable of successfully introducing at least one gene into the host cell capable of expressing the protein of choice.
  • Conventional viral and non-viral based gene transfer methods can be used to introduce nucleic acids into mammalian cells or target tissues. Such methods can be used to administer nucleic acids encoding reprogramming polypeptides to cells in vitro. Preferably, nucleic acids are administered for in vivo or ex vivo gene therapy uses. Non-viral vector delivery systems include DNA plasmids, naked nucleic acid, and nucleic acid complexed with a delivery vehicle such as a liposome. Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell.
  • Methods of non-viral delivery of nucleic acids include lipofection, microinjection, ballistics, virosomes, liposomes, immunoliposomes, polycation or lipid-nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. Lipofection reagents are sold commercially (e.g., Transfectam™ and Lipofectin™). Cationic and neutral lipids suitable for efficient receptor-recognition lipofection of polynucleotides are known. Nucleic acid can be delivered to cells (ex vivo administration) or to target tissues (in vivo administration). The preparation of lipid:nucleic acid complexes, including targeted liposomes such as immunolipid complexes, is well known to those of skill in the art.
  • The use of RNA or DNA virus-based systems for the delivery of nucleic acids take advantage of highly evolved processes for targeting a virus to specific cells in the body and trafficking the viral payload to the nucleus. Viral vectors can be administered directly to patients (in vivo) or they can be used to treat cells in vitro, wherein the modified cells are administered to patients (ex vivo). Conventional viral based systems for the delivery include retroviral, lentiviral, poxviral, adenoviral, adeno-associated viral, vesicular stomatitis viral and herpesviral vectors, although integration in the host genome is possible with certain viral vectors, including the retrovirus, lentivirus, and adeno-associated virus gene transfer methods, often resulting in long term expression of the inserted transgene. Additionally, high transduction efficiencies have been observed in many different cell types and target tissues.
  • pLASN and MFG-S are examples of retroviral vectors that have been used in clinical trials. In applications for which transient expression is preferred, adenoviral-based systems are useful. Adenoviral based vectors are capable of very high transduction efficiency in many cell types and are capable of infecting, and hence delivering nucleic acid to, both dividing and non-dividing cells. With such vectors, high titers and levels of expression have been obtained. Adenovirus vectors can be produced in large quantities in a relatively simple system.
  • Gene therapy vectors can be delivered in vivo by administration to an individual patient, typically by systemic administration (e.g., intravenous, intraperitoneal, intramuscular, subdermal, or intracranial infusion) or topical application. Alternatively, vectors can be delivered to cells ex vivo, such as cells explanted from an individual patient (e.g., lymphocytes, bone marrow aspirates, tissue biopsy) or universal donor hematopoietic stem cells, followed by reimplantation of the cells into a patient, usually after selection for cells which have been reprogrammed.
  • Ex vivo cell transfection for diagnostics, research, or for gene therapy (e.g., via re-infusion of the transfected cells into the host organism) is well known to those of skill in the art. In a preferred embodiment, cells are isolated from the subject organism, transfected with a nucleic acid (gene or cDNA), and re-infused back into the subject organism (e.g., patient). Various cell types suitable for ex vivo transfection are well known to those of skill in the art.
  • Vectors (e.g., retroviruses, adenoviruses, liposomes, etc.) containing therapeutic nucleic acids can be also administered directly to the organism for transfection of cells in vivo. Alternatively, naked DNA can be administered. Administration is by any of the routes normally used for introducing a molecule into ultimate contact with blood or tissue cells. Suitable methods of administering such nucleic acids are available and well known to those of skill in the art, and, although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route.
  • Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition.
  • Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions of the present invention.
    • Delivery of Polypeptides
  • In most, if not all the methods described herein, an alternative possibility consists of bypassing the use of a polynucleotide and contacting a cell of a first type cell directly with a compound (e.g. a polypeptide) for which an increased intracellular level is desired. In other embodiments, for example in certain in vitro situations, the cells are cultured in a medium containing one or more functional polypeptides.
  • An important factor in the administration of polypeptides is ensuring that the polypeptide has the ability to traverse the plasma membrane of a cell, or the membrane of an intra-cellular compartment such as the nucleus. Cellular membranes are composed of lipid-protein bilayers that are freely permeable to small, nonionic lipophilic compounds and are inherently impermeable to polar compounds, macromolecules, and therapeutic or diagnostic agents. However, proteins, lipids and other compounds, which have the ability to translocate polypeptides across a cell membrane, have been described. For example, “membrane translocation polypeptides” have amphiphilic or hydrophobic amino acid subsequences that have the ability to act as membrane-translocating carriers. Polypeptides for which an increased intracellular level is desired according to the invention can be linked to suitable peptide sequences for facilitating their uptake into cells. Other suitable chemical moieties that provide enhanced cellular uptake can also be linked, either covalently or non-covalently, to the polypeptides. Other suitable carriers having the ability to transport polypeptides across cell membranes may also be used.
  • A desired polypeptide can also be introduced into an animal cell, preferably a mammalian cell, via liposomes and liposome derivatives such as immunoliposomes. The term “liposome” refers to vesicles comprised of one or more concentrically ordered lipid bilayers, which encapsulate an aqueous phase. The aqueous phase typically contains the compound to be delivered to the cell. In certain embodiments, it may be desirable to target a liposome using targeting moieties that are specific to a particular cell type, tissue, and the like. Targeting of liposomes using a variety of targeting moieties (e.g., ligands, receptors, and monoclonal antibodies) has been previously described.
    • Cells and Cell Lines
  • The invention encompasses the cells, cell lines, stem cells and purified cell preparations derived from any of the methods described herein. In some embodiments, the cells, cells lines, stem cells and purified cells preparations of the invention are of mammalian origins, including but not limited to human, primates, rodent, dog, cat, horse, cow, or sheep. In preferred embodiments, they originate from a human.
  • Accordingly, another aspect of the invention relates to modified cells, cell lines, pluripotent, multipotent or unipotent cells and purified cell preparations, wherein any of these cells comprise an exogenous polynucleotide encoding Musashi1 (Msi1); Msi1 and Ngn2; Msi1 and MBD2; and Ngn2 and MBD2; Msi1, Ngn2 and MBD2; Msi1, Ngn2, Nestin and MBD2; and other potential combinations from Table A preferably including Msi1 and Ngn2 and MBD2. In preferred embodiments the cell according to the invention is a stem-like cell, more preferably a Neural Stem-Like Cell (NSLC), the cell possessing one or more of the following characteristics:
      • expression of one or more neural stem cell marker selected from the group consisting of Sox2, Nestin, GFAP, Msi1, and Ngn2;
      • decreased expression of one or more genes specific to the cell that the NSLC was obtained from (e.g. see Table C);
      • forms neurospheres in the neurosphere colony formation assay;
      • capable of being cultured in suspension or as an adherent culture;
      • capable of proliferating without the presence of an exogenous reprogramming agent for over 1 month, preferably over 2 months, over 3 months, over 5 months and even for more than a year;
      • capable of dividing every 36 hours at low passage;
      • positive for telomerase activity;
      • capable of differentiation into a neuronal-like cell, astrocyte-like cell, oligodendrocyte-like cell and combinations thereof;
      • decreased expression of telomerase and one or more neural stem cell markers after differentiation;
      • having one or more morphological neurite-like processes (axons and/or dendrites) greater than one cell diameter in length after differentiation into a neuronal-like cell;
      • expression of at least one neural-specific antigen selected from the group consisting of neural-specific tubulin, microtubule associated protein 2, NCAM, and marker for a neurotransmitter after differentiation into a neuronal-like cell;
      • expression of one or more functional neural markers (e.g. synapsin) after differentiation into a neuronal-like cell;
      • capable of releasing one or more neurotrophic factors (e.g. BDNF) after differentiation into a neuronal-like cell;
      • negative in a tumor colony forming assay;
      • negative for tumor growth in SCID mice;
      • negative for teratoma growth in SCID mice;
      • capable of significantly improving one or more functional measures after placement of an adequate number of NSLCs into the void in a brain ablation model;
      • capable of significantly improving or maintaining one or more functional measures after injecting an adequate number of NSLCs into an EAE model; and
      • capable of improving one or more functional measures more significantly than hNPCs in CNS injury or neurodegenerative models.
  • Examples of all of the above items can be found in the Examples section of this application.
  • In preferred embodiments, a NSLC according to the inventions possesses all of the following characteristics:
      • ability to self-renew for significantly longer than a somatic cell;
      • is not a cancerous cell;
      • is stable and not artificially maintained by forced gene expression or by similar means and may be maintained in standard neural stem cell media;
      • can differentiate to a progenitor, precursor, somatic cell or to another more differentiated cell type of the same lineage;
      • has the characteristics of a stem cell and not just certain markers or gene expression or morphological appearance; and
      • does not exhibit uncontrolled growth, teratoma formation, and tumor formation in vivo.
  • In one particular embodiment, the reprogrammed cells (NSLCs) according to the invention are capable of proliferating for several months without losing their neural stem cell markers and their ability to differentiate towards neuron-like, astrocyte-like, and oligodendrocyte-like cells. The generation of the neural lineages is characterized based on morphology, phenotypic changes and functionality.
  • In some embodiments, the cells of the invention may have one or more of the following characteristics and properties: self-renewal, multilineage differentiation in vitro and in vivo, clonogenicity, a normal karyotype, extensive proliferation in vitro under well defined culture conditions, and the ability to be frozen and thawed, as well as any of the commonly known and/or desired properties or characteristics typical of stem cells. The cells of the invention may further express molecular markers of multipotent or pluripotent cells (i.e. gene and surface markers as defined previously).
  • Another aspect of the invention relates to the production of tissue specific autologous (self) stem and/or progenitor cells. These stem and/or progenitor cells may be used in cell therapy applications to treat diseases of cellular degeneration. Diseases of cellular degeneration include, for example, neurodegenerative diseases such as stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis, Amyotrophic lateral sclerosis, macular degeneration, osteolytic diseases such as osteoporosis, osteoarthritis, bone fractures, bone breaks, diabetes, liver injury, degenerative diseases, myocardial infarct, burns and cancer. It is envisioned that cells according to the invention may be implanted or transplanted into a host. An advantage of the invention is that large numbers of autologous stem cells can be produced for implantation without the risk of immune system mediated rejection. Those cells can lead to production of tissue suitable for transplant into the individual. Since the tissue is derived from the transplant recipient, it should not stimulate an immune response, as would tissue from an unrelated donor. Such transplants can constitute tissues (e.g. vein, artery, skin, muscle), solid organ transplants (e.g., heart, liver, kidney), neuronal cell transplants, or bone marrow transplants such as are used in the treatment of various malignancies such as, for example, leukemias and lymphomas. Neural stem cell, neuroprogenitor, or neuronal cell (as well as NSLCs and derivations thereof) transplants can also be used in the treatment of, for example, neurological disorders, stroke, spinal cord injury, Parkinson's disease, and the like, as well as potentially some non-neurological disorders such as a cardiac infarct.
  • Another aspect of the invention relates to a method to produce ex vivo engineered tissues for subsequent implantation or transplantation into a host, wherein the cellular components of those engineered tissues comprise cells according to the invention, or cells derived therefrom. For example, expanded cultures of the cells of the invention may be differentiated by in vitro treatment with growth factors and/or morphogens. Populations of differentiated cells are then implanted into the recipient host near the site of injury or damage, or cultured in vitro to generate engineered tissues, as described.
  • The methods and cells of the invention described herein can be used to immortalize cells, for example to generate a cell line. Using the methods disclosed herein, a somatic cell can be transformed into one possessing a dedifferentiated phenotype, thereby facilitating the generation of cell lines from a variety of tissues. Therefore, the invention encompasses such immortalized cells.
  • In addition, the methods of deriving the cells according to the invention, may be helpful in scientific and therapeutic applications including, but not limited to, (a) scientific discovery and research involving cellular development and genetic research (e.g. uses in lieu of human stem cells as a model cell line to study the differentiation, dedifferentiation, or reprogramming of human cells), (b) drug development and discovery (e.g., screening for efficacy and toxicity of certain drug candidates and chemicals, screening for prospective drugs or agents which mediate the differentiation, dedifferentiation, or reprogramming of cells), (c) gene therapy (e.g., as a delivery device for gene therapy), and (d) treatment of injuries, trauma, diseases and disorders including, but not limited to, Parkinson's, Alzehimer's, Huntington's, Tay-Sachs, Gauchers, spinal cord injury, stoke, burns and other skin damage, heart disease, diabetes, Lupus, osteoarthritis, liver diseases, hormone disorders, kidney disease, leukemia, lymphoma, multiple sclerosis, rheumatoid arthritis, Duchenne's Musclar Dystrophy, Ontogenesis Imperfecto, birth defects, infertility, pregnancy loss, and other cancers, degenerative and other diseases and disorders.
  • Additional aspects concern therapeutic methods, methods of treatment and methods of regenerating a tissue or organ in a mammal (e.g. a human subject). One particular method concerns a method of regenerating a mammalian tissue or organ which comprises contacting the tissue or organ to be regenerated with a SLC, NSLC, or other desired cell or artificial tissue construct as defined herein. The SLC, NSLC, desired cell or artificial tissue construct may be placed in proximity to the tissue or organ to be regenerated by administering to the subject using any suitable route (e.g. injecting the cell intrathecally, directly into the tissue or organ, or into the blood stream).
  • Another method for repairing or regenerating a tissue or organ in a subject in need thereof comprises administering to the subject a compound inducing a direct or indirect endogenous expression of at least one gene regulator in cells of the tissue or organ and/or a compound inducing a direct or indirect endogenous expression of at least one gene regulator in cells capable of transformation or dedifferentiation in vivo in the subject. Accordingly, the expression of the at least one gene regulator reprograms the cells into desired cells of a different type (e.g. neural stem-like cells), and these cells of a different type are effective in repairing or regenerating said tissue or organ.
  • Another method comprises obtaining cells or tissue from a patient (e.g. hematopoietic stem cells, fibroblasts, or keratinocytes), reprogramming a plurality of such cells or the tissue, and reintroducing the reprogrammed cells or tissue into the patient. A related aspect concerns pharmaceutical compositions comprising a plurality of a desired cell, SLC and/or Neural Stem-Like Cell (NSLC) or reprogrammed tissue as defined herein.
  • The therapeutic methods of the invention may be applicable to the regeneration or repair of various tissues and organs including, but not limited to, the brain, the spine cord, the heart, the eye, the retina, the cochlea, the skin, muscles, intestines, pancreas (including beta cells), kidney, liver, lungs, bone, bone marrow, cartilage, cartilage discs, hair follicles, teeth, blood vessels, glands (including endocrine and exocrine glands), ovaries, reproductive organs, mammary and breast tissue.
  • A related aspect concerns pharmaceutical compositions comprising a plurality of desired cell, SLC and/or Neural Stem-Like Cell (NSLC) as defined herein.
    • Tissues
  • Another aspect of the invention relates to a tissue containing reprogrammed cells as defined herein that can be implanted into a subject in need thereof.
  • In some embodiments the present invention provides for the reprogramming of cells within a tissue, for example an in vitro produced 3D tissue construct comprising cells and extracellular matrix produced by these cells. In addition, transfected cells can be seeded on top of these 3D tissue constructs that can be made completely autologously, thus preventing host rejection, making it completely immunocompatible and as carrier for reprogrammed cells to be transplanted in vivo. Advantageously, these newly created cells can be used in their undifferentiated and/or differentiated state within these tissues for in vitro diagnostic purposes or transplanted into a patient in need of such a construct in cell therapy/tissue replacement approaches.
  • The invention further encompasses 3D Neuronal-Like multilayer tissue. Cells within CDM reprogrammed to Neural Stem-Like Cells according to the invention readily differentiate into neuronal-like cells, astrocyte-like cells, and oligodendrocyte-like cells within the CDM. It is thus possible to use CDM and reprogramming methods of the invention to reprogram the cells within the CDM to form 3D Neuronal-Like multilayer tissue (up to >30 cell layers). Such 3D tissue comprises neurons (or specifically, neuron-like cells), astrocytes (or specifically, astrocyte-like cells), and oligodendrocytes (or specifically, oligodendrocyte-like cells) and it can be made completely autologously, can be manually handled and implanted with relative ease, or can used as an in vitro CNS tissue model.
  • One particular aspect concerns an artificial tissue construct which comprises a 3D assembly of in vitro cultured cells and extracellular matrix produced by these cells. The cells may be desired cells, SLC and/or a plurality of Neural Stem-Like Cell (NSLC) obtained using any one of the methods described herein.
    • Screening Methods
  • Another aspect of the invention relates to methods for identifying new compounds (e.g. small molecules, drugs, etc) capable of transforming a cell of a first type to a desired cell of a different type. These new compounds may be usefull for research purposes or as medicaments for use in repairing or regenerating tissues in a subject.
  • The Examples section provides principles, methods and techniques useful for screening and identifying such desirable active compounds. For instance, those skilled in the art will understand that it is conceivable to screen for compounds that will induce transformation of a cell of a first type to a NSLC by replacing the “induction” or “biological activity” provided by the transient increase of Musashi1, NGN2 or MBD2 in the cell by a candidate compound to be tested (e.g. a library of small molecules or compounds) and measuring activity or efficacy of the candidate compound in generating the NSLC. Individual or mixture of active compounds would be selected if they have the same activity and/or if they can provide the same or similar effects as these polypeptides (e.g. cell transformation and/or appearance of any desirable markers or desirable characteristics as defined hereinbefore). For example, a compound or mixture of compounds capable of transforming a fibroblast into a NSLC could be identified by:
      • (i) Setting up, culturing and transforming the fibroblasts into NSLC as in Example 1;
      • (ii) Screening a library of compounds by replacing Msi1, Ngn2 and/or MBD2 with each candidate compound in a different well;
      • (iii) Identify a compound ‘hit’ when the candidate compound is able to transform the fibroblasts into NSLCs approximately as well as the replaced Msi1, Ngn2 and/or MBD2;
      • (iv) If compound from part (iii) did not replace all of Msi1, Ngn2 and MBD2, and is not able to transform the fibroblasts into NSLCs by itself, then by including the compound from (iii) in each well, screening a library of compounds by replacing the Msi1, Ngn2 and/or MBD2 that was not removed in part (ii) with each candidate compound in a different well;
      • (v) Identify a compound ‘hit’ when the candidate compound is able to transform, along with the compound from part (iii), the fibroblasts into NSLCs approximately as well as the replaced Msi1, Ngn2 and/or MBD2;
      • (vi) If compound from part (V) did not replace all of Msi1, Ngn2 and/or MBD2, and is not able to transform the fibroblasts into NSLCs together with the compound from part (iii), then by including the compound from (iii) and (v) in each well, screening a library of compounds by replacing the Msi1, Ngn2 or MBD2 that was not removed in part (ii) and (iv) with each candidate compound in a different well;
      • (vii) Identify a compound ‘hit’ when the candidate compound is able to transform, along with the compound from part (iii) and (v), the fibroblasts into NSLCs approximately as well as the replaced Msi1, Ngn2 or MBD2;
      • (viii) A combination of the compounds from part (iii), (v) and (vii) will be able to transform the fibroblasts into NSLC; modifications to these compounds can be made and further screened to identify more effective or safe versions of these compounds.
  • The same principles are applicable for other desired types of stem-like cells including pluripotent-like cells, mesendoderm-like cells, pancreatic progenitor-like cells, etc. Tables A and B, and the Examples section provides, for each of these types of cells, a list of potential genes and/or compounds to be considered in such screening methods.
  • Accordingly, the present invention encompasses these and any equivalent screening methods where candidate compounds are tested for their efficacy in transforming a cell of a first type to a desired cell of a different type when compared to the efficacy of the reprogramming factor and/or gene regulator as defined herein.
    • Delivery of Neurotrophic Factors
  • Local delivery of neurotrophic factors has been suggested as a method to treat several neurological conditions. Strategies using neurotrophic molecules focus on preventing the progressive loss of neurons, maintaining neuronal connections and function (neuroprotection), and inducing additional regenerative responses in neurons such as increased neurotransmitter turnover and/or axonal sprouting (neuroregeneration). Up to date, several therapeutic strategies to deliver neurotrophic-factors in animal models have been explored, but so far testing of the effects of growth factors on the brain and nervous system have been limited to direct peripheral injection of large doses of these factors, which carries a significant risk of side effects. Accordingly, a related aspect of the invention relates to overcoming these problems by using NSLC cells and cell lines according to the invention which can stably express and secrete growth factors of potential interest after transplantation.
  • To summarize, the present invention provides a plentiful source of Neural Stem-Like Cells, Neuron-Like Cells, Astrocyte-Like Cells or Oligodendrocyte-Like Cells for potential clinical treatments which require transplantation of neural stem cells, neurons, astrocytes or oligodendrocytes 1) to compensate for a loss of host cells (ex. neurons) or 2) as vehicles to deliver genetically-based drugs. Further, the invention provides a novel neurological tool for use in basic research and drug screening.
  • Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures, embodiments, claims, and examples described herein. Such equivalents are considered to be within the scope of this invention and covered by the claims appended hereto. The invention is further illustrated by the following examples, which should not be construed as further limiting.
    • EXAMPLES
  • The examples set forth herein below provide exemplary methods for obtaining Reprogrammed and Dedifferentiated cells, including Neural Stem-Like Cells (NSLCs). Also provided are exemplary protocols, molecular tools, probes, primers and techniques.
    • Example I Preparation of Human Fibroblast Cells
  • Human Foreskin fibroblast (HFF) cells were purchased from American Type Culture
  • Collection (ATCC, Manassas, Va.) and expanded in cell culture flasks with Dulbecco's Modified Eagle's Medium (DMEM, Invitrogen), supplemented with 10% heat-inactivated fetal calf serum (FCS, Hyclone Laboratories), 0.1 mM non-essential amino acids, and 1.0 mM sodium pyruvate (Invitrogen) at 37° C., 5% CO2. The medium was changed twice per week. Cells were trypsinized using Trypsin 0.25% for 4 minutes at 37° C., followed by adding trypsin inhibitor solution, pelleting the cells by centrifugation, washing the cells once with PBS, and plating the cells at a ratio of 1:2 onto tissue culture flasks until a suitable number of cells was reached.
  • Cells were then trypsinized and plated (8×104 cells/well) in cell culture plates pre-coated with Laminin (10 μg/ml, Sigma) in two different composition of CDM medium: CDM I Medium consisting of a 3:1 ratio of Dulbecco's modified Eagle medium (DMEM, high glucose (4.5 g/L) with L-glutamine and sodium pyruvate) and Ham's F-12 medium supplemented with the following components: EGF (4.2×10−1° M), bFGF (2.8×10−1° M), ITS (8.6×10−5M), dexamethasone (1.0×10−7M), L-3,3′,5-triiodothyronine (2.0×10−1° M), ethanolamine (10−4M), GlutaMAX™ (4×10−3M), and glutathione (3.3×10−6M), but without the presence of L-ascorbic acid.
  • CDM II Medium consisting of a 3:1 ratio of Dulbecco's modified Eagle medium (DMEM, high glucose (4.5 g/L) with L-glutamine and sodium pyruvate) and Ham's F-12 medium supplemented with the following components: EGF (2.5 ng/ml), bFGF (10 ng/ml), ethanolamine (2.03 mg/ml), insulin (10 mg/ml), Selenious acid (2.5 μg/ml), dexamethasone (19.7 μg/ml), L-3,3′,5-triiodothyronine (675 ng/ml), GlutaMAX™ (4×10−3M), and glutathione (3.3×10−6M).
    • Transient Transfection of HFF by Lipofectamine Using Constructed Vectors
  • After two days in culture, cells were transfected with pCMV6-XL5-MBD2 (2 μg) (a DNA demethylator) using lipofectamine reagent (Invitrogen) as per the manufacturer's protocol. The DNA-lipid complex was added to cells and incubated for 24 h at 372C, 5% CO2. After 24 hours of transfection with the DNA demethylator, the medium was changed and cells were transfected by pCMV6-XL5-Musashi1 (2 μg, Origene) or pCMV6-XL4-Ngn2 (2 μg, Origene) for 24 h. After 24 hours, the medium was changed to Neural Progenitor Basal Medium (NPBM, Lonza) supplemented with Noggin (20 ng/ml, Peprotech), EGF (20 ng/ml, Peprotech), and bFGF (20 ng/ml, Peprotech) and cultured in this Proliferation Medium. Cells were retransfected after three days and incubated at 372C, 5% CO2 and 5% O2. After 7 days in proliferation conditions, 50% of the Proliferation Medium was changed to Differentiation Medium (NbActive, BrainBits™) supplemented with Forskolin (10 μM, Tocris), all-trans-Retinoic Acid (ATRA, 5 μM, Spectrum), bFGF (20 ng/ml, Peprotech), NGF (20 ng/ml, Peprotech), and BDNF (20 ng/ml, Peprotech); medium was changed every day by increasing the percentage of Differentiation Medium over Proliferation Medium, and the cells were cultured for 20 days.
  • Visual observation of reprogrammed cells was performed by light microscopic observation every day following transfection using bright field at 10× magnification. Samples were collected at different time points (6, 12, and 20 days) to analyze neuronal gene expression and protein levels by gene array and immunohistochemistry. Following transfection, reprogramming cells displayed a rapid change in cellular morphology within 3 days post-transfection (FIG. 1). The cells were more rounded and the cell's cytoplasm retracted towards the nucleus forming contracted cell bodies with extended cytoplasmic extensions and exhibiting neuronal perikaryal appearance at day 6 and 12, which was maintained until day 20. However, this morphology was not observed in untransfected cells at day 6 and 12.
    • Gene Array Analysis
  • Characterization of the newly engineering cells after transfection was performed using a neuronal gene-array containing 48 partial cDNAs coding for these genes and controls.
  • RNA was isolated from samples using QIAshredder™ (Qiagen) and RNeasy™ Plus mini Kit (Qiagen) as per manufacturer's instructions. DNase I treatment was performed on the RNeasy™ Column to further remove the transfected plasmid DNA using Rnase-Free DNase Set (Qiagen). RNA was eluted in 35 μl of RNase-free water. Before cDNA synthesis, all RNA samples were quantified using the NanoDrop 1000™ (ThermoScientific). cDNA was prepared using the High Capacity cDNA archive kit (Applied Biosystems) as per the manufacturer's instructions. 400 ng of RNA was used in each 50 μl RT reaction. The resulting cDNA samples were used immediately for TLDA analysis. For each card of the Taqman™ low-density array (TLDA), there are eight separate loading ports that feed into 48 separate wells for a total of 384 wells per card. Each 2 μl well contains specific, user-defined primers and probes, capable of detecting a single gene. In this study, a customized Neuronal Markers 2 TLDA was configured into eight identical 48-gene sets, i.e. 1 loading port for each 48-gene set. Genes were chosen based on literature. Each set of 48 genes also contains three housekeeping genes: ACTIN, GAPDH, and PPIA.
  • A sample-specific master mix was made for each sample by mixing cDNA (160 ng for each loading port), 2× Taqman™ Gene Expression Master Mix (Applied Biosystems) and nuclease-free water (USB) for a total of 100 μl per loading port. After gentle mixing and centrifugation, the mixture was then transferred into a loading port on a TLDA card. The array was centrifuged twice for 1 minute each at 1200 rpm to distribute the samples from the loading port into each well. The card was then sealed and PCR amplification was performed using Applied Biosystems 7900HT™ Fast Real-time PCR system. Thermal cycler conditions were as follows: 2 minutes at 50° C., 10 minutes at 94.5° C., and 30 seconds at 97° C., 1 minute at 59.7° C. for 40 cycles. 1 TLDA's was prepared for 8 samples.
  • Relative Expression values were calculated using the Comparative CT method. Briefly, this technique uses the formula 2−ΔΔCT to calculate the expression of target genes normalized to a calibrator. The threshold cycle (CT) indicates the cycle number at which the amount of amplified target reaches a fixed threshold. CT values range from 0 to 40 (the latter representing the default upper limit PCR cycle number that defines failure to detect a signal). ΔCT values [ΔCT=CT (target gene)−CT (Average of 3 Housekeeping genes)] were calculated for HFF Ctrl, and subsequently used as the calibrator for the respective samples. All gene expression values were assigned a relative value of 1.00 for the calibrator, which is used to determine comparative gene expression such that ΔΔCT=ΔCT (Treated)−ΔCT (HFF Ctrl). Relative Expression is calculated using the formula 2−ΔΔCT.
  • Quantitative comparison of astrocyte, neuron, and oligodendrocyte gene expression allowed identification of the majority of the genes that are differentially expressed in reprogrammed cells. Data in Table 1 were analyzed by using a significance analysis algorithm to identify genes that were reproducibly found to be enriched in reprogrammed cells compared to untransfected cells. After the transfection with Msi1 or Ngn2 in the presence of MBD2, the expression of oligodendrocytes progenitors such as NKx2.2, olig2, and MAG and two markers for astrocytes (GFAP and AQP4) were highly increased. Also, several markers of early neuronal cells were enhanced after the transfection of HFF. TDLA data revealed a remarkable increase in specific markers for interneurons, such as somatostatin and calbindin1. The induction of Doublecortin (DCX), which is expressed by migrating immature cells during development, and acetylcholine (ACHE) mRNA, an early marker of neuronal cells, were highly expressed in the reprogrammed cells (Table 1). Transfection increased the expression of dihydropyrimidinase-like 3 (DPYSL3), an early marker of newborn neurons, to fivefold with Msi1 and seven fold with Ngn2. Expression of Microtubule-Associated Protein 2 (MAP2), an essential marker for development and maintenance of early neuronal morphology and neuronal cell adhesion molecule, were highly expressed with Msi1 and Ngn2 (Table 1). The expression of enolase-2, a marker of mature neurons, was 20-fold enhanced by Msi1 and Ngn2. Member of the NeuroD family NeuroD1 was highly expressed after transfection with Msi1 to 84 fold and to 34 by Ngn2.
  • Gene expression of growth factors such as IGF-1, IGF2, NPY and CSF-3 was also enhanced in reprogrammed cells. The expression of VEGF and GDNF genes were up-regulated to almost five fold and seven fold by Msi1 and Ngn2, respectively. However, the expression of BDNF, EGF, and bFGF were not activated and even down-regulated as compared to untransfected cells. The expression of growth associated protein (GAP-43), a growth- and regeneration-associated marker of neurons, and expression of netrin, implicated in neuronal development and guidance, were highly enriched in reprogrammed cells. Expression of receptors for growth and neurotrophin factors was increased, such as type III receptor tyrosine kinase, neurotrophic tyrosine kinase, and neurotrophic tyrosine kinase receptor. Vimentin and fibronectin, markers for fibroblasts, were down-regulated in reprogrammed cells compared to the untransfected control fibroblast cultures.
  • TABLE 1
    Gene array of transfected human fibroblast cells by Msi1/MBD2 and
    Ngn2/MBD2. Gene array was performed on samples after two weeks of differentiation.
    Expression values are given relative to untransfected fibroblasts.
    Relative Relative
    Common name Company expression expression
    Symbol and description Gene ID to Msi1 to Ngn2
    Astrocytes and oligodendrocytes markers
    -NKx2-2 -Markers for oligodendrocyte NM_002509.2 very high very high
    -OLIG2 progenitors NM_005806.2 47.511 8.38
    -MAG -Oligodendrocyte lineage NM-080600.1 212.61 4.51
    transcription factor 2
    -GFAP -Myelin-associated glycoprotein NM_002055.4 very high very high
    -AQP4 NM_001650.4 83.77 56.86
    -Glial fibrillary acidic protein
    -Aquaporin 4
    NC markers
    -SST -Somatostatin, specific marker for NM_001048.3 32.73 35.34
    -CALB1 interneurons NM_004929.2 18.21 13.22
    -Tubulin1A -Calbindin 1, interneuron marker NM_006009.2 7.45 9.32
    -NES -Are necessary for axonal growth NM_006617.1 1.61 1.54
    -DCX -Precursor neurons (nestin) NM_178151.1 very high very high
    -ACHE -An early neuronal marker NM_015831.2 9.02 13.22
    (Doublecortin)
    -ENO2 -Acetylcholinesterase, marker of early NM_001975.2 22.62 20.68
    -NEUROD1 neuronal development NM_002500.2 84.22 34.27
    -A marker for neurons cells, enolase
    -Neural marker; expression gradually
    -DPYSL3 increased from neural precursor to NM_001387.2 5.33 7.02
    fully differentiated neuron
    -MAP2 -Dihydropyrimidinase-like3, marker NM_002374.3 86.38 89.67
    of immature neurons
    -Microtubule-associated protein 2,
    -NCAM essential for development of early NM_18135.3 very high very high
    neuronal morphology and
    maintenance of adult neuronal
    -CEND1 morphology NM_016564.3 4.80 5.57
    -Neural cell adhesion molecule 1
    -Cell cycle exit & neuronal
    differentiation, early marker of
    proliferating precursor cells that will
    differentiate to neurons
    Neuroregeneration and survival genes
    -FGF2 -Fibroblast growth factor-Epidermal NM_002006.4 0.06 0.11
    -EGF growth factor, Hs00153181_ml 0.99 0.56
    -IGF-1 -Insulin growth factor-1, NM_000618.2 58.92 21.21
    -IGF-2 -Insulin growth factor-2 NM_0000612.3 very high very high
    -CSF3 -Granulocyte colony-stimulating NM_2219.1 very high 42.60
    -BDNF factor- Brain derived growth factor, NM-199231.1 0.05 0.03
    -GDNF neurogenesis NM-000614.2 4.77 6.89
    -CNTF -Glial derived neurotrophic factor NM_001025366. 1.86 1.09
    -VEGF -Ciliary neurotrophic factor 1 6.67 7.32
    -BMP-4 -Vascular endothelial growth factor NM_130850.1 5.96 8.57
    -KDR -Bone morphogenetic protein 4 NM_002253.1 31.78 6.83
    -NTRK2 -Type III receptor tyrosine kinase) NM_006180.3 10.31 13.37
    -NPY -Neurotrophic tyrosine kinase receptor very high very high
    (TrkB) NM_00905.2
    -PIK3CG -Neuropeptide factors very high very high
    -STAT3 NM_002649.2 2.14 3.65
    -Gap43 -phosphoinositide-3-kinase, NM_213662.1 very high very high
    -NTN1 -Signal transduction transcription 3 NM_002045.2 26.84 23.98
    -Growth associated protein 43 _NM_006180.3
    -NTRk2 -Netrinl, implicated in neuronal 10.31 13.37
    -Slit development and guidance NM_024003.1
    -Vimentin -Neurotrophic tyrosine kinase, very high very high
    -Fibronectin receptor, type 2 NM_003061.1 0.11 0.13
    Hs00185584 0.15 0.23
    -Axonal guidance molecules NM_212474.1
    -Radial glia and fibroblast marker
    -fibronectin is a marker for fibroblasts
    • Immunohistochemical Analysis
  • Cells were fixed with a 4% formaldehyde/PBS solution for 10 min at room temperature and subsequently permeabilized for 5 min with 0.1% Triton X-100™ in 4% formaldehyde/PBS. After two brief washes with PBS, unspecific antibody binding was blocked by a 30 min incubation with 5% normal goat serum in PBS. Then primary antibodies were added in 5% normal goat serum/PBS as follows: Mouse anti-Nestin (1:100, BD) as an intermediate microfilament present in neural stem cells and mouse anti-NCAM (1:100, Neuromics) as neuronal adhesion molecule. After a 2 h incubation the cells were washed 4 times for 5 min each with 0.1% Tween™/PBS. Appropriate fluorescence-tagged secondary antibody was used for visualization; Goat anti-mouse 546 (1:200, invitrogen) prepared in 5% normal goat serum/PBS was used. After incubation for one hour, cells were washed in 0.1% Tween™/PBS three times for 5 min each. The DNA stain Hoechst33342 (Invitrogen) was used as a marker of nuclei (dilution 1:5000 in PBS, 10 min incubation). Fluorescence images were taken with a Cellomics™ ArrayScan HCS Reader microscopy system. To determine an estimate of the percentage of cells adopting neuronal or glial phenotypes, random fields were selected and for each field the total number of cells (as determined by counting Hoechst stained nuclei) and the total number of cells positive for neuronal or glial markers were determined.
  • To confirm that these cells exhibited markers of neuronal lineages, cells were immunostained for nestin and NCAM. This analysis revealed that reprogrammed cells expressed both proteins. As shown in FIG. 2, NCAM was present in cells during the 6 days post-transfection and increase at day 12 and 20 following differentiation, while the inverse pattern was observed for the nestin staining.
  • This study showed the ability to reprogram HFF cells using one neurogenic transcription factor with the presence of a DNA demethylator towards cells that expressed neuronal genes and proteins specific to neural stem cells and neuronal cells. These reprogrammed cells were stable in culture for at least 2 weeks.
    • Example II Comparison of Reprogramming Efficiency of Three Different Neurogenic Genes
  • HFF cells were cultured as described in Example I and plated in CDM I medium. Cells were transfected using the Amaxa Nucleofector™™ Device (Lonza). The HFFs were harvested with TrypLE™ (Gibco), resuspended in CDM Medium and centrifuged for 10 min at 90×g (1×106 cells/tube). The supernatant was discarded and gently resuspended in 100 μl of Basic Nucleofector™ Solution (basic Nucleofector™ kit for primary mammalian fibroblasts, Lonza). Each 100 μl of cell suspension was combined with a different mix of plasmid DNA (for example, sample 1 was mixed with 2 μg of pCMV6-XL5-Pax6 and 2 μg pCMV6-XL5-MBD2). Cell suspension was transferred into an Amaxa certified cuvette and transfected with the appropriate program (U023). The sample was transferred without any further resuspension into a coated culture plate with LAS-Lysine/Alanine (BrainBits™, 50 μg/ml) and the cells were incubated at 37° C., 5% CO2. These steps were repeated for each sample that was transfected. After 24 hours, the medium was changed to Proliferation Medium. After two days, cells were retransfected using lipofectamine as described in Example I and incubated at 37° C., 5% CO2 and 5% O2. After 6 days, differentiation was induced with Differentiation Medium that gradually replaced the Proliferation Medium over several days. Cells were collected at day 14 for RT-PCR and immunohistochemistry analysis.
    • Gene Expression Analysis
  • RNA isolation and quantification was performed as previously described in Example I. cDNA was prepared using the High Capacity cDNA RT kit (Applied Biosystems) as per the manufacturer's instructions with a final cDNA concentration of 2 ng/μl. Real-time PCR was then performed for each gene of interest using the FAST PCR master mix (Applied Biosystems) and the Taqman™® Gene Expression Assays (Applied Biosystems) listed below:
  • Gene Name Assay ID
    ACHE Hs00241307_m1
    NES Hs00707120_s1
    TUBB3 Hs00964962_g1
    GFAP Hs00157674_m1
    PAX6 Hs00240871_m1
    MSI1 Hs01045894_m1
    NGN2 Hs00702774_s1
    MAP2 Hs00258900_m1
    GAPDH (housekeeping gene) Hs99999905_m1
    PPIA (housekeeping gene) Hs99999904_m1
  • The FAST 96-well reaction was performed with 8 ng cDNA per well in a 10 μl reaction with 40 cycles. Thermal cycler conditions were as follows: 20 seconds at 95° C., and 1 second at 95° C., 20 seconds at 60° C. for 40 cycles.
  • Relative Expression values were calculated as previously described in Example I, except the Average of 2 Housekeeping genes (GAPDH & PPIA) was used for normalization instead of the Average of 3 Housekeeping genes. Identification of neuronal lineage genes was investigated following the transfection with three independent vectors containing Msi1, Ngn2, and Pax6.
  • As shown in Table 2, after 14 days following transfection, relative expression of mRNA of neuronal lineage was undetectable in untransfected cells (HFF), while the cells transfected with Msi1 or Ngn2 in the presence of MBD2 expressed neural stem cell markers (Nestin and Sox2), however the expression of Sox2 was much more highly expressed than nestin following transfection with Ngn2 or Msi1. Neuronal and astrocyte specific genes (βIII-Tubulin, MAP2b, GFAP, and ACHE) was increased as well. mRNAs level of the tripotent-associated genes βIII-tubulin, MAP2b, acetylcholine, and GFAP were undetectable in Pax6 transfected cells, indicating that Pax6 alone was not implicated in the reprogramming process toward neuronal lineage.
  • TABLE 2
    Relative expression of gene expression of different neuronal lineage performed by RT-PCR following
    the transfection of HFF by Msi1, Ngn2, or Pax6 in the presence of MBD2 and cultured for 14 days.
    MSI1 NGN2 PAX6 NES TUBB3
    Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel.
    Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp.
    #
    1 Control 1.00 0.07 1.08 0.57 1.11 0.67 1.00 0.02 1.00
    Untransfect.
    #
    2 4077.82 248.02 1.18 0.66 487.09 69.58 8.62 0.00 6.58
    MSI1/MBD2
    #
    3 14.16 0.63 47803.26 192.78 624.31 91.27 8.62 0.02 8.33
    NGN2/MBD2
    #
    4 1.70 0.36 0.27 0.01 29564.43 357.89 0.46 0.00 0.49
    PAX6/MBD2
    TUBB3 ACHE GFAP MAP2 SOX2
    Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std.
    Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev.
    #
    1 Control 0.01 1.02 0.29 1.00 0.06 1.00 0.01 1.00 0.09
    Untransfect.
    #
    2 0.11 6.58 0.64 215.71 20.65 5.50 0.46 3499.53 184.85
    MSI1/MBD2
    #
    3 0.02 8.33 0.97 365.60 5.11 5.42 0.00 4039.03 8.65
    NGN2/MBD2
    #
    4 0.02 1.98 0.48 1.15 0.13 0.55 0.04 1.00 0.03
    PAX6/MBD2
    • Immunohistochemical Analysis
  • Fluorescent immunohistochemical staining was performed as previously described in Example I. In agreement with the RT-PCR data, immunohistochemical analysis of these cultures revealed that reprogrammed cells (with Msi1 or Ngn2) generated morphologically complex neurons that were positive for MAP2b, indicating the differentiation of NSLCs to neuron-like cells (NLCs) (FIG. 3). However, the positive staining for these markers was undetectable after transfection with Pax6/MBD2. Moreover, the newly formed neurons expressed the markers for and developed long neurites with growth cones at their ends, expressed neural specific genes, and ceased to proliferate when they were exposed to differentiation conditions.
    • Example III Transfection of HFF by Various Combinations of Vectors and Disruption of Cell Cytoskeleton
  • Various combinations of neurogenic regulators and cytokines for epigenetic modifications were tested to ascertain their effect on reprogramming efficiency. Starting one day before transfection, cells were treated with or without cytochalasin B (Calbiochem), with the concentration decreased every day over five days during media changes (starting with 10 μg/ml Cytochalasin B on day 1 to 7.5 μg/ml, 5 μg/ml, 2.5 μg/ml, and 0 μg/ml over the subsequent four days) in order to investigate the effect of disrupting the cell cytoskeleton on the process of reprogramming. Cells were transiently transfected as described in Example II with one or two vectors containing one neurogenic transcription factors by nucleofection. Cells were co-transfected with either of two DNA demethylators, MBD2 or GAdd45B, (e.g. 2×106 cells were transfected with pCMV6-XL5Msi1 (2 μg) and pCMV6-XL5-MBD2 (2 μg)). After 24 hours, the medium was changed to Neural Proliferation Medium (NeuroCult™ proliferation Kit, StemCell Technologies) consisting of DMEM/F12 (1:1), glucose (0.6%), sodium bicarbonate (0.1%), glutamine (20 mM), HEPES (5 mM), insulin (230 μg/ml), transferrin (100 μg/ml), progesterone (200 nM), putrescine (90 μg/ml), and sodium selenite (300 nM) and supplemented with Noggin (20 ng/ml, Peprotech), recombinant hFGF (20 ng/ml, Peprotech), and recombinant hEGF (20 ng/ml, Peprotech) and cells were cultured for two weeks at 372C, 5% CO2 and 5% O2. Cells were then analyzed for neural stem cell markers.
    • Gene Expression Analysis
  • Gene expression analysis was performed for neural stem-specific markers (Sox2, Nestin, GFAP) and a fibroblast-specific marker (Col5A2) by RT-PCR as previously described in Example I. RT-PCR analysis showed that the relative expression of Sox2, nestin and GFAP was enhanced after transfecting the cells with the neurogenic transcription factors. As shown in Table 3, transfecting the cells with one transcription factor Msi1 in the presence of Gadd45b was associated with up-regulation of relative expression of Sox2 (22.3±5.26) and GFAP (10.14±0.15) and the expression of the these genes was highly increase when transfecting the cells with Ngn2 by 20 fold and 10 fold respectively. Combining the two neurogenic factors (Msi1 and Ngn2) with Gadd45b enhanced further the expression of Sox2 and GFAP. Transfecting the cells with one transcription factor (Msi1 or Ngn2) in the presence of MBD2 was associated with up-regulation of relative expression of Sox2, Nestin, and GFAP and down-regulation of Col5A2, while co-transfection with Gadd45b did not increased the expression of nestin and the expression of Col5A2 was not regulated. The enhancement of neural stem cells relative expression was observed when transfecting the cells with two neurogenic genes in combination with MBD2; a small increase in the expression was noticed in the presence of cytochalasin B under certain conditions. An increase in the relative expression of the neural stem-specific markers (Sox2, Nestin, GFAP) and a decrease in the fibroblast-specific gene (COL5A2) was observed after transfection with Msi1/Ngn2/MBD2, Msi1/Ngn2/Gadd45b, Msi1/MBD2 or Ngn2/MBD2 (Table 3). This study demonstrated that MBD2 increased more reprogramming efficiency then GDA45b and showed that cytochalasin B had no effect of its own in the control cultures.
  • TABLE 3
    RT-PCR analysis of relative expression of neuronal precursor cell markers such as nestin, Sox2,
    and GFAP after transfection of fibroblast cells with different combinations with or without the
    co-treatment with cytochalasin B. Relative expression of Sox2, nestin, and GFAP in NSLCs was
    increased after transfection with both transcription factors (Ngn2 and Msi1) with MBD2 as the
    DNA demethyaltor. As demonstrated, this upregulation of neural stem cell gene expression was
    associated with a decrease of CoL5A2, a specific gene for fibroblast cells.
    COL5A2 FBN2 NES MAP2
    Rel. Std. Rel. Std. Rel. Std. Rel. Std.
    Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev.
    #1, +CytoB, 1.00 0.07 1.00 0.01 1.00 0.04 1.00 0.05
    Control
    #2, −CytoB, 1.00 0.03 1.00 0.08 1.00 0.00 1.00 0.09
    Control
    #3, +CytoB, 0.85 0.04 0.75 0.02 0.60 0.01 0.29 0.01
    Msi1, GAD45b
    #4, −CytoB, 0.87 0.03 1.81 0.09 1.84 0.04 2.31 0.00
    Msi1, GAD45b
    #5, +CytoB, 0.84 0.04 0.77 0.03 0.44 0.00 0.24 0.00
    Ngn2, GAD45b
    #6, −CytoB, 0.75 0.07 1.97 0.02 1.83 0.00 4.40 0.16
    Ngn2, GAD45b
    #7, +CytoB, 0.74 0.12 1.08 0.00 0.89 0.01 0.51 0.00
    Pax6, GAD45b
    #8, −CytoB, 0.66 0.04 2.41 0.09 2.70 0.03 4.96 0.30
    Pax6, GAD45b
    #9, +CytoB, 0.14 0.01 0.28 0.01 1.30 0.03 4.07 0.11
    Msi1, Ngn2,
    GAD45b
    #10, −CytoB, 0.12 0.00 0.73 0.03 5.28 0.21 50.84 1.23
    Msi1, Ngn2
    GAD45b
    #11, +CytoB, 0.10 0.00 0.26 0.01 1.11 0.01 3.69 0.09
    Msi1, Ngn2
    MBD2
    #12, −CytoB, 0.44 0.01 1.47 0.06 5.49 0.14 47.30 0.11
    Msi1, Ngn2
    MBD2
    #13, +CytoB, 1.11 0.04 1.09 0.06 0.92 0.08 0.68 0.01
    GAD45b
    #14 , −CytoB, 0.94 0.01 2.22 0.00 2.82 0.02 6.49 0.30
    GAD45b
    #15, +CytoB, 0.83 0.00 0.83 0.05 0.36 0.01 0.16 0.01
    MBD2
    #16, −CytoB, 0.68 0.02 1.55 0.04 1.57 0.05 1.47 0.01
    MBD2
    #17, +CytoB, 1.10 0.01 1.16 0.03 1.37 0.01 1.12 0.06
    Msi1, Ngn2
    #18, −CytoB, 0.93 0.04 2.52 0.10 3.48 0.01 9.01 0.02
    Msi1, Ngn2
    #19, +CytoB, 0.20 0.03 0.36 0.01 1.25 0.05 6.68 0.31
    Msi1, MBD2
    #20, −CytoB, 0.12 0.00 0.64 0.03 4.70 0.22 77.51 0.11
    Msi1, MBD2
    #21, +CytoB, 0.17 0.01 0.28 0.00 1.16 0.04 5.73 0.06
    Ngn2, MBD2
    #22, −CytoB, 0.17 0.00 0.78 0.03 4.32 0.08 68.89 5.26
    Ngn2, MBD2
    #23, +CytoB, 0.71 0.05 0.79 0.06 0.87 0.01 0.63 0.06
    Msi1
    #24, −CytoB, 0.66 0.04 1.92 0.17 2.03 0.02 2.77 0.02
    Msi1
    TUBB3 SOX2 ACHE GFAP
    Rel. Std. Rel. Std. Rel. Std. Rel. Std.
    Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev.
    #1, +CytoB, 1.00 0.05 1.00 0.05 1.00 0.10 1.00 0.11
    Control
    #2, −CytoB, 1.00 0.09 1.15 0.80 1.01 0.18 1.00 0.01
    Control
    #3, +CytoB, 0.44 0.00 22.39 5.26 0.81 0.19 10.14 0.15
    Msi1, GAD45b
    #4, −CytoB, 2.09 0.03 20.28 5.33 1.99 0.74 6.03 0.05
    Msi1, GAD45b
    #5, +CytoB, 0.36 0.01 470.84 13.43 0.63 0.05 103.22 0.80
    Ngn2, GAD45b
    #6, −CytoB, 2.02 0.10 789.33 60.35 1.70 0.13 110.48 4.90
    Ngn2, GAD45b
    #7, +CytoB, 0.63 0.04 1.64 0.98 0.86 0.12 2.49 0.21
    Pax6, GAD45b
    #8, −CytoB, 3.48 0.07 0.46 0.33 2.97 1.04 0.43 0.09
    Pax6, GAD45b
    #9, +CytoB, 0.84 0.00 54768.27 6709.56 0.81 0.24 3391.96 64.63
    Msi1, Ngn2,
    GAD45b
    #10, −CytoB, 4.93 0.28 17400.66 822.88 3.58 0.10 1255.76 5.27
    Msi1, Ngn2
    GAD45b
    #11, +CytoB, 0.76 0.00 55588.41 1331.20 0.55 0.14 2849.96 261.51
    Msi1, Ngn2
    MBD2
    #12, −CytoB, 5.50 0.31 14587.46 789.19 3.90 0.13 1424.04 39.29
    Msi1, Ngn2
    MBD2
    #13, +CytoB, 0.82 0.03 63.93 2.81 1.19 0.17 17.43 1.86
    GAD45b
    #14 , −CytoB, 4.01 0.05 6.12 0.61 2.34 0.17 1.42 0.10
    GAD45b
    #15, +CytoB, 0.36 0.00 3.42 3.74 0.63 0.37 2.18 0.12
    MBD2
    #16, −CytoB, 2.00 0.00 0.52 0.29 1.45 0.15 0.55 0.04
    MBD2
    #17, +CytoB, 0.86 0.06 5.59 1.48 1.07 0.27 1.70 0.46
    Msi1, Ngn2
    #18, −CytoB, 4.55 0.18 1.78 1.46 3.83 0.42 0.59 0.01
    Msi1, Ngn2
    #19, +CytoB, 0.72 0.02 66592.29 3481.89 2.57 0.03 4450.08 131.85
    Msi1, MBD2
    #20, −CytoB, 4.12 0.11 19128.03 1542.00 8.14 0.13 999.22 24.75
    Msi1, MBD2
    #21, +CytoB, 0.62 0.00 67945.51 3000.74 2.15 0.04 4736.83 11.92
    Ngn2, MBD2
    #22, −CytoB, 4.01 0.04 16570.91 92.96 7.04 0.53 1427.13 13.19
    Ngn2, MBD2
    #23, +CytoB, 0.67 0.04 2.86 0.70 1.08 0.08 2.08 0.11
    Msi1
    #24, −CytoB, 2.68 0.02 0.32 0.12 1.85 0.65 0.58 0.04
    Msi1
    • Immunohistochemical Analysis
  • Fluorescent immunohistochemical staining was performed as previously described in Example I. Table 4 shows the percentage of Nestin and Sox2 in each condition, with the highest percentage of Sox2 (38.18±1.75%) and nestin (28.18±2.77%) positive cells observed after transfecting the cells simultaneously with both neurogenic transcription factors and in the presence of a DNA demethylator and cytochalasin B. A slight increase of Sox2 positive cells (10.42±10.27%) and nestin positive cells (4.85±1.10%) was detected following transfection with one transcription factor Msi1 and MBD2. Same tendency of nestin and Sox2 positive cells was observed following transfection with Ngn2 and MBD2. Disrupting the cell cytoskeleton with Cytochalasin B significantly enhanced reprogramming, but had no reprogramming effect on its own (Table 4).
  • TABLE 4
    Percentage of positive cells for Sox2 and nestin after transfection of fibroblast cells
    with different expression vectors with or without the presence of cytochalasin B. After
    transfection the cells were cultured in proliferation medium (StemCell Technologies)
    supplemented by EGF (20ng/ml, Peprotech) and FGF (20ng/ml, Peprotech) for two weeks at
    37° C./5% CO2/5% O2. The percentage of immunopositive cells was determined by Cellomics™
    and represented as mean ± SD (n = 3-5).
    % of Sox2 positive cells % of Nestin positive cells
    +CytoB −Cyto B +CytoB −CytoB
    Untransfected cells  0.02 ± 0.01   0.01 ± 0.00   0.14 ± 0.04  0.11 ± 0.09
    Ngn2  0.35 ± 0.36   0.15 ± 0.05   2.34 ± 0.99  1.04 ± 0.21
    Msi1  0.23 ± 0.15   0.12 ± 0.09   1.95 ± 0.11  1.11 ± 0.18
    Gadd45b  0.30 ± 0.17   0.29 ± 0.11   4.94 ± 0.25  2.33 ± 0.42
    MBD2  0.22 ± 0.13   0.22 ± 0.11    2.8 ± 0.11  1.53 ± 0.6 
    Msi1/Ngn2  0.19 ± 0.13   0.32 ± 0.05   1.91 ± 0.56  2.59 ± 1.28
    Msi1/MBD2 10.42 ± 10.27  8.84 ± 11.63  4.85 ± 1.10  2.06 ± 0.08
    Msi1/Gadd45b  0.06 ± 0.01   0.14 ± 0.17   0.55 ± 0.06  0.24 ± 0.11
    Ngn2/MBD2 11.17 ± 0.08   9.07 ± 11.31   5.7 ± 0.10  2.18 ± 0.23
    Ngn2/GAdd45b  0.29 ± 0.11   0.95 ± 0.17   1.17 ± 0.54  0.98 ± 0.25
    Msi1/Ngn2/MBD2 38.18 ± 1.75  22.03 ± 1.90  28.18 ± 2.77 14.54 ± 0.45
    Msi1/Ngn2/Gadd45b 22.65 ± 5.03  18.54 ± 9.40  18.72 ± 6.26  8.70 ± 4.51
  • Various DNA demethylators were tested as well for their effect on reprogramming efficiency. Cells were co-transfected with one vector (MSI1/NGN2) containing two neurogenic pCMV6-Msi1-Ngn2 factors with various DNA demethylators. Simultaneously another neurogenic factor was tested for its effect on cells de-differentiation towards NSCs, pCMV-XL-Nestin individually or in combination with pCMV-Msi1-Ngn2, pCMV-XL5-Msi1, or pCMV-XL4-Ngn2 in the presence of MBD2 as previously described in Example II.
  • Cells were co-transfected pCMV-Msi1-Ngn2 with different DNA demethylators (MBD1, MBD2, MBD3, MBD4, MeCP2, AICDA). Another assay was performed to assess the effect of nestin on the reprogramming efficiency; therefore cells were transfected with nestin individually or in combination with one vector containing one neurogenic factor (Msi1 or Ngn2) or both neurogenic factors in the presence of MBD2. Cells were cultured following transfection in the presence of proliferation medium supplemented with EGF (20 ng/ml), FGF (20 ng/ml), and Noggin (20 ng/ml) with and without VPA (1 mM) treatment for 12 days at 37° C., 5% CO2 and 5% O2.
  • Gene expression analysis and immunohistochemistry was performed to analyse neural specific gene and protein expression (βIII-tubulin, GFAP, Sox2, Nestin) as described in Example II. Transfecting cells with Msi1 and Ngn2 in the presence of various DNA demethylators revealed and confirm previous data showing that the among various DNA demethylators used in this study, MBD2 promotes the expression of neural stem genes (Sox2, GFAP, Nestin) as shown in Table 5. Furthermore, transfecting cells with nestin with and without the presence of one neurogenic factor had no effect on the reprogramming efficiency into neural stem-like cells. However co-transfection with nestin and Msi1/Ngn2/MBD2 enhanced the expression of neural stem cells genes and this increase was more pronounced in the presence of VPA.
  • TABLE 5
    RT-PCR analysis of relative expression of neuronal precursor cell markers such as
    nestin, Sox2, βIII-tubulin, and GFAP after transfection of fibroblast cells with various
    combinations of pCMV-Msi1-Ngn2 (MSI1/NGN2), pCMV-XL5-Msi1, pCMV-
    XL4-Ngn2, pCMV-XL-Nestin with different combinations of DNA demethylators,
    with and without the co-treatment with VPA.
    TUBB3 GFAP SOX2 NES
    Rel. Std. Rel. Std. Rel. Std. Rel. Std.
    Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev.
    Day 12, Untransfected 1.00 0.11 1.00 0.05 1.01 0.16 1.00 0.13
    (−VPA)
    Day 12, Untransfected 1.00 0.03 1.00 0.06 1.00 0.00 1.00 0.02
    (+VPA)
    Day 12, 0.96 0.06 2.69 0.13 1.15 0.49 0.46 0.02
    MSI1/NGN2/MBD1 (−VPA)
    Day 12, 1.10 0.06 2.22 0.06 0.80 0.01 0.84 0.02
    MSI1/NGN2/MBD1 (+VPA)
    Day 12, 123.52 0.06 1638.53 99.86 61467.29 1487.21 31.77 0.17
    MSI1/NGN2/MBD2 (−VPA)
    Day 12, 232.00 0.08 1889.30 42.39 72022.15 7894.41 42.69 0.14
    MSI1/NGN2/MBD2 (+VPA)
    Day 12, 0.92 0.07 3.98 0.59 28.05 4.67 0.56 0.01
    MSI1/NGN2/MBD3 (−VPA)
    Day 12, 1.23 0.05 1.66 0.18 11.31 2.35 0.87 0.02
    MSI1/NGN2/MBD3 (+VPA)
    Day 12, 0.85 0.01 4.80 0.23 5.42 5.20 0.62 0.00
    MSI1/NGN2/MBD4 (−VPA)
    Day 12, 0.95 0.01 1.57 0.16 2.27 0.04 0.79 0.03
    MSI1/NGN2/MBD4 (+VPA)
    Day 12, 1.11 0.06 3.80 0.38 6.54 6.45 0.69 0.01
    MSI1/NGN2/MeCP2
    (−VPA)
    Day 12, 1.37 0.09 1.63 0.45 10.53 10.49 1.07 0.01
    MSI1/NGN2/MeCP2
    (+VPA)
    Day 12, 1.07 0.04 4.59 0.02 0.65 0.01 0.74 0.02
    MSI1/NGN2/AICDA (−VPA)
    Day 12, 1.10 0.01 2.37 0.29 1.21 0.16 0.91 0.04
    MSI1/NGN2/AICDA
    (+VPA)
    Day 12, Msi1/MBD2 1.31 0.17 3.78 0.49 0.70 0.02 0.78 0.00
    (−VPA)
    Day 12, Msi1/MBD2 1.36 0.07 1.75 0.31 1.26 0.03 1.15 0.03
    (+VPA)
    Day 12, Ngn2/MBD2 0.85 0.06 2.93 0.51 0.79 0.05 0.58 0.02
    (−VPA)
    Day 12, Ngn2/MBD2 1.41 0.05 1.60 0.11 2.30 0.06 1.03 0.03
    (+VPA)
    Day 12, Nes/Msi1 (−VPA) 0.84 0.03 3.21 0.72 0.76 0.01 0.51 0.01
    Day 12, Nes/Msi1 (+VPA) 0.86 0.09 1.82 0.30 2.14 1.02 0.94 0.01
    Day 12, Nes/Ngn2 (−VPA) 0.69 0.05 2.88 0.32 0.99 0.10 0.57 0.02
    Day 12, Nes/Ngn2 (+VPA) 0.88 0.01 1.53 0.19 2.71 0.02 0.83 0.03
    Day 12, 111.58 0.04 1423.56 82.87 72069.27 624.51 51.52 0.12
    Nes/MSI1/NGN2/MBD2
    (−VPA)
    Day 12, 321.00 0.04 2600.14 1.90 88932.00 708.72 82.74 0.18
    Nes/MSI1/NGN2/MBD2
    (+VPA)
    Day 12, Nes/MSI1/NGN2 0.74 0.11 2.60 0.28 1.98 0.97 0.55 0.01
    (−VPA)
    Day 12, Nes/MSI1/NGN2 0.86 0.00 1.70 0.49 1.70 0.04 0.88 0.05
    (+VPA)
    Day 12, Nes/MBD2 (−VPA) 0.76 0.12 3.15 0.17 0.87 0.03 0.44 0.00
    Day 12, Nes/MBD2 0.87 0.03 2.05 0.07 2.66 1.64 0.91 0.00
    (+VPA)
    Day 12, Nes/Msi1/MBD2 0.81 0.05 3.41 0.66 1.11 0.01 0.58 0.01
    (−VPA)
    Day 12, Nes/Msi1/MBD2 1.01 0.13 2.43 0.07 3.27 0.26 0.93 0.02
    (+VPA)
    Day 12, Nes/Ngn2/MBD2 1.19 0.07 5.71 1.30 4.11 0.07 0.91 0.04
    (−VPA)
    Day 12, Nes/Ngn2/MBD2 1.29 0.03 2.98 0.66 21.20 0.42 1.65 0.02
    (+VPA)
  • Immunohistochemistry analysis performed in parallel with RT-PCR data indicated that positive Sox2 cells were undetectable when transfecting the cells with Msi1/Ngn2 in the presence of MBD1, MBD3, MBD4, MeCP1, or AICADA (Table 6) and that among the different types of DNA demethylator genes tested only MBD2 plays a significant positive role in the reprogramming efficiency of HFF towards NSLCs when using the above neurogenic genes. Immunohistochemistry analysis revealed a small increase of immunopositive Sox2 cells (89.49±3.18) after co-transfecting the cells with nestin and Msi1/Ngn2 in the presence of MBD2 (Table 6).
  • TABLE 6
    Percentage of positive cells for Sox2 after transfection of fibroblast cells with different
    expression vectors with or without the presence of various DNA demethylators. After
    transfection the cells were cultured in proliferation medium (StemCell Technologies)
    supplemented by EGF (20ng/ml, Peprotech) and FGF (20ng/ml, Peprotech) for two weeks at
    37° C./5% CO2/5% O2 The percentage of immunopositive cells was determined by Cellomics ™
    and represented as mean ± SD (n = 3-5).
    % Sox2 positive ± stdv
    HFF untransfected  0.13 ± 0.12
    Msi-Ngn2 + MBD1  0.92 ± 0.13
    Msi-Ngn2 + MBD2 79.44 ± 9.86
    Msi-Ngn2 + MBD3  1.22 ± 0.82
    Msi-Ngn2 + MBD4  0.59 ± 0.03
    Msi-Ngn2 + MeCP2  1.10 ± 0.25
    Msi-Ngn2 + AICDA  0.69 ± 0.28
    Msi + MBD2  0.79 ± 0.28
    Ngn2 + MBD2  1.74 ± 1.01
    Nestin + Msi  0.91 ± 0.01
    Nestin + Ngn2  2.16 ± 1.44
    Nestin + MSI1/NGN2 + MBD2 89.49 ± 3.18
    Nestin + MSI1/NGN2 10.20 ± 0.21
    Nestin + MBD2  0.00 ± 0.00
    Nestin + Msi + MBD2  8.45 ± 0.08
    Nestin + Ngn2 + MBD2  5.71 ± 0.66
  • Another study was designed to test the effect of various neurogenic genes on the reprogramming efficiency towards neural stem-like cells. HFF cells were cultured as described in Example I, and transfected using the Nucleofector™® 96-well Shuttle® Device (Lonza) following procedure described in Example IV, except for the untreated HFF control and the untransfected HFF control (for determining the effect of the complete media & compound treatments on the cells). The cells that had been pre-treated with VPA and 5-Aza and the untreated cells were transfected with the mixes of DNA as described in Table 7. The cells were plated on Laminin-coated plates and incubated at 37° C., 5% CO2. Media was changed daily according to Table 7. Cells were analysed at day 3, 7, 12 by immunohistochemistry analysis and at Day 9 by gene array for multipotent and pluripotent gene expression.
    • Gene Array Analysis
  • An additional batch of cells treated according to 0a and 1a in Table 7 was analyzed at Day 9, along with HFFs, hNPCs, and passage 5 NSLCs (frozen from previous experiments from Example III) by the Pluripotency Gene Array (ABI) (Tables 8a and b) and a set of genes (Table 8c) to determine the gene expression profile of select pluripotency, ectoderm, endoderm, mesoderm, and neural lineage genes in passage 1 and passage 5 NSLCs compared to HFFs (from which they were created) and normal human neuroprogenitor cells (hNPCs). The results in Table 8 indicate that all the genes related to neural stem cells (some of the significantly expressed pluripotency markers and mesendoderm markers are also expressed in neural stem cells) and the neural lineage were significantly expressed in NSLCs as opposed to HFFs, and the expression pattern was a bit different from hNPCs indicating that NSLCs are similar to, but not identical, to the hNPCs tested. Passage 5 NSLCs 5 had a higher expression of stemness genes than Passage 1 NSLCs. hNPCs had a higher expression of neuronally committed genes than NSLCs, indicting their neuroprogenitor status versus the greater stemness status of NSLCs.
  • TABLE 7
    Plasmids and media composition from day 1 to day 12.
    From day −2 Plasmids transfected
    to day 0 at day 0 From day 1 to day 3 From day 3 to day 4 From day 4 to day 12
    0a Untreated No plasmid Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-2
    Egf + Fgf-2 medium + Egf + Fgf-2
    1a Untreated Msi1/Ngn2 + pCMV6- Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-2
    XL5-MBD2 Egf + Fgf-2 medium + Egf + Fgf-2
    1b Untreated Msi1/Ngn2 + pCMV6- Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-
    XL5-MBD2 Egf + Fgf-2 medium + Egf + Fgf-2 2 + SHH
    1c Untreated Msi1/Ngn2 + pCMV6- Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-
    XL5-MBD2 Egf + Fgf-2 + Noggin medium + Egf + Fgf-2 + 2 + Noggin (day 1 to day 7)/Forskolin
    Noggin (day 7 to day 12)
    1d Untreated Msi1/Ngn2 + pCMV6- Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-2
    XL5-MBD2 Egf + Fgf-2 medium + Egf + Fgf-2
    1e Untreated Msi1/Ngn2 + pCMV6- Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-2
    XL5-MBD2 Egf + Fgf-2 medium + Egf + Fgf-2
    1f Untreated Msi1/Ngn2 + pCMV6- Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-2
    XL5-MBD2 Egf + Fgf-2 medium + Egf + Fgf-2
    2 Untreated Msi1/Ngn2 + pCMV6- Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-2
    XL5-MBD2 Egf + Fgf-2 + CytoB medium + Egf + Fgf-2 +
    CytoB
    3 Untreated Msi1/Ngn2 Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-2
    Egf + Fgf-2 + VPA + 5-Aza medium + Egf + Fgf-2
    4 Untreated Msi1/Ngn2 Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-2
    Egf + Fgf-2 medium + Egf + Fgf-2
    5 Untreated pCMV6-XL5-Musashi Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-2
    Egf + Fgf-2 medium + Egf + Fgf-2
    6 Untreated pCMV6-XL5-Musashi Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-
    Egf + Fgf-2 + Noggin medium + Egf + Fgf-2 + 2 + Noggin+ Forskolin
    Noggin
    7 Untreated pCMV6-XL5-Musashi Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-2
    Egf + Fgf-2 + VPA + 5-Aza medium + Egf + Fgf-2
    8 Untreated pCMV6-XL5-Musashi Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-
    Egf + Fgf-2 + Noggin + VPA + medium + Egf + Fgf-2 + 2 + Noggin+ Forskolin
    5-Aza Noggin
    9 Untreated pCMV6-XL5-ZIC1 + Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-2
    pCMV6-XL4-Ngn2 + Egf + Fgf-2 medium + Egf + Fgf-2
    pCMV6-XL5-MBD2
    10 Untreated pCMV6-XL5-SOX1 + Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-2
    pCMV6-XL4-Ngn2 + Egf + Fgf-2 medium + Egf + Fgf-2
    pCMV6-XL5-MBD2
    11 Untreated pCMV6-XL5-Sox2 + Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-2
    pCMV6-XL4-Ngn2 + Egf + Fgf-2 medium + Egf + Fgf-2
    pCMV6-XL5-MBD2
    12 Untreated pCMV6-XL5-Nanog + Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-2
    pCMV6-XL4-Ngn2 + Egf + Fgf-2 medium + Egf + Fgf-2
    pCMV6-XL5-MBD2
    13 Untreated pCMV6-XL4-Oct4 + Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-2
    pCMV6-XL4-Ngn2 + Egf + Fgf-2 medium + Egf + Fgf-2
    pCMV6-XL5-MBD2
    14 VPA + 5-Aza Msi1/Ngn2 Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-2
    pre-treated Egf + Fgf-2 medium + Egf + Fgf-2
    15 VPA + 5-Aza pCMV6-XL5-Musashi Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-2
    pre-treated Egf + Fgf-2 + VPA + 5-Aza medium + Egf + Fgf-2
    16 VPA + 5-Aza pCMV6-XL5-Musashi Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-
    pre-treated Egf + Fgf-2 + Noggin + VPA + medium + Egf + Fgf-2 + 2 + Noggin + Forskolin
    5-Aza Noggin
    17 VPA + 5-Aza pCMV6-XL5-Musashi + Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-
    pre-treated pCMV6-XL5-MBD2 Egf + Fgf-2 + Noggin + VPA + medium + Egf + Fgf-2 + 2 + Noggin + Forskolin
    5-Aza Noggin
    18 VPA + 5-Aza pCMV6-XL4-Ngn2 Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-
    pre-treated Egf + Fgf-2 + Noggin + VPA + medium + Egf + Fgf-2 + 2 + Noggin + Forskolin
    5-Aza Noggin
    19 VPA + 5-Aza pCMV6-XL5-MBD2 Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-
    pre-treated Egf + Fgf-2 + Noggin + VPA + medium + Egf + Fgf-2 + 2 + Noggin + Forskolin
    5-Aza Noggin
    20 VPA + 5-Aza Ngn2 + pCMV6-XL5- Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-
    pre-treated MBD2 Egf + Fgf-2 + Noggin + VPA + medium + Egf + Fgf-2 + 2 + Noggin + Forskolin
    5-Aza Noggin
    21 VPA + 5-Aza No plasmid Neural proliferation medium + Neural proliferation Neural proliferation medium + Egf + Fgf-
    pre-treated Egf + Fgf-2 + Noggin + VPA + medium + Egf + Fgf-2 + 2 + Noggin + Forskolin
    5-Aza Noggin
    * Immunohistochemistry analysis performed in parallel with RT-PCR data indicated among all the combinations in this experiment where no cytochalasin B was used, positive Sox2 cells were detectable only in cells transfected with Msi1/Ngn2 with and without MBD2.
  • TABLE 8a
    Results for Human Stem Cell Pluripotency Array (n = 4 for each sample)-Embryonic Stem Cell Markers,
    Germ Cell Markers and Trophoblast Markers. For Relative Expression calculations, each sample was
    normalized to the average Ct of the 6 housekeeping genes (ACTB, 18S, CTNNB1, EEF1A1, GAPD,
    RAF1), and calibrated to the Untreated HFF (Passage 8) control. Relative Expression values with
    asterisk (*) indicate values with significant up or down-regulation (>2-fold or <0.5-fold). For these
    samples, for Ct values <35 is considered that the expression of the gene is adequate for quantification.
    For the Relative Expression values that are >2-fold or <0.5-fold but without asterisk, the values could
    have significant error due to the low expression of the gene (Ct > 35), and thus the up or down-regulation
    could be merely a result of the high standard deviation of the high Ct values of the genes, or fluctuations
    in the housekeeping genes. As for the Relative Expression values that are between 0.5-fold and 2-fold, it
    indicates no significant change in the expression of the gene for these samples.
    MSI1/NGN2/
    MBD2- Neural
    transfected HFF stem-like cells,
    Untreated HFF Untransfected HFF hNPC neurospheres (Day 9) NSLC
    (Passage 8) (Day 9) (Passage 4) (NSLC, Passage 1) (Passage 5)
    Gene Rel. Exp. Std. Dev. Rel. Exp. Std. Dev. Rel. Exp. Std. Dev. Rel. Exp. Std. Dev. Rel. Exp. Std. Dev.
    Embryonic Stem
    cell markers
    BRIX 1.03 0.30 0.47 0.10 0.78 0.22 0.78 0.25 0.83 0.10
    CD9 1.01 0.18 2.46* 0.62 1.86 0.29 2.24* 0.19 1.00 0.39
    COMMD3 1.08 0.53 0.94 0.36 0.94 0.40 0.98 0.40 1.05 0.59
    DNMT3B 1.07 0.50 0.34* 0.14 2.96* 0.84 1.90 0.41 0.35 0.34
    EBAF/LEFTY2 1.00 0.00 2.10 0.00 7.95 4.60 7.79 4.88 70.56* 26.12
    FGF4 1.00 0.00 2.10 0.00 1.44 0.00 1.54 0.00 1.37 0.00
    FOXD3 1.00 0.00 2.10 0.00 1.44 0.00 7.13 11.18 222.41* 63.43
    GABRB3 1.06 0.38 4.22* 0.71 66.65* 12.52 40.01* 4.54 1.62 0.98
    GAL 1.00 0.04 9.73* 0.32 0.03* 0.01 4.25* 0.46 2.89* 0.83
    GBX2 1.00 0.09 0.04 0.05 45.28* 4.59 90.92* 12.14 55.22* 2.36
    GDF3 1.00 0.00 2.10 0.00 1.44 0.00 1.54 0.00 1.37 0.00
    GRB7 1.02 0.24 0.30* 0.16 0.05* 0.04 0.29* 0.08 0.06* 0.08
    IFITM1 1.01 0.17 63.96* 6.04 0.04* 0.01 21.80* 4.31 3.35* 0.63
    IFITM2 1.00 0.12 3.84* 0.89 0.02* 0.00 0.65 0.11 0.43* 0.09
    IL6ST 1.01 0.21 2.19* 0.39 0.85 0.14 1.59 0.26 0.75 0.06
    IMP2 1.11 0.66 1.65 0.92 1.06 0.48 0.78 0.26 1.96 0.97
    KIT 1.02 0.26 1.15 0.30 0.02* 0.00 0.31* 0.09 0.00* 0.00
    LEFTB 1.61 1.15 12.28* 7.84 5.45 3.15 5.58 2.65 8.96* 4.12
    LIFR 2.29 3.57 13.51 16.55 6.31 7.24 12.98 9.81 2.85 4.31
    LIN28 4.69 8.62 5.25 8.88 28.38* 19.25 26.97* 8.68 32.13* 14.32
    NANOG 1.71 1.97 18.61 16.43 64.94* 28.32 70.87* 9.88 5.87 3.52
    NOG 1.03 0.27 0.18* 0.08 0.18* 0.06 0.22* 0.06 0.02* 0.00
    NR5A2 2.04 2.05 6.85 8.80 0.38 0.00 3.89 4.36 0.36 0.00
    NR6A1 1.11 0.66 1.37 0.31 5.08* 0.37 2.71* 0.63 2.04* 0.17
    PODXL 1.00 0.07 0.01* 0.01 0.80 0.11 2.09* 0.04 6.49* 0.64
    POU5F1 1.01 0.13 0.27* 0.17 0.89 0.09 0.71 0.09 0.19* 0.06
    PTEN 1.00 0.02 2.68* 0.29 0.87 0.04 1.07 0.12 0.80 0.14
    RESET 1.01 0.12 1.53 0.17 0.94 0.18 1.04 0.21 1.10 0.24
    SEMA3A 1.00 0.11 1.99 0.19 0.66 0.05 1.05 0.11 0.90 0.16
    SFRP2 1.11 0.56 122.57* 14.57 3480.98* 702.37 1500.84* 272.46 2.75 2.85
    SOX2 1.00 0.00 2.45 0.70 127594.46* 11326.91 88615.76* 15003.70 137424.37* 26622.02
    TDGF1 1.41 1.28 2.92 0.68 6.13 1.52 5.46 1.95 2.20 1.51
    TERT 1.00 0.00 2.10 0.00 10.81 18.75 10.74 18.41 6506.88* 893.84
    TFCP2L1 1.00 0.00 2.10 0.00 7.84 12.80 32.49 10.01 1.37 0.00
    UTF1 1.00 0.00 8.21 12.23 27.86 19.24 1.54 0.00 30.68 25.94
    XIST 1.00 0.00 2.10 0.00 24609.46* 4337.83 22637.95* 3988.10 1.37 0.00
    ZFP42 1.24 1.06 12.38 12.58 1.41 0.78 2.01 1.85 1.76 0.93
    Germ cell markers
    DDX4 1.00 0.00 2.10 0.00 1.44 0.00 5.84 8.60 19.11 20.49
    SYCP3 1.58 1.95 11.97 8.01 11.12 3.46 15.46 11.65 2.25 2.85
    Trophoblast
    markers
    CDX2 1.00 0.00 2.10 0.00 1.44 0.00 1.54 0.00 1.37 0.00
    CGB 1.02 0.24 2.08* 0.74 0.15* 0.16 0.57 0.41 0.09* 0.17
    EOMES 1.51 1.14 0.33 0.00 0.71 0.97 0.24 0.00 0.77 1.12
    GCM1 2.61 2.80 0.42 0.00 3.25 5.92 5.68 1.44 1.47 2.38
    KRT1 1.00 0.00 2.10 0.00 1.44 0.00 1.54 0.00 1.37 0.00
  • TABLE 8b
    Results for Human Stem Cell Pluripotency Array (n = 4 for each sample)-Ectoderm, Endoderm and Mesoderm
    Markers. For Relative Expression calculations, each sample was normalized to the average Ct of the 6 housekeeping
    genes (ACTB, 18S, CTNNB1, EEF1A1, GAPD, RAF1), and calibrated to the Untreated HFF (Passage 8) control.
    Relative Expression values with asterisk (*) indicate values with significant up or down-regulation (>2-fold or
    <0.5-fold). For these samples, for Ct values <35 is considered that the expression of the gene is adequate for
    quantification. For the Relative Expression values that are >2-fold or <0.5-fold but without asterisk, the
    values could have significant error due to the low expression of the gene (Ct > 35), and thus the up or
    down-regulation could be merely a result of the high standard deviation of the high Ct values of the genes, or
    fluctuations in the housekeeping genes. As for the Relative Expression values that are between 0.5-fold and
    2-fold, it indicates no significant change in the expression of the gene for these samples.
    MSI1/NGN2/MBD2- Neural stem-like
    Untreated HFF Untransfected transfected HFF (Day cells, NSLC
    (Passage 8) HFF (Day 9) hNPC neurospheres 9) (Passage 5)
    Rel. Std. Rel. Std. (Passage 4) (NSLC, Passage 1) Std.
    Gene Exp. Dev. Exp. Dev. Rel. Exp. Std. Dev. Rel. Exp. Std. Dev. Rel. Exp. Dev.
    Ectoderm markers
    CRABP2 1.04 0.35 26.14* 4.28 0.01* 0.01 21.11* 2.80 0.21* 0.05
    FGF5 1.01 0.15 0.21* 0.07 0.00* 0.00 0.10* 0.02 0.00* 0.00
    GFAP 1.22 0.84 9.89* 5.46 798.04* 162.37 487.99* 79.84 12052.09* 2984.71
    ISL1 1.01 0.12 2.19* 0.27 0.02* 0.02 0.42* 0.08 0.00* 0.00
    NES 1.10 0.58 3.19* 0.95 6.78* 0.95 3.84* 0.19 7.47* 0.54
    NEUROD1 1.00 0.00 2.10 0.00 1.44 0.00 2.32 1.57 25.54 6.42
    OLIG2 1.00 0.00 2.10 0.00 124181.50* 14735.13 80826.42* 27820.32 36172.45* 3145.67
    PAX6 1.11 0.48 0.06* 0.00 533.31* 120.59 326.02* 33.14 371.42* 77.50
    SYP 1.02 0.25 5.22* 2.10 229.40* 22.54 143.94* 17.41 16.48* 4.47
    TH 1.00 0.00 9.52 14.86 1218.08* 186.74 217.79* 45.71 348.31* 150.50
    Endoderm markers
    AFP 1.00 0.00 2.10 0.00 1.44 0.00 1.54 0.00 1.37 0.00
    FN1 1.00 0.06 1.41 0.10 0.02* 0.00 1.96 0.19 0.00* 0.00
    FOXA2 1.00 0.00 150.00* 55.92 1.44 0.00 1.54 0.00 1.37 0.00
    GATA4 1.00 0.00 11.93 19.67 7.22 11.56 9.14 12.35 1.37 0.00
    GATA6 1.00 0.09 0.37* 0.17 0.00* 0.00 0.44* 0.04 0.02* 0.01
    GCG 1.00 0.00 7.96 11.74 1.44 0.00 33.59* 22.17 1.37 0.00
    IAPP 1.00 0.00 2.10 0.00 1.44 0.00 1.54 0.00 1.37 0.00
    INS 1.00 0.00 2.10 0.00 1.44 0.00 12.67 22.26 1.37 0.00
    IPF1 1.00 0.00 2.10 0.00 1.44 0.00 1.54 0.00 1.37 0.00
    LAMA1 1.00 0.11 4.42* 0.86 78.49* 6.82 43.99* 2.79 46.49* 16.59
    LAMB1 1.02 0.26 12.51* 2.40 0.29* 0.09 2.27* 0.77 3.89* 1.12
    LAMC1 1.00 0.10 2.82* 0.10 1.54 0.33 3.01* 0.94 1.31 0.30
    NODAL 1.00 0.00 12.16 11.62 16.27 11.25 1.54 0.00 1.37 0.00
    PAX4 1.00 0.00 6.77 9.35 1.44 0.00 1.54 0.00 1.37 0.00
    PTF1A 1.00 0.00 2.10 0.00 1.44 0.00 1.54 0.00 1.37 0.00
    SERPINA1 1.03 0.30 0.79 0.53 0.24 0.00 1.52 1.17 0.99 0.68
    SOX17 1.00 0.00 2.10 0.00 1.44 0.00 1.35 5.63 1.37 0.00
    SST 1.25 1.00 52.58* 10.67 0.55 0.36 48.97* 8.70 0.92 0.42
    TAT 1.00 0.00 2.10 0.00 255.86* 84.52 106.04* 45.87 1.37 0.00
    Mesoderm markers
    ACTC 1.04 0.35 0.01* 0.00 0.02* 0.01 0.05* 0.01 0.01* 0.01
    CD34 1.67 1.69 501.85* 61.88 45.17* 27.01 113.96* 39.39 13203.40* 5385.80
    CDH5 1.00 0.00 4.12 4.06 16.69 8.07 32.41* 20.31 13447.65* 3220.80
    COL1A1 1.01 0.12 2.28* 0.41 0.00* 0.00 0.50* 0.05 0.02* 0.00
    COL2A1 3.56 6.27 103.52* 37.78 1813.86* 236.76 873.19* 259.80 3815.72* 839.02
    DES 1.00 0.07 1.94 0.33 1.09 0.33 0.87 0.07 0.22* 0.08
    FLT1 1.01 0.15 0.68 0.29 0.00 0.00 0.46* 0.05 0.00* 0.00
    HBB 3.08 4.01 0.39 0.00 0.27 0.00 0.29 0.00 0.26 0.00
    HBZ 1.14 0.63 3.53 1.32 0.25 0.22 0.61 0.63 2.88 1.20
    HLXB9 1.00 0.00 2.10 0.00 59.80* 16.35 24.94 3.14 35.12 40.50
    MYF5 1.77 1.87 0.69 0.00 0.47 0.00 0.51 0.00 0.45 0.00
    MYOD1 1.71 2.27 1.22 0.00 0.83 0.00 0.89 0.00 0.80 0.00
    NPPA 1.00 0.00 2.10 0.00 96.60* 76.23 18.97 26.98 32.37 10.96
    PECAM1 1.00 0.00 1041.24* 150.95 31.30* 24.22 964.70* 200.82 7305.03* 1127.69
    RUNX2 1.01 0.12 1.76 0.37 0.09* 0.02 0.78 0.23 1.18 0.27
    T 1.00 0.00 2.10 0.00 1.44 0.00 1.54 0.00 1.37 0.00
    WT1 2.09 3.13 1.11 0.00 0.76 0.00 2.72 3.82 4.24 4.21
  • TABLE 8c
    Results for relative expression of Embryonic Stem Cell, Ectoderm, Endoderm/mesoderm, and neuronal markers in
    untransfected and transfected HFF with Msi1/Ngn2/MBD2 calibrated to untreated HFF (passage 8). Genes with
    asterisk (*) indicate that the Ct values of the test samples are within the quantifiable range (Ct < 35), suggesting the
    expression of the gene in the test sample is adequate for quantification. For genes without asterisk, the values may
    be inaccurate due to the low expression of the gene (Ct > 35) and thus the up or down-regulation is merely a
    result of the high standard deviation of the high Ct values of the genes, or fluctuation of the housekeeping
    genes; the trend for these samples may be correct, but the absolute relative expression values may not. Expression of
    NGN3 and LIN28 were also tested but these two genes were not expressed in any of the test samples (data not shown).
    RT-PCR revealed a significant increase of ectoderm and neuronal markers.
    MSI1/NGN2/ Neural
    Untreated HFF Untransfected hNPC MBD2-transfected stem-like cells,
    (Passage 8) HFF (Day 9) neurospheres HFF (Day 9) NSLC
    Rel. Std. Rel. Std. (Passage 4) (NSLC, Passage 1) (Passage 5)
    Gene Exp. Dev. Exp. Dev. Rel. Exp. Std. Dev. Rel. Exp. Std. Dev. Rel. Exp. Std. Dev.
    Embryonic Stem
    Cell Markers
    OCT4* 1.04 0.38 7.27 0.81 6.26 0.05 6.63 0.51 3.15 0.58
    OCT4 (5′UTR) 1.04 0.41 0.08 0.00 2.07 0.11 1.82 0.53 0.55 0.59
    NANOG (5′UTR) 1.02 0.32 19.29 2.23 11.27 0.89 16.73 6.86 9.94 6.32
    FBXO15* 1.05 0.46 2.58 0.45 3.57 0.23 5.89 1.22 1.13 0.39
    ALPL* 1.03 0.33 0.57 0.73 652.20 46.60 194.23 10.82 13.04 4.04
    SALL4* 1.02 0.25 9.20 1.35 9.76 0.62 15.84 0.92 2.35 0.55
    NR0B1 (DAX1)* 1.01 0.19 18.62 4.70 2.64 0.11 11.59 3.17 0.06 0.00
    Ectoderm Markers
    ZIC1* 1.01 0.24 2.01 0.25 1889.80 93.48 1158.21 80.43 156.40 12.64
    SOX1* 1.00 0.01 2.05 0.06 1776.83 128.63 1052.75 243.07 47.98 2.12
    CDH1 (E-cadherin)* 1.00 0.01 2.05 0.06 264.59 6.22 59.14 7.57 18.20 3.73
    p63 1.00 0.01 68.37 72.49 18.01 5.33 39.72 12.76 37.83 6.76
    MSX1 1.00 0.05 4.19 0.56 0.10 0.01 1.53 0.35 0.09 0.00
    NOTCH1* 1.00 0.07 1.26 0.08 7.38 1.20 4.51 0.54 4.75 0.26
    SOX2* 1.00 0.01 2.50 0.57 340909.59 5659.15 194495.82 17929.15 219269.76 31399.68
    SOX2 (3′UTR)* 1.00 0.01 7.74 8.11 864191.09 60204.44 452684.80 26457.70 618245.01 7107.48
    Mesoderm/Endoderm
    Markers
    CXCR4* 1.05 0.46 12.45 5.64 5048.23 172.14 2763.82 30.29 3773.11 78.89
    Neuronal markers
    MAP2* 1.01 0.17 2.98 0.20 155.33 9.08 88.82 6.48 27.38 0.13
    TUBB3* 1.00 0.04 0.38 0.02 1.15 0.05 0.89 0.05 0.98 0.09
    ASCL1 (MASH1)* 1.29 1.16 11.19 0.22 42618.46 68.52 23554.16 1588.45 31358.79 2301.26
    NGN2* 1.00 0.01 2.05 0.06 19.45 6.64 247883.48 16409.80 968.11 191.73
    NGN2 (3′UTR)* 1.83 2.17 1.17 0.76 13.39 5.10 8.45 1.75 539.02 59.72
    MSI1* 1.00 0.01 263.87 70.10 100376.36 81.45 479098.05 2281.62 116105.29 2745.03
    MSI1 (3′UTR)* 1.01 0.20 13.61 2.00 3601.96 345.79 2163.87 59.84 3698.14 160.78
    ACHE* 1.00 0.00 2.00 0.26 25.00 3.71 12.84 0.84 21.30 0.30
    Glia markers
    CNP* 1.01 0.18 1.43 0.10 3.48 0.58 2.69 0.12 1.93 0.07
    SOX9* 1.00 0.04 3.54 0.06 88.25 9.71 41.11 2.70 26.96 0.53
    Note that custom primers (5′UTR) for detecting endogenous gene expression are generally not as sensitive and/or effective as standard primers (from the supplier's (Origene) catalog) that dtect overall gene expression (both endogenous and exogenous) of a particular gene.
  • In another part of the experiment, another batch of cells that were transfected with Msi1/Ngn2+pCMV6-XL5-MBD2 were plated on Poly-Ornithine (30 min at RT) and Laminin (1 h at RT) coated plates in CDM II medium in 5 different wells. On day 1, medium in two of the wells was switched to the same medium as in condition 1a (Table 7) until day 12. Medium was changed daily until day 12, at which point it was switched to either NS-A Differentiation Medium (StemCell Technologies) or NbActive4 (BrainBits™) medium that were both supplemented with BDNF (20 ng/ml), NT-3 (20 ng/ml), NGF (20 ng/ml), Retinoic acid (5 μM), Noggin (20 ng/ml) and Forskolin (10 μM). These cells showed a typical neural stem-like cell morphology by day 7, and proliferated until day 12. During the exposure to either of the two differentiation media, these NSLC changed to a more neuronal and glial phenotype as shown in the bright field pictures (FIG. 21), but only expressed GFAP by Day 17 (FIG. 22).
  • For the other three wells, on day 1 medium was switched to either NS-A Differentiation Medium (StemCell Technologies), NbActive4 (BrainBits), or CDM II medium; these first two were supplemented with the same cytokines as previously described but with the addition of Fgf-2 (20 ng/ml). On day 12, Fgf-2 was removed from the first two differentiation media while cells in the CDM II medium were switched to the NS-A Differentiation Medium (StemCell Technologies) supplemented with cytokines without Fgf-2. Between day 12 and day 17, media was changed every two to three days. During the first 12 days of culture, cells in all 3 media developed into a mix of more spindle shaped cells compared to untransfected fibroblasts and some into cells with a NSLC morphology; upon removal of Fgf-2 cell morphology turned into a very pronounced neuronal shape as well as glial cells with a network established between cells as shown in the bright field pictures (FIG. 21) that expressed GFAP and βIII-tubulin by Day 17 (FIG. 22).
  • An additional study was designed to assess the effect of Msi1, Ngn2 and MBD2 on their endogenous proteins levels in reprogrammed cells. Cells were transfected with the MSI1/NGN2 vector and MBD2 as previously described and cultured in proliferation condition at 37° C., 5% CO2 and 5% O2. Samples were collected at various time points from Day 2-10 and analyzed by RT-PCR to investigate the expression of endogenous genes and the expression of neural stem cell and neuronal genes at different time points. RT-PCR revealed a gradual loss of total Msi1, Ngn2 and MBD2 gene expression starting from Day 2 to Day 10, with the increase in MBD2 expression relative to control having been almost completely lost by Day 5. This decrease was associated with a significant activation of endogenous Msi1 and Ngn2 on Day 5, with another jump in endogenous gene expression at Day 9 (Table 9). A significant increase in Sox2 expression was detected at Day 4, and the expression of this ectoderm/neural stem cell/neuronal gene continued to increase with each subsequent timepoint (Table 10). GFAP (a neural stem cell and astrocyte marker) was slightly elevated already from Day 2 onwards, but significantly increased on Day 5 with a large jump in gene expression at Day 7 analysis timepoint and stayed at this expression level for the rest of the study period. Expression of the neural stem cell marker Nestin also started to slowly increase from Day 5 onwards. Expression of the neuronal genes βIII-tubulin (TUBB3) and Map2b were slightly elevated already from Day 2 onwards, but significantly increased on Day 5 onwards. Expression of a marker for acetylcholine receptors (found in neurons), acetylcholine esterase (ACHE), was also slightly elevated from Day 2 onwards, but did not significantly increased until Day 7 onwards. It should be noted that among the neural stem cell markers that were analyzed, the relative expression of Sox2 was highly and early expressed which could then be directly or indirectly interact with the exogenous Msi/Ngn2 and/or other genes in the activation of Nestin, GFAP, and endogenous Msi1 and Ngn2 and other genes that promote the reprogramming and cell fate change, as well as the activation of neuronal genes like βIII-tubulin (TUBB3), Map2b, and ACHE.
  • TABLE 9
    RT-PCR analysis of exogenous and endogenous relative expression of Msi1, Ngn2 and MBD2 from
    Day 2-10 after transfection of fibroblast cells with pCMV-Msi1-Ngn2(Msi1/Ngn2) and MBD2 and cultured
    for 10 days in proliferation medium. Cells were collected at different time point to analyse endogenous gene expression.
    Endogenous Endogenous Endogenous
    MSI1 MSI1 NGN2 NGN2 MBD2 MBD2
    Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std.
    Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev.
    #
    1 Day 12 Untransfected HFF 1.01 0.18 1.04 0.38 1.01 0.15 1.01 0.15 1.01 0.21 1.00 0.14
    #2 Day 12 HFF Msi1/Ngn2 + 1102.17 91.80 620.56 19.49 2208.36 375.09 51.09 14.69 1.09 0.00 0.83 0.06
    MBD2
    #
    3 Day 18 HFF Msi1/Ngn2 + 1470.36 164.35 950.07 152.50 71.57 52.59 122.66 39.63 1.21 0.02 0.73 0.08
    MBD2
    #
    4 Untransfected Keratinocytes 1.49 N/A 1.01 N/A 1.00 N/A 1.00 N/A 1.02 N/A 1.00 N/A
    #
    5 Day 12 Keratinocytes 4142.78 872.87 364.20 60.90 4656.42 232.63 102.01 3.18 0.40 0.14 0.74 0.30
    Msi1/Ngn2 + MBD2
    #
    6 Day 18 Keratinocytes 4830.20 291.17 486.38 19.59 50.01 6.99 43.08 13.78 0.40 0.01 0.67 0.01
    Msi1/Ngn2 + MBD2
    #7 Untransfected CD34+ 1.01 0.19 1.00 0.01 1.01 0.16 1.17 0.87 1.00 0.02 1.00 0.07
    #8 Day 18 CD34+ Msi1/Ngn2 + 3969.52 286.36 147.99 7.08 2.03 0.55 3.72 1.23 0.43 0.06 0.90 0.18
    MBD2
    hNPC (14 Oct. 2009, EXP0067) 7574.57 234.74 1141.14 49.15 8.18 5.64 6.27 5.19 0.58 0.00 2.35 0.03
  • TABLE 10
    RT-PCR analysis of relative expression of Nestin, Map2b, TUBB3, ACHE, GFAP, and Sox2 from
    Day 2-10 after transfection of fibroblast cells with pCMV-Msi1-Ngn2 (Msi1/Ngn2) and MBD2
    and cultured for 10 days in proliferation medium. Cells were collected at different time point to
    analyse endogenous gene expression.
    NES MAP2 TUBB3 ACHE GFAP SOX2
    Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std.
    Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev.
    #1 Untransfected Day 2 1.00 0.04 1.00 0.01 1.00 0.03 1.00 0.08 1.01 0.23 1.17 0.87
    #2 Msi1/Ngn2 + MBD2/ + 0.88 0.01 8.59 0.18 1.38 0.03 5.71 1.06 4.56 0.08 1.26 0.82
    Noggin Day 2
    #3 Untransfected Day 3 1.38 0.07 0.66 0.03 0.40 0.02 1.36 0.06 1.95 0.38 2.34 2.29
    #4 Msi1-Ngn2 + MBD2/ + 1.39 0.08 4.31 0.24 0.79 0.09 6.03 0.60 4.66 0.02 0.96 0.10
    Noggin Day 3
    #5 Untransfected Day 4 2.43 0.23 1.78 0.11 0.44 0.01 2.70 0.02 3.76 0.86 0.93 0.01
    #6 Msi1/Ngn2 + MBD2/ + 1.91 0.06 2.81 0.20 0.64 0.02 6.76 0.64 8.67 1.06 5.37 6.06
    Noggin Day 4
    #7 Untransfected Day 5 1.40 0.05 1.13 0.04 0.41 0.03 1.17 0.37 5.44 0.02 15.03 8.77
    #8 Msi1-Ngn2 + MBD2/ + 4.31 0.08 71.60 6.43 1.34 0.01 7.60 0.18 42.28 2.94 66377.25 4089.77
    Noggin Day 5
    #9 Untransfected Day 7 2.24 0.00 4.02 0.15 1.22 0.05 1.10 0.48 7.61 1.24 1.34 0.02
    #10 Msi1/Ngn2 + MBD2/ + 3.07 0.11 48.10 2.85 2.70 0.05 13.11 1.30 3271.10 149.81 44255.59 2004.08
    Noggin Day 7
    #11 Untransfected Day 9 4.37 0.23 14.55 0.96 1.75 0.14 3.35 0.36 15.95 0.23 429.09 119.98
    #12 Msi1-Ngn2 + MBD2/ + 7.97 0.16 123.55 3.27 2.79 0.12 16.59 0.03 3152.25 3.31 114149.70 3372.20
    Noggin Day 9
    #13 Untransfected Day 10 3.48 0.44 10.03 0.37 1.63 0.21 3.20 0.81 5.64 1.92 14.66 5.03
    #14 Msi1/Ngn2 + MBD2/ + 7.48 0.22 100.25 6.66 2.87 0.03 17.49 1.35 3374.03 22.47 101105.49 3996.44
    Noggin Day 10
    • Example IV
  • Comparison of the Nucleofector™® II Device and the Nucleofector™® 96-Well Shuttle® Device in the Reprogramming of HFF into NSLC in Adherent and Floating Conditions.
  • HFF cells were cultured as described in Example I, and transfected using the Nucleofector™® II Device (Lonza) as previously described in Example II or the Nucleofector™® 96-well Shuttle® Device (Lonza). The HFFs were harvested with TrypLE™ (Gibco), and 1×106 cells/transfection with the Nucleofector™® II Device for 10 min at 90 g and 6×105 cells/transfection with the Nucleofector™® 96-well Shuttle® Device for 5 min at 80×g. After centrifugation, the cell pellet was gently resuspended in either 100 μl of Basic Nucleofector™ Solution for the Nucleofector™® II or 20 μl of SE Solution (Cell line kit SE, Lonza) for the Nucleofector™® 96-well Shuttle®. For the Nucleofector™® II Device, each 100 μl of cell suspension was combined with 2 different mixes of plasmid DNA (sample 1 was mixed with 2 μg of pCMV6-XL5-Msi1 and 2 μg pCMV6-XL5-MBD2, and sample 2 with 2 μg of Msi1/Ngn2 and 2 μg pCMV6-XL5-MBD2). Each cell suspension was transferred into an Amaxa certified cuvette and transfected with the appropriate program (U-023). Right after transfection, 900 μl of warm CDM1 medium was added to each cuvette and the sample was transferred into a culture plate coated with Laminin (Stemgent, 10 μg/ml) at a cell density of 1×105 to 1.5×105 cells per cm2 or into non-cell culture treated Petri dishes for neurosphere formation. The cells were incubated at 37° C., 5% CO2 overnight. However for the Nucleofector™® 96-well Shuttle® Device, the steps described before were similar with the following exceptions: the cell suspension was mixed with 0.6 μg of each DNA of the same 2 DNA mixes, the cell suspension was transferred to a well of a 96-well Nucleoplate™ (Lonza) and transfected with the program FF-130™. After transfection, 80 μl of warm CDM1 medium was added to each well and the samples were left for 10 min in the incubator prior to being transferred into a laminin coated plate or non-cell culture treated Petri dishes at the same cell density as previously mentioned. For both devices, these steps were repeated for each sample that was transfected. Prior to transfection cells were cultured in CDM1 as described in Example I. After 24 hours, the medium was switched to a mix of 75% CDM medium and 25% Proliferation Medium which was supplemented with EGF (20 ng/ml), FGF-2 (20 ng/ml), Noggin (20 ng/ml) and Cytochalasin B (10 μg/ml) and the cells were incubated at 37° C., 5% CO2 and 5% O2. The medium was changed daily with an increased proportion of Neural proliferation medium up to 100% by Day 4 and a decreased proportion of Cytochalasin B that was completely omitted by Day 5. Forskolin (10 μM) was added to the medium from Day 4 onwards. The cells in floating conditions were pelleted by centrifugation and their medium changed daily as described for the adherent condition. Cells were collected at Day 3, 7, and 12 for immunohistochemistry analysis.
  • Fluorescence images were taken with a Cellomics™ ArrayScan HCS Reader™ microscopy system to determine an estimate of the percentage of cells positive for Sox2, a neural stem cell marker. This analysis revealed that in untransfected controls and at 3 days after transfection, no nuclear Sox2 staining was detectable. However, at Day 7 and Day 12 the percentage of Sox2 positive cells increased progressively under all transfection conditions except the pCMV6-XL5-Musashi and pCMV6-XL5-MBD2 Nucleofector™® II condition. The highest percentage at Day 12 was obtained with Msi1/Ngn2 and pCMV6-XL5-MBD2 transfected with the Nucleofector™® 96-well Shuttle® Device (˜80%). The same combination transfected with the Nucleofector™® II yielded only ˜35% positive cells. The pCMV6-XL5-Musashi and pCMV6-XL5-MBD2 with the Shuttle® produced ˜20% positive cells, while generally none were observed with the Nucleofector™® II. The percentage of positive cells varied strongly between wells. The staining indicated that the cell population was not homogenous, since fields of densely arranged Sox2 positive cells and complete fields with only negative cells could be found in all cases. In general the Shuttle® was initially more toxic to cells than the Nucleofector™® II, however at least in the case of Msi1/Ngn2 and pCMV6-XL5-MBD2 shuttle, the Sox2 positive population rapidly expanded from Day 7 to Day 12 to have twice as many Sox2 positive cells as compared to the Nucleofector™® II. The cells in floating conditions did not form spheres during the 12 day experiment in any of the conditions, suggesting that the formation of neurospheres requires either the generation of neural stem-like cells in adherent conditions first or more time.
  • Table 11 shows the percentage of Sox2 positive cells with a typical neural stem cell morphology using both the Nucleofector™® II Device and the Nucleofector™® 96-well Shuttle® Device. The latter had the advantages of requiring a smaller starting material (less cells and less DNA required) and in addition gave rise to a higher number of Sox2 positive cells. Moreover a very small population of Sox2 positive cells was observed with the Shuttle® Device only upon transfection with only one neurogenic transcription factor (Msi) in the presence of the DNA demethylator MBD2.
  • TABLE 11
    Percentage of positive cells for Sox2 after transfection of fibroblast cells with
    different expression vectors. After transfection the cells were cultured in
    proliferation medium (StemCell Technologies) supplemented by EGF
    (20 ng/ml, Peprotech) and FGF (20 ng/ml, Peprotech) for two weeks
    at 37° C./5% CO2/5% O2. The percentage of immunopositive cells was
    determined by Cellomics ™ and represented as mean ± SD (n = 3-5).
    % Sox2 positive cells
    Day
    3 Day 7 Day 12
    Total Total Total
    Cell Cell Cell
    Sox2 count Sox2 count Sox2 count
    Shuttle MSI1/NGN2 + MBD2 1.34 ±  6430 ± 31 ± 20 ± 10683 ± 78.17 ± 29341 ±
    0.10  566 8.03 1112 3.10 2527
    Msi + MBD2 1.08 ±  8253 ± 3.19 ±  8953 ± 19.05 ± 11082 ±
    0.61  399 3.57  672 17.88  2999
    Nucleofector ™ MSI1/NGN2 + MBD2 0.87 ± 21870 ± 14.30 ±   37321 ± 35.93 ± 33009 ±
    0.30 4476 1.83 6877 7.10 1567
    Msi + MBD2 0.64 ± 46793 ± 0.35 ± 34854 ±  0.51 ± 32095 ±
    0.07 8808 0.16 2186 0.25 3236
    • Example V Neurosphere Formation Assay and Cell Differentiation Analysis
  • Based on previous studies showing that greater proportional reprogramming is achieved by transfecting two neurogenic genes, this study was designed to evaluate the number of reprogramming cells by using the vector Msi1/Ngn2, containing two neurogenic transcription factors (Msi1 and Ngn2) and the role of DNA demethylator or DNA methylation inhibitor (5-azacytidine) and histone deacetylation inhibitor (VPA) in the reprogramming process.
  • HFFs were cultured and treated with cytochalasin B as described in Example III, and treated simultaneously with VPA (1 mM) and 5-Azacytidine (0.5 μM). After two days of treatment, cells were transfected by Nucleofection as described in Example II with the constructed vector Msi1/Ngn2. After preparing the cells, they were mixed with 2 μg of total DNA (Msi1/Ngn2) and cells that had not been treated with chemical inhibitors (VPA and 5-Aza) were co-transfect with MBD2 (2 μg), using the appropriate program (U023). The samples were transferred into a coated culture plate with Laminin (10 μg/ml, Sigma) and incubated in a humidified 37° C./5% O2/5% CO2 incubator. The medium was changed to the proliferation basal media, Neural Proliferation Medium (NeuroCult™ proliferation Kit, StemCell Technologies), with the presence of Noggin (20 ng/ml, Peprotech), recombinant hFGF (20 ng/ml, Peprotech), and recombinant hEGF (20 ng/ml, Peprotech). Following 6 days of transfection, cells were harvested using Accutase™ (Millipore), centrifuged (300×g, 5 min, RT) and plated in uncoated cell culture dishes in NeuroCult™ NSC Proliferation medium to investigate the capacity to grow cells in suspension as neurospheres or on Laminin coated-plates for adherent culture. To prevent loss of floating spheres during media changes, cells were sedimented by centrifugation at 150×g for 3 min at room temperature (RT). The pellet was then resuspended in fresh medium and plated into new uncoated, low-bind cell culture dishes. Cultures were incubated at 37° C., 5% CO2, 5% O2 and were fed daily for at least two months.
  • To investigate whether a single cell from human neural precursor cells (hNPCs) and human NSLCs was able to generate a neurosphere (a standard test for proving that a cell is a neural stem cell), neurospheres were dissociated into single cells and these single cells were isolated and cultured in proliferation medium in suspension, and neurosphere formation was monitored by taking bright field images using light microscope (Nikon, 10×) and by Cellomics™. These cells started to proliferate and grew as spheres starting day 6 to day 10 (FIG. 4A). Immunohistochemistry analysis of these spheres (Table 12 and FIG. 4) on Day 20, revealed immunopositive staining for the neural stem cells markers Sox2, Musashi, CD133, Nestin, and GFAP. Cells also stained positive for βIII-tubulin (a marker for neurons), O4 (a marker for oligodendrocytes), and GFAP (a marker for astrocytes), indicating the tri-potent differentiation potential of both sets of cells (NSLC and hNPC), and negative for NGFrec and NeuN (markers for differentiated neurons) indicating that the cells were not terminally differentiated.
  • TABLE 12
    Percentage of positive cells for neural stem cells, and neuronal, astrocyte and
    oligodendrocyte lineage markers in neurospheres formed from single NSLCs and hNPCs
    cultured in proliferation medium (StemCell Technologies) supplemented by EGF (20ng/ml,
    Peprotech) and FGF (20ng/ml, Peprotech) for 20 days at 37° C./5% CO2 /5% O2. The
    percentage of positive cells was determined by Cellomics ™ and represented as mean ± SD.
    % of positive cells NSLCs hNPCs
    Musashi 91.8 ± 6.8 88.6 ± 7.9 
    Nestin 78.6 ± 5.7 75.4 ± 12.0
    GFAP 69.2 ± 7.4 78.6 ± 8.4 
    βIII-tubulin 85.6 ± 6.4 76.6 ± 8.4 
    P75 0 0
    NeuN 0 0
    O4 65.4 ± 6.6 71.4 ± 7.5 
    CD133 0 0
  • HFF cells were cultured as described in Example I, and transfected using the Nucleofector™ II device (Lonza) as described in Example II. Cells were co-transfected with pCMV6-XL5-Msi/pCMV6-XL4-Ngn2, pCMV-Msi1-Ngn2 with MBD2 or pre-treated with VPA/5aza. Cells were cultured in proliferation medium as suspension or adherent cultures. Gene expression analysis on 8 samples was performed as previously described in Example I with the customized Neuronal Markers 2 TLDA (Table 13) which profiled the expression of 48 genes (including three housekeeping genes: ACTIN, GAPDH and PPIA) in four major categories; 1) fibroblast specific genes; 2) neuronal lineage specific genes; 3) Neural stem cell marker specific genes; and 4) Genes for growth factors and their receptors.
  • TABLE 13
    Neuronal Markers 2 TLDA Layout (Applied Biosystems)
    Gene Symbols
    1 2 3 4 5 6 7 8 9 10 11 12
     1 ACTB PPIA COL3A1 LOX
    Figure US20200165570A1-20200528-P00899
    		 SYT1 SNAP25 NEUROD1 MBP NKX2-2 GAPDH OLIG2
     2 VIM SOX3 SOX9 PROM1 SOX1 SOX2 KLF4
    Figure US20200165570A1-20200528-P00899
    		 STAT3 PIK3CO GDSF NGF
     3 ACTB PPIA COL3A1 LOX
    Figure US20200165570A1-20200528-P00899
    		 SYT1 SNAP25 NEUROD1 MBP NKX2-2 GAPDH OLIG2
     4 VIM SOX3 SOX9 PROM1 SOX1 SOX2 KLF4
    Figure US20200165570A1-20200528-P00899
    		 STAT3 PIK3CO GDSF NGF
     5 ACTB PPIA COL3A1 LOX
    Figure US20200165570A1-20200528-P00899
    		 SYT1 SNAP25 NEUROD1 MBP NKX2-2 GAPDH OLIG2
     6 VIM SOX3 SOX9 PROM1 SOX1 SOX2 KLF4
    Figure US20200165570A1-20200528-P00899
    		 STAT3 PIK3CO GDSF NGF
     7 ACTB PPIA COL3A1 LOX
    Figure US20200165570A1-20200528-P00899
    		 SYT1 SNAP25 NEUROD1 MBP NKX2-2 GAPDH OLIG2
     8 VIM SOX3 SOX9 PROM1 SOX1 SOX2 KLF4
    Figure US20200165570A1-20200528-P00899
    		 STAT3 PIK3CO GDSF NGF
     9 ACTB PPIA COL3A1 LOX
    Figure US20200165570A1-20200528-P00899
    		 SYT1 SNAP25 NEUROD1 MBP NKX2-2 GAPDH OLIG2
    10 VIM SOX3 SOX9 PROM1 SOX1 SOX2 KLF4
    Figure US20200165570A1-20200528-P00899
    		 STAT3 PIK3CO GDSF NGF
    11 ACTB PPIA COL3A1 LOX
    Figure US20200165570A1-20200528-P00899
    		 SYT1 SNAP25 NEUROD1 MBP NKX2-2 GAPDH OLIG2
    12 VIM SOX3 SOX9 PROM1 SOX1 SOX2 KLF4
    Figure US20200165570A1-20200528-P00899
    		 STAT3 PIK3CO GDSF NGF
    13 ACTB PPIA COL3A1 LOX
    Figure US20200165570A1-20200528-P00899
    		 SYT1 SNAP25 NEUROD1 MBP NKX2-2 GAPDH OLIG2
    14 VIM SOX3 SOX9 PROM1 SOX1 SOX2 KLF4
    Figure US20200165570A1-20200528-P00899
    		 STAT3 PIK3CO GDSF NGF
    15 ACTB PPIA COL3A1 LOX
    Figure US20200165570A1-20200528-P00899
    		 SYT1 SNAP25 NEUROD1 MBP NKX2-2 GAPDH OLIG2
    16 VIM SOX3 SOX9 PROM1 SOX1 SOX2 KLF4
    Figure US20200165570A1-20200528-P00899
    		 STAT3 PIK3CO GDSF NGF
    13 14 15 16 17 18 19 20 21 22 23 24
     1
    Figure US20200165570A1-20200528-P00899
    		 DIO2 GFAP NCAM1 FOX11 PDGFRA MKI67 NES CSPG4 DLX2 MS11 CROCC
     2 BDNF CNTF- GAP43 NRG1 NPY CSF3 BMP4 TGFB1 VEGFA NGFR EGFR KDR
    ZFP91-
    CNTF
     3
    Figure US20200165570A1-20200528-P00899
    		 DIO2 GFAP NCAM1 FOX11 PDGFRA MKI67 NES CSPG4 DLX2 MS11 CROCC
     4 BDNF CNTF- GAP43 NRG1 NPY CSF3 BMP4 TGFB1 VEGFA NGFR EGFR KDR
    ZFP91-
    CNTF
     5
    Figure US20200165570A1-20200528-P00899
    		 DIO2 GFAP NCAM1 FOX11 PDGFRA MKI67 NES CSPG4 DLX2 MS11 CROCC
     6 BDNF CNTF- GAP43 NRG1 NPY CSF3 BMP4 TGFB1 VEGFA NGFR EGFR KDR
    ZFP91-
    CNTF
     7
    Figure US20200165570A1-20200528-P00899
    		 DIO2 GFAP NCAM1 FOX11 PDGFRA MKI67 NES CSPG4 DLX2 MS11 CROCC
     8 BDNF CNTF- GAP43 NRG1 NPY CSF3 BMP4 TGFB1 VEGFA NGFR EGFR KDR
    ZFP91-
    CNTF
     9
    Figure US20200165570A1-20200528-P00899
    		 DIO2 GFAP NCAM1 FOX11 PDGFRA MKI67 NES CSPG4 DLX2 MS11 CROCC
    10 BDNF CNTF- GAP43 NRG1 NPY CSF3 BMP4 TGFB1 VEGFA NGFR EGFR KDR
    ZFP91-
    CNTF
    11
    Figure US20200165570A1-20200528-P00899
    		 DIO2 GFAP NCAM1 FOX11 PDGFRA MKI67 NES CSPG4 DLX2 MS11 CROCC
    12 BDNF CNTF- GAP43 NRG1 NPY CSF3 BMP4 TGFB1 VEGFA NGFR EGFR KDR
    ZFP91-
    CNTF
    13
    Figure US20200165570A1-20200528-P00899
    		 DIO2 GFAP NCAM1 FOX11 PDGFRA MKI67 NES CSPG4 DLX2 MS11 CROCC
    14 BDNF CNTF- GAP43 NRG1 NPY CSF3 BMP4 TGFB1 VEGFA NGFR EGFR KDR
    ZFP91-
    CNTF
    15
    Figure US20200165570A1-20200528-P00899
    		 DIO2 GFAP NCAM1 FOX11 PDGFRA MKI67 NES CSPG4 DLX2 MS11 CROCC
    16 BDNF CNTF- GAP43 NRG1 NPY CSF3 BMP4 TGFB1 VEGFA NGFR EGFR KDR
    ZFP91-
    CNTF
    Figure US20200165570A1-20200528-P00899
    indicates data missing or illegible when filed
    • Sample Information
  • Sample ID Sample Name TLDA Port
    1 HFF Ctrl 1
    2 ReNcell Undifferentiated Ctrl 2
    3 Msi1-Ngn2/MBD2 3
    4 Msi1-Ngn2/MBD2 4
    5 Msi1-Ngn2/VPA+AZA 5
    6 Msi1-Ngn2 6
    7 Msi1-Ngn2/MBD2, neurospheres 7
    8 Msi1-Ngn2/MBD2, neurospheres 8
  • As shown in Table 14, fibroblast-specific genes (Col3A1, Lox, S100A4) were down-regulated in reprogrammed cells, indicating the loss of fibroblast-specific genes following transfection (note that not all cells got transfected and reprogrammed, so the presence of fibroblast-specific gene expression in the cultures is mostly from the un-programmed fibroblasts left in the culture). The expression of these genes is observed to increase when HFFs were transfected in the absence of DNA demethylator or the DNA methylation inhibitor, indicating that down-regulation of differentiated markers of fibroblast cells requires DNA demethylation. The expression of ectoderm genes such as Msi1, Sox2, and Nestin was remarkably increased following transfection in conjunction with DNA demethylation. The expression of neuronal markers, such as synaptogamin1 (a synaptic vesicle protein) and NeuroD1 was up-regulated in transfected cells with Msi1/Ngn2/MBD2, and slightly increased in transfected cells with Msi1/Ngn2/VPA and 5-AZA. The selected three markers of oligodendrocytes were detected in the transfected cells with a strong increase of Olig2. Two markers for astrocytes, GFAP and ALDH1L1, were enhanced following transfection. The results support the idea that neurospheres are composed of heterogeneous progenitor subtypes.
  • Among the neurotrophic factors, expression of CNTF was slightly increased in the reprogrammed cells. The expression of GAP-43 and neuropeptide Y (NPY) were the most annotated genes. GAP-43 has long been acknowledged to play a pivotal role in axonal plasticity and is used as a marker of regenerating neurite outgrowth and synaptogenesis, both in embryonic development and in neuronal regeneration in injured brain and spinal cord. Expression of receptors for growth and neurotrophic factors was increased, such as neurotrophic receptor tyrosine kinase expression.
  • TABLE 14
    Gene array analysis was performed after one month of transfection of human fibroblast cells with Msi1/Ngn2, in the presence MBD2 or
    VPA and 5-Aza. Cells were cultured on coated culture plates as adherent cells or on untreated culture plates as neurospheres in proliferation
    medium (StemCell Technologies) supplemented with EGF (20 ng/ml) and FGF (20 ng/ml). Untransfected cells were considered as negative
    control and ReNcell (Millipore) as positive control.
    Relative expression to #1 HFF Ctrl
    #3 #4 #5 #7 #8
    #2 Msi1- Msi1- Msi1- #6 Msi1-Ngn2/ Msi1-Ngn2/
    ReNcell Ngn2/ Ngn2/ Ngn2/ Msi1- MBD2, VPA + AZA
    Symbol Common name and description Undiff MBD2 MBD2 VPA + AZA Ngn2 neurospheres neurospheres
    Fibroblast/ECM
    component
    COL3A1 Collagen, type III, alpha 1, fibroblast 0.00 0.03 0.02 0.02 11.92 0.00 0.00
    marker
    LOX Lysyl oxidase, ECM component 0.01 0.03 0.01 0.01 2.38 0.00 0.00
    FSP1 Fibroblast transcription site-1, 0.04 0.04 0.06 0.05 3.22 0.05 0.05
    enzyme for ECM remodeling
    Neuron markers
    SYT1 Synaptotagmin1, a synaptic vesicle 106.49 108.40 78.66 26.72 22.42 37.61 16.80
    protein in neurons
    SNAP25 SNAP25, mature neuron marker 4.72 6.10 7.89 3.11 3.19 6.47 4.00
    NEUROD1* Neurogenic differentiation 1, neuron 2.32 93.35 100.84 2.02 3.11 271.11 10.23
    marker
    Oligodendrocyte
    markers
    MBP* Myelin Basic Protein, mature 2.32 48.53 18.11 6.94 667.56 16.67 1.67
    oligodendrocyte marker
    NKX2-2* NK2 homeobox 2, remyelination 2.32 75.31 54.65 1.66 3.11 1.67 1.74
    OLIG2* Oligodendrocyte lineage transcription 2856.4 15594 67369 38733 3.11 92420 101733
    factor 2, oligodendrocyte progenitor
    Astrocyte markers
    ALDH1L1* Aldehyde dehydrogenase 1 family 6.20 3.77 4.65 1.66 0.02 5.87 9.59
    member L-1, astrocyte
    DIO2* Deiodinase iodothyronine type II, 23.20 0.00 0.00 0.00 0.51 0.00 0.00
    astrocyte marker
    GFAP Glial fibrillary acidic protein, 3342.1 6899.0 6291.0 4800.9 1.27 3118.7 3222.0
    astrocyte marker
    NSCS markers
    NCAM1 NCAM1, neuroblast marker 23.21 43.90 24.45 12.72 1.13 31.93 36.70
    PDGFRA Plate-derived growth factor receptor 0.05 0.01 0.01 0.00 4.42 0.00 0.01
    alpha, oligodendrocyte progenitor
    cells
    NES Nestin, neural progenitor 5.76 19.84 19.56 3.46 4.23 16.57 8.36
    MSI1*, ** Musashi I, neuroblast marker 5120.3 5985.2 5262.7 5645.1 204.34 3179.6 4113.6
    SOX1* Sox1, neural progenitor 679.21 223.59 373.14 361.67 3.11 287.82 323.23
    SOX2* Sox2, NSCs 1924084 2265299 1889166 1014816 3.11 1313765 1103212
    Neurotrophic/
    Growth Factor
    GDNF* Glial cell derived neurotrophic factor 0.01 0.02 0.02 0.00 1.69 0.00 0.00
    NGF* Nerve growth factor 0.00 0.00 0.00 0.00 1.48 0.00 0.00
    BDNF Brain derived neurotrophic factor 0.03 0.09 0.09 0.05 0.82 0.02 0.01
    CNTF* Ciliary neurotrophic factor 9.25 4.32 3.11 2.90 64.05 2.31 3.39
    GAP43 Growth associated protein 43, neural 917.52 3506.5 1530.8 452.75 584.00 746.25 578.52
    regeneration
    NRG1* Neuregulin 1, neural regeneration 0.01 0.00 0.00 0.00 0.40 0.00 0.00
    NPY* Neuropeptide Y, interneuron 2.32 675.69 465.04 153.54 3.11 1244.0 130.38
    CSF3* Colony stimulating factor 3, neural 0.50 0.03 0.02 0.58 18.62 0.02 0.02
    regeneration
    BMP4 Bone morphogenetic protein 4, 0.83 0.26 0.74 0.45 11.03 0.09 0.07
    remyelination marker
    TGFB1 Transforming growth factor, beta 1 0.85 2.39 0.92 0.83 0.65 0.45 0.58
    Angiogenesis
    VEGFA Vascular endothelial growth factor 2.77 14.93 15.01 2.67 3.82 2.80 3.21
    Neurotrophin/
    Growth Factor
    Receptors
    NGFR/P75 NGFR, neurotrophin receptor 5.35 3.29 5.78 9.10 7.53 7.26 17.51
    EGFR Epidermal growth factor receptor 0.89 0.77 0.86 0.79 1.63 1.44 1.25
    KDR* Kinase insert domain receptor, 210.87 259.42 263.45 51.85 0.07 11.23 17.50
    growth factor receptor
  • Further analysis and quantification of the adherent population of NSLCs showed that cells were positively stained for Sox2 (93.43±1.9%), nestin (60.76±5.7%), and GABA (37.48±4.9), while these markers were undetectable in untransfected cells (FIG. 5, Table 15). Furthermore, these cells stained positive for p75NTR (31.15±1.6), βIII-tubulin (37.55±0.6%) and GFAP (16.47±0.9). However, untransfected HFFs only stained positive for HFF markers (FIG. 5), such as fibronectin and fibroblast protein marker, while these markers were undetectable in reprogrammed cells, demonstrating that the reprogrammed cells lost markers of the original cells and adopted morphology and markers of neural stem cells and a neuronal lineage.
  • TABLE 15
    The percentage of cells stained positive for neural stem cell markers and fibroblast
    markers in untransfected cells and transfected cells with pMsi1/Ngn2/MBD2. Transfected cells
    (NSLCs) possess a high percentage of neural stem markers but a very low percentage of
    fibroblast markers as compared to untransfected cells. The percentage of immunopositive cells
    was determined by Cellomics ™ and represented as mean ± SD (n = 5).
    Transfected fibroblast cells Untransfected fibroblast cells
    Marker protein (% of average positive cells ± stdv) (% of average positive cells ± stdv)
    Sox2 93.43 ± 1.9  1.90 ± 0.5
    Nestin 60.76 ± 5.7  0.84 ± 0.2
    p75NTR 31.15 ± 1.6  3.95 ± 1.7
    NCAM 26.84 ± 3.8  0.87 ± 0.2
    S100 41.80 ± 0.6  1.60 ± 0.3
    GFAP 16.47 ± 0.9  3.84 ± 0.9
    βIII-Tubulin 37.55 ± 0.6  1.90 ± 0.9
    GABA 37.48 ± 4.9  2.54 ± 0.5
    Fibronectin  1.05 ± 0.7 94.19 ± 0.9
    Fibroblast marker protein  4.81 ± 1.0 50.30 ± 7.8
  • This study showed as well that NSLCs have the capacity to proliferate in culture and exhibit stable morphology, gene and protein expression that were maintained for the entire study period, which was for over five month in culture (Table 16).
  • TABLE 16
    Doubling time of NSLCs over serial passages. NSLCs were maintained in proliferation
    conditions for 35 passages in a 37° C., 5% CO2 and 5% O2 incubator. The time required
    for the cell population to double (g) was calculated for each passage, and was defined
    as g = (In2)/k, where k was the number of generations that occured per unit time (t)
    defined as, k = (In Nf - In N0)/t, where Nf was the final cell number and N0 the initial
    seeded cell number. The average generation time was 25.4 h over 35 passages.
    Passage
    number Time (h) LN N0 LN Nf k (h-1) g (h)
    2 168 11.513 15.577 0.024 38.655
    3 216 11.513 16.195 0.022 31.977
    4 192 11.513 18.258 0.035 39.730
    5 144 11.513 16.258 0.033 21.036
    6 144 11.513 16.258 0.033 21.036
    7 144 11.513 15.702 0.029 33.824
    8 168 11.513 15.870 0.026 26.729
    9 120 11.513 16.811 0.031 32.548
    10 144 11.513 15.415 0.027 35.580
    11 120 13.122 15.895 0.023 30
    12 120 11.513 15.747 0.035 19.645
    13 168 11.513 15.870 0.026 26.729
    14 168 12.429 15.870 0.020 23.847
    15 168 11.513 15.520 0.024 29.059
    16 192 11.513 16.167 0.024 28.596
    17 144 11.513 15.239 0.026 36.791
    18 168 11.513 15.790 0.025 37.229
    19 120 13.122 15.870 0.023 30.276
    20 144 13.122 16.249 0.022 31.922
    21 96 13.122 15.761 0.027 25.214
    22 120 13.122 15.870 0.023 30.276
    23 120 13.122 15.761 0.022 31.518
    24 96 13.122 15.687 0.027 25.943
    25 96 13.122 16.013 0.030 23.022
    26 96 13.122 16.067 0.031 22.599
    27 96 13.122 16.300 0.033 20.938
    28 120 13.122 16.482 0.028 24.752
    29 96 13.122 16.380 0.034 20.424
    30 96 13.122 16.300 0.033 19.938
    31 120 13.122 16.483 0.028 22.752
    32 96 13.122 16.062 0.031 20.640
    33 96 13.122 16.300 0.033 20.938
    34 96 13.122 16.077 0.031 15.519
    35 96 13.122 16.077 0.031 15.519
    • Gene Expression Microarray
  • Microarray expression analysis was performed to get a global overview to compare the gene expression profile of passage 7 NSLC to both HFF (the cells that the NSLC were created from) and hNPCs. NSLC (n=3), HFF (n=2), and hNPC (n=3) were resuspended in RNAlater™ (Qiagen) and shipped to Genotypics (India) where the samples were processed and the Gene Expression Microarray was performed.
  • In brief, Genotypics extracted RNA from the samples and performed Quality Control using an Agilent Bioanalyzer™. Labelling was done using Agilent's Quick Amp™ kit (cDNA synthesis and in vitro transcription), followed by Labelling QC. Hybridization was then performed using the 8×60K array, and scanning was done using high throughput Agilent scanner with SureScan™ technology. The Agilent Feature Extraction software was used for automated feature extraction, followed by Raw Data QC and Image QC. Advanced Data Analysis was then performed, including Pathway and Gene Ontology analysis using Agilent's GeneSpring GX™ v10.0 and Genotypic's Biointerpreter Software. The NSLC samples were compared to the HFF samples (Set 1) and hNPC samples (Set 2) The NSLC samples had a global gene expression pattern that was much closer to the hNPCs than the HFFs from which the NSLCs were created (FIG. 23). Pearson correlation analysis revealed that NSLCs are closely related to hNPCs, including in terms of neuronal lineage markers, regenerative genes and migration genes. These data confirm that NSLCs are similar, but not identical, to hNPCs.
  • Microarray analysis revealed an up-regulation of neural precursor genes in the NSLC samples as compared to the HFF samples. ACTL6A and PHF10, which both belong to the neural progenitors-specific chromatin remodelling complex (npbaf complex) and are required for the proliferation of neural progenitors, were up-regulated by 2.9-fold and 2.3 fold respectively. MSI2, which plays a role in the proliferation and maintenance of stem cells in the central nervous system, was up-regulated by 6-fold (Table X1). Glia genes were up-regulated in the NSLC samples as compared to the HFF samples. GFAP, is a neural stem cell- and astrocyte-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells, is highly up-regulated in the NSLC sample as compared to HFF (690-fold). OLIG1, which promotes formation and maturation of oligodendrocytes, especially within the brain, is also highly up-regulated in NSLC sample as compared to HFF (370-fold) (Table X2).
  • Table X3 lists a subset of regenerative genes that are up-regulated in the NSLC samples as compared to the HFF samples. SOX2, a gene critical for early embryogenesis and for embryonic stem cell pluripotency as well as neural stem cells, is highly up-regulated in the NSLC samples as compared to the HFF samples (5000-fold). CCND2, which is essential for the control of the cell cycle at the G1/S (start) transition, is also up-regulated in NSLC samples (70-fold as compared to HFF samples). As shown in Table X4, numerous fibroblast genes were down-regulated in the NSLC samples as compared to the HFF samples. This shows that the NSLC lose the expression of numerous fibroblast genes as it gets reprogrammed from HFF to NSLC.
  • Table X5 show that neural precursor genes were also up-regulated in the NSLC samples as compared to the hNPC samples. BDNF, which promotes the survival and differentiation of selected neuronal populations of the peripheral and central nervous systems during development, is even more highly expressed in NSLC samples than in hNPC samples (34-fold up-regulation). Table X6 shows that a subset of Glia genes are also up-regulated in the NSLC samples as compared to the hNPC samples. GFAP, a neural stem cell- and astrocyte-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells, is more highly expressed in NSLC samples than hNPC samples (13-fold). PLP1, the major myelin protein of the central nervous system which plays an important role in the formation or maintenance of the multilamellar structure of myelin, is also more highly expressed in NSLC samples than in hNPC samples (20-fold).
  • Regenerative genes were also up-regulated in the NSLC samples as compared to the hNPC samples (Table X7). BMP2, a neural crest marker, but which induces growth especially of cartilage and bone formation and BMP4, which in turn induces cartilage and bone formation and acts in mesoderm induction, tooth development, limb formation and fracture repair, but also in neural stem cells, were both more highly expressed in NSLC samples than in hNPC samples (18-fold and 20-fold respectively). GAP43, which is a major component of the motile growth cones that form the tips of elongating axons was more highly expressed in NSLC samples than hNPC samples (4-fold). This suggests the regenerative potential of NSLC. HOXB4, a transcription factor that is involved in development and also in the expansion of neural stem cells as well as hematopoietic stem and progenitor cells in vivo and in vitro making it a potential candidate for therapeutic stem cell expansion, was also more highly expressed in NSLCs than in hNPCs. This data indicates that NSLCs are more ‘stem-like’ or have more ‘sternness’ than hNPCs.
  • TABLE X1
    Up-regulated Neural Precursor genes (NSLC vs. HFF)
    Fold change
    of NSLC
    Accession compared
    GeneSymbol Number to HFF1 p-value
    ACTL6A NM_178042 2.90 0.000
    ADAM9 NM_001005845 2.64 0.004
    AIFM1 NM_004208 2.45 0.000
    BCAT1 NM_005504 3.23 0.000
    BMP2 NM_001200 17.49 0.000
    DLL1 NM_005618 40.32 0.000
    EDNRB NM_003991 933.03 0.000
    ERBB4 NM_005235 53.22 0.006
    GMNN NM_015895 4.42 0.000
    HES5 BC087840 102.33 0.000
    KIF1B NM_015074 9.45 0.002
    LIMK1 NM_002314 2.44 0.002
    MAPK8IP1 NM_005456 5.88 0.001
    MCHR1 NM_005297 68.19 0.001
    MEF2C NM_002397 2.91 0.000
    MSI2 NM_170721 6.76 0.000
    NMB NM_021077 3.65 0.000
    NOS2A NM_000625 279.45 0.000
    NOTCH1 NM_017617 6.75 0.000
    NPAS3 NM_022123 187.85 0.000
    PHF10 NM_018288 2.28 0.001
    PHLPP NM_194449 8.84 0.000
    SMAD1 NM_005900 4.74 0.000
    SNTG1 AL161971 34.05 0.000
    SP8 NM_198956 1392.67 0.000
    STAU2 AK002152 3.35 0.000
    STIL NM_003035 4.94 0.003
    1Fold change represents the up-regulation of the gene in the NSLC samples as compared to the HFF samples. (n = 2 for HFF samples, n = 3 for NSLC samples).
  • TABLE X2
    Up-regulated Glia genes (NSLC vs. HFF)
    Fold change
    of NSLC
    Accession compared
    GeneSymbol Number to HFF1 p-value
    ASTN1 NM_004319 51.44 0.000
    ATP1B2 NM_001678 186.64 0.000
    B3GAT1 NM_018644 1784.49 0.000
    BCL2 NM_000633 2.65 0.002
    BMP7 NM_001719 41.35 0.000
    CA14 NM_012113 43.44 0.000
    CLCN2 NM_004366 4.18 0.000
    CNDP1 NM_032649 4.39 0.010
    CP NM_000096 93.08 0.002
    CXCR4 NM_001008540 4124.29 0.000
    ERBB4 NM_005235 53.22 0.006
    FABP7 NM_001446 18702.36 0.000
    GAB1 NM_207123 2.44 0.001
    GFAP NM_002055 696.51 0.000
    GJB2 NM_004004 13.89 0.001
    ITGB8 NM_002214 8.48 0.005
    KCNJ10 NM_002241 263.42 0.000
    LMO3 NM_018640 194.32 0.000
    MAP6D1 NM_024871 3.99 0.000
    MAPT NM_016835 2.38 0.001
    NDE1 NM_017668 2.21 0.002
    NEFL NM_006158 10.30 0.001
    NKX6-2 NM_177400 10.83 0.026
    NOVA2 NM_002516 7.51 0.000
    NTN1 NM_004822 5.29 0.015
    NTRK3 NM_001012338 15.32 0.000
    OLIG1 NM_138983 372.11 0.000
    OLIG2 NM_005806 163.20 0.000
    PARD6A NM_016948 4.12 0.001
    PASK NM_015148 3.89 0.001
    PAX6 NM_001604 28.53 0.001
    PDCD11 ENST00000369797 2.23 0.001
    PDE6B NM_000283 5.55 0.001
    PER1 NM_002616 2.43 0.001
    PLP1 M54927 351.09 0.000
    PTK2 NM_153831 4.22 0.000
    QKI NM_206855 8.75 0.003
    S100B NM_006272 456.00 0.000
    SLC1A3 NM_004172 49.49 0.000
    SORL1 NM_003105 27.61 0.000
    SOX9 NM_000346 27.82 0.000
    SPRY2 NM_005842 15.83 0.000
    TARDBP NM_007375 2.69 0.005
    TSPAN12 NM_012338 259.78 0.000
  • TABLE X3
    Up-regulated Regenerative genes (NSLC vs. HFF)
    Fold change
    of NSLC
    Accession compared
    GeneSymbol Number to HFF1 p-value
    BMP2 NM_001200 17.49 0.000
    CCND2 NM_001759 72.79 0.000
    DLL1 NM_005618 40.32 0.000
    EGR1 NM_001964 2.19 0.000
    GAL NM_015973 25.93 0.000
    GAP43 NM_002045 1297.42 0.000
    HOXB4 NM_024015 102.34 0.000
    NFE2L2 AF323119 2.80 0.004
    NOTCH1 NM_017617 6.75 0.000
    PRPH NM_006262 6.44 0.000
    SEMA3A NM_006080 3.03 0.004
    SEMA6A NM_020796 23.58 0.000
    SOX2 NM_003106 5165.92 0.000
  • TABLE X4
    Down-regulated Fibroblast genes (NSLC vs. HFF)
    Fold change
    of NSLC
    Accession compared
    GeneSymbol Number to HFF1 p-value
    ACOT2 NM_006821 0.30 0.000
    AEBP1 NM_001129 0.16 0.001
    AGA NM_000027 0.35 0.000
    ANXA2 NM_001002857 0.26 0.029
    AP4E1 NM_007347 0.30 0.008
    APOE NM_000041 0.08 0.000
    ARHGDIB NM_001175 0.24 0.009
    ASAH1 NM_004315 0.31 0.000
    BDKRB1 NM_000710 0.00 0.001
    BDKRB2 NM_000623 0.00 0.000
    BDNF NM_170735 0.12 0.000
    BMP4 NM_001202 0.28 0.001
    C3 NM_000064 0.25 0.001
    C5orf13 NM_004772 0.18 0.000
    CACNA1C NM_000719 0.03 0.000
    CASP4 NM_033306 0.00 0.000
    CASP5 NM_004347 0.00 0.001
    CCL2 NM_002982 0.20 0.000
    CD36 NM_001001547 0.07 0.023
    CDC42EP2 NM_006779 0.06 0.000
    CD042EP3 NM_006449 0.41 0.000
    CD042EP5 NM_145057 0.41 0.040
    CDH11 NM_001797 0.00 0.000
    CEMP1 AL833099 0.30 0.001
    CFH NM_001014975 0.01 0.010
    CITED2 NM_006079 0.14 0.000
    COL12A1 NM_004370 0.00 0.001
    COL1A1 NM_000088 0.01 0.000
    COL1A2 NM_000089 0.00 0.001
    COL3A1 NM_000090 0.00 0.001
    COL5A1 NM_000093 0.00 0.000
    CPT1A NM_001876 0.16 0.002
    CROT NM_021151 0.27 0.002
    CTSA NM_000308 0.10 0.000
    CTSB NM_147780 0.11 0.001
    CXCL1 NM_001511 0.01 0.003
    CXCL12 NM_000609 0.00 0.001
    CYP27A1 NM_000784 0.28 0.011
    CYR61 NM_001554 0.10 0.000
    DCHS1 NM_003737 0.29 0.000
    DMPK NM_004409 0.36 0.000
    DPT NM_001937 0.05 0.006
    EFEMP1 NM_004105 0.00 0.000
    ELN NM_000501 0.13 0.001
    EMX2 NM_004098 0.00 0.001
    EPS8 NM_004447 0.18 0.000
    ETS1 NM_005238 0.15 0.003
    FAH NM_000137 0.17 0.000
    FAM14A NM_032036 0.22 0.001
    FAP NM_004460 0.00 0.000
    FBLN2 NM_001004019 0.18 0.000
    FBN1 NM_000138 0.01 0.002
    FGF1 NM_000800 0.20 0.004
    FGF13 NM_004114 0.04 0.006
    FGF2 NM_002006 0.06 0.000
    FGF5 NM_004464 0.01 0.003
    FGF7 NM_002009 0.04 0.001
    FGF9 NM_002010 0.01 0.000
    FGFR1 NM_023110 0.34 0.026
    FHL2 NM_201555 0.11 0.000
    FN1 NM_212482 0.00 0.001
    FSTL1 NM_007085 0.09 0.000
    GADD45B NM_015675 0.09 0.001
    GALNT6 NM_007210 0.13 0.001
    GAS6 NM_000820 0.02 0.000
    GBA NM_001005749 0.22 0.002
    GBAP NR_002188 0.19 0.000
    GCH1 NM_000161 0.22 0.001
    GGTA1 NR_003191 0.28 0.013
    GIT2 NM_057169 0.37 0.003
    GJA1 NM_000165 0.46 0.001
    GLIS1 NM_147193 0.02 0.000
    GM2A AK127910 0.25 0.010
    GNS NM_002076 0.29 0.000
    GPC3 NM_004484 0.22 0.038
    GREM1 NM_013372 0.00 0.011
    GSTM1 NM_146421 0.27 0.001
    HAAO NM_012205 0.43 0.001
    HERPUD1 NM_014685 0.19 0.000
    HEXA NM_000520 0.24 0.000
    HEXB NM_000521 0.36 0.000
    HGF NM_001010932 0.09 0.028
    HGS NM_004712 0.26 0.029
    HIF1A NM_181054 0.36 0.005
    HLA-A NM_002116 0.31 0.002
    HLA-H NR_001434 0.19 0.001
    HOXB13 NM_006361 0.03 0.004
    HR NM_005144 0.18 0.002
    HSPG2 NM_005529 0.19 0.004
    IDUA NM_000203 0.16 0.000
    IGF1 NM_000618 0.10 0.004
    IGFBP7 NM_001553 0.28 0.040
    IKBKG NM_003639 0.42 0.001
    IRF1 NM_002198 0.28 0.002
    ITGA1 NM_181501 0.00 0.001
    ITGB3 NM_000212 0.05 0.000
    KLF4 NM_004235 0.05 0.002
    LEP NM_000230 0.07 0.001
    LEPRE1 NM_022356 0.24 0.000
    LMNA NM_005572 0.42 0.000
    LOX NM_002317 0.01 0.000
    LOXL4 NM_032211 0.10 0.003
    LRRC8C NM_032270 0.15 0.013
    MAGEL2 AJ243531 0.31 0.002
    MAN2B1 NM_000528 0.45 0.006
    MAP3K8 NM_005204 0.27 0.001
    MEIS2 NM_170677 0.00 0.001
    MKNK1 NM_003684 0.37 0.005
    MMP1 NM_002421 0.00 0.000
    MMP14 NM_004995 0.07 0.001
    MMP2 NM_004530 0.04 0.000
    MMP3 NM_002422 0.00 0.001
    MOXD1 NM_015529 0.24 0.000
    MRAS NM_012219 0.15 0.001
    MSX2 NM_002449 0.15 0.031
    MTHFR NM_005957 0.27 0.014
    MYC NM_002467 0.05 0.000
    MYL6 NM_079423 0.33 0.001
    MYL9 NM_181526 0.01 0.000
    NAGLU NM_000263 0.23 0.000
    NBL1 NM_182744 0.11 0.000
    NEK9 NM_033116 0.41 0.001
    NF2 NM_181831 0.46 0.000
    NPC1 NM_000271 0.34 0.000
    OPTN NM_001008211 0.04 0.000
    P4HB NM_000918 0.37 0.001
    PALLD NM_016081 0.29 0.001
    PAPPA NM_002581 0.05 0.000
    PCDHGB4 NM_032098 0.28 0.001
    PCK2 NM_004563 0.04 0.000
    PCOLCE NM_002593 0.00 0.000
    PDGFRA NM_006206 0.02 0.010
    PEX14 BC017848 0.48 0.000
    PFKL NM_001002021 0.35 0.004
    PPARG NM_138711 0.01 0.000
    PPFIBP2 NM_003621 0.08 0.000
    PRR5 NM_015366 0.23 0.022
    PSEN2 NM_012486 0.34 0.002
    PTGS1 NM_000962 0.29 0.000
    PXDN AF200348 0.12 0.000
    PYCARD NM_013258 0.03 0.000
    QSOX1 NM_002826 0.09 0.000
    RASSF1 NM_170713 0.30 0.001
    RBMS1 NM_002897 0.14 0.001
    RECK NM_021111 0.07 0.000
    RET NM_020975 0.35 0.015
    RFPL1S NR_002727 0.22 0.039
    ROD1 NM_005156 0.37 0.001
    RSU1 NM_012425 0.41 0.002
    S100A4 NM_002961 0.03 0.000
    SAMD9 NM_017654 0.07 0.007
    SCARB2 NM_005506 0.42 0.001
    SDC2 NM_002998 0.38 0.000
    SDPR NM_004657 0.03 0.005
    SENP2 AF151697 0.44 0.006
    SEPP1 NM_001085486 0.00 0.005
    SFRP1 NM_003012 0.37 0.000
    SHOC2 NM_007373 0.39 0.000
    SIGIRR NM_021805 0.47 0.000
    SLC17A5 NM_012434 0.14 0.001
    SLC22A5 NM_003060 0.21 0.001
    SLC9A3R2 NM_004785 0.29 0.000
    SMPD1 NM_000543 0.17 0.000
    STAT1 NM_139266 0.19 0.000
    STAT6 NM_003153 0.00 0.000
    STS NM_000351 0.10 0.007
    STYK1 NM_018423 0.05 0.013
    SUMF1 NM_182760 0.28 0.000
    TAGLN NM_001001522 0.01 0.000
    TFAP2A NM_003220 0.03 0.005
    THBS2 NM_003247 0.02 0.000
    THRA NM_199334 0.31 0.000
    THRB NM_000461 0.10 0.014
    TNXB NM_019105 0.26 0.043
    TPM2 NM_213674 0.12 0.000
    TRIOBP NM_007032 0.15 0.003
    TRIP11 NM_004239 0.45 0.001
    TSC22D3 NM_004089 0.14 0.000
    TWIST1 NM_000474 0.01 0.003
    VCAN NM_004385 0.04 0.000
    VCL NM_014000 0.28 0.000
    VLDLR NM_003383 0.15 0.000
    WISP1 NM_003882 0.05 0.013
    WNT5A NM_003392 0.01 0.000
    YAP1 NM_006106 0.41 0.007
    ZBTB7B NM_015872 0.44 0.000
  • TABLE X5
    Up-regulated Neural Precursor genes (NSLC vs. hNPC)
    Fold change of
    NSLC
    compared
    GeneSymbol Accession Number to hNPC2 p-value
    ACTL6A NM_178042 2.33 0.000
    BCAT1 NM_005504 9.92 0.000
    BDNF NM_170735 33.90 0.000
    BMP2 NM_001200 17.71 0.000
    CDKN2A NM_058197 5.57 0.000
    COL18A1 NM_030582 7.22 0.001
    DIAPH1 NM_005219 2.33 0.001
    EDNRB NM_003991 2.78 0.000
    IDE NM_004969 2.74 0.000
    LIMK1 NM_002314 3.61 0.000
    MAPK8IP1 NM_005456 2.77 0.000
    MCHR1 NM_005297 4.02 0.000
    MYLIP NM_013262 4.22 0.000
    NEDD4 NM_006154 2.23 0.000
    NOS2A NM_000625 267.58 0.000
    PCSK9 NM_174936 9.65 0.000
    PSEN2 NM_000447 2.07 0.000
    SMAD1 NM_005900 3.09 0.000
    TBX1 NM_080647 3.65 0.028
    TGFB1 NM_000660 6.66 0.000
    2Fold change represents the up-regulation of the gene in the NSLC samples as compared to the hNPC samples. (n = 3 for hNPC samples, n = 3 for NSLC samples).
  • TABLE X6
    Up-regulated Glia genes (NSLC vs. hNPC)
    Fold change of NSLC
    GeneSymbol Accession Number compared to hNPC1 p-value
    ACSL4 NM_004458 2.10 0.000
    BDNF NM_170735 33.90 0.000
    BMP4 NM_001202 20.55 0.001
    CP NM_000096 159.46 0.000
    CSPG4 NM_001897 4.94 0.000
    FOXC1 NM_001453 5.12 0.000
    GFAP NM_002055 13.67 0.000
    GJB2 NM_004004 7.25 0.000
    GLIPR1 NM_006851 5.58 0.000
    ITGA3 NM_002204 24.64 0.000
    LMO3 NM_018640 129.25 0.000
    NEFL NM_006158 7.14 0.000
    NKX6-2 NM_177400 11.50 0.000
    NRTN NM_004558 3.39 0.001
    PDCD11 NM_014976 2.48 0.000
    PLP1 NM_000533 20.64 0.000
    TGFB1 NM_000660 6.66 0.000
    TSPAN12 NM_012338 2.58 0.006
  • TABLE X7
    Up-regulated Regenerative genes (NSLC vs. hNPC)
    Fold change of NSLC
    GeneSymbol Accession Number compared to hNPC1 p-value
    ATR NM_001184 2.57 0.000
    BMP2 NM_001200 17.71 0.000
    BMP4 NM_001202 20.55 0.001
    CAV3 NM_001234 26.23 0.000
    CCND1 NM_053056 10.34 0.000
    CDKN2A NM_058197 5.57 0.000
    CEBPB NM_005194 2.58 0.000
    GAL NM_015973 12.21 0.000
    GAP43 NM_002045 4.27 0.000
    HOXB4 NM_024015 133.37 0.000
    SMAD3 NM_005902 2.27 0.000
  • In order to investigate the differentiation potential of NSLCs to neuronal lineages (Neurons, astrocytes, and oligodendrocytes), neurospheres were dissociated and plated in laminin/poly-D-Lysine (10 μg/ml; Sigma) in differentiation medium for two weeks. The differentiation towards neuronal lineage was performed using two different mediums: NbActive medium (BrainBits™) supplemented with Brain Derived Neurotrophin Factor (BDNF, 20 ng/ml, Peprotech), all-trans-retinoic acid (ATRA, 5 μM, Spectrum), and bFGF (40 ng/ml, Peprotech) or NeuroCult™ differentiation medium (NeuroCult™ Differentiation kit, StemCell Technologies), supplemented with BDNF (20 ng/ml, Peprotech) and bFGF (40 ng/ml, Peprotech). After two weeks in culture, the cells were stained with the neuronal marker βIII-tubulin, astrocyte markers GFAP and Sloop, and oligodendrocyte marker CNPase. The cells were fixed with 4% formaldehyde and the primary antibodies were added in 5% normal goat serum/PBS as follows: Mouse antibody βIII-tubulin (1:200, Abcam), rabbit antibody s100β (1:100, Abcam), and Chicken antibody CNPase (1:50, Abcam). Secondary antibodies are added in 5% normal goat serum/PBS as follows: Goat anti mouse Alexa546™ (1:200, Invitrogen), Goat anti rabbit Alexa488™ (1:200, Invitrogen), and Goat anti-chicken cy5 (1:100, Jackson ImmunoResearch Labs).
  • Immunohistochemistry analysis showed that NbActive medium promoted the differentiation equally to neuronal (48.66±14.07%, βIII-tubulin) and potential early oligodendrocyte lineages (50.01±4.04%, CNPase) and to a lower percentage of astrocyte cells (2.68±1.13%, sloop), while NS-A differentiation medium induced the differentiation mainly to neurons (64.89±4.11%, βIII-tubulin) and astrocytes (35.94±4.04%, S100beta), and a low percentage of potential early oligodendrocytes cells (8.68±2.71%, CNPase). The NSC-A medium was selected over NbActive for further differentiation studies. Differentiation of cells in NS-A differentiation medium promote the differentiation of hNPC and NSLC similarly as shown in Table 17 by the decrease of the percentage of sox2, musashi and nestin positive cells. NSLCs were differentiated to neuronal (74.3±0.1, GABA), astrocyte lineage (65.6±0.0, S100beta) and to a lower percentage of oligodendrocyte cells (5.2±0.6, CNPase). The same pattern of tripotent lineage differentiation was observed with hNPCs (Table 17).
  • TABLE 17
    The percentage of cells stained positive for neural stem cell and neuronal lineage
    markers in transfected and untransfected cells. NSLCs and hNPCs were cultured in
    NS-A-differentiation medium supplemented with BDNF (20 ng/ml) and FGF (40 ng/ml),
    cultures were incubated at 37° C., 5% CO2, 5% O2 for three weeks. The percentage of
    immunopositive cells was determined by Cellomics ™ and represented as mean ± SD (n = 5).
    Sox2 Nestin Musashi S100 O4 GABA
    Tripotent hNPC 73.8 ± 0.5 46.1 ± 45.2 22.1 ± 7.0 20.8 ± 1.3 6.4 ± 2.9 68.5 ± 1.6
    medium
    NSLC 68.6 ± 3.9 41.0 ± 5.4  26.7 ± 5.0 65.6 ± 0.0 8.2 ± 0.6 74.3 ± 0.1
  • Several additional antibodies to neuronal antigens were used to characterize, in more detail, the nature of differentiated cells. Antibodies against microtubule-associated protein (MAP2b), NCAM, and synaptophysin were used as recommended by the antibody manufacturer. After three weeks in differentiation medium, there was a differentiation-induced reduction in markers of precursors cells and an increase in mature neuronal markers. The percentage of neural precursor markers such as Sox2 were decreased during differentiation, while p75NTR, βIII-tubulin and GABA were increased with lengthening differentiation time (FIG. 6); however, O4 positive cells were very low after 3 weeks of differentiation of hNPCs (6.4±2.9) and NSLCs (8.2±0.6). Synaptophysin, an antibody used to identify functional neuronal cells, was increased following 2 and 3 weeks of differentiation, indicating maturity of the neuronal cells. GABA and acetylcholine markers were increased following 2 weeks of differentiation and decreased at week 3.
  • The morphological changes and expression of a number of neuronal antigens and genes show that the above method results in normal and viable neuronal cells. Additionally, the newly formed neuronal cells have the morphological criteria of neurons. In addition to the above markers, the differentiated cells were evaluated by characterizing morphological markers of neurite differentiation. Neuron type cells (cells strongly expressing βIII-tubulin) showed neurite formation after differentiation, including an increase in the average number of neurites per neuron (from e.g. 1.38±0.1) The same pattern was observed in βIII-tubulin positive cells. Accordingly, the average neurite length (118.3±3.5 μm) and the number of branch points (3.28±0.3) per neuron also increased. The differentiated neuron-like cells developed long neurites that were greater than three cell diameters in length with a growth cone at the end, expressed neuron-specific genes, and stopped proliferating after the induction of differentiation.
  • Further differentiation was performed using an optimised medium that promoted the differentiation towards oligodendrocyte lineage. NSLCs and hNPCs were cultured in NS-A differentiation medium as described previously supplemented with FGF-2 (10 ng/ml, Peprotech) and sonic hedgehog (SHH, 100 ng/ml, Peprotech) for 4 days. After 4 days medium was changed to NS-A differentiation medium supplemented by T3 (60 ng/ml, Peprotech), IGF1 (10 ng/ml, Peprotech), NT-3 (10 ng/ml, Peprotech), and PDGF (10 ng/ml, Peprotech). Cells were cultured for 20 days at 37° C., 5% CO2.
  • TABLE 18
    The percentage of cells stained positive for neural stem cell and neuronal lineage
    markers in transfected and untransfected cells. NSLCs and hNPCs were cultured in
    differentiation medium supplemented with SHH (100 ng/ml, Peprotech), T3 (60 ng/ml,
    Peprotech), IGF1 (10 ng/ml, Peprotech), NT-3 (10 ng/ml, Peprotech), and PDGF (10 ng/ml,
    Peprotech) to induce differentiation towards oligodendrocytes. The percentage of
    immunopositive cells was determined by Cellomics ™ and represented as mean ± SD (n = 5).
    % of positive
    cells Sox2 Nestin Musashi S100 O4 GABA
    hNPC 84.3 ± 3.7 26.9 ± 4.4 51.8 ± 2.9  33.4 ± 1.9 40.1 ± 6.4  89.6 ± 0.8
    NSLC 69.3 ± 4.4 24.3 ± 2.5 45.1 ± 11.1 51.6 ± 9.5 8.5 ± 0.6 76.9 ± 1.4
  • Quantification of the differentiation of hNPCs and NSLCs revealed a population of cells that were positively stained for O4. As shown in Table 18, the percentage of O4 positive cells was more pronounced in differentiated hNPC (40.1±6.4%) as compared to differentiated NSLCs (8.5±0.6%) when using the above differentiation protocol.
  • This study showed that transfecting the cells with one or two neurogenic transcription factors in the presence of a DNA demethylator or small molecules for epigenetic modification achieves stable reprogrammed cells (NSLCs). Like a DNA demethylator, epigenetic modification (inhibition of acetylation and methylation) are sometimes useful in boosting the reprogramming process. These cells possess and retain neural stem cell properties as determined by: (1) the expression of neural stem cell genes and proteins, (2) the capacity to generate and grow as neurospheres starting from a single cell, and (3) to differentiate to neuronal lineages in differentiation conditions. When differentiated to neurons, cells display one or more neural-specific morphological, physiological and/or immunological features associated with a neuronal cell type. Useful criteria include morphological features (long processes or neurites), physiological, and/or immunological features such as expression of a set of neuronal-specific markers or antigens. Furthermore, NSLCs readily turn into a tripotent-like precursor cell with differentiation potential to a high percentage of neuronal, astrocytes and lower percentage of oligodendrocyte populations.
    • Example VI Implication of BMP Signaling Pathway in the Reprogramming of HFFs
  • This study was designed to evaluate the role of Noggin in the process of de-differentiation of HFFs towards NSLCs. HFFs were cultured and treated with cytochalasin B as described in Example III. After two days of treatment, cells were transfected by Nucleofection as described in Example II with the constructed vector Msi1/Ngn2. Briefly, after preparing the cells, they were mixed with 2 μg of total DNA (Msi1/Ngn2) and were co-transfect with MBD2 (2 μg), by the Amaxa's Nucleofector™ according to the manufacturer's protocol. The samples were then transferred into a Laminin (10 μg/ml, Sigma) coated culture plate and cultured in the presence of Neural Proliferation Medium (NeuroCult™ proliferation Kit, StemCell Technologies) with recombinant hFGF (20 ng/ml, Peprotech), recombinant hEGF (20 ng/ml, Peprotech), and with or without the presence of Noggin (20 ng/ml, Peprotech). Samples were collected at different time points (1, 3, 4, 6, and 8 days) to analyze neuronal gene expression by RT-PCR and protein expression levels by immunohistochemistry.
  • Fluorescent immunohistochemical staining was performed on samples after 4 days of transfection as previously described in Example I. Transfected cells were stained and analyzed for expression of Sox2, the percentage of Sox2 was 33.3±1.00% in the presence of Noggin compared to 27.5±0.50% without the presence of noggin at day 4. RT-PCR analysis of relative expression of neuronal precursor cell markers such as nestin and Sox2 after transfection of HFFs with pCMV-Msi1-2A-Ngn2 and pCMV6-XL5-MBD2 with or without the presence of Noggin (20 ng/ml) was associated with an increase in nestin and Sox2 starting at day 3 and maintained until day 8 (Table 19). No difference in the expression was noticed in the absence of Noggin. Inhibiting the BMP signaling pathway by Noggin thus enhanced reprogramming, but had no reprogramming effect on its own.
  • TABLE 19
    RT-PCR analysis of relative expression of neuronal precursor cell markers such as nestin and Sox2 after
    transfection of HFF with pCMV-Msi1-2A-Ngn2 and pCMV6-XL5-MBD2 with or without Noggin (20 ng/ml).
    Relative expression of Sox2, and nestin was increased after transfection with and without Noggin.
    ACHE GFAP NES SOX2 TUBB3
    Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std.
    Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev.
    #1 Msi1/Ngn2 + 7.08 1.70 2.97 0.42 1.33 0.10 0.93 0.91 1.37 0.10
    MBD2/+Noggin
    Day 1
    #2 Msi1/Ngn2 + 7.34 1.03 2.01 0.08 1.28 0.18 0.60 0.10 0.98 0.05
    MBD2/+Noggin
    Day 2
    #3 Msi1/Ngn2 + 9.67 2.41 15.13 1.66 1.98 0.20 6333.63 277.87 0.95 0.07
    MBD2/+Noggin
    Day 3
    #4 Msi1/Ngn2 + 11.68 2.65 194.07 25.22 4.19 0.52 20231.33 1034.29 1.90 0.45
    MBD2/+Noggin
    Day 4
    #5 Msi1/Ngn2 + 3.58 0.66 227.99 16.83 1.68 0.09 6298.51 289.84 0.96 0.17
    MBD2/+Noggin
    Day 6
    #6 Msi1/Ngn2 + 10.89 0.57 650.34 22.92 4.42 0.03 18134.90 63.93 1.81 0.06
    MBD2/+Noggin
    Day 8
    #7 Ctrl 1.01 0.19 1.00 0.05 1.00 0.02 1.12 0.70 1.00 0.09
    Untransfected
    +Noggin Day 1
    #8 Msi1/Ngn2 + 2.79 0.83 1.62 0.19 0.99 0.08 1.28 0.25 0.75 0.01
    MBD2/−Noggin
    Day 1
    #9 Msi1/Ngn2 + 3.79 0.91 1.47 0.08 1.23 0.08 1.36 0.08 0.72 0.07
    MBD2/−Noggin
    Day 2
    #10 Msi1/Ngn2 + 6.18 0.59 14.60 1.85 2.62 0.30 10949.28 448.28 0.90 0.01
    MBD2/−Noggin
    Day 3
    #11 Msi1/Ngn2 + 5.63 0.74 74.56 16.56 2.97 0.21 19623.99 3109.69 0.75 0.11
    MBD2/−Noggin
    Day 4
    #12 Msi1/Ngn2 + 3.21 0.96 232.42 5.47 1.47 0.07 15311.64 1909.23 0.86 0.03
    MBD2/−Noggin
    Day 6
    #13 Msi1/Ngn2 + 3.82 0.52 496.99 75.81 3.32 0.32 26892.31 1817.05 2.05 0.10
    MBD2/−Noggin
    Day 8
    #14 Ctrl 1.08 0.57 1.01 0.14 1.00 0.04 1.15 0.81 1.00 0.00
    Untransfected
    −Noggin Day 1
    • Example VII
  • NSLCs Created from HFF Cells are not Skin-Derived Precursors (SKPs)
  • It's known that cells termed skin-derived precursors (SKPs) may reside in adult human skin (Fernandes et al., 2004). These cells are capable of proliferating in response to EGF and bFGF and express nestin, versican and fibronectin, and can differentiate into both neuronal and mesodermal progeny. In order to verify that NSLCs are distinct from SKPs, differentiation towards adipocyte cells was performed. Adipose derived stem cells (ADSC) were maintained in StemPro™ MSC serum free medium (Invitrogen) on flasks coated with CellStart™ (Invitrogen). CellStart™ was diluted 1:100 in dPBS/Ca2+/Mg2+ and the flask incubated for 2 hours at 37° C. Cells are passaged every 3 to 4 days using Accutase™ and medium was changed every 2 days. Three to four days before initiating differentiation, ADSCs and NSLCs were seeded in 6-wellplates in CellStart™ (1:100 in dPBS/Ca2+/Mg2+/2 hours at 37° C.) coated tissue culture plates. When cells reached confluence (after 3 to 4 days), proliferation media were replaced by differentiation medium consisting in DMEM/F12 (50:50), ITS (1:100), HEPES (1:100), GlutaMAX™ (1:100), T3 (0.2 nM), Rosiglitasone (0.5 μg/ml), IBMX (100 μM) and Dexamethasone (1 μM). Three days after, IBMX and dexamethasone were withdrawn from the differentiation medium. At day 10, cells were fixed with a 4% formaldehyde solution for 10 min and stained with Oil Red O (Invitrogen) staining solution for 15 min. Staining was removed and cells washed twice with PBS. Adipose cells appeared red with lipid droplets specifically stained with Oil Red O, however NSLCs were stained negative, with no presence of lipid droplets in the cells, and the cells adopted neuronal cell morphology.
  • Immunohistochemistry analysis confirmed that NSLCs are distinct from SKPs (FIG. 24): NSLCs stained positive for p75NTR and negative for fibronectin and versican, while SKPs express fibronectin and versican and do not express p75NTR (Fernandes et al., 2004). This study indicates that NSLCs represent a tripotent-like precursor cell and they are not a subpopulation of SKPs.
    • Example VIII
  • BDNF Release from Neural-Like Cells (NLCs)
  • Neural Stem-Like Cells (NSLCs) differentiated into neuronal and glial cells were kept in culture for 55 days, and BDNF released in the conditioned medium was measured by antigen-capture ELISA at different time points and compared to the release in mature neurons (ScienCell), undifferentiated Neural Human Normal Precursor cells (NHNP, Lonza) as well as to undifferentiated NSLCs and untransfected cells (HFF). Conditioned medium from each group was collected, centrifuged, and then stored at −80° C. until assaying. BDNF concentrations were measured by ELISA kits (BDNF Emax Immunoassay System, Promega Corporation, USA), according to the manufacturer's instructions. Briefly, 96-well ELISA immunoplates were coated with Anti-BDNF (CatNb # G700B) diluted 1/1000 in carbonate buffer (pH 9.7) and incubated at 4° C. overnight. The following day, all wells were washed with TBS-Tween™ 0.5% before incubation with Block/Sample buffer 1× at room temperature for one hour without shaking. After blocking, standards and samples were added to the plates and incubated and shaken (450±100 rpm) for 2 h at room temperature. Subsequently, after washing with TBS-Tween™ wash buffer, plates were incubated for 2 h with Anti-Human BDNF pAb (1:500 dilution in Block & Sample 1× Buffer) at 4° C. After incubation, plates were washed five times with TBS-Tween™ 0.5% wash buffer and 100 μl of diluted Anti-IgYHRP Conjugate was added to each well (1:200 dilution in Block & Sample 1× Buffer) and incubated for 1 hour at room temperature with shaking (450±100 rpm). Then, plates were washed five times with TBS-Tween™ 0.5% wash buffer and 100 μl of TMB One Solution was added to each well. Following 10 minutes incubation at room temperature with shaking (450±100 rpm) for the BDNF plate, a blue color formed in the wells. After stopping the reaction by adding 100 μl of 1N hydrochloric acid, the absorbance was read at 450 nm on a microplate reader (Synergy 4™) within 30 minutes of stopping the reactions. Concentration of released BDNF in the supernatants was determined according to the standard curves.
  • ELISA results revealed that BDNF was released at the same concentration from differentiated Neuron-Like Cells (NLCs differentiated from NSLCs) and normal Human neuron cells starting at day 11 and remained until day 55 (Table 20), while no BDNF (except for tiny amounts in the untransfected HFF group) was released in the other groups.
  • TABLE 20
    Quantification of BDNF release by Neural-Like Cells (NLCs) that had been
    differentiated for 55 days from Neural Stem-Like Cells (NSLCs) that had
    been created from transfected HFFs. BDNF release from NLCs into the
    medium, at different time points, was measured by antigen-capture
    ELISA and compared to BDNF release of normal mature human
    neurons (ScienCell).
    Control medium Neurons NLC
    day
    0 
    day 11 1.55 30.25 22.99
    day 18 0.33 29.49 25.15
    day 24 0.33 22.01 26.39
    day 34 0.23 25.53 32.21
    day 41 0.27 19.02 22.43
    day 55 0.02 20.73 30.01
  • In addition to adopting neuronal morphology criteria, the NLCs were functional and possessed the capacity to release neurotrophic factor (BDNF). Generating reprogrammed neuronal-like cell lines that can locally deliver these neurotrophic factors could be used as a method to treat several neurological conditions and may offer crucial benefits in regeneration and functional recovery from brain and other injuries.
    • Example IX
  • Reprogramming of Different Cell Types Towards NSLCs:
  • This study was performed to investigate the capacity of keratinocytes (Invitrogen), human Adipocytes Derived Stem Cells (ADSCs, Invitrogen) and human hematopoietic stem cells (CD34+, Invitrogen) cells into neural stem-like cells.
  • Preparation of Human CD34+ Cells, Human ADSC and Human Keratinocytes:
  • Human mobilized peripheral blood CD34+ cells were purchased from StemCell Technologies and expanded as a floating culture in Petri Dishes in complete StemPro™®-34 Serum-free Medium (Invitrogen) supplemented with Stem Cell Factor (SCF, 150 g/ml, Peprotech), Granulocyte Colony-Stimulating Factor (GM-CSF, 37.5 ng/ml, Peprotech) and IL-3 (75 ng/ml, Peprotech). Medium supplemented with cytokines was changed everyday 2-3 days after centrifugation of the cell suspension at 300×g for 10 min. Every other day the cytokines were added directly to the culture without changing the media. Cells were incubated at 37° C., 5% CO2. For their passaging, cells were centrifugated, resuspended in the above medium plus cytokines and placed into the adequate number of Petri dishes.
  • Human Adipose-Derived Stem Cells (ADSC) were purchased from Invitrogen and expanded in complete StemPro™ MSC Serum-free medium (Invitrogen) on CellStart™™ (Invitrogen) coated flasks (diluted 1:100 in PBS containing Ca2+/Mg2+) at a cell density of 1×104 cells/cm2. Medium was replaced every two days with fresh pre-warmed complete StemPro™ MSC SFM. Cells were incubated at 37° C., 5% CO2. Cells were sub-passaged when 80% confluent by incubation for 3-5 min in pre-warmed TrypLE™™ (Invitrogen) and then collected in StemPro™ MSC medium. After centrifugation at 1500 rpm for 5 min, cells were seeded on CellStart™™ coated flasks as described above.
  • Primary human keratinocytes were purchased from Invitrogen and expanded in Defined Keratinocyte Serum-free medium on Coating matrix (Invitrogen) coated flasks (Invitrogen) at a cell density of 5×103 cells/cm2. The cells were incubated at 37° C., 5% CO2 Media was replaced with fresh, complete growth media every two to three days until subculture. Once the cells had reached 70-80% confluency, media was removed and the cells were incubated in Versene™ (Invitrogen) for 3-5 min at room temperature. Versene™ was removed, and pre-warmed 0.05% trypsin-EDTA (Invitrogen) was added to the flasks. After 5-10 min incubation, growth medium containing Soybean Trypsin inhibitor (Invitrogen) was added to the flasks and the cells gently triturated. After centrifugation at 100×g for 10 min, cells were resuspended in the desired volume of pre-warmed, complete growth medium on coated flasks as described above.
  • Prior to transfection, cells were trypsinized and transiently co-transfected with pCMV-Msi1-Ngn2 and pCMV6-XL5-MBD2 as previously described in Example IV using the Shuttle and plated into a culture plate coated with laminin (Sigma, 10 μg/ml). Starting one day after transfection, cells were treated with VPA (1 mM) for 4 days and the medium was changed gradually to proliferation medium supplemented with FGF (20 ng/ml) and EGF (20 ng/ml) and were cultured for 18 days at 372C, 5% CO2 and 5% O2. Cells were then analyzed for neural stem cell markers by RT-PCR and Immunohistochemistry.
  • Further analysis and quantification of the reprogrammed cells revealed a population of NSLCs engendered from keratinocyte and CD34+ cells. RT-PCR Analysis revealed an increase of relative expression of neural stem cell markers such as Sox2, nestin, GFAP, and βIII-tubulin after transfecting Keratinocyte and CD34+ by Msi1 and Ngn2. Relative expression of nestin and GFAP was enhanced in NSLCs created from keratinocytes and CD34+ cells as compared to NSLCs from HFFs; however, the reverse was true for Sox2 and ACHE expression. βIII-tubulin (TUBB3) and Map2b expression was highest in NSLCs created from CD34+ cells, followed by NSLCs created from HFF (Table 21). This data shows that different types of NSLCs with different gene expression profiles (and characteristics) can be created from different types of starting/source cells (and the same has been observed for creating some other types of stem-like cells discussed in this application). The data is also intriguing since it was not expected that keratinocytes (which are derived from the ectoderm just as endogenous neural stem cells) would have a lower expression than HFFs for all the genes analyzed except for Nestin (it was expected that keratinocytes would be the easiest to reprogram into NSLCs since they are derived from the ectoderm).
  • TABLE 21
    RT-PCR analysis was performed after one month of transfection of human fibroblasts (HFF), Keratinocytes, and CD34+ cells with
    Msi1/Ngn2 (MSI1/NGN2), in the presence MBD2 with VPA treatment. Cells were cultured on coated culture plates in proliferation
    medium (StemCell Technologies) supplemented with EGF (20 ng/ml) and FGF (20 ng/ml) for 18 days. Untransfected cells were
    considered as negative control.
    NES MAP2 TUBB3 ACHE GFAP SOX2
    Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std.
    Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev.
    #
    1 Day 12 1.00 0.07 1.00  0.05 1.00 0.01 1.01 0.15 1.00 0.02 1.08 0.59
    Untransfected
    HFF
    #
    2 Day 12 HFF 2.25 0.03 21.48  2.09 3.41 0.45 12.92 1.88 558.69 80.08 71513.12 14146.80
    Msi1/Ngn2 +
    MBD2
    #
    3 Day18 HFF 2.56 0.15 17.12  0.14 2.65 0.02 4.13 0.64 75.96 8.82 84794.40 318.54
    Msi1/Ngn2 +
    MBD2
    #
    4 1.07 0.54 1.00  0.07 1.00 0.02 1.01 0.19 1.06 0.48 1.00 0.01
    Untransfected
    Keratinocytes
    #
    5 Day 12 11452.65 1137.13 0.96  0.11 6.78 0.28 1.09 0.05 5815.54 510.91 975.81 7.47
    Keratinocytes
    Msi1/Ngn2 +
    MBD2
    #
    6 Day 18 12593.79 431.06 0.93  0.04 6.41 0.27 0.48 0.03 1295.15 32.05 1047.17 139.48
    Keratinocytes
    Msi1/Ngn2 +
    MBD2
    #
    7 1.00 0.04 1.01  0.16 1.00 0.00 1.00 0.01 1.10 0.66 1.01 0.21
    Untransfected
    CD34
    #
    8 Day 18 839.57 134.51 346.61 33.97 33.91 4.38 0.28 0.00 2790.18 304.43 25080.35 35.93
    CD34+
    Msi1/Ngn2 +
    MBD2
    hNPC 4.56 0.07 278.36 11.50 0.81 0.06 72.65 1.83 1285.73 5.27 565552.30 41717.72
  • Immunohistochemistry revealed positive staining for GFAP, Sox2, and nestin as shown in FIG. 7. NSLCs developed from HFF yield a higher percentage of positive staining for Sox2 and GFAP (55.8±3.8 and 78.1±2.4) as compared to CD34+ cells (42.8±2.7 and 24.2±4.4), and keratinocytes (47.1±2.1 and 43.4±8.9). The percentage of nestin positive cells was high in Keratinocytes (77.6±10.7) and HFF (68.45±12.9) and lower in CD34+ cells (15.5±2.7) (Table 22). Sox2 and Nestin positive staining was undetectable in ADSCs.
  • TABLE 22
    The percentage of Sox2 and nestin positive cells for neural stem cell
    markers after transfecting fibroblast, keratinocyte, and CD34+ cells
    with pCMV-Msi1-Ngn2 in the presence of MBD2 and VPA. Cells
    were cultured on coated culture plates in proliferation medium
    (StemCell Technologies) supplemented with EGF (20 ng/ml) and
    FGF (20 ng/ml) for 18 days. Untransfected cells were considered
    as negative control. The percentage of immunopositive cells was
    determined by Cellomics ™ and represented as mean ± SD (n = 5).
    Untransfected
    % positive cells cells Fibroblasts Keratinocytes CD34+
    Sox2 1.5 ± 1.7 55.8 ± 3.8 47.1 ± 2.1 42.8 ± 2.7
    GFAP 0.04 +/− 0.2 78.1 ± 2.4 43.4 ± 8.9 24.2 ± 4.4
    Nestin 0.3 +/− 0.3 68.45 ± 12.9  77.6 ± 10.7 15.5 ± 2.7
  • NSLCs generated from keratinocytes and CD34+ cells were tested for tripotent capacity. Further differentiation studies were performed to induce differentiation of these NSLCs towards neuronal lineage, using NeuroCult™ differentiation medium (NeuroCult™ differentiation Kit, StemCell Technologies) supplemented with BDNF (20 ng/ml, Peprotech) and bFGF (40 ng/ml, Peprotech) as described in Example V. NSLCs generated from HFFs and hNPCs were used as controls, cultures were incubated at 37° C., 5% CO2, 5% O2 for three weeks. Samples were collected or fixed at Day 14 and 28 following differentiation for further analysis. RT-PCR analysis revealed decrease of undifferentiated genes (Nestin and Sox2) and increased of differentiated genes (Map2, βIII-tubulin, CNPase, and GFAP) as shown in Tables 23A, 23B, 23C and 23D.
  • TABLE 23A
    RT-PCR analysis was performed on NSLCs generated from human fibroblasts (HFF), keratinocytes, and CD34+ cells
    that were cultured on Poly-D-Lysin/Laminin coated culture plates in differentiation medium for 28 days
    (StemCell Technologies) supplemented with BDNF (20 ng/ml) and FGF (40 ng/ml). hNPCs (Lonza)
    were considered as a positive control. hNPCs had a much lower increase in ACHE, GFAP, and MAP2b
    (which actually decreased in hNPCs), but an increase in Nestin, compared to NSLCs under differentiation conditions.
    NES MAP2 TUBB3 ACHE GFAP SOX2 SOX9 CNP
    Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std.
    Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev.
    hNPC Control 1.00 0.08 1.00 0.10 1.00 0.08 1.01 0.16 1.00 0.09 1.01 0.16 1.00 0.12 1.00 0.09
    Diff. hNPC 3.86 0.20 0.65 0.05 4.87 0.57 0.74 0.52 97.26 7.13 1.85 0.21 0.50 0.04 1.43 0.05
    Day 14
    Diff. hNPC 1.86 0.06 0.68 0.02 3.67 0.13 1.33 0.09 102.74 1.89 1.29 0.01 0.73 0.05 1.37 0.02
    Day 28
    NSLC Control 1.00 0.04 1.00 0.04 1.00 0.04 1.00 0.03 1.00 0.01 1.00 0.01 1.00 0.02 1.00 0.05
    Diff. NSLC 1.38 0.01 1.00 0.09 2.06 0.02 1.57 0.24 1.79 0.12 0.73 0.01 0.56 0.01 1.31 0.05
    Day 14
    Diff. NSLC 0.62 0.02 0.90 0.08 5.14 0.21 6.47 0.78 5.70 0.15 1.30 0.02 0.79 0.03 1.41 0.01
    Day 28
    HFF-NS 1.00 0.00 1.00 0.05 1.00 0.01 1.00 0.07 1.00 0.00 1.00 0.07 1.00 0.01 1.00 0.02
    Control
    Diff. HFF-NS 2.70 0.08 3.08 0.12 3.24 0.14 59.93 5.85 478.97 0.27 2.90 0.32 0.81 0.03 4.02 0.35
    Day 14
    Diff. HFF-NS 1.27 0.05 1.48 0.11 1.59 0.03 24.62 1.00 576.80 20.98 1.52 0.00 0.86 0.08 2.74 0.23
    Day 28
    Kerat-NS 1.00 0.06 1.00 0.02 1.00 0.03 1.00 0.11 1.00 0.01 1.00 0.07 1.00 0.02 1.00 0.01
    Control
    Diff. Kerat-NS 2.43 0.06 3.48 0.08 2.82 0.11 56.22 5.58 665.91 10.52 3.09 0.29 1.01 0.14 3.72 0.17
    Day 14
    Diff. Kerat-NS 0.81 0.03 1.72 0.00 1.61 0.18 26.09 1.12 673.65 11.34 1.29 0.03 1.12 0.03 2.02 0.05
    Day 28
    CD34+-NS 1.00 0.05 1.00 0.07 1.00 0.04 1.00 0.08 1.00 0.00 1.00 0.08 1.00 0.02 1.00 0.07
    Control
    Diff. CD34+-NS 2.21 0.04 3.47 0.07 2.75 0.04 57.87 6.68 407.54 52.07 2.90 0.18 1.10 0.05 3.54 0.02
    Day 14
    Diff. CD34+-NS 0.79 0.04 1.48 0.01 1.83 0.37 26.92 3.73 485.51 10.66 1.02 0.04 1.20 0.09 2.34 0.05
    Day 28
  • TABLE 23B
    RT-PCR analysis was performed on undifferentiated NSLCs generated from human fibroblasts (HFF), keratinocytes, and
    CD34+ cells that were cultured on Laminin coated culture plates in Proliferation medium for 4 days (StemCell Technologies)
    supplemented with EGF (20 ng/ml) and FGF (20 ng/ml). Relative expression calibrated to undifferentiated hNPCs.
    NES MAP2 TUBB3 ACHE GFAP SOX2 SOX9 CNP
    Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std.
    Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev.
    Undifferentiated 1.00 0.08 1.00 0.10 1.00 0.08 1.01 0.16 1.00 0.09 1.01 0.16 1.00 0.12 1.00 0.09
    hNPC Control
    Day
    4
    Undifferentiated 1.23 0.05 0.12 0.00 1.12 0.04 0.09 0.00 21.45 0.26 0.65 0.01 0.28 0.01 0.37 0.02
    NSLC Control
    Day
    4
    Undifferentiated 0.94 0.00 0.12 0.01 0.92 0.01 0.03 0.00 0.38 0.00 0.37 0.02 0.32 0.00 0.31 0.00
    HFF-NS
    Control Day
    4
    Undifferentiated 1.00 0.06 0.09 0.00 0.97 0.03 0.03 0.00 0.23 0.00 0.38 0.03 0.26 0.00 0.30 0.00
    Kerat-NS
    Control Day
    4
    Undifferentiated 1.10 0.05 0.12 0.01 0.95 0.04 0.04 0.00 0.33 0.00 0.44 0.04 0.26 0.00 0.30 0.02
    CD34+-NS
    Control Day
    4
  • TABLE 23C
    RT-PCR analysis was performed on differentiated NSLCs generated from human fibroblasts (HFF), keratinocytes, and CD34+ cells
    that were cultured on Poly-D-Lysin/Laminin coated culture plates in differentiation medium for 14 days (StemCell Technologies)
    supplemented BDNF (20 ng/ml) and FGF (40 ng/ml). Relative expression calibrated to Day 14 differentiated hNPCs.
    NES MAP2 TUBB3 ACHE GFAP SOX2 SOX9 CNP
    Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std.
    Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev.
    Diff. hNPC 1.00 0.05 1.00 0.07 1.00 0.12 1.15 0.80 1.00 0.07 1.00 0.11 1.00 0.08 1.00 0.03
    Day 14
    Diff. NSLC 0.44 0.00 0.18 0.02 0.47 0.00 0.22 0.03 0.40 0.03 0.26 0.00 0.31 0.00 0.34 0.01
    Day 14
    Diff. HFF-NS 0.66 0.02 0.56 0.02 0.62 0.03 2.96 0.29 1.86 0.00 0.58 0.06 0.52 0.02 0.87 0.08
    Day 14
    Diff. Kerat-NS 0.63 0.02 0.51 0.01 0.56 0.02 2.78 0.28 1.56 0.02 0.64 0.06 0.54 0.08 0.79 0.04
    Day 14
    Diff. CD34+-NS 0.63 0.01 0.62 0.01 0.54 0.01 3.77 0.43 1.39 0.18 0.69 0.04 0.58 0.03 0.76 0.00
    Day 14
  • TABLE 23D
    RT-PCR analysis was performed on differentiated NSLCs generated from human fibroblasts (HFF), keratinocytes, and CD34+ cells
    that were cultured on Poly D-Lysin/Laminin coated culture plates in differentiation medium for 28 days (StemCell Technologies)
    supplemented with BDNF (20 ng/ml) and FGF (40 ng/ml). Relative expression calibrated to Day 28 differentiated hNPCs.
    NES MAP2 TUBB3 ACHE GFAP SOX2 SOX9 CNP
    Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std.
    Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev.
    Diff. hNPC 1.00 0.03 1.00 0.02 1.00 0.04 1.00 0.07 1.00 0.02 1.00 0.01 1.00 0.07 1.00 0.02
    Day 28
    Diff. NSLC 0.41 0.01 0.15 0.01 1.56 0.06 0.44 0.05 1.19 0.03 0.66 0.01 0.30 0.01 0.38 0.00
    Day 28
    Diff. HFF-NS 0.64 0.03 0.26 0.02 0.40 0.01 0.59 0.02 2.12 0.08 0.43 0.00 0.38 0.04 0.62 0.05
    Day 28
    Diff. Kerat-NS 0.44 0.02 0.24 0.00 0.42 0.05 0.62 0.03 1.50 0.03 0.38 0.01 0.40 0.01 0.44 0.01
    Day 28
    Diff. CD34+-NS 0.47 0.03 0.25 0.00 0.47 0.10 0.85 0.12 1.57 0.03 0.35 0.01 0.43 0.03 0.52 0.01
    Day 28
  • Fluorescent immunohistochemical staining was performed on samples after 14 days and 28 days of differentiation. The expression of Sox2 and Nestin was decreased time dependently in differentiated cells (HFF, keratinocyte, and CD34+). This decrease was associated with an increase of differentiated markers at day 28 such as GFAP (68.51±11.87 for HFF-NC, 59.55±9.12 for Keratinocyte NC, and 61.70±1.48 for CD34+-NC). A high percentage for βIII-tubulin positive cells was generated from differentiated NSLCs generated from HFF (57.83±4.49) as compared to βIII-tubulin positive cells generated from Keratinocytes (23.27±2.91) and CD34+ cells (39.15±7.99) (Table 24)
  • TABLE 24
    The percentage of cells stained positive for neural stem cell markers and neuronal
    lineage markers in hNPCs (Lonza) and transfected keratinocytes, HFF, and CD34+ cells
    with pMsi1/Ngn2/MBD2. Transfected cells (NSLCs) were cultured in Proliferation
    medium or differentiation medium for 28 days at 37° C., 5% CO2, 5% O2. The
    percentage of immunopositive cells (Sox2, Nestin, GFAP, S100 beta, and βIII-tubulin)
    was determined by Cellomics ™ and represented as mean ± SD (n = 5).
    Proliferation 14 days 28 days
    % positive cells conditions differentiation differentiation
    hNPC Sox2 96.23 ± 0.51  59.05 ± 3.01  41.43 ± 6.05 
    Nestin 41.47 ± 0.23  10.77 ± 4.78  16.14 ± 7.41 
    S100β 37.38 ± 7.85  49.51 ± 2.39  n.d.
    βIII-tubulin 2.34 ± 0.43 11.54 ± 4.03  23.34 ± 4.77 
    GFAP 1.16 ± 0.14 23.42 ± 2.51  48.04 ± 8.30 
    HFF-NC Sox2 93.28 ± 0.53  79.48 ± 0.54  52.06 ± 9.07 
    Nestin 29.29 ± 4.72  1.15 ± 0.46 2.18 ± 1.96
    S100β 13.51 ± 0.28  80.75 ± 3.50  79.38 ± 10.62
    βIII-tubulin 3.91 ± 0.33 42.16 ± 15.07 57.83 ± 4.49 
    GFAP 8.41 ± 0.73 59.66 ± 11.48 68.51 ± 11.87
    Keratinocyte-NC Sox2 96.55 ± 1.01  76.93 ± 5.13  63.11 ± 8.54 
    Nestin 40.10 ± 8.41  2.67 ± 1.61 3.57 ± 0.48
    S100β 13.58 ± 4.97  76.6 ± 9.72 74.75 ± 11.21
    βIII-tubulin 6.42 ± 2.94 20.58 ± 8.34  23.27 ± 2.91 
    GFAP 9.36 ± 0.34 43.43 ± 2.44  59.55 ± 9.12 
    CD34+-NC Sox2 95.49 ± 2.6  81.18 ± 1.24  63.46 ± 5.14 
    Nestin 51.68 ± 14.27 12.64 ± 1.27  8.46 ± 4.6 
    S100β 30.1 ± 1.03 72.40 ± 4.5  79.57 ± 8.52 
    βIII-tubulin 5.82 ± 2.08 25.04 ± 19.95 39.15 ± 7.99 
    GFAP 13.99 ± 5.48  51.79 ± 13.68 61.70 ± 1.48 
    n.d. = not determined;
    ± = standard deviation
    CD34+-NC: neuronal cells generated after differentiation of NSLCs generated from CD34+ cells. Each data point represents the analysis of at least 1000 cells from at least 8 images.
  • The % of Sox2 positive cells decreased faster, the % of Nestin positive cells generally decreased slower, and the % of cells expressing one of the differentiation markers (sloop, βIII-tubulin, GFAP) generally increased slower in hNPCs than in the NSLCs during differentiation. Out of the three types of created NSLC lines, the % of cells expressing one of the differentiation markers (sloop, βIII-tubulin, GFAP) generally increased slowest in NSLCs created from keratinocytes and fastest in NSLCs created from HFFs.
  • This study indicates that NSLCs can be created from keratinocytes and CD34+ blood cells, and these cells share morphology and markers similarly to NSLCs generated from HFF. Similarly to hNPCs, NSLCs created from keratinocytes, CD34+ cells, and HFFs had a tendency to differentiate more towards an astrocyte lineage than a neuronal lineage (except NSLCs created from HFFs had an almost similar number of βIII-tubulin positive and GFAP positive cells) as shown by the high percentage of GFAP positive cells during differentiation, which was confirmed by S100beta staining. However, the proportion of astrocyte and neuronal cells generated from hNPCs was lower in same culture conditions, indicating that NSLCs generated from HFF, Keratinocytes, and CD34+ cells can give rise to a higher number of neuronal and astrocyte cells as compared to hNPCs. NSLCs, whether created from HFFs, Keratinocytes or CD34+ cells (or potentially even some other cell), are tripotent cells and possess the capacity to differentiate to neurons, astrocytes, and oligodendrocytes similarly to hNPCs. However, RT-PCR and immunohistochemistry analysis of transfected ADSCs did not reveal any significant expression of neural stem cell genes, indicating a need to optimize conditions for turning ADSCs to NSLCs or to investigate the effect of others neurogenic factors that could turn these into NSLCs.
    • Example X Fabrication 3D Extracellular Matrix (CDM)
  • Fibroblast cells were cultured in DMEM medium in the presence of 10% FCS as described in Example I, followed by seeding onto 12-well plates pre-coated with laminin (10 μg/ml) at a concentration of 2×106 cells/ml in defined CDM Medium consisting of a 3:1 ratio of Dulbecco's modified Eagle medium (DMEM, high glucose (4.5 g/L) with L-glutamine and sodium pyruvate) and Ham's F-12 medium supplemented with the following components: EGF (4.2×10−10M), bFGF (2.8×10−10M), ITS (8.6×10−5M), dexamethasone (1.0×10−7M), L-ascorbic acid phosphate magnesium salt n-hydrate (3.2×10−4M), L-3,3′,5-triiodothyronine (2.0×10−10M), ethanolamine (10−4M), GlutaMAX™ (4×10−3M), glutathione (3.3×10−6M), and 1% penicillin/streptomycin/amphotericin B. By culturing the fibroblast cells at hyperconfluent density in this completely chemically defined medium causes them to enter a high synthetic phase with a slow-down in proliferation, leading to the production of a living tissue equivalent (LTE) consisting of multiple layers of fibroblasts within de novo 3D extracellular matrix (CDM) that is completely synthesized by the fibroblasts themselves.
  • Trans-Differentiation and Reprogramming of Cells within CDM
  • Day 14 CDM samples were treated with cytochalsin B (10 μg/ml, Calbiochem), with the concentration of cytochalsin B reduced from 10 μg/ml to 0 μg/ml (none) over 5 days while at the same time switching the medium from CDM Medium to NbActive medium. Samples were cultured for another 12 days at 37° C., 5% CO2, and the medium was changed every day. Samples were fixed to perform immunohistochemistry as described previously to detect Neuronal markers. The following antibodies were used: mouse anti-nestin 647 (1:100, BD) and anti-βIII-tubulin (1:200, Neuromics). No clear morphology change of the cells was observed within the CDM and the immunohistochemical analysis failed to detect βIII-tubulin positive cells. Thus, inducing the trans-differentiation of cells using only cytochalasin B and chemically-defined neural medium was not sufficient to reprogram the cells.
  • Next, Day 6 CDM samples grown in LAS pre-coated plates at 37° C. and 5% CO2, were exposed simultaneously to cytocahlasin B (10 μg/ml) over 5 days, histone deacetylation inhibitor (VPA, 4 mM, Calbiochem) and inhibitor of DNA methylation (5-Azacytidine, 5 μM, Sigma). Four days later, the medium was changed to differentiation medium consisting of a 3:1 ratio of CDM medium without the presence of EGF and NbActive medium (BrainBits™) supplemented with NT-3 (20 ng/ml, Peprotech) and BDNF (20 ng/ml, Peprotech). The ratio of the differentiation medium was increased gradually day after day until reaching 100% of complete differentiation medium. After two weeks of treatment, cells were fixed for immunohistochemical analysis to investigate the identity of the cells. FIG. 18 shows immunostained cells with βIII-tubulin at day 7, indicating the de-differentiation of fibroblast cells to neurons. However, one week later, these trans-differentiated cells reverted back to fibroblast cells and βIII-tubulin expression was lost (FIG. 8). The loss of morphology and βIII-tubulin expression after withdrawal of the priming agents indicate that complete conversion to functional and stable reprogrammed cells did not occur.
  • Next CDM was treated with VPA (4 mM), 5-Aza (5 μM) and cytochalasin B (10 μg/ml) as above. After 2 days of chemical treatment, fibroblast cells within the CDM were transfected with DNA using Lipofectamine reagent (Invitrogen) as per the manufacturer's protocol. 15 μg of the eukaryotic DNA expression vectors pCMV6-XL5-Pax6, pCMV6-XL5-Msi1 and pCMV6-XL4-Ngn2 (Origene) were used to transfect the cells. 24 hours later, the media was changed to Neural Progenitor Basal Medium (Lonza) supplemented with Noggin (50 ng/ml), EGF (20 ng/ml), and bFGF (20 ng/ml), and the cells were cultured at 37° C., 5% CO2 and 5% O2, and the medium was changed every day. At day 6, differentiation was initiated by adding gradually NBActive medium (BrainBits™) supplemented with NT-3 (20 ng/ml, Peprotech), all-trans-retinoic acid (ATRA, 5 μM, Spectrum), BDNF (20 ng/ml, Peprotech), and bFGF (40 ng/ml, Peprotech). To characterize the reprogrammed cells, immunohistochemical analysis and RT-PCR was performed at various time points according to the methods described in Example II using primers for nestin, βIII-tubulin, GFAP, MAP2b, and ACHE. In agreement with previous studies, un-transfected cells and cells transfected with Pax6 did not expressed genes specific for neuronal lineages (Table 25). On the other hand, following transfection with Msi1, levels of nestin and ACHE were increased to 4-fold and 8-fold, respectively, and this expression was maintained over the 12-day period. Also levels of GFAP mRNA was enhanced time dependently by approximately 14 times. Likewise, the same pattern was observed in Ngn2 transfected cells. While expression of βIII-tubulin and MAP2b were modestly increased following transfection with one neurogenic transcription factors the regulation of gene expression after transfecting the cells with two neurogenic factors, Msi1 or Ngn2 with Pax6, did not further increase the expression of neuronal genes. FIG. 19 shows that expression of these genes was enhanced when the cells were transfected with Msi1 and Ngn2, with βIII-tubulin enhanced to almost 6-fold at day 12.
  • TABLE 25
    RT-PCR analysis of relative expression of neuronal precursor cell markers such as nestin, βIII-tubulin, MAP2b, ACHE, and
    GFAP after transfection of fibroblast cells with pCMV6-XL5-Msi1, pCMV6-XL4-Ngn2, pCMV6-XL5-Pax6, and
    pCMV6-XL5-MBD2. After 24 h following transfection, CDM I Medium was changed and cells were cultured in proliferation
    medium (NPBM, Lonza) supplemented withEGF (20 ng/ml, Peprotech) and bFGF (20 ng/ml, Peprotech) for one week.
    Differentiation was induced by changing the medium to NbActive (BrainBits ™) supplemented with NT-3 (20 ng/ml),
    bFGF (20 ng/ml), ATRA (5 μM) and Forskolin (10 μM). Cells were incubated at 37° C., 5% CO2, 5% O2 for 12 days.
    Relative expression of Msi1, Ngn2, Pax6, nestin, βIII-tubulin, ACHE, MAP2b and GFAP in NSLCs and NLCs was
    increased after transfection with both transcription factors Ngn2 and Msi1 with MBD2 as the DNA demethylator.
    COL5A2 FBN2 NES MAP2 TUBB3 SOX2 ACHE GFAP
    Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std.
    Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev.
    #1, +CytoB, 1.00 0.07 1.00 0.01 1.00 0.04 1.00 0.05 1.00 0.05 1.00 0.05 1.00 0.10 1.00 0.11
    Control
    #2, −CytoB, 1.00 0.03 1.00 0.08 1.00 0.00 1.00 0.09 1.00 0.09 1.15 0.80 1.01 0.18 1.00 0.01
    Control
    #3, +CytoB, 0.85 0.04 0.75 0.02 0.60 0.01 0.29 0.01 0.44 0.00 22.39 5.26 0.81 0.19 10.14 0.15
    Msi1,
    GAD45b
    #4, −CytoB, 0.87 0.03 1.81 0.09 1.84 0.04 2.31 0.00 2.09 0.03 20.28 5.33 1.99 0.74 6.03 0.05
    Msi1,
    GAD45b
    #5, +CytoB, 0.84 0.04 0.77 0.03 0.44 0.00 0.24 0.00 0.36 0.01 470.84 13.43 0.63 0.05 103.22 0.80
    Ngn2,
    GAD45b
    #6, −CytoB, 0.75 0.07 1.97 0.02 1.83 0.00 4.40 0.16 2.02 0.10 789.33 60.35 1.70 0.13 110.48 4.90
    Ngn2,
    GAD45b
    #7, +CytoB, 0.74 0.12 1.08 0.00 0.89 0.01 0.51 0.00 0.63 0.04 1.64 0.98 0.86 0.12 2.49 0.21
    Pax6,
    GAD45b
    #8, −CytoB, 0.66 0.04 2.41 0.09 2.70 0.03 4.96 0.30 3.48 0.07 0.46 0.33 2.97 1.04 0.43 0.09
    Pax6,
    GAD45b
    #9, +CytoB, 0.14 0.01 0.28 0.01 1.30 0.03 4.07 0.11 0.84 0.00 54768.27 6709.56 0.81 0.24 3391.96 64.63
    Msi1, Ngn2,
    GAD45b
    #10, −CytoB, 0.12 0.00 0.73 0.03 5.28 0.21 50.84 1.23 4.93 0.28 17400.66 822.88 3.58 0.10 1255.76 5.27
    Msi1, Ngn2
    GAD45b
    #11, +CytoB, 0.10 0.00 0.26 0.01 1.11 0.01 3.69 0.09 0.76 0.00 55588.41 1331.20 0.55 0.14 2849.96 261.51
    Msi1, Ngn2
    MBD2
    #12 , −CytoB, 0.44 0.01 1.47 0.06 5.49 0.14 47.30 0.11 5.50 0.31 14587.46 789.19 3.90 0.13 1424.04 39.29
    Msi1, Ngn2
    MBD2
    #13, +CytoB. 1.11 0.04 1.09 0.06 0.92 0.08 0.68 0.01 0.82 0.03 63.93 2.81 1.19 0.17 17.43 1.86
    GAD45b
    #14 , −CytoB, 0.94 0.01 2.22 0.00 2.82 0.02 6.49 0.30 4.01 0.05 6.12 0.61 2.34 0.17 1.42 0.10
    GAD45b
    #15, +CytoB, 0.83 0.00 0.83 0.05 0.36 0.01 0.16 0.01 0.36 0.00 3.42 3.74 0.63 0.37 2.18 0.12
    MBD2
    #16, −CytoB, 0.68 0.02 1.55 0.04 1.57 0.05 1.47 0.01 2.00 0.00 0.52 0.29 1.45 0.15 0.55 0.04
    MBD2
    #17, +CytoB, 1.10 0.01 1.16 0.03 1.37 0.01 1.12 0.06 0.86 0.06 5.59 1.48 1.07 0.27 1.70 0.46
    Msi1, Ngn2
    #18, −CytoB, 0.93 0.04 2.52 0.10 3.48 0.01 9.01 0.02 4.55 0.18 1.78 1.46 3.83 0.42 0.59 0.01
    Msi1, Ngn2
    #19, +CytoB, 0.20 0.03 0.36 0.01 1.25 0.05 6.68 0.31 0.72 0.02 66592.29 3481.89 2.57 0.03 4450.08 131.85
    Msi1, MBD2
    #20, −CytoB, 0.12 0.00 0.64 0.03 4.70 0.22 77.51 0.11 4.12 0.11 19128.03 1542.00 8.14 0.13 999.22 24.75
    Msi1, MBD2
    #21, +CytoB, 0.17 0.01 0.28 0.00 1.16 0.04 5.73 0.06 0.62 0.00 67945.51 3000.74 2.15 0.04 4736.83 11.92
    Ngn2, MBD2
    #22, −CytoB, 0.17 0.00 0.78 0.03 4.32 0.08 68.89 5.26 4.01 0.04 16570.91 92.96 7.04 0.53 1427.13 13.19
    Ngn2, MBD2
    #23, +CytoB, 0.71 0.05 0.79 0.06 0.87 0.01 0.63 0.06 0.67 0.04 2.86 0.70 1.08 0.08 2.08 0.11
    Msi1
    #24, −CytoB, 0.66 0.04 1.92 0.17 2.03 0.02 2.77 0.02 2.68 0.02 0.32 0.12 1.85 0.65 0.58 0.04
    Msi1
  • Same pattern of gene expression was observed when transfecting the cells with three transcription factors (Msi1, Ngn2, and Pax6), but the expression was less pronounced than in cells transfecting with just Msi1 and Ngn2. In terms of immunohistochemical analysis after the 12 days of the transfection, cells displayed neuronal markers after transfection with Msi1 or Ngn2, as indicated by the expression of nestin and MAP2b (FIG. 9). Cells transfected with pCMV-XL-PAx6 did not stain for Nestin and MAP2b.
  • This study shows that transfecting cells within CDM with only one neurogenic factor (Msi1 or Ngn2) induces morphological changes and expression of one or more markers of neural stem cells and neuronal cells. Since the reprogrammed cells expressed a key neurogenic factor, a neuronal precursor marker, and a mature neuronal marker at low percentage (10%), this suggests that cells within the CDM were transformed to NSLCs and then started to differentiated through the various phases of the neuronal determination and differentiation program induced in neural stem cells.
    • Example XI
  • Gene Expression Analysis of Reprogrammed Cells within CDM
  • This study was designed to test the effect of transfecting cells with Msi1 and Ngn2 in the presence of MBD2 in the reprogramming process. Cells were transfected after two days of pre-treatment with cytocahlasin B with the DNA expression vectors using Lipofectamine reagent as described in Example X. 15 μg of eukaryotic DNA expression vectors pCMV6-XL5-Musashi or pCMV6-XL4-Ngn2, and pCMV6-XL5-MBD2 (Origene), were used to co-transfect cells. After 24 hours, the media was changed to CDM:Neural Progenitor Maintenance Medium (1:1)supplemented with Noggin (50 ng/ml), EGF (20 ng/ml), and bFGF (20 ng/ml). Medium was changed every day by increasing the percentage of NPBM and decreasing CDM medium. Cells were cultured for 6 days at 372C, 5% CO2 and 5% O2. After one week, differentiation was initiated by gradually supplementing the NPBM Medium with NT-3 (20 ng/ml, Peprotech), all-trans-retinoic acid (ATRA, 5 μM, Spectrum), BDNF (20 ng/ml, Peprotech), and bFGF (40 ng/ml, Peprotech). Samples were collected at the end of the study (day 14) and data were analyzed by gene array to identify genes that were reproducibly found to be specific for neuronal lineages.
    • Gene Expression Analysis
  • Gene expression analysis on 8 samples was performed as previously described in Example I with the customized Neuronal Markers 2 TLDA In order to identify the expression of genes related to neural stem cells, neuronal cells and glial cells, and growth factors expressed by the cells after transfection. The expression of oligodendrocyte genes, such as NKx2.2, olig2, and MAG was increased by Msi1 and Ngn2; however, the increased was more pronounced by Msi1 as compared to Ngn2 (Table 26). Two markers for astrocytes (GFAP and AQP4) were highly expressed after transfection with Msi1 and Ngn2 in the presence of the DNA demethylator MBD2. Interestingly, several markers of early neuronal cells were enhanced; 12 days after transfection, TDLA data revealed increases in specific markers for interneurons, such as somatostatin and calbindin1. Doublecortin (DCX), which is expressed by migrating immature cells during development, and acetylcholine (ACHE), an early marker of neuronal cells, were highly expressed in reprogrammed cells (Table 26). Transfection with Msi1 or Ngn2 increased the expression of dihydropyrimidinase-like 3 (DPYSL3), an early marker of newborn neurons to five-fold with Msi1 and seven-fold with Ngn2. Expression of microtubule-associated protein 2 (MAP2), an essential marker for development and maintenance of early neuronal morphology, and neuronal cell adhesion molecule (NCAM) were highly expressed with Msi1 and Ngn2. The expression of enolase-2, a marker of mature neurons, was 20-fold enhanced by Msi1 and Ngn2. Member of the NeuroD family NeuroD1 was highly expressed after transfection with Msi1 to 84.22 fold and to 34.27 by Ngn2. Gene expression of growth factors such as IGF-1, IGF-2, NPY and CSF-3 was enhanced following transfection with Msi1 or Ngn2. The expression of VEGF and GDNF genes were increased to almost five-fold and seven-fold by Msi1 and Ngn2, respectively. However in transfected cells, the expression of BDNF, EGF, and bFGF were not activated and even down-regulated as compared to untransfected cells. The expression of growth associated protein (GAP-43), a growth- and regeneration-associated marker of neurite extension, and expression of netrin, implicated in neuronal development and guidance, were highly expressed in transfected cells (Table 26). Expression of receptors for growth and neurotrophic factors was increased, such as type III receptor tyrosine kinase, Neurotrophic tyrosine kinase receptor, and neurotrophic tyrosine kinase. The fibroblast-specific markers vimentin and fibronectin were down-regulated in the reprogrammed cells.
  • Transfection of HFF with only Msi1 and Ngn2 in the presence of MBD2 increased the expression of glial cells and neuronal cells markers.
  • TABLE 26
    Gene array of CDM transfected with pMsi1 and pNgn2 following the pre-treatment
    with cytochalasin B (10 μg/ml), VPA (4 mM) and 5-Azacytidine (5 μM). Transfected cells were
    cultured in differentiation medium (NbActive, BrainBits ™) supplemented by ATRA (5 μM), bFGF
    (40 ng/ml) and BDNF (20 ng/ml).
    Relative Relative
    Expression Expression
    Symbol Common name and description Company Gene ID Msi1 Ngn2
    Astrorytes and oligodendrocytes markers
    -NKx2-2 -Markers for oligodendrocyte progenitors NM_002509.2 1.72 10.19
    -OLIG2 -Oligodendrocyte lineage transcription factor 2 NM_005806.2 1.72 1.52
    -MBP -Myelin-basic protein NM_001025090.1 1.72 1.52
    -GFAP -Glial fibrillary acidic protein NM_002055.4 6.04 2.41
    -AQP4 -Aquaporin 4 NM_001650.4 1.72 1.52
    -D102 -Deiodinase iodothyronine type II NM_013989.3 8.29 10.61
    NC markers
    -SST -Somatostatin, specific marker for intemeurons NM_001048.3 very high very high
    -CALB1 -Calbindin 1, interneuron marker NM_004929.2 1.72 1.52
    -Tubulin1A -Are necessary for axonal growth NM_006009.2 0.63 0.76
    -NES -Precursor neurons (nestin) NM_006617.1 2.42 2.86
    -DCX -An early neuronal marker (Doublecortin) NM_178151.1 1.72 1 52
    -ACHE -Acctylcholinesterase, marker of early neuronal NM_015831.2 10.68 20.37
    development
    -ENO2 -A marker for neurons cells, enolase NM_001975.2 0.55 0.54
    -NEUROD1 -Neural marker expression gradually increased NM_002500.2 1.72 1 50
    from neural precursor to fully differentiated
    neuron
    -DPYSL3 -Dihydropyrimidinase-like 3, maker of NM _001387.2 0.62 0.71
    immature neurons
    -MAP2 -Microtubule-associated protein 2, essential for NM_0023743 1.99 1.70
    development of early neuronal morphology and
    maintenance of adult neuroral morphology
    -NCAM -Neural cell adhesion molecule 1 NM_18135.3 3.11 5.72
    -CEND1 Cell cycle exit & neuronal differentiation, early NM _0165643 6.68 8.28
    marker of proliferating precursor cells that will
    differentiate to neurons
    Neuroregeneration and survival genes
    -FGF2 -Fibroblast growth factor NM_002006.4 1.19 1.26
    -EGF -Epidermal growth factor, Hs00153l81_m1 28.37 52.13
    -IGF-1 -Insulin growth factor-1, NM _000618.2 0.82 1.03
    -IGF-2 -Insulin growth factor-2 NM_0000612.3 0.99 1.21
    -CSF3 -Granulocyte colony-stimulating factor NM_2219.1 very high very high
    -BDNF - Brain derived growth factor, neurogenesis NM_199231.1 8.54 7.84
    -GDNF - Glial derivcd neurotrophic factor NM_000614.2 0.63 0.91
    -CNTF - Ciliary neurotrophic factor NM_001025366.1 3.80 14.92
    -VEGF -Vascular endothelial growth factor NM_130850.1 6.28 7.22
    -BMP-4 -Bone morphogenetie protein 4 NM_002253.1 1.17 1.34
    -KDR -Type III receptor tyrosine kinase) NM_006180.3 113.85 43.87
    -NTRK2 -Neurotrophic tyrosine kinase recepto (TrkB) NM_000905.2 0.02 0.02
    -NPY -Neuropeptide Y NM_009905.2 33.39 1.52
    -NTF-5 -Neurotrophin 5 NM_006179.3 4.43 5.93
    -PIK3CG -phosphoinositide-3-kinase, NM_002649.2 1.70 1.50
    -STAT3 -Signal transduction transcription 3 NM_213662.1 3.15 2.24
    -Gap43 -Growth associated protein 43 NM_002045.2 1.82 2.98
    -NTN1 -Netrin1, implicated in neuronal development NM_004822.2 0.50 0.29
    and guidance
    -NTRk2 -Neurotrophic tyrosine kinase, receptor, type 2 NM_006180.3 0.02 0.02
    -LICAM -L1 cell adhesion molecule, associated with NM_024003.1 0.08 0.11
    regenerating axons
    -LIMK1 -LIM domain kinase 1 NM_ 002314.2 2.88 2.96
    -Vimentin -Radial glia and fibroblast marker NM_003380.2 0.21 0.20
    -Fibronectin -fibronectin is a marker for fibroblasts NM_212474.1 0.15 0.14
    • Example XII
  • Reprogramming of Cells within CDM by Lipofectamine and Nucleofection
  • This study was designed to improve transfection of CDM by combining lipofectamine and nucleofection and using two vectors pCMV6-XL5-Msi1 and pCMV6-XL4-Ngn2 individually or in combination together with pCMV-XL5-MBD2. Cells within Day 4 CDM were lipotransfected for 6 hours with Msi1/MBD2, Ngn2/MBD2 or Msi/Ngn2/MBD2 after 2 days of pre-treatment with or without cytochalasin B. In parallel, transfection was performed on fresh HFFs after the 6 hours using Nucleofection as described in Example II, and transferred on top of the CDM when the lipofectamine media was changed to fresh CDM medium. After 24 hours, the medium was changed to Neural Progenitor Basal Medium (NPBM, Lonza) with the presence of Noggin (50 ng/ml, Peprotech), recombinant hFGF (20 ng/ml, Peprotech), and recombinant hEGF (20 ng/ml, Peprotech). Differentiation was induced at day 7, by adding NSA-A differentiation medium (StemCell Technologies) for 21 days.
    • Gene Expression Analysis
  • Samples were collected at 8, 15, and 21 days to evaluate the nature of newly formed cells by analyzing the expression of several neuronal marker genes using RT-PCR according to the methods previously described in Example I. As shown in Table 27, cells transfected with one neurogenic transcription factor (Msi1 or Ngn2) express high levels of nestin and βIII-tubulin at day 8. The same pattern of expression was observed at day 15 and 21, while the expression was slightly decreased in the absence of cytochalasin B in cells transfected with Ngn2. The expression of all genes, except the mature neuronal marker MAP2b, were remarkably increased in cells transfected with both neurogenic transcription factors. The upregulation of these genes was slightly reduced in the absence of cytochalasin B, indicating its role in enhancing reprogramming.
  • TABLE 27
    RT-PCR analysis of relative expression of neuronal stem cell markers such as nestin, Sox2, and GFAP after transfection of fibroblast cells
    within the CDM with different combinations with or without the co-treatment with cytochalasin B. Relative expression of Sox2, nestin, and
    GFAP in NSLCs was increased after transfection with both transcription factors Ngn2 and Msi1 with MBD2 as the DNA demethylator.
    MSI1 NGN2 TUBB3 GFAP NES MAP2
    Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std. Rel. Std.
    Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev.
    #1 Day8 CDM −CytoB Control 1.11 0.21 1.33 0.20 1.10 0.02 0.91 0.02 1.18 0.09 0.91 0.02
    #2 Day8 CDM −CytoB Control 1.11 0.17 0.65 0.08 0.92 0.06 0.91 0.11 0.82 0.01 0.91 0.11
    #3 Day8 CDM −CytoB Control 0.83 0.01 0.71 0.86 0.99 0.04 1.21 0.00 1.03 0.00 1.21 0.00
    #4 Day8 CDM +CytoB Control 7.42 0.35 1.52 0.53 1.32 0.16 0.44 0.06 1.04 0.02 0.44 0.06
    #5 Day8 CDM +CytoB Control 7.01 0.42 2.14 0.58 1.23 0.07 0.62 0.05 1.02 0.06 0.62 0.05
    #6 Day8 CDM +CytoB Control 9.15 0.48 0.76 0.08 0.40 0.05 0.59 0.14 0.34 0.16 0.59 0.14
    #7 Day15 CDM −CytoB Control 1.45 0.07 1.53 0.33 1.32 0.01 0.90 0.07 1.31 0.03 0.90 0.07
    #8 Day15 CDM −CytoB Control 0.79 0.02 2.01 1.49 0.91 0.03 1.14 0.16 0.91 0.01 1.14 0.16
    #9 Day15 CDM −CytoB Control 0.87 0.04 0.64 0.72 0.84 0.08 0.98 0.15 0.84 0.01 0.98 0.15
    #10 Day15 CDM +CytoB Control 1.27 0.14 0.99 0.66 1.70 0.21 0.36 0.02 1.08 0.08 0.36 0.02
    #11 Day15 CDM +CytoB Control 1.39 0.04 0.97 0.65 2.65 0.38 0.44 0.06 1.97 0.30 0.44 0.06
    #12 Day15 CDM +CytoB Control 1.09 0.21 0.49 0.46 1.32 0.14 0.47 0.15 2.45 0.15 0.47 0.15
    #13 Day21 CDM −CytoB Control 1.21 0.00 1.06 0.06 1.10 0.01 0.86 0.16 1.07 0.01 0.86 0.16
    #14 Day21 CDM −CytoB Control 0.97 0.09 2.16 0.77 0.96 0.01 1.11 0.10 0.94 0.01 1.11 0.10
    #15 Day21 CDM −CytoB Control 0.86 0.02 1.01 1.27 0.94 0.00 1.08 0.26 0.99 0.04 1.08 0.26
    #16 Day21 CDM +CytoB Control 1.41 0.21 1.29 1.64 2.46 0.07 0.88 0.22 1.58 0.05 0.88 0.22
    #17 Day21 CDM +CytoB Control 2.24 0.00 0.35 0.01 2.23 0.03 0.55 0.16 1.57 0.02 0.55 0.16
    #18 Day21 CDM +CytoB Control 2.18 0.14 0.77 0.06 2.29 0.12 0.54 0.04 1.47 0.04 0.54 0.04
    #19 Day8 CDM −CytoB 694.16 18.10 0.51 0.05 1.46 0.04 2.18 0.13 1.02 0.03 2.18 0.13
    Msi1/MBD2
    #20 Day8 CDM −CytoB 2.38 0.29 4106.88 48.57 0.46 0.02 1.88 0.14 0.99 0.02 1.88 0.14
    Ngn2/MBD2
    #21 Day8 CDM −CytoB 365.04 6.71 2702.81 55.69 4.44 0.02 2.95 0.38 5.11 0.05 2.95 0.38
    Msi1/Ngn2/MBD2
    #22 Day8 CDM +CytoB 1262.00 63.21 0.75 0.91 0.54 0.03 2.48 0.11 1.16 0.05 2.48 0.11
    Msi1/MBD2
    #23 Day8 CDM +CytoB 2.34 0.20 10963.51 19.89 0.53 0.00 2.27 0.26 1.00 0.06 2.27 0.26
    Ngn2/MBD2
    #24 Day8 CDM +CytoB 869.15 65.33 6401.28 87.12 4.58 0.01 3.65 0.13 3.15 0.00 3.65 0.13
    Msi1/Ngn2/MBD2
    #25 Day15 CDM −CytoB 41.07 1.74 2.58 0.36 1.43 0.05 0.58 0.06 1.34 0.07 0.58 0.06
    Msi1/MBD2
    #26 Day15 CDM −CytoB 0.73 0.02 2192.64 15.74 0.95 0.08 1.01 0.09 0.99 0.03 1.01 0.09
    Ngn2/MBD2
    #27 Day15 CDM −CytoB 45.59 2.33 3318.42 51.51 5.32 0.08 3.80 0.01 4.32 0.01 4.80 0.01
    Msi1/Ngn2/MBD2
    #28 Day15 CDM +CytoB 106.34 4.43 4.90 1.70 1.47 0.01 0.57 0.10 1.19 0.03 0.57 0.10
    Msi1/MBD2
    #29 Day15 CDM +CytoB 1.09 0.11 6715.95 505.86 1.30 0.05 0.70 0.17 1.18 0.07 0.70 0.17
    Ngn2/MBD2
    #30 Day15 CDM +CytoB 46.77 0.76 2816.33 90.83 5.76 0.02 4.52 0.09 3.60 0.03 5.52 0.09
    Msi1/Ngn2/MBD2
    #31Day21 CDM +CytoB 22.94 1.09 10.09 2.72 1.08 0.07 0.58 0.08 1.17 0.02 0.58 0.08
    Msi1/MBD2
    #32 Day21 CDM −CytoB 0.78 0.02 4450.56 255.75 1.00 0.03 0.75 0.21 1.09 0.03 0.75 0.21
    Ngn2/MBD2
    #33 Day21 CDM −CytoB 24.02 0.86 2509.95 64.00 5.18 0.05 4.74 0.16 4.37 0.06 3.74 0.16
    Msi1/Ngn2/MBD2
    #34 Day21 CDM +CytoB 54.17 1.41 8.31 3.32 1.42 0.05 0.70 0.22 1.71 0.02 0.70 0.22
    Msi1/MBD2
    #35 Day21 CDM +CytoB 1.19 0.15 1180.19 27.29 1.21 0.06 1.03 0.34 1.31 0.04 1.03 0.34
    Ngn2/MBD2
    #36 Day21 CDM +CytoB 81.66 1.34 7789.96 345.72 5.24 0.05 5.84 0.10 4.37 0.05 5.84 0.10
    Msi1/Ngn2/MBD2
    • Immunohistochemical Analysis
  • Samples were collected at 4, 8, 14, and 21 days to evaluate the nature of any reprogrammed cells by analyzing the expression of several neuronal markers using immunohistochemical analysis according to the methods previously described in Example I. The immunohistochemical analysis at various time points revealed that within the first 8 days the expression of nestin was induced in a large proportion of cells and decreased time-dependently after inducing the differentiation (FIG. 10).
  • This study indicates that upon transfecting the cells with one or two neurogenic genes in the presence of cytochalasin B and MBD2, reprogrammed cells were stable in culture, responded to environmental changes (proliferation vs differentiation), and expressed neuronal markers for at least 24 days in culture.
    • Example XIII Telomerase Activity of NSLCs
  • Telomerase is active in neural precursor cells and suggest that its regulation is an important parameter for cellular proliferation to occur in the mammalian brain (Caporaso G L et, 2003). This study was performed to evaluate telomerase activity in cell extracts of adherent NSLCs (NSLCs cultured on laminin-coated plates) as well as NSLCs in floating neurospheres (NSLCs cultured in plates with a low-bind surface) at early (P7) and late passage (P27). The telomerase activity of the 4 samples was measured by the PCR-based telomere repeat amplification protocol (TRAP) using the TRAPeze® Telomerase Detection Kit (Chemicon). Briefly, the cells were grown in 24-well plates, washed in PBS, and homogenized for 30 min on ice in buffer containing 10 mM Tris-HCl, pH 7.5, 1 mM MgCl2, 1 mM EGTA, 0.1 mM Benzamidine, 5 mM β-mercaptoethanol, 0.5% CHAPS and 10% Glycerol (1×CHAPS Lysis Buffer, provided in kit) and RNase Inhibitor. The samples were spun down and the protein concentration of the supernatant was determined using the BCA Assay. 900 ng of protein from each cell extract was added directly to the TRAP reaction mixture containing TRAP reaction buffer, dNTPs, template substrate (TS) primer, TRAP primer mix and Taq polymerase. The reaction mixtures were incubated at 30° C. for 30 minutes for template synthesis, followed by a PCR procedure (95° C./15 min for initial denaturation, 94° C./30 sec, 59° C./30 sec, 72° C./1 min for 32 cycles) for amplification of the extended telomerase products. To detect telomerase activity, polyacrylamide gel electrophoresis (PAGE) was performed for the reaction products on a 10% non-denaturing TBE gel. After electrophoresis, the gel was stained with SYBR® Green I Nucleic Acid Gel Stain for 30 minutes, followed by image capture using a Gel-Documentation System (Alpha Innotech).
  • All 4 samples were telomerase positive (as indicated by the TRAP product ladder) as shown in FIG. 11. As expected, the Heat-treated control (ΔH) showed no Telomerase activity (Negative Control). A 36 bp internal control band (S-IC) is used to monitor PCR amplification (to distinguish false-negative results). This S-IC band was observed for all samples except for the test samples. This may have been due to the excessively high telomerase activity in the test samples; amplification of the TRAP products and the S-IC control band are semi-competitive. All controls gave expected results (No TRAP products for CHAPS ctrl, and TRAP ladder of products for the positive control cells and the TSR8 control).
    • Example XIV Tumor Formation Assay
  • Malignantly transformed cells show reduced requirements for extracellular growth promoting factors, are not restricted by cell-cell contact, and are often immortal. Anchorage-independent growth and proliferation is one of the hallmarks of malignant transformation, which is considered the most accurate and stringent in vitro assay for detecting malignant transformation of cells.
  • Adherent and neurosphere NSLCs at early and late passage (P7 and P25), as well as normal human neuroprogenitor cells (hNPCs), were investigated for the anchorage-independent growth. HFFs were used as a negative control and cervical carcinoma HeLa cells were used as a positive control. Cells were sedimented by centrifugation at 150×g for 3 min at room temperature (RT). The assay was performed using the CytoSelect™ 96-well cell transformation assay (CellBiolabs). The base agar layer (1.2%) was dissolved in 2×DMEM/20% PBS solution and 50 μl of the agar solution was added to the plate and incubated for 30 min at 4° C. to solidify. Prior to adding the cell agar layer, the plate was allowed to warm up for 15 minutes at 37° C. The cells were resuspended at different density (20.000 and 5000 cells/well), except the hNPCs were resuspended only at 5000 cells/well due to a lack of enough cells. The cells were mixed with the 1.2% agar solution, 2×DMEM/20% PBS, and cell suspension (1:1:1), and 75 μl of the mixture was transferred to wells already containing the solidified base agar layer, and was then placed in 4° C. for 15 minutes to allow the cell agar layer to solidify. 100 μl of proliferation medium (StemCell Technologies) was added and the plate was incubated for 8 days at 37° C. and 5% CO2 before being solubilized, lysed and detected by the CyQuant™ GR dye in a fluorescence plate reader. The fluorescence measurement was performed using the Flexstation™ (Molecular Devices) with a 485/538 nm filter.
  • TABLE 28
    Fluorescence measurement (Relative Fluorescence Unit, RFU) indicate
    that under the same conditions only carcinoma HeLa cells grow as an
    anchorage-independent colony, while both hNPCs and NSLCs
    (adherent and floating neurospheres) were negative for tumor growth
    in the standard agar plate tumor formation assay (CytoSelect ™
    cell transformation kit, Cell Biolabs Inc.).
    Cell
    density/Cell
    types Hela HFF NSLCs HNPCs
    20.000 60.05 ± 8.70 14.82 ± 1.57 19.22 ± 1.85 19.00 ± 2.71
    10.000 39.03 ± 3.97 13.73 ± 1.05 14.99 ± 1.12 21.61 ± 9.95
    5000 24.70 ± 3.89 11.65 ± 0.57 12.29 ± 0.79 12.45 ± 0.73
  • As shown in Table 28, fluorescence measurement indicated that under the same conditions only carcinoma HeLa cells significantly grew and proliferated as anchorage-independent colonies, while both hNPCs and NSLCs (adherent and floating neurospheres) were negative for tumor growth (same value as HFFs (negative control) for 5,000 and 10,000 cells) in the standard agar plate tumor formation assay by visual observation of cells by light microscopic observation using bright field at 10× confirm Fluorescence measurement. Thus the transient transfection method and genes used allows the reprogramming of cells without the neoplastic transformation that generally occurs with stable transfection or certain genes via a series of genetic and epigenetic alterations that yield a cell population that is capable of proliferating independently of both external and internal signals that normally restrain growth.
    • Example XVI
  • No Genomic Integration of Plasmid DNA in NSLCs from Transient Transfection
  • The DNA plasmid Msi1/Ngn2 (designed and constructed in house) was used in transient transfection for generation of NSLCs along with MBD2 (for sample 1), or 5-Aza and VPA (for sample 2). Two weeks after transfection, Southern blot was performed to test for possible genomic integration of the plasmid DNA. 3 μg of genomic DNA extracted from the NSLC samples, as well as from HFF (a human fibroblast cell line) used as a negative control, was digested with several restriction enzymes including BgIII, PstI and StuI, subjected to electrophoresis on a 1% agarose gel and transferred to a positively charged nylon membrane (Roche). The membrane was hybridized in the DIG Easy Hyb™ buffer (Roche) at 42° C. overnight with a 1.2 kb Dig-labeled PCR probe amplified from the plasmid DNA using a set of primers. The membrane was washed twice at room temperature with 2×SSC, 0.1% SDS for 5 min per wash, twice with 0.5×SSC, 0.1% SDS at 65° C. for 15 min per wash. Hybridization signals of the membrane were detected using the CDP-Star™ substrate (Roche). The membrane was exposed to an X-ray film for analysis. The signals were stripped from the membrane using stripping buffer (0.2 M NaOH, 0.1% SDS). The membrane was re-hybridized with a 0.9 kb Dig-labeled PCR probe amplified from the plasmid DNA using a set of primers.
  • The Southern blot analysis (FIG. 12) with the 1.2 kb Dig-labeled PCR probe revealed distinct signals in the positive control samples where the Msi1/Ngn2 plasmid DNA was spiked into HFF genomic DNA for the equivalence of 1, 10 or 100 integrations per genome. There were a few weak and identical bands that appeared in the restriction enzyme digested genomic DNA from HFF, NSLC samples #1 and #2, suggesting that there is no plasmid DNA integration in the genomic DNA of NSLCs. These bands may represent the endogenous Ngn2 gene since the 1.2 kb Dig-labeled PCR probe contains a small part of the Ngn2 gene. This data shows that no, or only a tiny number of, NSLCs had plasmid integration into the host genome after transient transfection, and that the transfected genes are only present in the cell for a short period of time (less than two weeks).
    • Example XVII
  • Neuroprotective Effect of Transplanted hNSLCs in:
    • 1) Animal Model of Multiple Sclerosis.
  • Multiple Sclerosis (MS) is an incurable inflammatory demyelinating disease of the central nervous system (CNS) (Frohman E M et al 2006). Therapies for MS rely on manipulation of the immune system, but with often modest effectiveness on reducing clinical episodes or permanent neurological disability, requiring frequent injections, and with sometimes-significant side effects (Langer-Gould A et al 2004). Experimental Allergic Encephalomyelitis (EAE) is an animal model of MS commonly used for studying disease mechanisms and testing potential therapies. EAE can be induced in a variety of species and strains of animals [mice, Rat, marmoset monkey, rhesus macaques] using various CNS antigens [Myelin Oligodendrocyte Glycoprotein (MOG), proteolipid protein (PLP) and myelin basic protein (MBP)].
  • After obtaining all appropriate animal approvals for the experiments, Female 7 to 8 weeks old C57BL/6 mice were purchased from Charles Rivers, and housed at MISPRO animal facility for one week before experimentation for adaption to the new environment. C57BL/6 mice were injected s.c. with 100 μg MOG 35-55 in CFA (Sheldon Biotechnology, McGill University) containing 5 mg/ml Mycobacterium tuberculosis H37Ra (Difco, inc), at 2 sites on the back. All mice received 200 ng pertussis toxin (List Biological Laboratories, Inc) i.p. on day 0 and 2, while clinical scores were calculated blindly daily during a 43 day period, according to the 0-5 scale as follows: 1, limp tail or waddling gait with tail tonicity; 2, waddling gait with limp tail (ataxia); 2.5, ataxia with partial limb paralysis; 3, full paralysis of 1 limb; 3.5, full paralysis of 1 limb with partial paralysis of second limb; 4, full paralysis of 2 limbs; 4.5, moribund; and 5, death.
  • Treatment of EAE Animal Model with and without the Cells:
  • hNSLC and hNPCs (1.5×106 cells in 200 μl PBS/each mouse) were given by single injection i.v. via the tail vein when the animals started to show symptoms of EAE (day 13 i.v). Both animals groups received cyclosporine (10 mg/kg/day) one day before the injection of cells and daily from the day of transplantation to avoid any rejection of the human cells. Sham-treated age-, sex-, and strain-matched mice, injected i.p. with PBS alone, were used as controls. All groups of animals were observed for 43 days. Animals were sacrificed at 43 days p.t., brains and spinal cord were harvested in 30% sucrose in PBS. Statistical analysis of the clinical scores revealed that the clinical signs of EAE were significantly attenuated in NSLC-injected animals as compared to control and hNPCs-injected animals. Cumulative scores was significantly reduced in the NSLC transplanted animals (FIG. 13) and the treatment has no effect on body weight.
    • 2) Hemiplegic Animal Model (Unilateral Ablation of the Left Sensorimotor Cortex in Adult Rats).
  • After obtaining all appropriate animal approvals for the experiments, 8 rats per group (Sprague-Dawley, 250-300 g, Charles River) were anaesthetized using ketamine (Bimeda-MTC)/xylazine (50/10 mg/kg, Novopharm) and placed onto a stereotaxic frame. A midline cranial incision was performed with a sterile surgical scalpel blade, the cranial vault exposed and the bregma identified. The skull above the sensorimotor cortex was opened and the sensorimotor cortex area [0.5-4.0 mm caudal to bregma and 1.8-3.8 mm lateral to the midline (Paxinos and Watson 1986)] was carefully aspirated. After ablation, the treatments (Alginate, Alginate+hNPC, Alginate+NSLCs, RMx+NSLCs, RMx Only, Fibrin Gel, or Saline) were applied directly on the brain after ablation. The opening in the skull was then filled with Bone Wax. In case of a bleeding, small pieces of sterile homeostatic tissue were inserted into the lesion in order to stop the bleeding. The sutures were performed using Ethicon™ monofilament suture ½ circle needle shape. Surgeries were performed in sterile clean rooms, and topical antibiotics (Cicatrin®, GlaxoSmithKline) were applied to the exposed skull and scalp to limit local infection. Rats were immunosuppressed by daily injection i.p. of cyclosporine A (10 mg/kg/day) starting the day before the surgery until the end of the study period. The purpose of the cyclosporine A injection was to reduce the rat's immune reaction to the treatment. The immune-suppression was sustained until the end of the study to ensure that any potential failure of regeneration (if taken place) was not due to the immune reaction against the treatment. Functional scores were performed weekly, in all groups, sensorimotor impairment was evaluated based on the behavioural tests as described below.
  • Rotarod Test:
  • The rotarod speed was manually calibrated for the 10 and 20 RPM speed before all procedures. Animals were required to perch on the stationary rod for 30 sec to acclimate themselves to the environment. During this time, if any animal fell, it was placed back on the rod until it had achieved stationary capabilities for a period of 30 seconds. The animals were allowed 3 trials. The animals that were comfortable staying on the stationary rod for 30 sec were allowed to run with a constant speed of 10 and 20 RPM for 60 sec, and the number of falls were electronically recorded.
  • Beam Walking:
  • Beam walking measures hindlimb coordination by means of distance travelled across 100 cm beam (2.3 cm in diameter, 48 cm off the floor). Rats were systematically trained to walk along the elevated beam from start to finish with the aim of completing the task. A safe location, i.e, a flat box, is placed at the end of the beam so that the rat is motivated to complete the task.
  • Scale used for evaluation of beam-walking performance
    Scale Performance characteristic
    1 Animals fail to traverse the beam and do not place the hindlimb on the horizontal surface
    of the beam
    2 Animals fail to traverse the beam, but place the hindlimb on the horizontal surface of the
    beam and maintain balance
    3 Animals traverse the beam while dragging the hindlimb
    4 Animals traverse the beam and place the hindlimb at least once during the traverse
    5 Animals traverse the beam using the hindlimb to aid less than 50% of its steps on the
    beam
    6 Animals traverse the beam using the left hindlimb to aid more than 50% of its steps on
    the beam
    7 Animals traverse the beam with no more than two foot slips
    8 Normal animals
  • Before the surgery, all the animals fell at least once from the rotarod, not because they had a walking or coordination problem, but because the speed was high. After the surgery (2 days), all the animals showed signs of significant walking and coordination problems leading to an increase in the number of falls from the rotarod. Three weeks after the surgery, the number of falls was clearly reduced for the animals receiving NSLCs as treatment compared to controls (FIG. 14).
  • Animals passed the beam-walking test before the surgery without any difficulty. The rats crossed the 100 cm beam and got to the safe spot without falling off the beam. Two days after surgery, all groups completely failed to pass the test, and the animals were not able to stay in balance on the beam. One week after the surgery, all the animals showed some improvement in their walking capacity, but no significant difference was noticeable between the different treated groups. From week 4 until week 26, the animals treated with NSLCs as well as RMx showed significant improvements in their walking capacity compared to the controls (FIG. 15).
    • Example XVIII
  • Transfection of HFF by Various Combinations of Genes Using the Shuttle® Device and Treatment with Different Small Molecules for Reprogramming to Mesendoderm-Like Cells
  • HFF cells were cultured as described in CDM II medium as described in Example I with only modifying EGF (5 ng/ml) and FGF (10 ng/ml), and transfecting using the Nucleofector™® 96-well Shuttle® Device (Lonza) following the procedure described in Example IV. The cells were transfected with various combinations of cDNA clones as described in Table 29. After transfection, the cells were plated on 0.1% Gelatin-coated plates and incubated at 37° C., 5% CO2, 5% O2. Medium was changed every other day according to Table 30. Cells were analyzed at Day 4 by Quantitative Real-time PCR.
  • TABLE 29
    Various combinations of plasmids with potential to transfect the
    cells towards mesendoderm lineage.
    Day -2 to Day 0 Plasmids transfected at Day 01
     1 Untreated Oct4, FoxD3, MBD2
     2 Oct4, T, MBD2
     3 Oct4, Mixl1, MBD2
     4 Oct4, Sox17, MBD2
     5 FoxD3, T, MBD2
     6 FoxD3, Mixl1, MBD2
     7 FoxD3, Sox17, MBD2
     8 T, Mixl1, MBD2
     9 T, Sox17, MBD2
    10 Mixl1, Sox17, MBD2
    13 Pre-treated with Oct4, FoxD3
    14 VPA & 5-Aza FoxD3, T
    15 FoxD3, Mixl1
    16 FoxD3, Sox17
    17 Oct4, FoxD3, T
    18 Mixl1, Sox17, FoxA2
    19 Oct4, FoxD3, T
    20 Mixl1, Sox17, FoxA2
    1where Oct4 = pCMV6-XL4-Oct4, FoxD3 = pCMV6-XL5-FoxD3, MBD2 = pCMV6-AC-MBD2, T = pCMV6-XL5-T, Mixl1= pCMV6-XL5-MIXL1, Sox17 = pCMV6-XL4-SOX17, FoxA2 = pCMV6-XL5-FOXA2. All clones were purchased from Origene and prepared using the EndoFree Plasmid Maxi Kit (Qiagen).
  • TABLE 30
    Medium composition from Day -2 to Day 10
    Media Composition2
    Day 0 Day 1 Day 2 to Day 3 Day 4 to Day 7 Day 8 to Day 10
    CDM II (3:1 of CDM II (50%) + IMDM/F12 + IMDM/F12 + IMDM/F12 +
    DMEM:F12; IMDM/F12 NEAA + ITS + NEAA + ITS + NEAA + ITS +
    GlutaMAX ™ 100x, (50%) + NEAA + HSA + bFGF + HSA + bFGF + HSA + bFGF +
    Dexthamesone, ITS + HSA + EGF + VPA + EGF + Activin EGF + BMP4
    19.7 μg/ml, bFGF + EGF + Activin A + A + CHIR99021 +
    Glutathione (500 VPA + Activin CHIR99021 + BMP4
    μg/ml, L-Ascorbic A + CHIR99021 BMP4
    75 mg/ml, Selenious
    acid 2.5 μg/ml,
    Insulin solution
    10 mg/ml, T3
    675 ng/ml,
    ethanolamine
    500X, bFGF
    2.5 ug/ml, and Egf
    (1.25 ug/ml) +
    Activin A + HSA
    2Supplements added to media at the following concentrations: Activin A (Peprotech, 30 ng/ml), HSA (Baxter, 0.5%), NEAA (Gibco, 1X), ITS (Gibco, 1X), EGF (Peprotech, 5 ng/ml), bFGF (Peprotech, 10 ng/ml), CHIR99021 (Stemgent, 2 uM), VPA (Stemgent, 1 mM), 5-Aza (Sigma, 0.5 uM), BMP4 (Peprotech, 10 ng/ml)
  • Cells were collected on Day 4 by detaching with TrypLE™, followed by centrifugation at 80×g for 5 minutes. Supernatant was aspirated and the cell pellet was frozen at −86° C. until ready for RNA Isolation. RNA isolation and quantification was performed as previously described in Example I. cDNA was prepared and quantitative real-time PCR was performed as previously described in Example II, except the following Taqman™® Gene Expression Assays (Applied Biosystems) were used:
  • Gene Taqman ™ ® Assay ID
    GAPDH (housekeeper) Hs99999905_m1
    PPIA (housekeeper) Hs99999904_m1
    FOXA2 Hs00232764_m1
    SOX17 Hs00751752_s1
    Endogenous T Hs00610073_g1
    GSC Hs00418279_m1
    CXCR4 Hs00607978_s1
    GATA4 Hs00171403_m1
    CER1 Hs00193796_m1
    CDH1 (E-cadherin) Hs01023894_m1
    p63 Hs00978340_m1
    SOX2 SOX2_1078-ANY
  • TABLE 31
    Relative Expression FoxA2, Sox17, and Cxcr4 after transfecting HFFs once with
    various gene combinations with potential to reprogram cells into mesoendoderm-like
    cells. The exact values are not significantly accurate due to low RNA yield, however a
    trend of increasing gene expression was detected for FoxA2, Sox17, and CXCR4.
    FOXA2 SOX17 CXCR4
    Rel. Std. Rel. Std. Rel. Std.
    Exp. Dev. Exp. Dev. Exp. Dev.
    Untreated HFF 1.00 0.04 1.00 0.04 1.00 0.04
    Day 4 HFF untransf. 1.01 0.06 1.01 0.06 4.77 2.51
    (+G.F),
    Day 4 HFF untransf. 1.38 0.11 1.38 0.11 1.38 0.11
    (−G.F),
    Day 4 HFF Untransf. 0.98 0.02 0.98 0.02 3.32 3.31
    (+G.F.),
    Day 4 HFF Untransf. 4.12 4.07 1.28 0.06 1.28 0.06
    (−G.F.),
    Day 4 Oct4/FoxD3/MBD2 4.67 4.60 3.19 2.78 76.43 7.91
    Day 4 Oct4/T/MBD2 3.91 3.55 4.33 2.36 15.18 2.52
    Day 4 Oct4/Mixl1/MBD2 2.66 1.77 10.33 0.43 7.31 3.21
    Day 4 Oct4/Sox17/MBD2 14.19 4.85 413533.31 127089.61 56.04 0.71
    Day 4 FoxD3/T/MBD2 38.62 38.00 3.12 1.32 42.41 5.23
    Day 4 FoxD3/Mixl1/MBD2 7.76 5.29 2.41 0.30 137.17 27.74
    Day 4 FoxD3/Sox17/MBD2 26.02 1.95 50904.45 1523.33 131.03 17.53
    Day 4 T/Mixl1/MBD2 3.67 3.26 5.64 4.15 14.04 2.89
    Day 4 T/Sox17/MBD2 9.76 9.70 209797.21 24533.81 111.35 16.40
    Day 4 Mixl1/Sox17/MBD2 3.60 3.10 237310.10 57448.60 36.76 1.07
    Day 4 Oct4/FoxD3 13.87 0.16 13.87 0.16 35.44 14.57
    Day 4 FoxD3/T 60.93 60.18 19.45 1.51 19.45 1.51
    Day 4 FoxD3/Mixl1 21.20 2.31 28.96 8.66 62.31 55.82
    Day 4 FoxD3/Sox17 96.88 3.60 54177.20 3313.15 44.57 41.51
    Day 4 Oct4/FoxD3/T 25.99 18.15 12.27 1.26 21.17 11.33
    Day 4 Mixl1/Sox17/FoxA2 1850864.68 98259.84 112641.65 15923.21 23.18 23.10
    Day 4 Oct4/FoxD3/T 9.52 5.61 1.52 0.02 35.74 4.36
    (IMDM/F12)
    Day 4 Mixl1/Sox17/FoxA2 486705.82 19101.53 57060.09 1262.81 13.44 2.36
    (IMDM/F12)
  • TABLE 32
    Expression of GATA4, CDH1 (E-cadherin), p63, and SOX2 relative to untreated HFF
    control
    4 days after transfecting HFF cells with various gene combinations with potential
    to reprogram cells into mesoendoderm-like cells.
    CDH1
    GATA4 (E-cadherin) p63 SOX2
    Rel. Std. Rel. Std. Rel. Std. Rel. Std.
    Exp. Dev. Exp. Dev. Exp. Dev. Exp. Dev.
    Untreated HFF 1.00 0.04 1.00 0.04 1.00 0.04 1.00 0.04
    Day 4 HFF untransf. (+G.F), 12.13 0.70 1.01 0.06 3.09 1.45 1.11 0.21
    Day 4 HFF untransf. (−G.F), 4.48 0.85 1.38 0.11 3.11 2.54 1.38 0.11
    Day 4 HFF Untransf. (+G.F.), 2.37 2.00 0.98 0.02 4.41 4.40 1.94 1.34
    Day 4 HFF Untransf. (−G.F.), 6.12 3.33 1.28 0.06 13.23 7.43 1.28 0.06
    Day 4 Oct4/FoxD3/MBD2 95.23 27.44 98.90 21.58 1.81 0.86 12.72 1.53
    Day 4 Oct4/T/MBD2 33.66 10.30 1.42 0.02 2.05 0.87 2.62 1.67
    Day4 Oct4/Mixl1/MBD2 106.33 5.70 1.43 0.03 8.68 0.99 25.68 2.18
    Day 4 Oct4/Sox17/MBD2 23.50 5.39 4.65 4.43 95.23 13.86 18.77 6.94
    Day 4 FoxD3/T/MBD2 121.36 11.68 26.85 0.02 2.22 0.04 16.99 4.74
    Day 4 FoxD3/Mixl1/MBD2 130.21 21.04 69.19 22.84 4.05 3.56 1.52 0.01
    Day 4 FoxD3/Sox17/MBD2 99.49 30.30 6.89 3.69 1.78 0.01 15.19 9.08
    Day 4 T/Mixl1/MBD2 110.30 3.55 1.36 0.00 1.36 0.00 6.64 2.25
    Day 4 T/Sox17/MBD2 53.19 4.02 2.69 1.86 18.01 0.54 14.21 5.21
    Day 4 Mixl1/Sox17/MBD2 16.53 16.50 2.91 2.13 13.44 6.68 10.55 3.27
    Day 4 Oct4/FoxD3 66.45 26.34 47.31 47.30 13.87 0.16 23.87 14.31
    Day 4 FoxD3/T 68.25 68.00 39.08 29.27 19.45 1.51 19.45 1.51
    Day 4 FoxD3/Mixl1 78.18 78.00 21.20 2.31 21.20 2.31 25.10 3.20
    Day 4 FoxD3/Sox17 176.45 93.54 15.64 0.60 15.64 0.60 26.78 16.35
    Day 4 Oct4/FoxD3/T 12.27 1.26 12.27 1.26 12.27 1.26 12.27 1.26
    Day 4 Mixl1/Sox17/FoxA2 85.89 64.52 20.06 20.00 3.67 0.13 13.66 0.66
    Day 4 Oct4/FoxD3/T 89.05 50.00 10.40 8.14 1.52 0.02 1.52 0.02
    Day 4 Mixl1/Sox17/FoxA2 6.16 6.10 1.23 0.04 1.23 0.04 1.23 0.04
  • Identification of gene combinations that may induce the formation of Mesendoderm-like cells was investigated by transfection with combinations of Oct4, Sox17, FoxD3, T, MixI1, FoxA2, and MBD2. As shown in Table 25 and 26, the Relative Expression of CXCR4 and GATA4, both Mesendoderm/Endoderm/Mesoderm markers, appear to be up-regulated in various combinations, most noticeably in FoxD3/MixI1/MBD2 and FoxD3/Sox17/MBD2. Similarly, FOXA2, a marker for Endoderm and Mesoderm, was up-regulated FoxD3/Sox17-transfected sample, although the expression is still very low. Four days following transfection, SOX17 is still highly expressed in the SOX17-transfected samples (50,000 to 400,000-fold as compared to the untreated HFF sample). The SOX17 gene expression represents leftover plasmid DNA (exogenous SOX17) that still remains 4 days post-transfection, and any endogenous SOX17 expression that may have been induced. Ectoderm markers CDH1, p63 and Sox2 were also up-regulated in some samples (e.g. Oct4/FoxD3/MBD2, Oct4/Sox17/MBD2).
  • Reprogramming HFFs into Pancreatic Progenitor-Like Cells:
  • HFF cells were cultured as described in Example I, and transfected using the Nucleofector™® 96-well Shuttle® Device (Lonza) following the procedure described in Example IV. The cells were transfected with various combinations of cDNA clones as described in Table 27. After transfection, the cells were plated on Fibronectin-coated collagen gels and incubated at 37° C., 5% CO2, 5% O2. Fibronectin-coated Collagen gel plates were prepared prior to transfection. Rat Tail Collagen I (Gibco) was diluted to 1.125 mg/ml using 10×PBS and distilled water, where 125 μl was added to each well of a 24-well plate and incubated in 37° C. for 40 minutes. After rinsing with 1×PBS, Fibronectin (BD Biosciences) was added on top of the gel at a concentration of 1.9 ug/well. Media was changed every other day according to Table 33. Cells were analyzed at Day 7 by Quantitative Real-time PCR.
  • TABLE 33
    Plasmids and media composition from Day 0 to Day 14
    Plasmids transfected Media Composition2
    at Day 01 Day 0 Day 1 to Day 3 Day 4 to Day 14
     1 FoxD3, Sox17, Pdx1, CDM II + Activin DMEM/F12 + NEAA + DMEM/F12 + NEAA +
    MBD2 A + HSA ITS + HSA + B27 + ITS + HSA + B27 +
     2 FoxD3, Sox17, Ngn3, EGF + bFGF + Activin EGF + bFGF + Retinoic
    MBD2 A + CHIR99021 + Na Acid + FGF10 +
     3 FoxD3, Mixl1, Pdx1, Butyrate Cyclopamine + Noggin
    MBD2
     4 FoxD3, Mixl1, Ngn3,
    MBD2
     5 Sox17, Mixl1, Pdx1,
    MBD2
     6 Sox17, Mixl1, Ngn3,
    MBD2
     7 FoxD3, Sox17, Mixl1, DMEM/F12 + NEAA +
    Pdx1 ITS + HSA+ B27 +
     8 FoxD3, Sox17, Mixl1, EGF + bFGF + Activin
    Ngn3 A + CHIR99021 + Na
     9 FoxD3, Sox17, Pdx1, Butyrate + VPA + 5-Aza
    Ngn3
    10 FoxD3, Mixl1, Pdx1,
    Ngn3
    11 Sox17, Mixl1, Pdx1,
    Ngn3
    1where FoxD3 = pCMV6-XL5-FoxD3, Sox17 = pCMV6-XL4-SOX17, Mixl1 = pCMV6-XL5-MIXL1, Pdx1 = pCMV6-XL5-Pdx1, and Ngn3 = pCMV6-XL5-Ngn3. All clones were purchased from Origene and prepared using the EndoFree Plasmid Maxi Kit (Qiagen).
    2Supplements added to media at the following concentrations: Activin A (Peprotech, 30 ng/ml), HSA (Baxter, 0.5%), NEAA (Gibco, 1X), ITS (Gibco, 1X), B27 (Gibco, 1%), EGF (Peprotech, 5 ng/ml), bFGF (Peprotech, 10 ng/ml), CHIR99021 (Stemgent, 2 uM), Na Butyrate (Stemgent, 1 mM), VPA (Stemgent, 1 mM), 5-Aza (Sigma, 0.5 uM), Retinoic Acid (Sigma, 2 uM), FGF10 (Peprotech, 50 ng/ml), Cyclopamine (Stemgent, 2.5 uM), Noggin (Peprotech, 50 ng/m1)
  • Cells were collected on Day 7 and RNA isolation and quantification was performed as previously described in Example I. cDNA was prepared and quantitative real-time PCR was performed as previously described in Example II, except the following Taqman™® Gene Expression Assays (Applied Biosystems) were used:
  • Gene Taqman ™  ® Assay ID
    GAPDH (housekeeper) Hs99999905_m1
    PPIA (housekeeper) Hs99999904_m1
    FOXA2 Hs00232764_m1
    SOX17 Hs00751752_s1
    GATA4 Hs00171403_m1
    Endo PDX1 PDX1_1201
    SOX9 Hs00165814_m1
    NGN3 Hs01875204_s1
    NKX2-2 Hs00159616_m1
    PAX4 Hs00173014_m1
    INS Hs02741908_m1
    CXCR4 Hs00607978_s1
  • Identification of gene combinations that may induce the formation of Pancreatic Progenitor-like cells was investigated by transfection with combinations of FoxD3, Sox17, Pdx1, Ngn3, MixI1, and MBD2. FoxA2, a marker for Endoderm and Mesoderm, was slightly up-regulated for the FoxD3/Sox17/Ngn3/MBD2-transfected sample as compared to the GFP mock-transfected control sample. Similarly, CXCR4, also a marker for both endoderm and mesoderm, was slightly up-regulated (3-fold compared to GFP-ctrl) for the FoxD3/MixI1/Ngn3/MBD2-transfected sample. 7 days following transfection, SOX17 can still be detected for the samples transfected with SOX17 at varying levels (4 to 570-fold up-regulation as compared to the GFP-ctrl). The highest SOX17 expression up-regulation is detected for the sample transfected with Sox17/MixI1/Pdx1/Ngn3 (570-fold as compared to GFP-ctrl), which may suggest that this gene combination may increase the amount of SOX17 RNA in cells.
    • Example XIX
  • Reprogramming Human Adipocytes Derived Stem Cells (ADSC) to Pluripotent-Like Stem Cells (PLSC):
  • ADSCs (Invitrogen Corporation) were cultured in cell culture flasks with complete StemPro™-43 medium (Invitrogen) at 37° C., 5% CO2 and the medium was changed 3 times per week. After 3 days in culture cells (passage 5) were trypsinized and counted to be transfected. Cells were transiently transfected with one plasmid: pCMV6-Oct4-2A-Klf4-2A-Nanog, pCMV-Sall4-2A-Oct4-2A-Klf4-2A-Nanog, pCMV-Dax1-2A-Oct4-2A-klf4, pCMV-FoxD3-2A-Oct4-2A-klf4, pCMV-Oct4-2A-Klf4-2A-Sall4, pCMV-MBD2-2A-Oct4-2A-Klf4-2A, pCMV-AGR2-2A-Oct4-2A-Klf4-2A, or Rex1-EF-Oct4-2A-Klf4 (2 μg); or by two plasmids: pEF-Oct4nuc-IRES2-MBD2 with pCMV-Sox2nuc-IREC-Lin28 or pCMV-Klf4nuc-IRES2-Tpt1 nuc or pEF-Stella-IRES2-NPM2, using Nucleofector™ as described in Example II. Following the transfection cells were cultured in 6-well plates in suspension with 50:50 ratio of adipocytes complete medium (StemPro™-43) and embryonic stem cells medium (mTeSR1). After two days in culture, cells were re-transfected with the same plasmids listed above and cells were plated in 96 well-plates coated with Matrigel™ (BD Biosciences) in the presence of mTesR complete medium supplemeneted with thiazovivin (0.5 μM), an ALK-5 inhibitor (SB 341542, Stemgent, 2 μM), and inhibitor of MEK (PD0325901, Stemgent, 0.5 μM). Medium was changed every day and cells were cultured for 22 days at 37° C., 5% CO2, 5% O2. Alkaline Phosphatase Detection Kit (AP, Millipore) and immunohistochemistry were performed to analyse the expression of pluripotency markers. ALP staining was performed using AP detection kit (Millipore) according to manufacturer's instructions.
  • Visual observation of reprogrammed cells was performed by Cellomics™ using a live staining for SSEA-4647 (BD Biosciences) and IRA-1-81555 (BD Biosciences) starting on Day 6 after transfection and every 5 days thereafter. Reprogrammed colonies of PLSCs, positively stained with SSEA-4 and TRA1-81, was observed only with Plasmid pCMV-Sall4-2A-Oct4-2A-Klf4-2A-Nanog, pEF-Rex1-EF-Oct4-2A-Klf4-2A-RFP, pEF-Oct4nuc-IRES1-MBD2 with pCMV-Sox2nuc-IRES1-Lin28, and pEF-Oct4nuc-IRES1-MBD2 with pCMV-Klf4nuc-IRES2-Tpt1nuc. These colonies emerged around Day 6 and maintained in culture up to the end of the study period (Day 22) with a stable morphology. Among the plasmids cited above, pCMV-Sall4-2A-Oct4-2A-Klf4-Nanog and pEF-Rex1-EF-Oct4-2A-Klf4-2A-RFP gave the highest number of colonies. Live staining showed that these colonies express typical pluripotency markers, including SSEA-4 and TRA1-81, and further analysis of these colonies showed that the colonies also expressed other ESC markers such as alkaline phosphatase and Oct4 (FIG. 16). When the cultures were treated with PD0325901 and SB431542 for up to 22 days, a 4-fold improvement in efficiency over the conventional method was obtained following the transfection of ADSCs with pCMV-Sall4-2A-Oct4-2A-Klf4-Nanog and pEF-Rex1-EF-Oct4-2A-Klf4-2A-RFP.
  • Based on the previous study, the highest reprogramming efficiency was observed using pEF-Rex1-EF-Oct4-2A-Klf4-2A-RFP and pCMV-Sall4-2A-Oct4-2A-Klf4-2A-Nanog. Another study was designed to ascertain the effect of pEF-Rex1-EF-Oct4-2A-Klf4-2A-RFP on the reprogramming efficiency and to investigate the effect of individual pluripotent genes Rex1, Oct4, and Klf4 in different combinations. ADSCs were transfected as above with pEF-Rex1-EF-Oct4-2A-Klf4-2A-RFP, pCMV6-XL5-Rex1, pCMV6-XL4-Oct4/pCMV6-XL5-Klf4, pCMV6-XL5-Rex1/pCMV6-XL4-Oct4, or pCMV6-XL5-Rex1/pCMV6-XL5-Klf4. After the second transfection, ADSC were cultured in 96-well plates coated with Matrigel™ for 24 days in the presence of mTeSR1 medium supplemented with SB341542 and PD 0.325901 at 37° C., 5% CO2, 5% O2. In order to characterize subpopulations of cells after transfection, live staining, immunohistochemistry, and AP staining was used to follow the change in pluripotent markers. 1-5% of total cells transfected with Rex1/Oct4 or Rex1/Klf4 showed a SSEA4+ and TRA-1-81+ phenotype, and this pattern was stable until the end of the study period (Day 22). The observation over time showed that the phenotype of these colonies moved from an early SSEA-4+ phenotype to a late Oct4+/Sox2/Nanog+ phenotype by Day 22, which is closer to the final reprogrammed state of a pluripotent-like stem cell (FIG. 17).
  • Various genes were tested for their effect on reprogramming efficiency towards pluripotent-like cells. ADSC cells were cultured as described in Example IX with 2 days VPA and 5-AZA pre-treatment (1 mM and 0.5 μM respectively) in StemPro™ MSC SFM medium. Cells were transfected using the Nucleofector™® 96-well Shuttle® Device (Lonza) following procedure described in Example IV and using the transfection program EW-104 with the DNA mixes described in Table 34. Following transfection the cells were plated in StemPro™ MSC SFM medium described in example A on Matrigel™ (BD Biosciences) coated 24 well plates and incubated at 37° C., 5% CO2, 5% O2. On Day 1, media was changed to a mix of 75% StemPro™ MSC and 25% hES cell medium; the percentage of StemPro™ MSC was decreased every day over four days to have 100% hES cell medium by Day 4. From then onwards the medium was changed every two days. The hES cell medium consisted in Dulbecco's Modified Eagle's Medium (DMEM, Invitrogen) supplemented with 20% Knockout™ Serum Replacement (KSR, Invitrogen), 1 mM GlutaMAX™, 100 μM Non-essential Amino acids, 100 μM β-mercaptoethanol and 10 ng/ml Fgf-2. Different inhibitors and growth factors were added through the course of the experiment; these are listed in Table 34. Cells were analysed at Day 7 and Day 14 by immunohistochemistry analysis and at Day 7 by RT-PCR.
  • TABLE 34
    Plasmids and media composition from Day 1 to Day 14.
    From Plasmids
    day −2 transfected at From day 1 to From day 3 to From day 7 to
    to day 0 day 0 day 3 day 7 day 14
     1 VPA + 5- pCMV6-XL4- StemPro ™/hES StemPro ™/hES hES medium
    Aza pre- Oct4 + medium + ActivinA medium + ActivinA
    treated pCMV6-XL5- (30 ng/ml) + (30 ng/ml) +
    Sox2 + CHIR99021 CHIR99021
    pCMV6-XL5- (3 μM) (3 μM)
    MBD2
     2 VPA + 5- pCMV6-XL4- StemPro ™/hES StemPro ™/hES hES medium
    Aza pre- Oct4 + medium + ActivinA medium + ActivinA
    treated pCMV6-XL5- (30 ng/ml) + (30 ng/ml) +
    FoxD3 + CHIR99021 CHIR99021
    pCMV6-XL5- (3 μM) (3 μM)
    MBD2
     3 VPA + 5- pCMV6-XL4- StemPro ™/hES StemPro ™/hES hES medium
    Aza pre- Oct4 + medium + ActivinA medium + ActivinA
    treated pCMV6-XL5- (30 ng/ml) + (30 ng/ml) +
    UTF1 + CHIR99021 CHIR99021
    pCMV6-XL5- (3 μM) (3 μM)
    MBD2
     4 VPA + 5- pCMV6-XL4- StemPro ™/hES StemPro ™/hES hES medium
    Aza pre- Oct4 + medium + ActivinA medium + ActivinA
    treated pCMV6-XL4- (30 ng/ml) + (30 ng/ml) +
    DPPA4 + CHIR99021 CHIR99021
    pCMV6-XL5- (3 μM) (3 μM)
    MBD2
     5 VPA + 5- pCMV6-XL5- StemPro ™/hES StemPro ™/hES hES medium
    Aza pre- Sox2 + medium + ActivinA medium + ActivinA
    treated pCMV6-XL5- (30 ng/ml) + (30 ng/ml) +
    FoxD3 + CHIR99021 CHIR99021
    pCMV6-XL5- (3 μM) (3 μM)
    MBD2
     6 VPA + 5- pCMV6-XL5- StemPro ™/hES StemPro ™/hES hES medium
    Aza pre- Sox2 + medium + ActivinA medium + ActivinA
    treated pCMV6-XL5- (30 ng/ml) + (30 ng/ml) +
    UTF1 + CHIR99021 CHIR99021
    pCMV6-XL5- (3 μM) (3 μM)
    MBD2
     7 VPA + 5- pCMV6-XL5- StemPro ™/hES StemPro ™/hES hES medium
    Aza pre- Sox2 + medium + ActivinA medium + ActivinA
    treated pCMV6-XL4- (30 ng/ml) + (30 ng/ml) +
    DPPA4 + CHIR99021 CHIR99021
    pCMV6-XL5- (3 μM) (3 μM)
    MBD2
     8 VPA + 5- pCMV6-XL5- StemPro ™/hES StemPro ™/hES hES medium
    Aza pre- FoxD3 + medium + ActivinA medium + ActivinA
    treated pCMV6-XL5- (30 ng/ml) + (30 ng/ml) +
    UTF1 + CHIR99021 CHIR99021
    pCMV6-XL5- (3 μM) (3 μM)
    MBD2
     9 VPA + 5- pCMV6-XL5- StemPro ™/hES StemPro ™/hES hES medium
    Aza pre- FoxD3 + medium + ActivinA medium + ActivinA
    treated pCMV6-XL4- (30 ng/ml) + (30 ng/ml) +
    DPPA4 + CHIR99021 CHIR99021
    pCMV6-XL5- (3 μM) (3 μM)
    MBD2
    10 VPA + 5- pCMV6-XL5- StemPro ™/hES StemPro ™/hES hES medium
    Aza pre- UTF1 + medium + ActivinA medium + ActivinA
    treated pCMV6-XL4- (30 ng/ml) + (30 ng/ml) +
    DPPA4 + CHIR99021 CHIR99021
    pCMV6-XL5- (3 μM) (3 μM)
    MBD2
    11 VPA + 5- pCMV6-XL4- StemPro ™/hES StemPro ™/hES hES medium
    Aza pre- Oct4 + medium + ActivinA medium + ActivinA
    treated pCMV6-XL5- (30 ng/ml) + (30 ng/ml) +
    Sox2 + CHIR99021 CHIR99021
    pCMV6-XL5- (3 μM) + VPA + 5- (3 μM)
    FoxD3 Aza
    12 VPA + 5- pCMV6-XL4- StemPro ™/hES StemPro ™/hES hES medium
    Aza pre- Oct4 + medium + ActivinA medium + ActivinA
    treated pCMV6-XL5- (30 ng/ml) + (30 ng/ml) +
    Sox2 + CHIR99021 CHIR99021
    pCMV6-XL5- (3 μM) + VPA + 5- (3 μM)
    UTF1 Aza
    13 VPA + 5- pCMV6-XL4- StemPro ™/hES StemPro ™/hES hES medium
    Aza pre- Oct4 + medium + ActivinA medium + ActivinA
    treated pCMV6-XL5- (30 ng/ml) + (30 ng/ml) +
    Sox2 + CHIR99021 CHIR99021
    pCMV6-XL4- (3 μM) + VPA + 5- (3 μM)
    DPPA4 Aza
    14 VPA + 5- pCMV6-XL4- StemPro ™/hES StemPro ™/hES hES medium
    Aza pre- Oct4 + medium + ActivinA medium + ActivinA
    treated pCMV6-XL5- (30 ng/ml) + (30 ng/ml) +
    FoxD3 + CHIR99021 CHIR99021
    pCMV6-XL5- (3 μM) + VPA + 5- (3 μM)
    UTF1 Aza
    15 VPA + 5- pCMV6-XL4- StemPro ™/hES StemPro ™/hES hES medium
    Aza pre- Oct4 + medium + ActivinA medium + ActivinA
    treated pCMV6-XL5- (30 ng/ml) + (30 ng/ml) +
    FoxD3 + CHIR99021 CHIR99021
    pCMV6-XL4- (3 μM) + VPA + 5- (3 μM)
    DPPA4 Aza
    16 VPA + 5- pCMV6-XL4- StemPro ™/hES StemPro ™/hES hES medium
    Aza pre- Oct4 + medium + ActivinA medium + ActivinA
    treated pCMV6-XL5- (30 ng/ml) + (30 ng/ml) +
    UTF1 + CHIR99021 CHIR99021
    pCMV6-XL4- (3 μM) + VPA + 5- (3 μM)
    DPPA4 Aza
    17 VPA + 5- pCMV6-XL5- StemPro ™/hES StemPro ™/hES hES medium
    Aza pre- Sox2 + medium + ActivinA medium + ActivinA
    treated pCMV6-XL5- (30 ng/ml) + (30 ng/ml) +
    FoxD3 + CHIR99021 CHIR99021
    pCMV6-XL5- (3 μM) + VPA + 5- (3 μM)
    UTF1 Aza
    18 VPA + 5- pCMV6-XL5- StemPro ™/hES StemPro ™/hES hES medium
    Aza pre- Sox2 + medium + ActivinA medium + ActivinA
    treated pCMV6-XL5- (30 ng/ml) + (30 ng/ml) +
    FoxD3 + CHIR99021 CHIR99021
    pCMV6-XL4- (3 μM) + VPA + 5- (3 μM)
    DPPA4 Aza
    19 VPA + 5- pCMV6-XL5- StemPro ™/hES StemPro ™/hES hES medium
    Aza pre- Sox2 + medium + ActivinA medium + ActivinA
    treated pCMV6-XL5- (30 ng/ml) + (30 ng/ml) +
    UTF1 + CHIR99021 CHIR99021
    pCMV6-XL4- (3 μM) + VPA + 5- (3 μM)
    DPPA4 Aza
    20 VPA + 5- pCMV6-XL5- StemPro ™/hES StemPro ™/hES hES medium
    Aza pre- FoxD3 + medium + ActivinA medium + ActivinA
    treated pCMV6-XL5- (30 ng/ml) + (30 ng/ml) +
    UTF1 + CHIR99021 CHIR99021
    pCMV6-XL4- (3 μM) + VPA + 5- (3 μM)
    DPPA4 Aza
    21 VPA + 5- GFP StemPro ™/hES StemPro ™/hES hES medium
    Aza pre- medium + ActivinA medium + ActivinA
    treated (30 ng/ml) + (30 ng/ml) +
    CHIR99021 CHIR99021
    (3 μM) (3 μM)
    +/or− VPA + 5-Aza
  • In order to characterize subpopulations of cells after transfection, live staining, immunohistochemistry, and AP staining was performed to follow the change in pluripotent markers. Cells transfected with either Oct4/UTF1/MBD2, Oct4/Dppa4/MBD2, FoxD3/Dppa4/MBD2, Oct4/FoxD3/Dppa4, or Sox2/FoxD3/UTF1 showed positive colonies for TRA1-60, TRA1-81, and SSEA4. This observation indicated that MBD2 generally had no effect by itself on reprogramming towards pluripotent-like cells, except in the case of Oct4/FoxD3/MBD2 transfection. Colonies started to form on Day 7 and continued to form until Day 14 (FIG. 18) (the end of the study period). These colonies were positive for AP as well.
  • These results were confirmed by RT-PCR analysis showing up-regulation of Oct4 expression as shown in Table 35. Relative expression for SOX2 was also slightly up-regulation in Day 7 after transfecting cells with Oct4/Foxd3/MBD2. There is also a trend of Sox2 up-regulation following transfection with Oct4/Sox2/Foxd3 and Oct4/Foxd3/Utf1.
  • TABLE 35
    Relative expression of Pluripotent genes after transfecting ADSCs
    with various combinations of vectors as described in Table 34.
    OCT4 Endogenous SOX2
    Rel. Std. Rel. Std.
    Exp. Dev. Exp. Dev.
     #1 Day 7, Oct4/Sox2/MBD2 25.20 1.89 3.89 2.06
     #2 Day 7, Oct4/Foxd3/ 11.28 0.13 18.79 0.03
    MBD2
     #3 Day 7, Oct4/Utf1/MBD2 2.01 0.20 2.93 1.73
     #4 Day 7, Oct4/Dppa4/ 9.68 1.36 1.18 0.15
    MBD2
     #5 Day 7, Sox2/Foxd3/ 1.06 0.55 2.68 2.90
    MBD2
     #6 Day 7, Sox2/Utf1/MBD2 0.66 0.10 3.36 0.68
     #7 Day 7, Sox2/Dppa4/ 0.74 0.00 5.03 4.73
    MBD2
     #8 Day 7, Foxd3/Utf1/ 1.31 0.61 4.15 2.92
    MBD2
     #9 Day 7, Foxd3/Dppa4/ 0.63 0.02 3.90 2.17
    MBD2
    #10 Day 7, Utf1/Dppa4/ 0.96 0.04 4.97 1.92
    MBD2
    #11 Day 7, Oct4/Sox2/Foxd3 48.17 1.89 7.68 1.79
    #12 Day 7, Oct4/Sox2/Utf1 48.97 6.93 3.71 0.39
    #13 Day 7, Oct4/Sox2/Dppa4 32.40 2.74 4.61 2.37
    #14 Day 7, Oct4/Foxd3/Utf1 4.30 0.91 9.83 3.03
    #15 Day 7, Oct4/Foxd3/ 4.21 0.11 4.57 0.85
    Dppa4
    #16 Day 7, Oct4/Utf1/Dppa4 10.29 3.70 3.53 1.63
    #17 Day 7, Sox2/Foxd3/Utf1 1.42 0.83 3.32 2.12
    #18 Day 7, Sox2/Foxd3/ 1.19 0.14 3.37 1.23
    Dppa4
    #19 Day 7, Sox2/Utf1/Dppa4 1.34 0.09 2.33 2.91
    #20 Day 7, Foxd3/Utf1/ 0.72 0.07 2.45 0.27
    Dppa4
    #21 Day 7, GFP 1.02 0.29 1.01 0.17
    (−VPA/−5aza)
    #22 Day 7, Untransf. ADSC 1.25 N/A 0.30 N/A
    (−VPA/−5aza)
    #23 Day 7, GFP 1.01 0.20 1.87 2.23
    (+VPA/+5aza)
    #24 Day 7, Untransf. ADSC 1.45 N/A 0.27 N/A
    (+VPA/+5aza)

    Reprogramming Efficiency of Defined Pluripotency Factors on HFF after Triple Transfection (One Transfection Every 3 Days)
  • HFF cells were cultured as described in Example I with the exception of the concentrations of VPA and 5-AZA that were respectively 2 mM and 2.5 μM. Cells were transfected using the Nucleofector™® II Device (Lonza) following procedure described in Example II with the exception of the DNA quantity: 1 μg of each of the 3 plasmids DNA was used. The cells that had been pre-treated with VPA and 5-Aza and the untreated cells were both transfected with a mix of pCMV-Oct4nuc-IRES2-Sox2nuc, pCMV-Klf4nuc-IRES2-Cmycnuc or pCMV-Nanognuc-IRES2-Lin28. Following transfection the cells were plated in the fibroblasts medium described in Example I, supplemented with or without VPA and 5-AZA on Matrigel™ (BDBiosciences) coated on 6-well plates and incubated at 37° C., 5% CO2. On Day 1 and 2, media was changed to 100% mTeSR1 medium (StemCell Technologies) supplemented with or without VPA and 5-AZA. On Day 3 and Day 6, cells from each condition were detached by incubation in TrypLE™ for 5 min, counted and centrifuged. Cells were retransfected as above and plated on Matrigel™ coated plates in mTeSR1 medium supplemented with or without VPA and 5-AZA. Media was changed daily as described for day 1 and 2. Medium was supplemented in Y27632 (Stemgent, 10 μM) from day 7 to day 14 to promote viability and clonal expansion of potential reprogrammed cells. Cells were analysed at Day 20 using the Alkaline Phosphatase Detection Kit (Millipore) and by immunohistochemistry analysis.
  • This analysis revealed that after three transfections, three clones were found to be positive for alkaline phosphatase activity and showed a rounded cell/colony morphology. Staining with antibodies against the embryonic stem (ES) cell markers SSEA-4 and TRA-1-81 confirmed that these clones were pluripotent-like (FIG. 19). Surrounding HFF cells were negative for these markers. These clones were obtained only in the condition that did not contain inhibitors (i.e.: VPA and 5-AZA). Unexpectedly, no clones were observed for the condition treated with these inhibitors.
  • Reprogramming of NSLCs into Pluripotency
  • NSLC and neuronal stem cells derived from BG-01, a human ES cell line that expresses markers that are characteristic of ES cells including SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, and OCT-3/4, were reprogrammed into pluripotency. BG-01 cells had previously been cultured in conditions to induce the differentiation towards neural stem cells as described by Chambers S M et al., 2009. NSLCs and BG-01-NSC were cultured in proliferation medium supplemented with FGF (20 ng/ml) and EGF (20 ng/ml). NSLCs and BG-01-NSCs were transfected as previously described in Example 11 by two episomal vectors, pEF-Oct4nuc-IRES2-MBD2 (NC1) or pCMV-FoxD3-2A-Oct4-2A-Klf4 (F72). Following transfection cells were collected and plated onto uncoated petri-dishes in the presence of Proliferation medium and mTeSR1 medium (50:50) in proliferation conditions at 37° C., 5% CO2. After 48 hours, cells were re-transfected by the same plasmid and plated in 96-well plates coated with Matrigel™ and cultured in the presence of mTeSR1 medium supplemented by the small molecules BIX01294 (Stemgent, 2 μM) and BayK8644 (Stemgent, 2 μM) at 37° C., 5% O2 for 22 days. Live staining and immunohistochemistry were performed to characterize subpopulations of cells for pluripotency markers.
  • NSLCs and BG-01-NSCs were positively stained with SSEA-4 starting on Day 7 and maintained until 22 days in culture (the end of the study) (FIG. 20). Within ten days, cells that were morphologically similar to ESCs were observed and they expressed a wide panel of pluripotency markers, including SSEA-4, TRA1-81, Nanog and Oct4 (FIG. 20). This study identified another way to get pluripotent-like cells from somatic cells via Neural Stem-Like Cells (NSLCs). The utility of NSLCs could offer multiple advantages for reprogramming towards pluripotent-like cells. For example, obviating the requirement for tumorigenic genes like c-Myc reduces the risk of inducing cancerous cells. For neurodegenerative and neurodegenerative applications these cells could represent an invaluable source of cells to investigate furthermore human pluripotent cell induction, and also represent a potential source of cells for deriving patient-specific multipotent and pluripotent stem cells for modeling human disease.
    • Example XX Teratoma Formation Assay in SCID Mice
  • Transplantation of human pluripotent stem cells (SC) into “severely compromised immuno-deficient” (SCID) mice leads to the formation of differentiated tumors comprising all three germ layers for pluripotent stem cells, resembling spontaneous human teratomas, and specialized tissue for multipotent stem cells. These assays are considered the standards in the literature for demonstrating differentiation potential of pluripotent stem cells and hold promise as a standard for assessing safety among SC-derived cell populations intended for therapeutic applications
  • After all appropriate animal approvals for the experiment has been obtained, 24 mice were purchased from Charles Rivers, and housed at MISPRO animal facility for one week without any experimentation for adaption to the new environment. One million human NSLCs, normal human neuroprogenitor cells (hNPCs), or human embryonic stem (ES) cells in 100 μl Phosphate buffered saline, calcium- and magnesium-free (CMF-PBS) were injected with a 21-G needle intramuscularly into the right hind limb of the 4-week-old male SCID-beige mice under anesthesia with Ketamine/xylazine (8 mice per group). Following injection, the syringe was aspirated up and down a couple of times in a culture dish containing medium to verify that the cells were injected and not stuck inside the syringe.
  • The mice were maintained for 12 weeks and monitored for clinical signs and any tumor growth regularly. Any specialized tissue or teratoma growth was monitored by external examination and an increase in the size of the muscle relative to the same muscle on the left hind limb. When a specialized tissue or teratoma was identified, the location and size of the growth was measured (using measuring calipers) and recorded. The specialized tissue or teratoma is usually first identified as a small growth of the muscle size compared to the left control muscle. Animals were monitored weekly until onset of any tumor growth, and daily after tumors appeared. After 12 weeks, the mice were sacrificed by CO2 euthanasia. Each entire animal was observed for any tumor growth anywhere on the animal, and the injected muscle and the comparable left muscle control were measured (with measuring calipers)(see results table below) and then removed and stored in 4% paraformaldehyde solution for histological analysis. The sizes of the muscles were as follows:
  • Left leg (control) Right leg (treated)
    Dorso-ventral Dorso-ventral
    Treatment width Lateral width width Lateral width
    Human Embryonic Stem Cells 6.44 ± 0.11 5.03 ± 0.17 6.91 ± 0.15  5.3 ± 0.14
    Human Neuroprogenitor Cells 6.60 ± 0.17 5.43 ± 0.15 7.01 ± 0.23 5.58 ± 0.13
    Human NSLC 6.85 ± 0.2  5.32 ± 0.14 6.86 ± 0.21 5.33 ± 0.11
    Values represent the Average of 8 mice ± the standard error
  • Measurement of the size of the muscles revealed that all the human embryonic stem cell injected muscles were bigger than the comparable left muscle controls, indicating teratoma growth in the ES cell injected muscles. About half of all the human neuroprogenitor cell injected muscles were bigger than the comparable left muscle controls, while the mice injected with NSLC did not show any difference between the muscles (treated with the cells or not). The mice injected with NSLC did not show any evidence of tumor or teratoma growth.
    • REFERENCES
    • Zeitlow R, Lane E L, Dunnet S B, Rosser A E. Human stem cells for CNSrepair. Cell Tissue Res. 2008; 331(1):301-22.
    • Mimeault, M., Hauke, R. & Batra, S. K. 2007. Stem cells: a revolution in therapeutics-recent advances in stem cell biology and their therapeutic applications in regenerative medicine and cancer therapies. Clin Pharmacol Ther, 82, 252-64.
    • Levesque, M F and Neuman T. Transdiffentiation of transfected epidermal basal cells into neural progenitor cells, neuronal cells and/or glial cells. Patent, filling date 2000.
    • Shea T B. Neuritogenesis in mouse NB2a/d1 neuroblastoma cells: triggering by calcium influx and involvement of actin and tubulin dynamics. Cell Biol Int Rep. 1990; 14(11):967-79.
    • Yeomans N D, Trier J S, Moxey P C, and Markezin E T. Maturation and differentiation of cultured fetal stomach. Effects of corticosteroids, pentagastrin, and cytochalasin B. Gastroenterology 1976; 71(5):770-7.
    • Paterson F C, Rudland P S. Microtubule-disrupting drugs increase the frequency of conversion of a rat mammary epithelial stem cell line to elongated, myoepithelial-like cells in culture. J Cell Phsiol. 1985; 125(1):135-50.
    • Bouwens L. Transdifferentiation versus stem cell hypothesis for the regeneration of islet beta-cells in the pancreas. Micro Res Tech. 1998; 43(4):332-6.
    • Bouwens L. Cytokeratins and cell differentiation in the pancreas. J Pathol. 1998b; 184(3):234-9.
    • Theise N D, Nimmakayalu M, Gardner R, IIlei P B, Morgan G, Teperman L, Henegariu O, Krause D S. Liver from bone marrow in humans. Hepatology 2000; 32(1):11-6.
    • Woodbury D, Schwarz E J, Prockop D J, Black I B. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res. 2000; 61(4):364-70.
    • Brunet, J F; Ghysen, A. Deconstructing cell determination: proneural genes and neuronal identity. Bioessays. 1999; 21:313-318.
    • Bertrand N, Castro D S, and Guillemot F. Proneural genes and the specification of neural cell types. Nat Rev Neurosci. 2002; 3(7):517-30.
    • McCormick M B, Tamimi R M, Snider L, Asakura A, Bergstrom D, Tapscott S J. NeuroD2 and neuroD3: distinct expression patterns and transcriptional activation potentials within the neuroD gene family. Mol Cell Biol. 1996; 16(10):5792-800.
    • Guillemot F, Lo L C, Johnson J E, Auerbach A, Anderson D J, Joyner A I. Mammalian achaete-scute homolog 1 is required for the early development of olfactory and autonomic neurons. Cell 1993; 75(3):463-76.
    • Fode C, Gradwohl G, Morin X, Dierich A, LeMeur M, Goridis C, Guillemot F. The bHLH protein NEUROGENIN 2 is a determination factor for epibranchial placode-derived sensory neurons. Neuron 1998; 20(3):483-94.
    • Fernandes K J L, McKenzie I A, Mill P, Smith K M, Akhavan M, Barnabé-Heider F, Biernaskie J, Junek A, et al. A dermal niche for multipotent adult skin-derived precursor cells. Nature Cell Biology 2004; 6:1082-1093.
    • Jacobsen F, Hirsch T, Mittler D, Schulte M, Lehnhardt M, Druecke D, Homann H H, Steinau H U, Steinstraesser L. Polybrene improves transfection efficacy of recombinant replication-deficient adenovirus in cutaneous cells and burned skin. J Gene Med. 2006; 8(2):138-46.
    • Kearns C M, Gash D M. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res. 1995; 672(1-2):104-11.
    • Gash D M, Zhang Z, Ovadia A, Cass W A, Yi A, Simmerman L, Russel D, Martin D, Lapchak P A, Collins F, Hoffer B J, Gerhardt G A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996; 380(6571):252-5.
    • Lindner M D, Winn S R, Baetge E E, Hammang J P, Gentile F T, Doherty E, McDermott P E, Frydel B, Ullman M D, Schallert T et al. Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms. Exp Neurol. 1995; 132(1):62-76.
    • Kordower J H, Emborg M E, Bloch J, Ma S Y, Chu Y, Leventhal L, McBride J, Chen E Y, Palfi S, Roitberg B Z, Brown W D, Holden J E, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000; 290(5492):767-73.
    • Martinez-Serrano A, Bjorklund A. Immortalized neural progenitor cells for CNS gene transfer and repair. Trends Neurosci. 1997; 20(11):530-8.
    • Chambers S M, Fasano C A, Papapetrou E P, Tomishima M, Sadelain M, Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol. 2009; 27(3):275-80.
  • Headings are included herein for reference and to aid in locating certain sections These headings are not intended to limit the scope of the concepts described therein under, and these concepts may have applicability in other sections throughout the entire specification Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
  • It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the present invention and scope of the appended claims.

Claims (12)

What is claimed is:
1. A method of obtaining a pluripotent-like multipotent cell, comprising:
i) providing a cell of a first type, which is not a pluripotent-like multipotent cell;
ii) contacting the cell of a first type with an agent capable of remodeling the chromatin and/or DNA of the cell, wherein the agent capable of remodeling the chromatin and/or DNA is a histone acetylator, an inhibitor of histone deacetylation, a DNA demethylator, and/or an inhibitor of DNA methylation;
iii) transiently increasing expression of at least one pluripotent gene regulator in the cell of a first type, to a level at which the at least one pluripotent gene regulator is capable of driving transformation of the cell of a first type into the pluripotent-like multipotent cell, wherein the at least one pluripotent gene regulator comprises Oct4, Klf4, Sa114, Nanog, Rex1, Lin28, Sox2, Tpt1, DPPA4 (Stella), DPPA3 or a combination thereof; and
iv) placing or maintaining the cell in a differentiation medium and maintaining intracellular levels of the at least one pluripotent gene regulator for a sufficient period of time to allow a stable pluripotent-like multipotent cell to be obtained;
wherein the pluripotent-like multipotent cell so obtained does not exhibit teratoma formation in vivo.
2. The method of claim 1, wherein, in step (ii), the remodeling agent is methyl-CpG binding domain protein 2 (MBD2), DNA-damage-inducible beta (Gadd45b), valproic acid or 5-azacytidine.
3. The method of claim 1, wherein, in step (ii), the remodeling agent is methyl-CpG binding domain protein 2 (MBD2).
4. The method of claim 1, wherein the pluripotent-like multipotent cell so obtained expresses one or more pluripotent-like cell marker selected from the group consisting of Oct4, Sox2, Nanog, SSEA-4, TRA1-60, TRA1-81 and AP.
5. The method of claim 1, wherein the pluripotent-like multipotent cell so obtained possesses all of the following characteristics:
(i) can self-renew for significantly longer than a somatic cell;
(ii) is not a cancerous cell;
(iii) is stable and not artificially maintained by forced gene expression and may be maintained in standard cell media;
(v) can differentiate to a unipotent or somatic cell; and
(vi) does not exhibit uncontrolled growth or tumor formation in vivo.
6. The method of claim 1, wherein a plurality of pluripotent-like multipotent cells are obtained and wherein the plurality of pluripotent-like multipotent cells are organized within a three-dimensional structure.
7. The method of claim 1, wherein the cell of the first type is selected from the group consisting of an adipose-derived stem cell, a mesenchymal stem cell, a hematopoietic stem cell, a skin derived precursor cell, a hair follicle cell, a fibroblast, a keratinocyte, an epidermal cell, an endothelial cell, an epithelial cell, a granulosa epithelial cell, a melanocyte, an adipocyte, a chondrocyte, a hepatocyte, a B lymphocyte, a T lymphocyte, a granulocyte, a macrophage, a monocyte, a mononuclear cell, a sertoli cell, a neuron, a glial cell, a cardiac muscle cell, and another muscle cell.
8. The method of claim 7, wherein the cell of the first cell type is a human fibroblast cell, a human keratinocyte, a human adipose derived stem cell, a human mesenchymal stem cell, or a human hematopoietic stem cell.
9. The method of claim 1, further comprising treating the cells of a first cell type with a cytoskeleton disruptor.
10. The method of claim 9, wherein the cytoskeleton disruptor is Cytochalasin B or a myosin inhibitor.
11. The method of claim 1, wherein the pluripotent-like multipotent cell obtained is capable of differentiating into a unipotent or somatic cell.
12. The method of claim 1, wherein in step (iii), the cell of a first type is transfected with at least one expression vector encoding polypeptide(s) selected from the group consisting of: Oct4, Klf4, Sall4, Nanog, Rex1, Lin28, Sox2, Tpt1, DPPA4 (Stella) and DPPA3.
US16/752,462 2009-10-31 2020-01-24 Methods for reprogramming cells and uses thereof Abandoned US20200165570A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/752,462 US20200165570A1 (en) 2009-10-31 2020-01-24 Methods for reprogramming cells and uses thereof
US18/188,421 US20230227785A1 (en) 2009-10-31 2023-03-22 Methods for reprogramming cells and uses thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US25696709P 2009-10-31 2009-10-31
PCT/CA2010/001727 WO2011050476A1 (en) 2009-10-31 2010-11-01 Methods for reprogramming cells and uses thereof
US201213504988A 2012-04-30 2012-04-30
US15/298,006 US10131879B2 (en) 2009-10-31 2016-10-19 Methods for reprogramming cells and uses thereof
US16/195,005 US10557123B2 (en) 2009-10-31 2018-11-19 Methods for reprogramming cells and uses thereof
US16/752,462 US20200165570A1 (en) 2009-10-31 2020-01-24 Methods for reprogramming cells and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US16/195,005 Continuation US10557123B2 (en) 2009-10-31 2018-11-19 Methods for reprogramming cells and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/188,421 Continuation US20230227785A1 (en) 2009-10-31 2023-03-22 Methods for reprogramming cells and uses thereof

Publications (1)

Publication Number Publication Date
US20200165570A1 true US20200165570A1 (en) 2020-05-28

Family

ID=43921216

Family Applications (7)

Application Number Title Priority Date Filing Date
US13/504,988 Active US9528087B2 (en) 2009-10-31 2010-11-01 Methods for reprogramming cells and uses thereof
US15/297,972 Active US10017737B2 (en) 2009-10-31 2016-10-19 Methods for reprogramming cells and uses thereof
US15/298,006 Active US10131879B2 (en) 2009-10-31 2016-10-19 Methods for reprogramming cells and uses thereof
US15/298,034 Active US10260046B2 (en) 2009-10-31 2016-10-19 Methods for reprogramming cells and uses thereof
US16/195,005 Active US10557123B2 (en) 2009-10-31 2018-11-19 Methods for reprogramming cells and uses thereof
US16/752,462 Abandoned US20200165570A1 (en) 2009-10-31 2020-01-24 Methods for reprogramming cells and uses thereof
US18/188,421 Pending US20230227785A1 (en) 2009-10-31 2023-03-22 Methods for reprogramming cells and uses thereof

Family Applications Before (5)

Application Number Title Priority Date Filing Date
US13/504,988 Active US9528087B2 (en) 2009-10-31 2010-11-01 Methods for reprogramming cells and uses thereof
US15/297,972 Active US10017737B2 (en) 2009-10-31 2016-10-19 Methods for reprogramming cells and uses thereof
US15/298,006 Active US10131879B2 (en) 2009-10-31 2016-10-19 Methods for reprogramming cells and uses thereof
US15/298,034 Active US10260046B2 (en) 2009-10-31 2016-10-19 Methods for reprogramming cells and uses thereof
US16/195,005 Active US10557123B2 (en) 2009-10-31 2018-11-19 Methods for reprogramming cells and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US18/188,421 Pending US20230227785A1 (en) 2009-10-31 2023-03-22 Methods for reprogramming cells and uses thereof

Country Status (17)

Country Link
US (7) US9528087B2 (en)
EP (2) EP2494039B1 (en)
JP (5) JP5982286B2 (en)
KR (3) KR102134240B1 (en)
AU (3) AU2010312240B2 (en)
BR (1) BR112012009921B1 (en)
CA (1) CA2779310C (en)
DK (1) DK2494039T3 (en)
ES (1) ES2739672T3 (en)
HR (1) HRP20191213T1 (en)
IL (3) IL219453A (en)
LT (1) LT2494039T (en)
MX (1) MX353245B (en)
SG (1) SG10201702120VA (en)
SI (1) SI2494039T1 (en)
WO (1) WO2011050476A1 (en)
ZA (1) ZA201203902B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11795439B2 (en) 2009-10-31 2023-10-24 Genesis Technologies Limited Methods for reprogramming cells and uses thereof
US12024722B2 (en) 2009-10-31 2024-07-02 Genesis Technologies Limited Methods for reprogramming cells and uses thereof

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7642091B2 (en) 2005-02-24 2010-01-05 Jau-Nan Lee Human trophoblast stem cells and use thereof
CA2779310C (en) * 2009-10-31 2021-11-30 New World Laboratories Inc. Methods for reprogramming cells and uses thereof
US9228170B2 (en) * 2010-02-05 2016-01-05 Auckland Uniservices Limited Cell programming
JP6163104B2 (en) * 2010-11-15 2017-07-12 アクセラレイテッド・バイオサイエンシズ・コーポレーション Generation of neural stem cells from human trophoblast stem cells
KR102703637B1 (en) 2010-12-22 2024-09-05 페이트 세러퓨틱스, 인코포레이티드 Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
KR101376635B1 (en) * 2011-01-14 2014-03-24 한국생명공학연구원 Composition for reprogramming cells into induced pluripotent stem cells comprising Rex1 and method to produce induced pluripotent stem cells using the same
WO2013013105A2 (en) * 2011-07-19 2013-01-24 Vivoscript,Inc. Compositions and methods for re-programming cells without genetic modification for repairing cartilage damage
US9428730B2 (en) 2012-02-29 2016-08-30 Mead Johnson Nutrition Company Coatings and culture media for promoting neurogenesis in adipose tissue derived stem cells
US20130224782A1 (en) * 2012-02-29 2013-08-29 Chenzhong Kuang Neurogenesis screening method and system using adipose tissue derived stem cells
GB201118964D0 (en) * 2011-11-03 2011-12-14 Ucl Business Plc Method
AU2012350353B2 (en) * 2011-12-13 2018-01-04 Unisa Ventures Pty Ltd Method of producing multipotent stem cells
CN102604894B (en) * 2012-02-29 2014-07-30 中国科学院广州生物医药与健康研究院 Culture medium for preparing neural stem cells and application thereof
WO2013138368A1 (en) * 2012-03-12 2013-09-19 Loma Linda University Medical Center Substances and methods for the treatment of cerebral amyloid angiopathy related conditions or diseases
US10561742B2 (en) 2012-07-19 2020-02-18 The Penn State Research Foundation Methods and compositions for treatment of disease or injury of the nervous system
US20140134139A1 (en) * 2012-11-07 2014-05-15 Northwestern University Cd34+ cells and methods of use
CN105143445B (en) 2012-11-29 2020-07-07 宝生物欧洲公司 Maturation of hepatocyte-like cells derived from human pluripotent stem cells
CN113604423A (en) 2012-11-30 2021-11-05 艾克塞利瑞提德生物技术公司 Methods of differentiating stem cells by modulating MIR-124
EP2938196B1 (en) * 2012-12-14 2019-04-03 Celularity, Inc. Anoikis resistant placental stem cells and uses thereof
AU2013362880B2 (en) * 2012-12-17 2019-01-17 Vashe CHANDRAKANTHAN Methods of generating cells with multilineage potential
PT2970890T (en) * 2013-03-14 2020-04-24 Massachusetts Inst Technology Compositions and methods for epithelial stem cell expansion and culture
US20160032317A1 (en) * 2013-03-14 2016-02-04 Children's Medical Center Corporation Compositions and methods for reprogramming hematopoietic stem cell lineages
WO2014170488A1 (en) * 2013-04-19 2014-10-23 Universita' Degli Studi Di Milano Methods for the conversion of somatic cells into pancreatic-hormone secreting cells
KR101655383B1 (en) 2013-07-27 2016-09-08 고려대학교 산학협력단 Composition for Maintaining Chromosome Stability of Pluripotent Stem Cells Comprising Small Molecules
CA2926372C (en) * 2013-10-10 2023-09-26 Mcmaster University Diagnosis and monitoring of endometriosis through bdnf and full-length ntrk2 levels
US20160298080A1 (en) * 2013-12-03 2016-10-13 The Johns Hopkins University Method for highly efficient conversion of human stem cells to lineage-specific neurons
US9512406B2 (en) 2013-12-20 2016-12-06 The J. David Gladstone Institute, a testamentary trust established under the Will of J. David Gladstone Generating hepatocytes
FR3016372B1 (en) * 2014-01-13 2018-01-19 Centre Leon Berard PROCESS FOR THE PREPARATION OF INDUCED PLURIPOTENT CELLS
JP2017509322A (en) * 2014-01-29 2017-04-06 ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー） Differentiation of differentiated cells
EP3114214B1 (en) 2014-03-04 2023-11-01 Fate Therapeutics, Inc. Improved reprogramming methods and cell culture platforms
US20150353623A1 (en) * 2014-04-03 2015-12-10 Loma Linda University Substances and methods for the treatment of cerebral amyloid angiopathy related conditions or diseases
US9259357B2 (en) 2014-04-16 2016-02-16 Loma Linda University Composition, preparation, and use of chitosan shards for biomedical applications
KR101731624B1 (en) * 2014-07-01 2017-05-04 광주과학기술원 Compositions for inducing a cell re-programming
KR20230019500A (en) 2014-09-03 2023-02-08 더 브리검 앤드 우먼즈 하스피털, 인크. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
US9730975B2 (en) 2014-11-25 2017-08-15 The Penn State Research Foundation Chemical reprogramming of human glial cells into neurons for brain and spinal cord repair
JP6836990B2 (en) 2014-11-26 2021-03-03 アクセラレイテッド・バイオサイエンシズ・コーポレーション Induced hepatocytes and their use
MA41296A (en) * 2014-12-30 2017-11-07 Orgenesis Ltd TRANSDIFFERENTIATION PROCESSES AND METHODS FOR USING THE SAME
US10839509B2 (en) 2015-07-10 2020-11-17 3Scan Inc. Spatial multiplexing of histological stains
CN105062953A (en) * 2015-08-06 2015-11-18 深圳爱生再生医学科技有限公司 Method for three-dimensional induction of transformation of mesenchymal stem cells into islet cells
KR20180055918A (en) 2015-10-16 2018-05-25 페이트 세러퓨틱스, 인코포레이티드 Platform for the induction and maintenance of ground-state versatility
JP2019506153A (en) 2016-01-08 2019-03-07 マサチューセッツ インスティテュート オブ テクノロジー Production of differentiated enteroendocrine cells and insulin-producing cells
US10973930B2 (en) 2016-02-18 2021-04-13 The Penn State Research Foundation Generating GABAergic neurons in brains
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
CN107142240B (en) * 2016-06-03 2021-01-29 中国人民解放军军事医学科学院野战输血研究所 Method for reprogramming epithelial cells derived from digestive tract into endoderm stem/progenitor cells and application
CN105861447B (en) * 2016-06-13 2017-12-19 广州市搏克生物技术有限公司 A kind of non-viral iPSCs inducing compositions and its kit
JP7118901B2 (en) 2016-06-20 2022-08-16 ジェネシス テクノロジーズ リミティド Automated cell processing system and method
CA3048220A1 (en) 2016-12-30 2018-07-05 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
CA3054120A1 (en) * 2017-02-24 2018-08-30 Koji Tanabe Nerve cell production method by introduction of inducing factor rna
CN111471653B (en) * 2017-03-01 2022-11-25 中国科学院动物研究所 Method for converting non-neuron cells into neuron cells
AU2017421792B2 (en) * 2017-06-30 2022-03-10 Stemlab Inc. Method for directly reprogramming cells in urine into keratinocyte stem cells and method for preparing composition for promoting skin regeneration by using reprogrammed keratinocyte stem cells
US20210230550A1 (en) * 2018-01-29 2021-07-29 Institute Of Zoology, Chinese Academy Of Sciences Cell induction method
CN110093310B (en) * 2018-01-29 2021-07-02 中国科学院动物研究所 Method for converting fibroblasts into immortalized cells and application thereof
CN110093309B (en) * 2018-01-29 2021-07-02 中国科学院动物研究所 Method for inducing transdifferentiation of fibroblasts into adipocytes
CN110093305B (en) * 2018-01-29 2021-07-02 中国科学院动物研究所 Method for inducing hepatocyte in-vitro amplification
CA3087869A1 (en) * 2018-02-02 2019-08-08 The Penn State Research Foundation Methods and materials for treating brain injuries
CN110305846A (en) * 2018-03-20 2019-10-08 中山大学中山眼科中心 The preparation method of pattern of retinal ganglion cells
SG11202011395RA (en) * 2018-06-22 2020-12-30 Skin2Neuron Pty Ltd Expansion and differentiation of neuronal precursor cells
AU2019321641A1 (en) 2018-08-17 2021-04-15 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating Jag-1
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
AU2019343166A1 (en) * 2018-09-19 2021-05-20 Regeneration Biomedical, Inc. WNT-activated adipose-derived stem cell apparatuses, methods and systems
US11518971B2 (en) 2018-11-27 2022-12-06 Research Triangle Institute Method and apparatus for spatial control of cellular growth
JP7285591B2 (en) * 2019-01-02 2023-06-02 セラピューティクス バイオ A novel glial-like cell differentiated from a somatic cell, a method for producing the same, a cocktail composition for producing the same, a cell therapeutic agent for preventing or treating neurological diseases containing the same, and a method for preventing and treating neurological diseases by administering the same
US20220110979A1 (en) * 2019-01-11 2022-04-14 Figene, Llc Fibroblast regenerative cells
AU2020268341A1 (en) 2019-05-06 2021-12-02 Accelerated Biosciences Corp. Precursory regulatory cytotrophoblast cells and uses thereof
KR102183208B1 (en) * 2019-07-25 2020-11-25 한국과학기술연구원 Methods for reprogramming astrocytes into neurons in spinal cord injury(SCI) animal model using Ngn2
AU2020402020A1 (en) * 2019-12-09 2022-06-23 The Brigham And Women's Hospital, Inc. Methods for generating hematopoietic stem cells
CN111471651A (en) * 2020-04-24 2020-07-31 中国人民解放军第四军医大学 Serum-free medium for human adipose-derived stem cells and preparation method thereof
CN113862218B (en) * 2021-10-12 2024-06-25 广州医科大学附属第一医院（广州呼吸中心） Tumor-associated perivascular cell subpopulation and preparation method and application thereof
US20230257969A1 (en) * 2022-02-16 2023-08-17 Caterpillar Inc. Adapter retention plug

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009018832A1 (en) * 2007-08-09 2009-02-12 Rigshospitalet Method for increasing the plasticity level of a cell
WO2010124143A1 (en) * 2009-04-23 2010-10-28 Nevada Cancer Institute Reprogramming of somatic cells with purified proteins
US9771563B2 (en) * 2008-03-17 2017-09-26 The Scripps Research Institute Chemical approaches for generation of induced pluripotent stem cells

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087168A (en) 1999-01-20 2000-07-11 Cedars Sinai Medical Center Conversion of non-neuronal cells into neurons: transdifferentiation of epidermal cells
US20020136709A1 (en) 2000-12-12 2002-09-26 Nucleus Remodeling, Inc. In vitro-derived adult pluripotent stem cells and uses therefor
AU2002313817A1 (en) * 2001-08-27 2003-03-10 Advanced Cell Technology, Inc. Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies
US20030217378A1 (en) 2002-04-05 2003-11-20 The University Of Georgia Research Foundation, Inc Cloning using rapidly matured oocytes
US7732203B2 (en) * 2002-08-17 2010-06-08 Ajoll University Industry Cooperation Foundation Method for transdifferentiating mesenchymal stem cells into neuronal cells
US8178349B2 (en) 2005-02-09 2012-05-15 Burnham Institute For Medical Research Homogeneous neural precursor cells
US8440460B2 (en) 2005-07-27 2013-05-14 The Board Of Regents Of The University Of Texas System Methods for transdifferentiating cells
CN101389761A (en) 2006-02-27 2009-03-18 银怎株式会社 De-differentiation of astrocytes into neural stem cell using bmi-1
AU2007332799A1 (en) * 2006-12-07 2008-06-19 Teva Pharmaceutical Industries Ltd. Method of generation and expansion of tissue-progenitor cells and mature tissue cells from intact bone marrow or intact umbilical cord tissue
RU2492232C2 (en) * 2007-08-31 2013-09-10 Уайтхэд Инститьют Фор Байомедикал Рисерч STIMULATION OF PATHWAY Wnt IN REPROGRAMMING SOMATIC CELLS
CA2660123C (en) 2007-10-31 2017-05-09 Kyoto University Nuclear reprogramming method
US20090136461A1 (en) * 2007-11-28 2009-05-28 Moon Suk Kim Neuronal differentiation method of adult stem cells using small molecules
EP2245140A2 (en) * 2007-11-30 2010-11-03 New York Medical College Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure
AU2008338989A1 (en) 2007-12-17 2009-06-25 Gliamed, Inc. Stem-like cells and method for reprogramming adult mammalian somatic cells
JP2011516082A (en) * 2008-04-07 2011-05-26 ニューポテンシャル，インコーポレイテッド Cell reprogramming by inducing pluripotency genes through the use of small molecule modifiers
JP5608645B2 (en) 2008-11-05 2014-10-15 学校法人慶應義塾 Neural stem cell production method
EP2393915A4 (en) 2009-02-05 2012-12-26 Regenertech Pty Ltd Method of producing progenitor cells from differentiated cells
JP5921430B2 (en) * 2009-05-20 2016-05-24 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Methods for determining the cardiac developmental potential of mammalian cells
CA2779310C (en) * 2009-10-31 2021-11-30 New World Laboratories Inc. Methods for reprogramming cells and uses thereof
US9453205B2 (en) * 2009-10-31 2016-09-27 Genesis Technologies Limited Methods for reprogramming cells and uses thereof
US20130097717A1 (en) * 2010-06-23 2013-04-18 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification for treatment of cardiovascular diseases
WO2013033213A1 (en) * 2011-08-30 2013-03-07 The J. David Gladstone Institutes Methods for generating cardiomyocytes
US9540612B2 (en) 2012-01-30 2017-01-10 Icahn School Of Medicine At Mount Sinai Methods for programming differentiated cells into hematopoietic stem cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009018832A1 (en) * 2007-08-09 2009-02-12 Rigshospitalet Method for increasing the plasticity level of a cell
US9771563B2 (en) * 2008-03-17 2017-09-26 The Scripps Research Institute Chemical approaches for generation of induced pluripotent stem cells
WO2010124143A1 (en) * 2009-04-23 2010-10-28 Nevada Cancer Institute Reprogramming of somatic cells with purified proteins

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11795439B2 (en) 2009-10-31 2023-10-24 Genesis Technologies Limited Methods for reprogramming cells and uses thereof
US12024722B2 (en) 2009-10-31 2024-07-02 Genesis Technologies Limited Methods for reprogramming cells and uses thereof

Also Published As

Publication number Publication date
EP3567103B1 (en) 2023-09-06
AU2010312240B2 (en) 2016-12-15
KR102014977B1 (en) 2019-08-27
KR20190100467A (en) 2019-08-28
EP2494039A1 (en) 2012-09-05
KR20120094488A (en) 2012-08-24
IL219453A (en) 2017-09-28
US9528087B2 (en) 2016-12-27
SG10201702120VA (en) 2017-05-30
JP5982286B2 (en) 2016-08-31
AU2019202451A1 (en) 2019-05-02
US10260046B2 (en) 2019-04-16
EP3567103C0 (en) 2023-09-06
CA2779310A1 (en) 2011-05-05
LT2494039T (en) 2019-07-25
US10557123B2 (en) 2020-02-11
BR112012009921B1 (en) 2021-06-29
JP2016146841A (en) 2016-08-18
US20190085294A1 (en) 2019-03-21
HRP20191213T1 (en) 2019-10-04
JP2022120163A (en) 2022-08-17
SI2494039T1 (en) 2020-03-31
MX353245B (en) 2018-01-08
US20170101623A1 (en) 2017-04-13
US20120220034A1 (en) 2012-08-30
IL219453A0 (en) 2012-06-28
KR102134240B1 (en) 2020-07-16
IL254144A0 (en) 2017-10-31
IL272848B (en) 2021-04-29
KR20180034695A (en) 2018-04-04
AU2019202451B2 (en) 2021-05-27
ES2739672T3 (en) 2020-02-03
EP2494039B1 (en) 2019-06-19
AU2017201774A1 (en) 2017-04-06
AU2017201774B2 (en) 2019-03-07
JP2013509159A (en) 2013-03-14
JP2020124219A (en) 2020-08-20
KR101874463B1 (en) 2018-08-02
WO2011050476A1 (en) 2011-05-05
US20230227785A1 (en) 2023-07-20
JP7407865B2 (en) 2024-01-04
US10017737B2 (en) 2018-07-10
EP2494039A4 (en) 2013-07-17
DK2494039T3 (en) 2019-08-19
US20170101622A1 (en) 2017-04-13
US20170101626A1 (en) 2017-04-13
US10131879B2 (en) 2018-11-20
EP3567103A1 (en) 2019-11-13
ZA201203902B (en) 2013-02-27
CA2779310C (en) 2021-11-30
JP2018183152A (en) 2018-11-22
BR112012009921A2 (en) 2016-03-08
MX2012004881A (en) 2012-08-17
AU2010312240A1 (en) 2012-05-24
IL272848A (en) 2020-04-30

Similar Documents

Publication Publication Date Title
US20230227785A1 (en) Methods for reprogramming cells and uses thereof
US11795439B2 (en) Methods for reprogramming cells and uses thereof
US12024722B2 (en) Methods for reprogramming cells and uses thereof

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION